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Glossary of Terms 
90-90-90: An ambitious treatment target to help end the AIDS epidemic. By 2020, 90% of all people 
living with HIV will know their HIV status; 90% of all people who know their HIV-positive status will 
receive sustained antiretroviral therapy (ART); and 90% of all people receiving ART will have viral load 
(VL) suppression (VLS). 
 
Acquired Immunodeficiency Syndrome (AIDS): AIDS is a disease that can develop after HIV infection 
causes severe damage to the immune system, leaving the body vulnerable to life-threatening 
conditions, such as infections and cancers. 
 
Adolescents: In this report, individuals aged 10-14 years of age are referred to as young adolescents and 
young people aged 15-19 years are referred to as older adolescents. Note: older adolescents are often 
categorized as part of the adult population for reporting purposes. 
 
Adults: Unless otherwise noted, in this survey, adults are defined as the population of individuals aged 
15-59 years. 
 
Antiretroviral Therapy (ART): Treatment with antiretroviral (ARV) drugs that inhibit the ability of HIV to 
multiply in the body, leading to improved health and survival among people living with HIV. 
 
CD4+ T-Cells: CD4+ T-cells (CD4) are white blood cells that are an essential part of the human immune 
system. These cells are often referred to as T-helper cells. HIV attacks and kills CD4 cells, leaving the 
body vulnerable to a wide range of infections. The CD4 count is used to determine the degree of 
weakness of the immune system from HIV infection. 
 
Children: Unless otherwise noted, in this survey, the population of individuals 0-14 years of age are 
defined as children. 
 
De Facto Household Resident: A person who slept in the household the night prior to the survey. 
 
Enumeration Area (EA): A limited geographic area defined by the national statistical authority and the 
primary sampling unit for the Population-based HIV Impact Assessment (PHIA) surveys.  
 
Head of Household: The person who is recognized within the household as being the head and is aged 
18 years and older or is considered an emancipated minor (a young person aged 15-17 years who is 
married, the parent of a child, or has left home and is self-sufficient, as defined by law in Lesotho). 
 
Human Immunodeficiency Virus (HIV): HIV is the virus that causes AIDS. The virus is passed from person 
to person through blood, semen, vaginal fluids, and breast milk. HIV attacks CD4 cells in the body, 
leaving the HIV-positive person vulnerable to illnesses that a healthy immune system would have 
eliminated. 
GLOSSARY OF TERMS 
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HIV Incidence: A measure of the frequency with which new cases of HIV occur in a population over a 
period of time. The denominator is the population at risk; the numerator is the number of new cases 
that occur during a given time period. 
 
HIV Prevalence: The proportion of living persons in a population who are HIV positive at a specific point 
in time. The denominator is the total population; the numerator is the number of HIV-positive persons. 
 
HIV Viral Load (VL): The concentration of HIV ribonucleic acid (HIV RNA) in the blood, usually expressed 
as copies per milliliter (mL). 
 
HIV Viral Load Suppression (VLS): An HIV VL of less than 1,000 copies per mL. 
 
Household: A person or group of persons related or unrelated to each other who live in the same 
compound (fenced or unfenced), who normally live and eat together, making a common provision for 
food or other essentials for living, and have one person whom they identify as head of that household.  
 
Informed consent: Informed consent is a legal condition whereby a person can give consent based upon 
a clear understanding of the facts, implications, and future consequences of an action. In order to give 
informed consent, the individual concerned must have adequate reasoning faculties and be in 
possession of all relevant facts at the time he or she gives consent. 
 
Male circumcision: Male circumcision is the removal of the entire foreskin (prepuce) from the penis. 
Medically supervised adult male circumcision is scientifically proven to reduce a man’s risk of acquiring 
HIV infection through heterosexual intercourse.  
 
Prevention of mother-to-child transmission (PMTCT): Activities to prevent an HIV-positive woman 
passing HIV to her baby during pregnancy, labor and delivery, or breastfeeding. The World Health 
Organization recommends effective PMTCT to include a four-fold approach: (1) primary prevention of 
HIV infection among women of childbearing age; (2) preventing unintended pregnancies among women 
living with HIV; (3) preventing HIV transmission from women living with HIV to their infants; and (4) 
providing appropriate treatment, care, and support to mothers living with HIV, their children, and 
families.  
 
Severe immunosuppression: When the body’s ability to mount an immune response to fight infections 
or disease is dramatically reduced, primarily due to HIV, as measured by a CD4 count less than 200 cells 
per microliter (µL). 
 
Tuberculosis (TB): Tuberculosis is a contagious bacterial disease that can spread through the air when a 
person with pulmonary TB coughs or sneezes. TB is the leading cause of death among people living with 
HIV in Africa.  
 
Young adults: Unless otherwise noted, in this report, young adults are defined as individuals aged 20-24 
years. 
 
Young people: In this report, young people are defined as the population aged 15-24 years, including 
both older adolescents and young adults.   
  
 
8 
List of Abbreviations 
AIDS  Acquired Immunodeficiency Syndrome 
ANC Antenatal Care 
ART Antiretroviral Therapy 
ARV Antiretroviral 
BOS Bureau of Statistics 
CDC U.S. Centers for Disease Control and Prevention 
CD4 CD4+ T-Cell 
CI Confidence Interval 
DBS Dried Blood Spot 
DNA Deoxyribonucleic Acid 
DSD Differentiated Service Delivery 
EA Enumeration Area 
EIA Enzyme Immunoassay 
EID Early Infant Diagnosis 
GBV Gender-Based Violence 
HBTC Home-Based HIV Testing and Counseling 
HIV Human Immunodeficiency Virus 
IPV Intimate Partner Violence 
IQR Interquartile Range 
LAg Limiting Antigen 
mL Milliliters 
µL Microliters 
LePHIA Lesotho Population-based HIV Impact Assessment 
MDRI Mean Duration of Recent Infection 
MOH Ministry of Health 
MTCT Mother-to-Child Transmission 
NNRTI Nonnucleoside Reverse Transcriptase Inhibitors  
NRL National Reference Laboratory 
NRTI Nucleoside Reverse Transcriptase Inhibitors  
ODn Normalized Optical Density 
PCR Polymerase Chain Reaction 
PEPFAR U.S. President’s Emergency Plan for AIDS Relief 
PFR Proportion False Recent 
PHIA Population-based HIV Impact Assessment 
PMTCT Prevention of Mother-to-Child Transmission of HIV 
POC Point of Care 
PrEP Pre-Exposure Prophylaxis 
LIST OF ABBREVIATIONS 
  
 
9 
QA Quality Assurance 
QC Quality Control 
RNA Ribonucleic Acid 
RR Response Rate 
SMS Short Message Service 
T Time Cutoff 
TB Tuberculosis 
TNA Total Nucleic Acid 
UNAIDS Joint United Nations Programme on HIV / AIDS 
VL Viral Load 
VLS Viral Load Suppression 
VMMC Voluntary Medical Male Circumcision 
WHO World Health Organization 
 
 
 
 
 
 
 
 
  
  
 
10 
List of Tables and Figures 
Chapter 2    Survey Design, Methods, and Response Rates ................................................................ 19 
Table 2.1.A Distribution of sampled enumeration areas and households, by district ......................... 19 
Figure 2.4.A Household-based HIV testing algorithm, ages 18 months and older,  
LePHIA 2016-2017 ............................................................................................................. 24 
Figure 2.5.A HIV-1 recent infection testing algorithm (LAg/VL algorithm), ages 18 months and 
 older, LePHIA 2016-2017 .................................................................................................. 26 
Figure 2.5.B HIV-1 recent infection testing algorithm (LAg/VL/ARV algorithm), ages 18 months and 
older, LePHIA 2016-2017 ................................................................................................... 27 
Table 2.7.A Household response rates ................................................................................................. 29 
Table 2.7.B Interview and blood draw response rates......................................................................... 30 
Chapter 3    Survey Household Characteristics ................................................................................... 31 
Table 3.3.A Household composition ..................................................................................................... 32 
Table 3.3.B Distribution of de facto household population by age and sex ........................................ 32 
Table 3.3.C De facto household population by age, sex, and residence.............................................. 33 
Figure 3.3.A Distribution of the de facto population by sex and age, LePHIA 2016-2017 .................... 33 
Figure 3.3.B Household population by age, sex, and residence, LePHIA 2016-2017 ............................ 34 
Table 3.4.A Prevalence of HIV-affected households ............................................................................ 34 
Table 3.4.B HIV-affected households by number of HIV-positive members ....................................... 34 
Table 3.4.C Prevalence of households with an HIV-positive head of household................................. 35 
Figure 3.4.A Prevalence of HIV-affected households by residence, LePHIA 2016-2017 ....................... 35 
Figure 3.4.B HIV-affected households by number of HIV-positive members and residence,  
LePHIA 2016-2017 ............................................................................................................. 35 
Figure 3.4.C Prevalence of households with an HIV-positive head of household by sex,  
LePHIA 2016-2017 ............................................................................................................. 36 
Chapter 4    Survey Respondent Characteristics ................................................................................. 37 
Table 4.3.A Demographic characteristics of the older adolescent and adult population.................... 38 
Table 4.4.A  Demographic characteristics of the young adolescent population .................................. 39 
Table 4.4.B Demographic characteristics of the pediatric population ................................................. 40 
Chapter 5    HIV Incidence ................................................................................................................. 41 
Table 5.3.A Annual HIV incidence using LAg/VL testing algorithm ...................................................... 42 
Table 5.3.B Annual HIV incidence using LAg/VL/ARV testing algorithm .............................................. 42 
Chapter 6    HIV Prevalence .............................................................................................................. 44 
Table 6.3.A HIV prevalence by demographic characteristics: Ages 15-59 years .................................. 45 
Table 6.3.B HIV prevalence by demographic characteristics: Ages 15-49 years .................................. 46 
Figure 6.3.A HIV prevalence by marital status: Ages 15-59 years, LePHIA 2016-2017 ......................... 47 
Table 6.4.A HIV prevalence by age and sex .......................................................................................... 48 
Figure 6.4.A HIV prevalence by age and sex, LePHIA 2016-2017 .......................................................... 48 
Figure 6.5.A HIV prevalence among adults, by district, LePHIA 2016-2017 (map) ............................... 49 
Figure 6.5.B HIV prevalence among adults, by district, LePHIA 2016-2017 (bar graph) ....................... 50 
Chapter 7    HIV Testing .................................................................................................................... 51 
Table 7.3.A Self-reported HIV testing: Men ......................................................................................... 53 
LIST OF TABLES AND FIGURES 
  
 
11 
Table 7.3.B Self-reported HIV testing: Women .................................................................................... 54 
Table 7.3.C Self-reported HIV testing: Total ......................................................................................... 55 
Figure 7.3.A Proportion of adults who self-reported having received an HIV test in the last 12 
months, by age and sex, LePHIA 2016-2017 ..................................................................... 57 
Chapter 8    HIV Diagnosis and Treatment ......................................................................................... 58 
Table 8.3.A HIV treatment status: Men ................................................................................................ 59 
Table 8.3.B HIV treatment status: Women .......................................................................................... 60 
Table 8.3.C HIV treatment status: Total ............................................................................................... 62 
Figure 8.3.A Proportion of HIV-positive adults reporting awareness of their HIV-positive status  
and antiretroviral therapy (ART) status, by age and sex, LePHIA 2016-2017 ................... 63 
Table 8.4.A Concordance of self-reported treatment status versus presence of antiretrovirals  
(ARVs): Men ....................................................................................................................... 63 
Table 8.4.B Concordance of self-reported treatment status versus presence of antiretrovirals  
(ARVs): Women.................................................................................................................. 64 
Table 8.4.C Concordance of self-reported treatment status versus presence of antiretrovirals  
(ARVs): Total ...................................................................................................................... 64 
Chapter 9    Viral Load Suppression ................................................................................................... 66 
Table 9.3.A Viral load suppression by demographic characteristics .................................................... 66 
Figure 9.3.A Viral load suppression (<1000 copies/mL) among HIV-positive adults, by district,  
LePHIA 2016-2017 (map) ................................................................................................... 68 
Figure 9.3.B Viral load suppression (<1000 copies/mL) among HIV-positive adults, by district,  
LePHIA 2016-2017 (bar graph) .......................................................................................... 69 
Table 9.4.A Viral load suppression by age (5-year age groups) ........................................................... 69 
Table 9.4.B Viral load suppression by age (10-to-15-year age groups) ............................................... 70 
Figure 9.4.A Proportion of viral load suppression (<1000 copies/mL) among people living with  
HIV, by age and sex, LePHIA 2016-2017 ............................................................................ 70 
Chapter 10    UNAIDS 90-90-90 Targets ............................................................................................. 71 
Table 10.3.A Adult 90-90-90 (self-reported antiretroviral therapy (ART) status; conditional 
percentages) ...................................................................................................................... 72 
Table 10.3.B Adult 90-90-90 (self-reported antiretroviral (ART) status and laboratory antiretroviral 
(ARV) data; conditional percentages)................................................................................ 73 
Figure 10.3.A Adult 90-90-90 (adjusted for laboratory antiretroviral data among adults),  
LePHIA 2016-2017 ............................................................................................................. 74 
Chapter 11    Clinical Perspectives on People Living with HIV ............................................................. 75 
Figure 11.3.A CD4 count distribution among HIV-positive adults, by antiretroviral therapy (ART)  
status, LePHIA 2016-2017.................................................................................................. 76 
Table 11.3.A Median CD4 count and severe immunosuppression ........................................................ 77 
Table 11.4.A Late HIV diagnosis .............................................................................................................. 79 
Table 11.5.A Retention on antiretroviral therapy (ART): people initiating ART LESS THAN 12  
months prior to the survey ................................................................................................ 80 
Table 11.5.B Retention on antiretroviral therapy (ART): people initiating ART MORE THAN 12  
months prior to the survey ................................................................................................ 81 
Table 11.6.A Resistance to antiretrovirals (ARVs) .................................................................................. 83 
Table 11.6.B HIV Subtype ....................................................................................................................... 83 
Chapter 12    Prevention of Mother-to-Child Transmission ................................................................ 85 
Table 12.3.A Antenatal care ................................................................................................................... 86 
Table 12.4.A Breastfeeding status by child’s age and mother’s HIV status ........................................... 87 
Table 12.5.A Prevention of mother-to-child transmission: known HIV status ...................................... 87 
  
 
12 
Table 12.6.A Prevention of mother-to-child transmission: HIV-positive pregnant women who  
received antiretrovirals (ARVs) .......................................................................................... 89 
Table 12.7.A Mother-to-child transmission of HIV ................................................................................. 90 
Chapter 13    Young People ............................................................................................................... 92 
Table 13.3.A Sex before the age of 15 years .......................................................................................... 93 
Table 13.4.A Young people, knowledge about HIV prevention: Young men ......................................... 94 
Table 13.4.B Young people, knowledge about HIV prevention: Young women .................................... 95 
Table 13.4.C Young people, knowledge about HIV prevention: Total ................................................... 96 
Figure 13.7.A Young people 90-90-90 (laboratory ARV-adjusted data among young people  
aged 15-24 years), LePHIA 2016-2017 .............................................................................. 98 
Chapter 14    Children ..................................................................................................................... 100 
Table 14.4.A Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data; conditional 
percentages) .................................................................................................................... 101 
Table 14.4.B Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data and  
laboratory antiretroviral (ARV) data; conditional percentages) ..................................... 101 
Figure 14.4.A Pediatric 90-90-90 (laboratory antiretroviral (ARV)-adjusted data among children  
aged 0-14 years), LePHIA 2016-2017 .............................................................................. 102 
Chapter 15    HIV Risk Factors ......................................................................................................... 103 
Table 15.3.A HIV prevalence by sexual behavior ................................................................................. 104 
Table 15.4.A Condom use at last sex with a non-marital, non-cohabitating partner: Men ................ 105 
Table 15.4.B Condom use at last sex with a non-marital, non-cohabitating partner: Women ........... 107 
Table 15.4.C Condom use at last sex with a non-marital, non-cohabitating partner: Total ................ 108 
Table 15.5.A Male circumcision ............................................................................................................ 109 
Chapter 16    Violence, Including Gender-Based Violence ................................................................ 112 
Table 16.3.A Recent sexual violence among ever partnered women aged 15-59 years, by 
demographic characteristics ........................................................................................... 113 
Table 16.4.A HIV prevalence by experience of sexual violence ........................................................... 114 
Table 16.5.A Experience of sexual and physical violence among girls aged 13-14 years .................... 115 
Chapter 17    Discriminatory Attitudes Towards People Living with HIV ........................................... 117 
Table 17.3.A Discriminatory attitudes toward people living with HIV ................................................. 118 
Chapter 18    Tuberculosis .............................................................................................................. 120 
Table 18.3.A Tuberculosis (TB) diagnoses and treatment characteristics of the population  
aged 15-59 years ............................................................................................................. 121 
Table 18.3.B Tuberculosis (TB) clinic attendance and services among HIV-positive adults ................ 122 
Chapter 19    External Migration ..................................................................................................... 124 
Table 19.3.A External migration characteristics of the population: Ages 15-59 years ........................ 124 
Table 19.3.B HIV prevalence by external migration characteristics: Ages 15-59 years ....................... 125 
 
 
 
  
  
 
13 
Foreword 
We are pleased to present the results from the Lesotho Population-based HIV Impact Assessment 
(LePHIA) 2016-2017, the first national survey to provide comprehensive information on important 
HIV/AIDS indicators at national and regional levels and measure progress toward the UNAIDS 90-90-90 
targets. This survey included a nationally representative sample of almost 9,000 households throughout 
Lesotho. It described demographic characteristics of respondents, reproductive history, prevention of 
mother-to-child transmission (PMTCT), male circumcision, HIV/AIDS knowledge and attitudes, HIV 
testing and awareness of HIV status, care and treatment, tuberculosis (TB), gender norms, and gender-
based violence (GBV). LePHIA also collected information about HIV testing and treatment in children.  
Through blood tests, we measured the national HIV incidence in adults and viral load suppression (VLS) 
and HIV prevalence in adults and children.   
 
This survey has come at the right time, as the global HIV prevention and treatment community is 
focusing on epidemic control. These data allow us to better monitor HIV programs, understand which 
sub-populations are still unaware of their HIV status, and measure progress toward population VLS at a 
sub-national level. Both the biological and behavioral data from LePHIA allow program planners to 
target the right populations with tailored interventions—and allow policy makers to appropriately 
improve service delivery models.  
 
LePHIA was led by the Government of Lesotho through the Ministry of Health (MOH), and conducted 
with funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and technical assistance 
through the U.S. Centers for Disease Control and Prevention (CDC). The survey was implemented from 
November 2016 to May 2017 by ICAP at Columbia University in collaboration with local partners, 
including the Lesotho Bureau of Statistics (BOS).  
 
We would like to acknowledge the efforts of national and international organizations in the planning 
and implementation of the survey and in writing this report, in particular, the LePHIA Technical Working 
Group and Steering Committee. We are especially grateful to our field staff and the respondents, who 
graciously provided their time and data for the benefit of the nation.  
 
Hon. Nkaku Kabi 
 
Minister of Health 
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Executive Summary 
The Lesotho Population-based HIV Impact Assessment (LePHIA) 2016-2017 was a nationally 
representative, cross-sectional, population-based survey of households across Lesotho. LePHIA focused 
on measuring key biological endpoints to provide direct estimates of HIV infection risk and burden, and 
of the effectiveness and population-level impact of the HIV-related prevention, care, and treatment 
interventions implemented in the country. Its primary objectives were to estimate the national-level 
annual HIV incidence among adults (the population aged 15-59 years), and the district-level prevalence 
of HIV viral load (VL) suppression (VLS) (defined as HIV ribonucleic acid [RNA] < 1000 copies per milliliter 
[mL]) among HIV-positive adults. In addition, LePHIA measured national and district-level adult HIV 
prevalence, CD4 counts, antiretroviral (ARV) drugs in blood, transmitted HIV drug resistance, pediatric 
HIV prevalence, and progress toward the 90-90-90 targets defined by UNAIDS. LePHIA is the first 
national survey to conduct these measurements in Lesotho. The survey also collected information on 
behaviors associated with HIV infection, such as external migration and gender-based violence (GBV). 
 
The survey used a two-stage, stratified cluster sample design, in which census enumeration areas (EA) 
(clusters) were selected in the first stage and households in the second stage. Data collection was 
conducted between the end of November 2016 and May 2017. The survey involved interviewing 8,824 
households. In the households surveyed, 14,028 adults and 4,870 children (the population aged 0-14 
years) were eligible to participate in the survey. Altogether, 92% (12,887) of eligible adults were 
interviewed, and 91% (11,682) of interviewed adults and 81% (3,966) of eligible children provided blood 
for biomarker assessment to determine their HIV status. LePHIA provided home-based HIV testing and 
counseling (HBTC) with return of results, and point-of-care (POC) CD4 counts for those who were HIV 
positive. HIV VL results and early infant diagnosis (EID) results were returned to participants through the 
health facilities of their choice. LePHIA provides weighted estimates. Analysis weights accounted for 
sample selection probabilities and were adjusted for nonresponse and noncoverage. The key findings of 
LePHIA were: 
 
▪ Annual HIV incidence among adults in Lesotho was 1.10%; 1.22% among women, and 1.00% among 
men, using the algorithm including ARV detection (see section 5.3). This corresponded to almost 
10,000 new cases of HIV annually among adults in the country in 2017. Annual incidence was 
highest in men aged 35-49 years (2.65%) and among older adolescent girls and young women (aged 
15-24 years) at 1.49%.” 
▪ HIV prevalence among adults in Lesotho was 25.6%: 30.4% among women and 20.8% among men. 
This corresponded to approximately 306,000 adults living with HIV in the country. The burden of HIV 
infection varied across the country.  
▪ The vast majority (86.9%) of the adults reported that they had ever been tested for HIV and received 
their results (91.3% of women and 82.7% of men). However, only 56.1% of adults reported having 
been tested and receiving their results in the 12 months preceding the survey (61.7% of women and 
50.5% of men).  
▪ In Lesotho, 67.6% of HIV-positive adults had VLS, 63.4% among men and 70.5% among women. The 
percentage of HIV-positive adults with VLS ranged from 58.8% in Mokhotlong to 71.7% in Berea. 
Above 35 years of age, the proportion with VLS was significantly higher. The prevalence of VLS was 
EXECUTIVE SUMMARY 
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51.0% among young people (the population aged 15-24 years, including older adolescents aged 15-
19 years and young adults aged 20-24 years), and 62.7% among children. 
▪ Based on self-report and ARV detection data, it was estimated that 81.0% of adults living with HIV 
knew their HIV status (76.6% of HIV-positive men and 84.0% of HIV-positive women), 91.8% of 
whom were receiving antiretroviral therapy (ART) (91.6% of men and 92.0% of women), and that 
87.7% of those on ART had achieved VLS (87.7% of men and women). It therefore appears that once 
men become aware of their status, they can achieve the same progress towards ART coverage and 
VLS as women.  
▪ Among women aged 15-49 years who delivered in the 12 months preceding the survey, 95.6% 
reported knowing their HIV status while pregnant, while 98.5% of HIV-positive women reported 
receiving ARVs during their pregnancy. However, among infants born in the previous 17 months to 
HIV-positive mothers, 2.8% were confirmed to be HIV positive as part of the virological testing 
performed in LePHIA. Other infants were still at risk of HIV as they were still breastfeeding. 
▪ Among young people, annual HIV incidence was estimated at 0.78% (95% confidence interval (CI) 
0.31- 1.25%), and was high in older adolescent girls and young women (1.49%). HIV prevalence in 
older adolescents was 4.2% (2.8% in boys and 5.7% in girls) and 10.4% in young adults aged 20-24 
years: 4.0% in young men and 16.7% in young women). Based on self-report and detection of ARVs 
in blood, 67.6% of young people living with HIV had been previously diagnosed with HIV (71.3% of 
older adolescent boys and young men and 66.4% of older adolescent girls and young women), and 
among those who had been previously diagnosed, 90.6% were on ART. Among those on treatment, 
only 77.2% achieved VLS. 
▪ The estimated HIV prevalence among children was 2.1%. Based on parents’ report and ARV 
detection data, it was estimated that 81.1% of children living with HIV were previously diagnosed, 
98.2% of those were on ART, but only 73.9% of those on ART had VLS.  
▪ HIV prevalence in women who reported engaging in paid sexual intercourse in the 12 months 
preceding the survey was 46.2%, and in men who reported paying for sex, it was 24.1%. Of those 
engaging in paid sexual intercourse, 51.4% of women and 36.3% of men reported not using a 
condom at last paid sexual intercourse. 
▪ Amongst married or cohabitating adults, 27.1% of men had an extra-marital partner in the past 12 
months compared to 11.9% of women. One third reported not using a condom with their last non-
marital partner. 
▪ Among men, 36.0% reported having undergone medical circumcision, 31.6% non-medical or 
traditional circumcision, and 30.7% were uncircumcised. 
▪ A history of sexual violence was associated with a significantly higher prevalence of HIV in women 
(39.3% vs 31.0% in women who did not report a history of being forced to have sex).  
▪ One in five people living with HIV (20.6%) reported having been diagnosed with tuberculosis (TB) 
during their lifetime. In all adults, TB was more common in men than in women. 
▪ Nearly one-quarter of all respondents reported having lived outside of Lesotho: 30.9% of men and 
17.8% of women. HIV prevalence was significantly higher in those who reported ever having lived 
outside Lesotho than in those who did not. 
▪ Despite living in a country where over one in three households (37.6%) had at least one HIV-positive 
member, only 28.3% of young people correctly responded to all questions in a set that assessed 
knowledge of HIV transmission and prevention (26.0% of older adolescent boys and young men and 
30.7% of older adolescent girls and young women). Furthermore, of those adults who had ever 
heard of HIV, 17.4% reported discriminatory attitudes towards people living with HIV, with the 
highest level seen among older adolescents. 
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LePHIA results indicate that HIV continues to cause a significant burden of disease in the country. 
Although there has been remarkable progress toward the achievement of the UNAIDS 90-90-90 targets 
in adults, significant gaps remain. The major challenge remains that of diagnosis, and a critical priority is 
to identify and link to care those living with HIV, but unaware of their HIV status. An additional challenge 
among young people and children is to ensure VLS among those receiving ART. It is unclear if the low 
prevalence of VLS is due to poor adherence or drug resistance. 
 
LePHIA incidence estimates indicated that there were almost 10,000 new cases of HIV infection among 
adults in 2017. The considerable variation in prevalence of HIV infection and VLS across districts and 
population groups, and the low frequency of preventative behaviors, such as condom use with high-risk 
partners and practices such as medical circumcision, indicate that the country requires an intensified, 
targeted approach to the delivery of a combination of effective, evidence-based, prevention 
interventions in order to reduce HIV acquisition and transmission. Increasing coverage of diagnosis, 
while sustaining high levels of treatment and VLS, are key to reducing new HIV infections in Lesotho. 
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Chapter 1    Introduction 
1.1 Background 
The Population-based HIV Impact Assessment (PHIA) is a multicountry project funded by the United 
States President’s Emergency Plan for AIDS Relief (PEPFAR) to conduct national HIV-focused surveys that 
describe the status of the HIV epidemic. The surveys measure important national and regional HIV-
related parameters, including progress toward the achievement of the Joint United Nations Programme 
on HIV/AIDS (UNAIDS) 90-90-90 targets,1 and will guide policy and funding priorities. 
 
LePHIA was led by the Government of Lesotho through the Ministry of Health (MOH) with technical 
assistance from the United States Centers for Disease Control and Prevention (CDC). The survey was 
implemented by ICAP at Columbia University in collaboration with the Lesotho Bureau of Statistics 
(BOS). LePHIA 2016-2017 received ethical approval from the Lesotho National Health Research and 
Ethics Committee, Westat Institutional Review Board, the CDC Institutional Review Board, and the 
Columbia University Medical Center Review Board. 
 
1.2 Overview of LePHIA 2016-2017 
LePHIA, a household-based national survey, was conducted between November 2016 and May 2017 to 
measure the status of Lesotho’s national HIV response. LePHIA offered HBTC with return of results and 
collected information about uptake of HIV care and treatment services. This survey was the first in 
Lesotho to measure national HIV incidence, VLS prevalence, pediatric HIV prevalence, CD4 count 
distribution, presence of ARVs in blood, and transmitted HIV drug resistance. The survey also collected 
information on selected behaviors associated with HIV acquisition and transmission, and on TB. 
 
Although HIV facility-based sentinel surveillance and previously conducted population-based studies 
provided useful knowledge regarding Lesotho’s HIV epidemic and HIV-control efforts, other critical 
information was still lacking to understand the current status of the epidemic and guide future 
interventions. While population-level outcomes and impact can be inferred and modeled from facility-
level data, this requires a series of untested assumptions about trends in the unobserved segments of 
the population. In addition, the population-based data that were available for HIV focused largely on 
knowledge, attitudes, and self-reported risk behaviors.  
 
With its focus on measuring key biological endpoints in a nationally representative sample of the 
population, LePHIA has provided direct estimates of HIV-infection risk and burden, the effectiveness and 
population-level impact of HIV-related prevention, care, and treatment interventions implemented in 
the country, and progress toward the achievement of the UNAIDS 90-90-90 targets. 
 
1.3 Specific Objectives 
The goal of the survey was to estimate HIV incidence and prevalence in Lesotho, to assess the coverage 
and impact of HIV services at the population level, and to characterize HIV-related risk behaviors using a 
nationally representative sample of adults and children. 
 
 
1 INTRODUCTION 
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Primary Objectives 
▪ To estimate national-level annual HIV incidence among adults (the population aged 15-59 years). 
▪ To estimate the subnational (district) prevalence of VLS among HIV-positive adults. 
 
Secondary Objectives 
▪ To estimate the national prevalence of HIV infection among children (defined as those aged 0-14 
years). 
▪ To estimate the national and subnational prevalence of HIV infection among adults. 
▪ To determine the distribution of CD4 counts among HIV-positive people aged 0-59 years. 
▪ To estimate the prevalence of detectable ARVs in blood and the frequency of transmitted drug 
resistance among HIV-positive people. 
▪ To describe the prevalence of reported HIV-related risk behaviors among adults. 
▪ To describe the uptake of HIV-related services among male and female participants aged 0-59 years. 
 
1.4 References 
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: An ambitious treatment target to 
help end the AIDS epidemic. Geneva: UNAIDS; 2014. 
http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Accessed December 20, 
2018. 
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Chapter 2    Survey Design, Methods, and Response Rates 
LePHIA was a nationally representative, cross-sectional, population-based survey of households across 
Lesotho. Its target population corresponded to children (those aged 0-14 years) and adults (those aged 
15-59 years). The survey population excluded institutionalized children and adults. 
 
2.1 Sample Frame and Design 
LePHIA used a two-stage, stratified cluster sample design. The sampling frame was comprised of all 
households in the country based on preliminary data from the 2016 Population and Housing Census, 
which includes 5,684 residential EAs, containing an estimated 568,429 households.1 The first stage 
selected 418 EAs (clusters) using a probability proportional to size method. The 418 EAs were stratified 
by ten districts: Butha Buthe, Leribe, Berea, Maseru, Mafeteng, Mohale’s Hoek, Quthing, Qacha’s Nek, 
Mokhotlong and Thaba Tseka. During the second stage, a sample of households was randomly selected 
within each EA, or cluster, using an equal probability method, where the average number of households 
selected per cluster was 26 and the actual number of households selected per cluster ranged from 15 to 
35 (Table 2.1.A). Urban areas were defined by the BOS, and were characterized by either high 
population density, or of a high level of economic activities or infrastructure. Peri-urban areas were 
defined as areas with moderate population density, or a lesser extent of economic activities or 
infrastructure. Rural areas were those with only minimal population density or little infrastructure or 
economic activities. 
 
The sample size was calculated to provide representative national estimates of HIV incidence among 
older adolescent girls and young women aged 15-24 years and adults aged 15-59 years with a relative 
standard error less than or equal to 30.0%, as well as representative district estimates of VLS prevalence 
among HIV-positive adults with 95% confidence intervals (CIs) with ±10% bounds around the point 
estimates. One-half of the households were randomly selected for inclusion of children, which was 
designed to provide a representative national estimate of pediatric HIV prevalence with a relative 
standard error less than or equal to 13.0%. The target sample size was 12,698 for adults and 4,222 for 
children.  
 
Table 2.1.A Distribution of sampled enumeration areas and households, by district 
 Enumeration Areas  Households 
District Urban Peri-urban Rural Total  Urban  Peri-urban Rural Total 
Maseru 62 9 31 102  1,624 239 794 2,657 
Mafeteng 11 3 27 41  264 76 719 1,059 
Mohale's Hoek 11 0 28 39  300 0 731 1,031 
Leribe 25 4 36 65  674 112 907 1,693 
Berea 20 6 25 51  523 168 637 1,328 
Quthing 7 2 17 26  191 63 422 676 
Butha Buthe  7 0 20 27  194 0 509 703 
Mokhotlong 3 1 17 21  88 28 431 547 
Qacha's Nek 5 0 15 20  129 0 392 521 
Thaba Tseka  3 2 21 26  85 51 541 677 
 
         
Total 154 27 237 418  4,072 737 6,083 10,892 
 
2 SURVEY DESIGN, METHODS, AND RESPONSE 
RATES 
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Appendix A: Sample Design and Weighting provides a more detailed explanation of the sampling and 
weighting processes. 
 
2.2 Eligibility Criteria, Recruitment, and Consent Procedures 
The eligible survey population included individuals living in the selected households, or visitors who 
slept in the household the night before the survey who were: 
▪ Women and men aged 18-59 years who were willing and able to provide written consent, 
▪ Adolescents aged 12-17 who were willing and able to provide written assent, and whose parents or 
guardians were willing and able to provide written permission for their participation, and  
▪ Children aged 0-11 years whose parents or guardians were willing and able to provide written 
consent for their participation. 
 
An electronic informed consent form was administered using a tablet (Appendix H). At each stage of the 
consent process, consent was indicated by signing or making a mark on the consent form on the tablet 
and on a printed copy, which was retained by the participant. A household-designated head provided 
written consent for household members to participate in the survey, after which individual members 
were rostered during a household interview. Adults and emancipated minors then provided written 
consent on the tablet for an interview. After completing the interview, they provided written consent 
for participation in the biomarker component of the survey, including HBTC, with return of HIV test 
results and CD4 counts during the household visit. Receipt of HIV test results was a requirement for 
participation in the biomarker component. If an individual did not want to receive his or her HIV test 
result, this was considered a refusal and the survey was concluded. Adults were also asked for written 
consent to store their blood samples in a repository to perform additional tests in the future, and for 
consent to share their contact information with the MOH or an implementing partner if HIV positive for 
active linkage to care. 
 
Adolescents aged 12-17 years were asked for assent to the interview and biomarker components after 
permission was granted by their parents or guardians. Parents provided consent for interview and 
biomarker testing for children aged 10-11 years, and provided consent for biomarker testing for children 
below the age of 10 years. In both cases, if a parent or guardian did not want to receive his or her child’s 
HIV test result, this was considered a refusal and the survey was concluded. Adolescents aged 12-17 
years were also asked for consent for linkage to care as in adults, and parents provided consent for 
children aged 0-11 years. 
 
Procedures with illiterate participants, or participants with a sight disability, involved the use of an 
impartial witness, chosen by the potential participant, who also signed or made a mark on the consent 
form on the tablet and the printed copy. If no witness could be identified, the potential participant or 
household (if the head of household was sight disabled or illiterate) was deemed ineligible. 
 
2.3 Survey Implementation 
 
Training of Field and Laboratory Staff  
Survey staff received training on both the contents of the data collection instruments and tablet use. 
The training curriculum included: 
▪ Scientific objectives of the survey 
▪ Survey design and methods 
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▪ Completion of survey forms 
▪ Data collection and security 
▪ Staff responsibilities 
▪ Recruitment of participants 
▪ Informed consent procedures, including human participants’ protection, privacy, and confidentiality 
▪ Blood collection for children and adults, including venipuncture and finger/heel stick 
▪ HBTC  
▪ CD4 count measurement using the POC Pima™ Analyzer 
▪ Referral of participants to health and social services 
▪ Consent for active linkage to care 
▪ Management and transportation of blood specimens 
▪ Biosafety 
▪ Communication skills 
▪ Protocol deviations, adverse events, and reporting of events  
 
Laboratory staff were trained in specimen management, including sample processing, labeling, and 
quality assurance (QA). Central laboratory staff were trained in VL measurement, early infant diagnosis, 
HIV confirmatory testing, and HIV recency testing using a limiting antigen (LAg) avidity enzyme 
immunoassay (EIA).  
 
Survey Staff 
Fieldwork started at the end of November 2016 and was completed in May 2017. Fieldwork was 
conducted by 24 locally hired field teams composed of a team leader, four nurse interviewers, two 
additional interviewers, and a driver. A total of 256 field staff including field coordinators, team leaders, 
nurses, interviewers, community-mobilization coordinators and community mobilizers, and drivers 
participated in data collection. Survey personnel were selected based on their qualifications and areas of 
expertise. Each field team was supervised by a team leader, and all teams were overseen by four 
regional coordinators, who guided and oversaw data collection activities, performed quality checks, and 
provided technical support (Appendix D). 
 
In addition, seven laboratory technicians processed samples and performed additional procedures for 
HIV-1 VL, infant virological HIV testing, and quality control (QC) and QA. National and international 
monitors periodically conducted direct observation of data collection activities in the field and in the 
laboratories to provide technical support and ensure quality. 
 
Community Sensitization and Mobilization 
Community mobilization was conducted prior to data collection to maximize community support and 
participation in the survey. The mobilization began before fieldwork commenced with a high-level 
national launch meeting under the leadership of Her Majesty the Queen Masenate Seeiso that included 
key national and district leaders, mass media, and other stakeholders. Additionally, a high-level 
advocacy session was held with all the Principal Chiefs of Lesotho. Community mobilization teams 
visited each EA prior to initiation of data collection and partnered with health surveillance assistants to 
meet key gatekeepers in the communities (chiefs, local government officials, and religious and 
community leaders). The mobilization teams held community sensitization meetings; disseminated 
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written informational materials, such as brochures and posters; and held discussions with selected 
households and other community residents.  
 
Supervision 
Data-collection teams were continuously overseen by field-based supervisors, and periodically 
monitored by national and international teams, with representation from collaborating institutions. 
Monitoring teams visited field and laboratory sites at least monthly, and provided direct supervision as 
well as verification of results by household revisits. Daily monitoring forms for household and individual 
outcome tracking were also reviewed by monitors for completeness. Field-based supervisors also 
supported teams by organizing supplies and transport of blood samples, coordinating community-
mobilization efforts, providing technical troubleshooting, and checking the quality of household 
procedures and data collected.  
 
The national and international monitoring teams observed and assessed the quality of survey 
procedures, including adherence to protocol and standard operating procedures, and identified and 
responded to challenges with data collection. Regular debriefing sessions were held between field-
based supervisors and monitoring teams. Monitoring reports were circulated to collaborating 
institutions and the LePHIA Technical Working Group to respond to any issues. 
 
Electronic Monitoring System 
An electronic dashboard system was established to monitor the progression of the survey. The 
dashboard summarized data uploaded to the PHIA server daily. The dashboard tracked coverage and 
completion of EAs, sampled households, household response rates (RRs), eligible household members 
providing consent to the interview, biomarker components of the survey, blood draws, individual RRs, 
and overall progress towards the achievement of the target sample.  
 
Questionnaire Data Collection 
Questionnaire and field laboratory data were collected on mobile tablet devices using an application 
programmed in Open Data Kit, an open-source mobile data collection application. The household 
interview collected information on household residents, assets, and economic support (see Appendix E). 
The adult interview was administered to participants above 15 years of age and included modules on 
demographic characteristics, sexual and reproductive health, marriage, migration, male circumcision, 
sexual activity, HIV/AIDS knowledge and attitudes, HIV testing and treatment history, TB, and gender 
norms (see Appendix F). Participants who reported awareness of their HIV-positive status were asked 
questions about their HIV care experience. Parents also answered questions about their children’s (ages 
0-14 years) health and participation in HIV services as a part of the adult interview. In each household, 
one female participant among those aged 13-59 years was also randomly selected to answer questions 
about her experiences with violence. Participants of any age who reported having experienced violence 
and minors who reported having experienced sexual exploitation were provided with referrals to social 
services. Female participants were interviewed by staff that were women, and male participants by staff 
that were men, whenever possible. The questionnaire was administered in the two languages most 
commonly used in Lesotho. The English and Sesotho versions of the questionnaires were reviewed and 
tested thoroughly for acceptability, feasibility, and flow of questions. 
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2.4 Field-Based Biomarker Testing 
 
Blood Collection 
Blood was collected by qualified survey staff from consenting participants: 14 mL of venous blood from 
adults above 15 years of age, and 6 mL of venous blood from children aged 2-14 years, and 1 mL of 
capillary blood from children aged 0-23 months (using finger-stick for children aged 6-23 months and 
heel-stick for infants below 6 months of age). Finger-stick capillary blood collection was also performed 
on children aged 2 years and older who refused or failed venous draw. 
 
Blood samples were labeled with a unique pre-printed bar-coded participant identification number and 
stored in temperature-controlled cooler boxes. At the end of each day, samples were transported to a 
satellite laboratory for processing into plasma aliquots and dried blood spots (DBS), and were frozen 
within 24 hours of blood collection. 
 
HIV Home-Based Testing and Counseling 
HIV HBTC was conducted in each household in accordance with national guidelines (Figure 2.4.A).2 As 
per these guidelines, the survey used a sequential rapid-testing algorithm in the field: Determine™ HIV-
1/2 (Abbott Molecular Inc., Des Plaines, Illinois, United States) as a screening test, and Uni-Gold™ 
(Trinity Biotech, plc., Wicklow, Ireland) as a confirmatory test. Individuals with a non-reactive result on 
the screening test were reported as HIV negative. Individuals with a reactive screening test underwent 
confirmatory testing. Those with reactive results on both the screening and confirmatory tests were 
classified as HIV positive. Individuals with a reactive screening test result, followed by a non-reactive 
confirmatory test result, were retested in parallel. If the results were repeatedly discordant, the 
individual was classified as indeterminate. 
 
HIV-seropositive participants were referred to HIV care and treatment services at a health facility of 
their choice, and were consented for contact for active linkage to care. For children below 12 years of 
age, results were returned to a parent or guardian. Participants with indeterminate results were advised 
to attend a facility in two weeks for repeat testing, as per national guidelines.  
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Figure 2.4.A Household-based HIV testing algorithm, ages 18 months and older, LePHIA 2016-2017 
 
 
 
 
 
 
 
For children less than the age of 18 months, only the screening test (Determine) was performed in the 
field. If the test was reactive, HIV total nucleic acid (TNA) polymerase chain reaction (PCR) for virologic 
testing of HIV infection was performed in the reference laboratory, as described below (Section 2.5). 
 
For participants who reported awareness of their HIV-positive status, but tested HIV negative at the 
time of the survey, additional laboratory-based testing was conducted using HIV DNA PCR for 
confirmation of the status. In conjunction with the MOH, survey staff revisited these participants and 
health providers to provide counseling and guidance on next steps to confirm these results, particularly 
for those on ART.  
 
On a weekly basis, QC was performed by field staff performing HIV testing using a panel of positive and 
negative dried tube specimens. In addition, QA proficiency testing was conducted twice in the course of 
the survey, using a panel of masked HIV-positive and negative dried tube specimens. Proficiency in the 
correct performance and interpretation of the HIV testing algorithm was assessed for each tester.   
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CD4+ T-Cell Count Measurement 
All participants who tested HIV positive during HBTC, and a random sample of 2.0% of those who tested 
HIV negative, received a CD4 count measurement in the field by qualified survey staff. The 
measurement was performed using the Pima™ CD4 Analyzer (Abbott Molecular Inc., Chicago, Illinois, 
United States, formerly Alere). 
 
2.5 Laboratory-Based Biomarker Testing 
 
Satellite and Central Laboratories 
Three satellite laboratories for the survey were established in existing health facility laboratories, and 
two mobile laboratories were utilized during implementation. The Lesotho National Reference 
Laboratory was used for more specialized tests. At each satellite and mobile laboratory, trained 
technicians performed processing of whole blood specimens into plasma aliquots and DBS cards for 
storage at -20°C, testing for QA, and HIV confirmatory testing. For QA of the HIV rapid testing conducted 
in the field, the first 50 samples tested by each field tester, and subsequently all indeterminate, and a 
random sample of 5.0% of specimens that tested HIV negative during HBTC, were retested in the 
laboratory using the national HIV rapid-testing algorithm. All specimens that tested HIV positive during 
HBTC, and those that had confirmed positive or indeterminate rapid test results during QA, underwent 
confirmatory testing using the Geenius HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, California, 
United States). A positive Geenius result defined HIV-positive status. Central laboratory procedures 
included HIV VL testing; HIV DNA PCR for infant virologic testing and for confirmation of status of those 
who reported awareness of their HIV-positive status, but tested negative in HBTC; HIV recency testing; 
and long-term storage of samples at -80°C. 
 
The survey conducted household revisits for investigation of discrepancies between the results of 
testing in the field and in the laboratory. The specimens collected during the revisit underwent 
comprehensive retesting in the laboratory. For each case, an analysis of the nature of the discrepancy, 
and potential sources of error, was performed to confirm the definitive HIV status for analytical 
purposes. 
 
Viral Load Testing 
The HIV-1 VL (HIV RNA copies per mL) of confirmed HIV-positive participants was measured using the 
Roche platform (Roche Diagnostics, Indianapolis, Indiana, United States), the COBAS AmpliPrep (which 
carries out automated extraction, purification, and preparation of HIV-1 RNA), and the TaqMan analyzer 
(which amplifies and quantifies the HIV-1 RNA load). For plasma, the 1.0 mL protocol was used, while 
DBS samples were referred to the National Institute for Communicable Disease in South Africa for VL 
measurement, using the Abbott Real Time HIV-1 assay (Abbott Molecular Inc., Chicago, Illinois, United 
States). 
 
VL results were returned within six to 12 weeks to the health facility chosen by each HIV-positive 
participant. Participants were provided with a referral form during HBTC for subsequent retrieval of 
their results. Survey staff also contacted each participant via Short Message Service (SMS), informing 
them that their VL results were available at the chosen facility and further advising them to seek care 
and treatment. 
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Infant HIV Virologic Testing 
For infants below 18 months of age who had a reactive test for HIV during HBTC, virologic testing was 
conducted via HIV TNA PCR using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative Test (Roche 
Molecular Systems, Branchburg, NJ, USA). Positive virological results were returned directly to the 
child’s parents either by phone call or home visit and negative results to the health facility selected by 
the child’s parent or guardian within eight weeks. Survey staff also contacted the parent or guardian via 
SMS to inform them that the child’s results were available at the facility. 
 
HIV Recent Infection Testing Algorithm 
To distinguish recent from long-term HIV infections, in order to estimate incidence, the survey used two 
different laboratory-based testing algorithms. Each algorithm employed a combination of assays: 1) HIV-
1 LAg-Avidity EIA (Sedia Biosciences Corporation, Portland, Oregon, United States) and VL (Figure 2.5.A) 
and 2) HIV-1 LAg Avidity EIA, VL, and ARV detection (Figure 2.5.B), as described in Appendix B. 
 
Specimens with median normalized optical density (ODn) ≤ 1.5 were classified as potential recent 
infections and their VL results were assessed. Specimens with VL < 1,000 copies/mL were classified as 
long-term infections, while those with VL ≥ 1,000 copies/mL were classified as recent infections (Figure 
2.5.A). In the ARV-adjusted algorithm, specimens with VL ≥ 1,000 copies/mL and with detectable ARVs 
were classified as long-term infections. Specimens with VL ≥ 1,000 copies/mL and without detectable 
ARVs were classified as recent infections. 
 
Figure 2.5.A HIV-1 recent infection testing algorithm (LAg/VL algorithm), ages 18 months and older, 
LePHIA 2016-2017  
 
1ODn: normalized optical density; 2mL: milliliter 
HIV-1 Seropositive Specimens
HIV-1 Limiting Antigen (LAg) Avidity test in Singlet 
(initial)
ODn1 >2.0
Long-term HIV 
Infection
ODn <2.0
Repeat LAg Avidity Test in 
Triplicate (confirmatory)
Median ODn >1.5
Long-term HIV 
Infection
Median ODn <1.5
HIV Viral Load <1000 
copies/mL2
Long-term HIV 
Infection
HIV Viral Load >1000 
copies/mL
Recent HIV 
Infection
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Figure 2.5.B HIV-1 recent infection testing algorithm (LAg/VL/ARV algorithm), ages 18 months and 
older, LePHIA 2016-2017 
 
 
1ODn: normalized optical density; 2mL: milliliter 
 
Detection of Antiretroviral Drug Resistance   
HIV resistance to ARVs was assessed for all those HIV-positive participants aged 18 months and older 
classified as recent HIV infections and a small subset of confirmed long-term infections. In addition, all 
infants below 18 months of age with confirmed infection were evaluated to determine vertical 
transmission of ARV-resistant HIV. Mutations in the HIV protease and reverse transcriptase genes that 
confer ARV drug resistance (according to the Stanford drug resistance database) were detected 
simultaneously by use of the CDC broadly sensitive in-house genotyping drug resistance assay. 
 
Specimens were sent to CDC in the United States where testing was performed at the International 
Laboratory Branch, a World Health Organization (WHO) designated Specialized Drug Resistance 
Laboratory for drug resistance testing.   
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Detection of Antiretrovirals  
Qualitative screening, for detectable concentrations of ARVs, was conducted on DBS specimens from all 
HIV-positive adults and children by means of high-resolution liquid chromatography coupled with 
tandem mass spectrometry. The method used for ARV detection was a modified version of the 
methodology described by Koal et al.3 This qualitative assay was highly specific, as it separates the 
parent compound from the fragments, and highly sensitive, with a limit of detection of 0.02 μg/mL for 
each drug, and a signal-to-noise ratio of at least 5:1 for all drugs. As detection of all ARVs in use at the 
time of the survey was cost-prohibitive, three ARVs were selected as markers for the most commonly 
prescribed first- and second-line regimens: efavirenz, nevirapine, and lopinavir. These ARVs were also 
selected based on their relatively long half-lives, allowing for a longer period of detection following 
intake.  
 
Detection of ARVs is considered indicative of participant use of a given drug at the time of blood 
collection. Results below the limit of detection among individuals who self-reported ART use indicate 
that there was no recent exposure to the regimen and that adherence to a prescribed regimen was sub-
optimal, but cannot be interpreted as “not on ART.” In addition, given the limited number of ARVs 
selected for detection, their absence could not rule out the use of other ART regimes that do not include 
them.   
 
ARV detection was performed by the Division of Clinical Pharmacology of the Department of Medicine at 
the University of Cape Town in South Africa. 
 
2.6 Data Processing and Analysis 
All field data were collected on tablets, transmitted to a central server using a secure virtual private 
network, and stored in a secure PostgreSQL database. Data cleaning was conducted using SAS 9.4 (SAS 
Institute Inc. Cary, North Carolina, United States). Laboratory data were cleaned and merged with the 
final questionnaire database using unique specimen bar codes and study identification numbers. 
 
All results presented in the report are based on weighted estimates unless otherwise noted. Analysis 
weights account for sample selection probabilities and are adjusted for nonresponse and noncoverage. 
Nonresponse adjusted weights were calculated for households, individual interviews, and individual 
blood draws in a hierarchical form. Adjustment for nonresponse for initial individual and blood-level 
weights was based on the development of weighting adjustment cells defined by a combination of 
variables that are potential predictors of response and HIV status. The nonresponse adjustment cells 
were constructed using the Chi-square Automatic Interaction Detector algorithm. The cells were defined 
based on data from the household interview for the adjustment of individual-level weights, and from 
both the household and individual interviews for the adjustment of blood sample-level weights. Post-
stratification adjustments were implemented to compensate for noncoverage in the sampling process. 
This final adjustment calibrated the nonresponse-adjusted individual and blood weights to make the 
sum of each set of weights conform to national population totals by sex and five-year age groups. 
 
Descriptive analyses of RRs, respondent characteristics, HIV prevalence, CD4 count distribution, HIV 
testing, self-reported HIV status, self-reported ART, VLS, prevention of mother-to-child transmission of 
HIV (PMTCT) indicators, and sexual behavior were conducted using SAS 9.4. 
 
Incidence estimates were based on the number of HIV infections identified as recent with the HIV-1 LAg 
Avidity plus VL algorithm, and obtained using the formula recommended by the WHO Incidence Working 
Group and Consortium for Evaluation and Performance of Incidence Assays, and with assay performance 
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characteristics of a mean duration of recent infection (MDRI)=130 days (95% CI: 118, 142), a time cutoff 
(T) = 1.0 year and proportion false recent (PFR) = 0.00. 
 
2.7 Response Rates 
Household RRs were calculated using the American Association for Public Opinion Research Response 
Rate 4 method as the number of complete and incomplete household interviews among all eligible 
households and those estimated to be eligible among those with unknown eligibility (households not 
located, not attempted, or unreachable).4 Vacant and destroyed households, not residential units, and 
household units with no eligible respondents were considered not eligible and excluded from the 
calculation.  
 
Individual interview RR were calculated as the number of individuals who were interviewed divided by 
the number of individuals eligible to participate in the survey. Blood draw RR for adults were calculated 
as the number of individuals who provided blood divided by the number of individuals who were 
interviewed. Blood draw RR for children were calculated as the number of individuals who provided 
blood divided by the number of individuals eligible to participate in the survey. 
 
Of the 10,892 selected households, 9,403 and 8,824 were occupied and interviewed, respectively. The 
overall household RR (unweighted) was 93.2% (91.2% and 91.4% in urban and peri-urban areas, 
respectively, and 94.9% in rural areas). After adjusting for differential sampling probabilities and 
nonresponse, the overall weighted household RR was 93.0% (Table 2.7.A). 
 
A total of 14,028 adults (6,135 men and 7,893 women) were eligible to participate in the survey. A total 
of 12,887 adults participated in the individual interview: interview RR (weighted) were 86.8% for men 
and 95.1% for women. Among those adults who were interviewed, 88.2% of men and 91.3% of women 
also had their blood drawn (weighted, Table 2.7.B). 
 
In LePHIA, children in half of the selected households were eligible for blood draw. Of the 3,118 eligible 
children aged 0-9 years, 77.6% of boys and 78.7% of girls had their blood drawn (weighted). Of the 1,752 
eligible young adolescents aged 10-14 years, 88.1% of young adolescent boys and 89.7% of young 
adolescent girls completed interviews and of those, 94.1% of young adolescent boys and 94.8% of young 
adolescent girls had their blood drawn (weighted, Table 2.7.B).  
 
Table 2.7.A Household response rates 
Number of households selected, occupied, and interviewed and household response rates (unweighted and weighted), by residence, LePHIA 
2016-2017  
Residence Total 
Result Urban Peri-urban Rural 
     
Household interviews 
    
Households selected 4,072 737 6,083 10,892 
Households occupied 3,646 638 5,119 9,403 
Households interviewed 3,344 589 4,891 8,824      
Household response rate1 (unweighted) 91.2 91.4 94.9 93.2 
Household response rate1 (weighted) 91.1 90.6 94.8 93.0 
1Household response rate was calculated using the American Association for Public Opinion Research (AAPOR) Response Rate 4 (RR4) 
method: https://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf. 
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Table 2.7.B Interview and blood draw response rates 
Number of eligible individuals and response rates for individual interviews1 and blood draws2 (unweighted and weighted), by residence and sex, 
LePHIA 2016-2017 
 Residence    
 Urban   Peri-urban  Rural  Total 
Result Male Female   Male Female   Male Female   Male Female 
Eligible individuals, ages 0-9 years            
Number of eligible individuals 465 452  84 104  1,028 985  1,577 1,541 
Blood draw response rate (unweighted) 71.4 68.8  76.2 76.9  82.4 85.7  78.8 80.1 
Blood draw response rate (weighted) 69.6 67.1  76.7 77.3  81.8 84.9  77.6 78.7 
            
Eligible individuals, ages 10-14 years            
Number of eligible individuals 232 250  70 57  602 541  904 848 
Interview response rate (unweighted) 90.9 88.8  87.1 89.5  88.0 91.1  88.7 90.3 
Interview response rate (weighted) 90.4 87.9  87.1 88.9  87.2 90.8  88.1 89.7 
Blood draw response rate (unweighted) 91.0 91.9  90.2 98.0  96.8 96.1  94.8 95.0 
Blood draw response rate (weighted) 90.1 91.8  90.2 98.2  96.4 95.9  94.1 94.8 
            
Eligible individuals, ages 15-24 years            
Number of eligible individuals 700 1,080  183 196  1,276 1,432  2,159 2,708 
Interview response rate (unweighted) 89.6 93.3  89.1 95.4  85.1 94.2  86.9 93.9 
Interview response rate (weighted) 89.0 93.0  86.9 95.3  84.6 94.3  86.3 93.8 
Blood draw response rate (unweighted) 87.7 91.7  87.1 88.2  91.9 94.1  90.1 92.7 
Blood draw response rate (weighted) 87.1 91.5  85.1 88.1  91.5 93.7  89.4 92.3 
            
Eligible individuals, ages 15-49 years            
Number of eligible individuals 2,111 2,926  401 470  2,961 3,475  5,473 6,871 
Interview response rate (unweighted) 86.6 94.1  84.0 96.4  87.3 95.8  86.8 95.1 
Interview response rate (weighted) 86.2 93.8  82.4 96.5  86.8 95.7  86.2 94.9 
Blood draw response rate (unweighted) 84.3 89.1  87.8 88.3  91.3 94.2  88.4 91.6 
Blood draw response rate (weighted) 83.8 88.8  86.0 86.9  91.2 93.7  87.8 91.0 
            
Eligible individuals, ages 15-59 years            
Number of eligible individuals 2,318 3,253  439 531  3,378 4,109  6,135 7,893 
Interview response rate (unweighted) 87.1 94.3  84.5 96.0  88.0 96.1  87.4 95.4 
Interview response rate (weighted) 86.6 93.9  83.0 96.3  87.5 96.0  86.8 95.1 
Blood draw response rate (unweighted) 84.6 89.0  88.4 88.8  91.7 94.7  88.8 91.9 
Blood draw response rate (weighted) 84.2 88.7  86.7 87.5  91.5 94.2  88.2 91.3 
1Interview response rate = number of individuals interviewed/number of eligible individuals 
2Blood draw response rate = number of individuals who provided blood/number of individuals interviewed 
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Chapter 3    Survey Household Characteristics 
3.1 Key Findings 
 
 
3.2 Background 
This chapter describes the characteristics of households surveyed in LePHIA. Household composition is 
described in terms of sex of the head of household and the size of the household. The age structure of 
the de facto household population is described by sex as well as area of residence. This chapter also 
describes the prevalence and composition of households impacted by HIV, which are households with 
one or more HIV-positive members. 
 
3.3 Household Composition 
In Lesotho, fifty-two percent (51.8%) of households reported having a female head and 48.2% reported 
having a male head. This distribution was similar for urban, peri-urban, and rural areas. The median 
household size was three members in all areas. The interquartile range (IQR) was two to five for the 
country as a whole, and in peri-urban and rural areas, but was slightly smaller in urban areas (IQR 1-4). 
The median number of children and adolescents below the age of 18 years in households was one in all 
areas, with an IQR of zero to two in urban and peri-urban areas, and was slightly larger in rural areas 
(IQR 0-3) (Table 3.3.A). 
 
The most populous age group in Lesotho was those aged 15-49 years, who comprised 47% of the de 
facto household population, whereas children (those aged 0-14 years) comprised 35.9% and adults aged 
50 years and older constituted 17.1% (6.6% men and 10.5% women; Figure 3.3.A; Table 3.3.B). The 
overall sex ratio was 84 male participants for every 100 female participants, with more boys than girls 
(103:100) aged 0-4 years, but a rapid decline in ratio to 86:100 in older adolescents (those aged 15-19 
years), followed by relative stability in adults aged 20-49 years (with overall mean of 79:100), and 
further reductions in adults above 50 years of age (with overall mean of 63:100). 
 
Overall, there were more children (less than the age of 15 years) and older adults (aged 50 years and 
older) in the de facto population in rural areas than in urban areas and peri-urban areas.  Among the 
rural population, 39.3% were children compared with 30.7% of the urban population and 34.5% of the 
peri-urban population (Table 3.3.C). Twenty percent (19.9%) of the rural de facto population was above 
50 years of age, in contrast to 15.7% in peri-urban and 13.0% in urban areas. The relative share of men 
and women aged 15-49 years in rural areas was similar (40.8% and 40.7%, respectively) as in peri-urban 
areas (50.8% and 49.0%, respectively) but larger for women compared to men in urban areas (58.4% vs. 
53.6%).  
▪ In Lesotho, more than half of households are female-headed.  
▪ About one-fifth (19.9%) of the population in rural areas is aged 50 years or more, compared to 
15.7% in peri-urban and 13.0% in urban areas. 
▪ Among female household heads, 41.1% were HIV-positive, as compared to 30.0% of male 
household heads. 
▪ Of all households, 37.6% had at least one HIV-positive member. 
 
3 SURVEY HOUSEHOLD CHARACTERISTICS 
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Table 3.3.A Household composition 
Percent distribution of households by sex of head of household; median (Q1, Q3) size of household and median (Q1, Q3) number of children 
under the age of 18 years, by residence, LePHIA 2016-2017  
Residence 
   
Characteristic Urban 
 
Peri-urban 
 
Rural 
 
Total 
Head of household 
           
Male  48.6 1,617 
 
47.2 283 
 
48.1 2,317 
 
48.2 4,217 
Female 51.4 1,727 
 
52.8 306 
 
51.9 2,574 
 
51.8 4,607 
            
Total 100.0 3,344 
 
100.0 589 
 
100.0 4,891 
 
100.0 8,824 
 
Residence 
   
 
Urban 
 
Peri-urban 
 
Rural 
 
Total 
Characteristic Median Q1, Q3 
 
Median Q1, Q3 
 
Median Q1, Q3 
 
Median Q1, Q3 
Size of households 3 (1, 4) 
 
3 (2, 5) 
 
3 (2, 5) 
 
3 (2, 5) 
Number of children under 18 years of age 1 (0, 2) 
 
1 (0, 2) 
 
1 (0, 3) 
 
1 (0, 2) 
 
Table 3.3.B Distribution of de facto household population by age and sex 
Percent distribution of the de facto household population, by five-year age groups and sex, LePHIA  
2016-2017  
Male 
 
Female 
 
Total 
Age Percent Number 
 
Percent Number 
 
Percent Number 
0-4 5.8 1,574 
 
5.6 1,536 
 
11.4 3,110 
5-9 6.0 1,652 
 
5.9 1,658 
 
11.9 3,310 
10-14 6.3 1,738 
 
6.3 1,744 
 
12.6 3,482 
15-19 4.3 1,173 
 
5.0 1,360 
 
9.4 2,533 
20-24 3.9 1,014 
 
5.2 1,363 
 
9.0 2,377 
25-29 3.7 976 
 
4.6 1,217 
 
8.4 2,193 
30-34 3.1 823 
 
3.9 1,007 
 
7.0 1,830 
35-39 2.6 668 
 
3.0 804 
 
5.6 1,472 
40-44 1.9 492 
 
2.5 655 
 
4.4 1,147 
45-49 1.5 389 
 
1.8 494 
 
3.3 883 
50-54 1.2 316 
 
1.9 509 
 
3.0 825 
55-59 1.3 346 
 
1.8 514 
 
3.1 860 
60-64 1.4 376 
 
1.9 538 
 
3.3 914 
65-69 1.0 289 
 
1.4 401 
 
2.5 690 
70-74 0.8 217 
 
1.3 353 
 
2.0 570 
75-79 0.6 153 
 
0.9 253 
 
1.4 406 
≥80 0.5 144 
 
1.3 366 
 
1.8 510 
         
Total 45.6 12,340 
 
54.4 14,772 
 
100.0 27,112 
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Table 3.3.C De facto household population by age, sex, and residence  
Percent distribution of the household population, by sex, age, and residence, LePHIA 2016-2017 
 Urban 
 Male  Female  Total 
Age Percent Number  Percent Number  Percent Number 
0-4 12.5 504  9.6 492  10.9 996 
5-14 22.4 921  17.8 926  19.8 1,847 
15-49 53.6 2,125  58.4 2,940  56.3 5,065 
≥50 11.5 473  14.2 745  13.0 1,218          
Total 100.0 4,023  100.0 5,103  100.0 9,126 
 Peri-urban 
 Male 
 
Female 
 
Total 
Age Percent Number 
 
Percent Number 
 
Percent Number 
0-4 11.5 95 
 
10.3 101 
 
10.8 196 
5-14 25.3 213 
 
22.4 225 
 
23.7 438 
15-49 50.8 404 
 
49.0 472 
 
49.8 876 
≥50 12.4 107 
 
18.3 187 
 
15.7 294 
 
        
Total 100.0 819 
 
100.0 985 
 
100.0 1,804 
 Rural 
 Male  Female  Total 
Age Percent Number  Percent Number  Percent Number 
0-4 12.9 975  10.7 943  11.7 1,918 
5-14 29.6 2,256  25.8 2,251  27.6 4,507 
15-49 40.8 3,006  40.7 3,488  40.8 6,494 
≥50 16.7 1,261  22.8 2,002  19.9 3,263          
Total 100.0 7,498  100.0 8,684  100.0 16,182 
 
 
 
Figure 3.3.A Distribution of the de facto population by sex and age, LePHIA 2016-2017 
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Figure 3.3.B Household population by age, sex, and residence, LePHIA 2016-2017 
 
 
3.4 Prevalence of HIV-Affected Households 
In Lesotho, 37.6% of all households had at least one HIV-positive member (Table 3.4.A). Among these 
HIV-affected households, 80.5% had only one HIV-positive member, whereas 17.7% had two HIV-
positive members, with the remaining 1.8% having three or more HIV-positive members (Table 3.4.B). 
The distribution was similar for urban, peri-urban, and rural households. 
 
Overall, 36.0% of households in the country had an HIV-positive head of household. Forty-one percent 
(41.1%) of female-headed households, compared to 30.0% of male-headed households, had the head of 
household affected by HIV (Table 3.4.C). 
 
Table 3.4.A Prevalence of HIV-affected households 
Percentage of households with at least one HIV-positive household member, by residence, LePHIA 2016-2017 
Residence Percent  Number 
Urban 38.7 2,782 
Peri-urban 34.5 477 
Rural 37.1 4,013    
Total 37.6 7272 
 
Table 3.4.B HIV-affected households by number of HIV-positive members 
Among households with at least one HIV-positive household member, percent distribution of households by number of HIV-positive 
household members, by residence, LePHIA 2016-2017  
Residence 
   
Number of HIV-positive 
 household members 
Urban  Peri-urban  Rural 
 
Total 
Percent  Number  Percent Number  Percent Number 
 
Percent Number 
1 78.5 836 
 
80.5 138 
 
82.1 1,217 
 
80.5 2,191 
2 19.7 208 
 
(18.5) 27 
 
16.0 236 
 
17.7 471 
3 * 18 
 
* 2 
 
(1.7) 26 
 
(1.7) 46 
4 * 1 
 
* 0 
 
* 2 
 
* 3 
5 * 0 
 
* 0 
 
* 0 
 
* 0 
≥6 * 0 
 
* 0 
 
* 0 
 
* 0             
Total 100.0 1,063 
 
100.0 167 
 
100.0 1,481 
 
100.0 2,711 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 3.4.C Prevalence of households with an HIV-positive head of household 
Percentage of households with an HIV-positive head of household, by sex of head of household, LePHIA 2016-2017 
Sex of head of household Percent  Number 
Male 30.0 2,416 
Female 41.1 2,852    
Total 36.0 5,268 
 
Figure 3.4.A Prevalence of HIV-affected households by residence, LePHIA 2016-2017 
 
 
Figure 3.4.B HIV-affected households by number of HIV-positive members and residence, LePHIA 
2016-2017 
 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
Estimates with an asterisk are based on a very small number (less than 25) of unweighted cases and have been suppressed. 
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Figure 3.4.C Prevalence of households with an HIV-positive head of household by sex, LePHIA 
2016-2017 
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Chapter 4    Survey Respondent Characteristics 
4.1 Key Findings 
 
 
4.2 Background 
LePHIA assessed key indicators and outcomes for children (those aged 0-14 years), adolescents, and 
adults. To provide context for these outcomes, this chapter summarizes the basic demographic and 
socioeconomic characteristics of survey respondents. In this report, most key indicators are stratified 
according to these characteristics. 
 
4.3 Demographic Characteristics of the Adult Population 
The population of Lesotho was fairly evenly distributed between rural and urban areas; 50.6% of adults 
lived in rural areas while 41.7% and 7.8% resided in urban and peri-urban areas, respectively (Table 
4.3.A). The vast majority resided in the lowlands of the country (69.3%). Almost a third of the 
respondents (32.0%) lived in the district of Maseru, and another 45.8% resided in districts along 
Lesotho’s western border with South Africa (Leribe, Berea, Mafeteng, and Mohale’s Hoek).  
 
Over half of the women (51.4%) were married or living with a partner, while only 43.9% of men were 
married or living with a partner. Near half of men (47.0%) had never been in a conjugal union compared 
to less than one-third among women (31.1%). While 6.3% of all respondents were currently divorced or 
separated, women were almost four times as likely to be widowed compared to men (11.0% vs. 3.1%, 
respectively). 
 
Ninety-five percent of all respondents had some formal schooling but, in general, women had more 
formal education. Among women, only 1.5% had never attended school compared to 8.6% of men. 
Approximately 40% of men and women had received primary education, while 40.5% of men and 49.0% 
of women had attended secondary schools. More than one in ten men and women had attended 
tertiary (any schooling after secondary school, including college, university and graduate education) 
institutions. 
 
Most respondents professed their religion as one of many Christian denominations with a predominant 
share being Catholic (40.7%), Lesotho Evangelical (18.1%), and with 8.3% identifying as Pentecostal and 
7.0% as Anglican (Table 4.3.A). Seven percent (7.0%) identified themselves as another, non-Christian, 
religion. 
 
4 SURVEY RESPONDENT CHARACTERISTICS 
▪ Over three-quarters of the adult population (those aged 15-59 years) resided in the lowland and 
foothill districts on Lesotho’s northwestern border with South Africa, with nearly one-third living in 
Maseru (32.0%). 
▪ Overall 95.0% of adult respondents had attended school and school attainment was higher among 
women relative to men; 49.0% of women reported having attended secondary school compared 
to 40.5% of men. 
▪ Almost four times as many women (11.0%) were widowed as men (3.1%). 
▪ Almost all (97.5%) young adolescents (those aged 10-14 years) were currently attending school. 
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Table 4.3.A Demographic characteristics of the older adolescent and adult population 
Percent distribution of the population aged 15-59 years, by sex and selected demographic characteristics, LePHIA 2016-2017 
 
Male 
 
Female 
 
Total 
Characteristic Percent Number   Percent Number   Percent Number 
Residence 
        
Urban 40.1 2,019 
 
43.2 3,067 
 
41.7 5,086 
Peri-urban 7.6 371 
 
7.9 510 
 
7.8 881 
Rural 52.2 2,971 
 
48.9 3,949 
 
50.6 6,920 
Ecological zone 
        
Lowlands 69.2 3,450 
 
69.5 4,852 
 
69.3 8,302 
Foothills 9.0 503 
 
7.7 611 
 
8.3 1,114 
Mountains 16.2 1,000 
 
16.7 1,459 
 
16.5 2,459 
Senqu River Valley 5.6 408 
 
6.1 604 
 
5.9 1,012 
District 
        
Maseru 32.7 1,430 
 
31.3 1,907 
 
32.0 3,337 
Mafeteng 8.2 528 
 
8.6 735 
 
8.4 1,263 
Mohale's Hoek 5.5 376 
 
6.0 587 
 
5.7 963 
Leribe 17.6 886 
 
17.1 1,242 
 
17.4 2,128 
Berea 14.1 688 
 
14.4 985 
 
14.3 1,673 
Quthing 3.7 275 
 
4.3 415 
 
4.0 690 
Butha Buthe  5.6 361 
 
5.1 456 
 
5.3 817 
Mokhotlong 4.6 289 
 
4.8 427 
 
4.7 716 
Qacha's Nek 2.4 200 
 
2.7 309 
 
2.5 509 
Thaba Tseka  5.6 328 
 
5.8 463 
 
5.7 791 
Marital status 
        
Never married / lived together 47.0 2,530 
 
31.1 2,265 
 
39.0 4,795 
Married or living together 43.9 2,288 
 
51.4 3,893 
 
47.6 6,181 
Divorced or separated 6.1 340 
 
6.5 490 
 
6.3 830 
Widowed 3.1 186 
 
11.0 870 
 
7.0 1,056 
Education 
        
No education 8.6 501 
 
1.5 121 
 
5.0 622 
Primary 40.5 2,227 
 
38.6 3,031 
 
39.5 5,258 
Secondary 40.5 2,121 
 
49.0 3,614 
 
44.7 5,735 
College / University 9.2 445 
 
9.6 665 
 
9.4 1,110 
Graduate / post-graduate  1.2 60 
 
1.4 93 
 
1.3 153 
Wealth quintile 
        
Lowest 17.4 1,054 
 
17.0 1,432 
 
17.2 2,486 
Second 19.4 1,105 
 
17.6 1,427 
 
18.5 2,532 
Middle 20.2 1,058 
 
20.0 1,483 
 
20.1 2,541 
Fourth  21.2 1,081 
 
21.1 1,515 
 
21.2 2,596 
Highest 21.7 1,050 
 
24.4 1,649 
 
23.0 2,699 
Religion 
        
Roman Catholic 42.0 2,198 
 
39.3 2,915 
 
40.7 5,113 
Lesotho Evangelical 19.5 1,020 
 
16.6 1,239 
 
18.1 2,259 
Anglican 7.3 392 
 
6.6 502 
 
7.0 894 
Pentecostal 7.2 390 
 
9.4 735 
 
8.3 1,125 
Other Christian 15.4 848 
 
20.1 1,522 
 
17.7 2,370 
Other religion 6.4 348 
 
7.6 579 
 
7.0 927 
Don't know 2.3 132 
 
(0.3) 28 
 
1.3 160 
Age 
        
15-19 17.7 1,001 
 
17.3 1,247 
 
17.5 2,248 
20-24 16.5 875 
 
16.8 1,297 
 
16.6 2,172 
25-29 16.0 827 
 
15.6 1,159 
 
15.8 1,986 
30-34 14.6 697 
 
13.5 965 
 
14.0 1,662 
35-39 11.4 573 
 
10.4 769 
 
10.9 1,342 
40-44 8.1 427 
 
8.0 625 
 
8.1 1,052 
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Table 4.3.A Demographic characteristics of the older adolescent and adult population (continued) 
Percent distribution of the population aged 15-59 years, by sex and selected demographic characteristics, LePHIA 2016-2017 
 
Male 
 
Female 
 
Total 
Characteristic Percent Number   Percent Number   Percent Number 
Age (cont.) 
        
45-49 6.1 352 
 
6.4 474 
 
6.2 826 
50-54 5.3 285 
 
6.4 490 
 
5.8 775 
55-59 4.3 324 
 
5.7 500 
 
5.0 824          
Total 15-24 34.2 1,876 
 
34.0 2,544 
 
34.1 4,420 
Total 15-49 90.4 4,752 
 
87.9 6,536 
 
89.2 11,288 
Total 15-59 100.0 5,361 
 
100.0 7,526 
 
100.0 12,887 
Note: Education categories refer to the highest level of education attended, whether or not that level was completed. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
4.4 Demographic Characteristics of the Pediatric and Young Adolescent Population 
Children younger than 10 years of age accounted for two-thirds (66.0%) of all children participating in 
the survey. Compared to adults, more children (ages 0-9 years) and young adolescents (ages 10-14 
years) resided in rural areas (50.6% vs 62.2%, respectively), and less resided in Maseru (32.0% vs. 24.8%) 
and Berea (14.3% vs 12.8%) (Tables 4.4.A and 4.4.B). One-fifth of children were found in the Mountains 
region (20.4%) and the majority lived in the Lowlands (60.9%). The distribution across the five wealth 
quintiles ranged from 15.3% in the highest wealth quintile to 24.4% in the lowest wealth quintile (Table 
4.4.B). The vast majority of young adolescents were currently attending school (97.5%) (Table 4.4.A). 
 
Table 4.4.A  Demographic characteristics of the young adolescent population 
Percent distribution of the young adolescent population aged 10-14 years, by sex and selected demographic characteristics,  
LePHIA 2016-2017 
 Male  Female  Total 
Characteristic Percent Number   Percent Number   Percent Number 
Residence         
Urban 27.8 211  30.7 222  29.2 433 
Peri-urban 8.6 61  7.7 51  8.1 112 
Rural 63.7 530  61.6 493  62.6 1,023 
         
District         
Maseru 23.6 151  27.5 165  25.5 316 
Mafeteng 9.7 87  9.1 80  9.4 167 
Mohale's Hoek 8.1 80  7.3 68  7.7 148 
Leribe 18.0 131  17.5 125  17.7 256 
Berea 13.5 98  11.6 79  12.6 177 
Quthing 5.9 56  5.4 51  5.7 107 
Butha Buthe 6.1 58  7.0 61  6.6 119 
Mokhotlong (4.9) 46  6.0 53  5.5 99 
Qacha's Nek (3.1) 38  (3.2) 38  3.2 76 
Thaba Tseka 7.0 57  (5.5) 46  6.2 103 
         
Education         
Currently attending school 96.3 770  98.7 756  97.5 1,526 
Not currently attending school (3.7) 32  * 10  (2.5) 42 
         
Total 10-14 100.0 802  100.0 766  100.0 1,568 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
  
 
40 
Table 4.4.B Demographic characteristics of the pediatric population 
Percent distribution of children aged 0-14 years, by sex and selected demographic characteristics, LePHIA 2016-2017 
 
Male 
 
Female 
 
Total 
Characteristic Percent Number   Percent Number   Percent Number 
Age 
        
0-17 months 8.4 201 
 
8.9 206 
 
8.7 407 
18-59 months 23.0 541 
 
22.3 516 
 
22.7 1,057 
5-9 years 34.5 772 
 
34.9 758 
 
34.7 1,530 
10-14 years 34.0 802 
 
33.9 766 
 
34.0 1,568          
Residence 
        
Urban 29.9 651 
 
31.0 652 
 
30.4 1,303 
Peri-urban 7.0 143 
 
7.8 151 
 
7.4 294 
Rural 63.1 1,522 
 
61.2 1,443 
 
62.2 2,965          
Ecological zone 
        
Lowlands 61.1 1,311 
 
60.6 1,248 
 
60.9 2,559 
Foothills 10.3 245 
 
10.7 244 
 
10.5 489 
Mountains 19.8 511 
 
21.0 537 
 
20.4 1,048 
Senqu River Valley 8.7 249 
 
7.7 217 
 
8.2 466          
District 
        
Maseru 24.6 461 
 
25.1 449 
 
24.8 910 
Mafeteng 9.1 234 
 
9.5 232 
 
9.3 466 
Mohale's Hoek 7.8 222 
 
7.5 204 
 
7.6 426 
Leribe 18.2 387 
 
18.2 381 
 
18.2 768 
Berea 13.4 279 
 
12.1 244 
 
12.8 523 
Quthing 5.3 150 
 
5.5 154 
 
5.4 304 
Butha Buthe  5.8 161 
 
6.2 163 
 
6.0 324 
Mokhotlong 5.4 146 
 
5.9 154 
 
5.6 300 
Qacha's Nek 3.1 106 
 
3.1 104 
 
3.1 210 
Thaba Tseka  7.2 170 
 
6.8 161 
 
7.0 331          
Wealth quintile 
        
Lowest 24.1 610 
 
24.8 607 
 
24.4 1,217 
Second 24.0 570 
 
23.9 556 
 
23.9 1,126 
Middle 20.0 445 
 
19.1 417 
 
19.5 862 
Fourth  16.9 376 
 
16.7 347 
 
16.8 723 
Highest 15.1 312 
 
15.6 310 
 
15.3 622          
Total 0-4 31.5 742 
 
31.2 722 
 
31.3 1,464 
Total 0-14 100.0 2,316 
 
100.0 2,246 
 
100.0 4,562 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
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Chapter 5    HIV Incidence 
5.1 Key Findings  
 
 
5.2 Background 
HIV prevalence is a measure of the relative burden of disease in a population, but is not optimal for 
measuring acute changes in an HIV epidemic, including changes in HIV transmission. HIV incidence is the 
measure of new HIV infections in a population over time. It can provide important information on the 
status of the HIV epidemic and can be used for effective targeted HIV prevention planning in groups that 
are most vulnerable to recent infection, and to measure the impact of HIV prevention programs. This 
chapter presents annual estimates of HIV incidence among adults at the national level. For the purposes 
of this analysis, HIV incidence is expressed as the cumulative incidence or risk of new infections in a 12-
month period, which is a close approximation to the instantaneous incidence rate. It is important to 
note that LePHIA was not powered to estimate incidence at the district level. 
 
Two laboratory-based incidence testing algorithms (HIV-1 LAg avidity plus VL and HIV-1 LAg avidity plus 
VL and ARV detection) were used to distinguish recent from long-term infection, and incidence 
estimates were obtained using the formula recommended by the WHO Incidence Working Group and 
Consortium for Evaluation and Performance of Incidence Assays, and with assay performance 
characteristics of a MDRI=130 days (95% CI: 118-142), with T=1.0 year and residual PFR=0.00 (see 
Chapter 2). Survey weights were used for all estimates. All HIV-positive participants aged 18 months and 
older were tested for recent infection using an HIV-1 LAg avidity assay. 
 
Incidence estimation was based on recent/long-term classification using algorithms with LAg avidity.1,2,3 
The original algorithm incorporated VL results to mitigate misclassification from persons who may be 
elite controllers or on ART – both groups characterized by low VL.  As ART coverage has increased, it has 
become apparent that some individuals on treatment for long periods of time have the potential to be 
misclassified by the LAg plus VL algorithm as a recent infection.  Although they may have suppressed VL 
for years, drug resistance or lack of adherence may result in VL ≥ 1000 copies/mL. Based in part on data 
from multiple PHIA surveys, the updated incidence algorithm includes ARV detection as a second 
exclusion criteria. The addition of ARV detection is expected to produce more accurate estimates of 
both HIV incidence and transmitted HIV drug resistance. 
 
  
5 HIV INCIDENCE 
▪ Annual incidence of HIV infection among adults (those aged 15-59 years) in Lesotho was 1.10%: 
1.22% among women, and 1.00% among men. This corresponds to almost 10,000 new cases of HIV 
infection annually among adults in the country in 2017. 
▪ Annual incidence was highest in men aged 35-49 years (2.65%) and in older adolescent girls and 
young women aged 15-24 years (1.49%). 
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5.3 HIV Incidence Among Adults 
 
HIV incidence estimates using LAg avidity and HIV viral load 
Using the LAg avidity assay and VL algorithm, estimated annual incidence was 1.47% (95% CI: 0.95%-
1.98%) among adults (1.22% among men and 1.74% among women), and 1.55% (95% CI: 0.99%-2.11%) 
among adults aged 15-49 years. Annual incidence peaked at 3.01% among men aged 35-49 years, and at 
2.73% among women aged 35-49 years. HIV incidence was significantly higher among young women 
aged 15-24 years at 1.81% (95% CI: 0.84%-2.77%) than among men in the same age bracket at 0.13% 
(95% CI: 0.00%-0.41%. Aside from within this age group, differences between sexes and age groups were 
not statistically significant. Note that LePHIA was not designed to compare incidence estimates across 
demographic sub-groups (Table 5.3.A). 
 
HIV incidence estimates using LAg avidity, HIV viral load, and ARV detection 
Using the LAg avidity assay, VL and ARV algorithm, estimated incidence was 1.10% (95% CI: 0.68%-
1.52%) among adults (1.00% among men and 1.22% among women). This corresponds to approximately 
9,835 new cases of HIV in Lesotho in 2017. HIV incidence for adults aged 15-49 years was estimated at 
1.19% (95% CI: 0.73%-1.65%; 1.09% among men and 1.31% among women). Annual incidence peaked 
among men aged 35-49 years (2.65%) and among young women aged 15-24 years (1.49%) (Table 5.3.B). 
 
Table 5.3.A Annual HIV incidence using LAg/VL testing algorithm 
Annual incidence of  HIV among adults aged 15-49 and 15-59 years, by sex and age, using the limiting antigen (LAg) + viral load (VL), LePHIA 
2016-2017  
Male 
 
Female 
 
Total 
Age Percentage 
annual incidence1 
95% CI 
 
Percentage 
annual incidence1 
95% CI   Percentage 
annual incidence1 
95% CI 
15-24 0.13 (0.00, 0.41) 
 
1.81 (0.84, 2.77) 
 
0.93 (0.42, 1.44) 
25-34 1.87 (0.44, 3.28) 
 
1.18 (0.16, 2.18) 
 
1.57 (0.67, 2.47) 
35-49 3.01 (0.60, 5.35) 
 
2.73 (0.87, 4.55) 
 
2.88 (1.24, 4.49) 
15-49 1.33 (0.55, 2.09) 
 
1.81 (1.12, 2.50) 
 
1.55 (0.99, 2.11) 
15-59 1.22 (0.51, 1.94) 
 
1.74 (1.11, 2.37) 
 
1.47 (0.95, 1.98) 
1Relates to Global AIDS Monitoring indicator 3.1: HIV incidence. 
 
Table 5.3.B Annual HIV incidence using LAg/VL/ARV testing algorithm 
Annual incidence of  HIV among adults aged 15-49 and 15-59 years, by sex and age, using the limiting antigen (LAg) + viral load (VL) + 
antiretrovirals (ARVs) algorithm, , LePHIA 2016-2017  
Male 
 
Female 
 
Total 
Age Percentage 
annual incidence1 
95% CI 
 
Percentage 
annual incidence1 
95% CI 
 
Percentage 
annual incidence1 
95% CI 
15-24 0.13 (0.00, 0.41) 
 
1.49 (0.58, 2.39) 
 
0.78 (0.31, 1.25) 
25-34 1.39 (0.14, 2.63) 
 
1.18 (0.16, 2.18) 
 
1.30 (0.49, 2.10) 
35-49 2.65 (0.55, 4.70) 
 
1.11 (0.00, 2.26) 
 
1.95 (0.69, 3.19) 
15-49 1.09 (0.45, 1.72) 
 
1.31 (0.73, 1.90) 
 
1.19 (0.73, 1.65) 
15-59 1.00 (0.42, 1.59) 
 
1.22 (0.69, 1.74) 
 
1.10 (0.68, 1.52) 
1Relates to Global AIDS Monitoring indicator 3.1: HIV incidence. 
 
5.4 Gaps and Unmet Needs 
▪ Incidence remains high and supports the need for a holistic approach to HIV prevention and 
treatment. Programs should be designed to use proven interventions while remaining flexible 
enough to incorporate scientific breakthroughs. 
▪ Effective interventions include combination prevention programs at the focus and scale necessary 
to stop transmission, especially among middle-aged men, adolescent girls, and young women.  
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Chapter 6    HIV Prevalence 
6.1 Key Findings  
 
 
6.2 Background 
This chapter presents representative estimates of prevalence of HIV infection among adults at the 
national and district level by selected demographic and behavioral characteristics. Additionally, this 
chapter presents an estimate of the number of HIV-positive adults living in Lesotho. HIV prevalence 
testing was conducted in each household using a serological rapid diagnostic testing algorithm based on 
Lesotho’s national guidelines, with laboratory confirmation of seropositive samples using a 
supplemental assay. Appendix A describes the sample design and Appendix C provides estimates of 
sampling errors. Appendix B describes the LePHIA HIV testing methodology. 
 
6.3 Adult HIV Prevalence by Demographic Characteristics 
Overall, HIV prevalence among adults was 25.6%: 20.8% in men and 30.4% in women. Prevalence in 
urban areas was 26.9%, compared to 24.9% in rural areas (Table 6.3.A). HIV prevalence among adults 
aged 15-49 years was 24.3%: 19.1% in men and 29.7% in women (Table 6.3.B).  
 
Among adults, HIV prevalence was 37.6% among those with no education, 20.4% among those with 
secondary school education and 13.4% among those with a tertiary education. HIV prevalence in women 
with no education was 41.7%, 25.3% among those with secondary education and 17.6% with a tertiary 
education. HIV prevalence in men with no education was 36.9%, 14.4% among those with secondary 
education and 9.1% among those with a tertiary education (Table 6.3.A). Among those who have never 
married—a group dominated by younger segments of the population—HIV prevalence was 11.2%. 
Among those who were married or living with a partner, HIV prevalence was 29.1%. In comparison, HIV 
prevalence was considerably higher (49.5%) among those who were divorced or separated and twice as 
high (58.8%) among those who were widowed compared to those who were married or living together 
(Table 6.3.A, Figure 6.3.A). 
 
HIV prevalence among women of childbearing age (ages 15-49 years) who were pregnant at the time of 
the survey, was estimated at 24.4%, compared to 29.9% among women of childbearing age who were 
not pregnant (Table 6.3.B). However, the women who were pregnant were overall younger than the 
women of childbearing age who were not. 
6 HIV PREVALENCE 
▪ Prevalence of HIV infection among adults (aged 15-59 years) in Lesotho was 25.6%: 30.4% among 
women and 20.8% among men. This corresponds to approximately 306,000 adults living with HIV 
in the country. 
▪ HIV prevalence among women aged 15-39 years was significantly higher than among men in the 
same age bracket. The greatest disparity was among those aged 20-24 years where prevalence in 
women (16.7%) was four times higher than in men (4.0%). 
▪ Prevalence in women peaks five years earlier than in men: 49.9% in women aged 35-39 years and 
46.9% in men aged 40-44 years.  
▪ The burden of HIV infection varies across the country. HIV prevalence among adults ranged from 
17.8% in Butha Buthe to 29.3% in Mohale’s Hoek.  
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Table 6.3.A HIV prevalence by demographic characteristics: Ages 15-59 years 
Prevalence of HIV among adults aged 15-59 years, by sex and selected demographic characteristics, LePHIA 2016-2017  
Male 
 
Female 
 
Total 
Characteristic Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number 
Residence 
        
Urban 21.7 1,709 
 
31.6 2,729 
 
26.9 4,438 
Peri-urban 19.0 328 
 
27.1 453 
 
23.1 781 
Rural 20.3 2,725 
 
29.8 3,738 
 
24.9 6,463          
Ecological zone 
        
Lowlands 20.9 3,014 
 
31.1 4,381 
 
26.0 7,395 
Foothills 20.4 447 
 
28.1 570 
 
23.9 1,017 
Mountains 21.4 924 
 
28.1 1,386 
 
24.8 2,310 
Senqu River Valley 18.7 377 
 
30.9 583 
 
25.0 960          
District 
        
Maseru 24.0 1,215 
 
31.7 1,684 
 
27.8 2,899 
Mafeteng 19.8 498 
 
32.9 701 
 
26.3 1,199 
Mohale's Hoek 25.1 341 
 
33.0 548 
 
29.3 889 
Leribe 18.5 803 
 
29.1 1,152 
 
23.7 1,955 
Berea 16.8 599 
 
29.1 878 
 
23.0 1,477 
Quthing 21.1 243 
 
31.0 399 
 
26.5 642 
Butha Buthe  12.6 299 
 
23.3 416 
 
17.8 715 
Mokhotlong 23.2 274 
 
29.0 405 
 
26.1 679 
Qacha's Nek 21.5 174 
 
29.7 284 
 
25.9 458 
Thaba Tseka  22.1 316 
 
30.3 453 
 
26.2 769          
Marital status 
        
Never married / lived together 7.3 2,243 
 
17.1 2,035 
 
11.2 4,278 
Married or living together 28.8 2,024 
 
29.4 3,607 
 
29.1 5,631 
Divorced or separated 47.5 309 
 
51.3 454 
 
49.5 763 
Widowed 54.8 171 
 
59.9 818 
 
58.8 989          
Education 
        
No education 36.9 464 
 
41.7 108 
 
37.6 572 
Primary 26.7 2,055 
 
40.0 2,870 
 
33.2 4,925 
Secondary 14.4 1,847 
 
25.3 3,330 
 
20.4 5,177 
College / University 9.1 352 
 
17.6 537 
 
13.4 889 
Graduate / post-graduate  (10.0) 39 
 
13.1 73 
 
11.7 112          
Wealth quintile 
        
Lowest 23.5 975 
 
29.5 1,372 
 
26.5 2,347 
Second 21.8 1,028 
 
32.8 1,354 
 
27.0 2,382 
Middle 25.2 946 
 
34.0 1,387 
 
29.6 2,333 
Fourth  19.4 948 
 
31.5 1,369 
 
25.4 2,317 
Highest 14.9 852 
 
25.4 1,419 
 
20.5 2,271          
Religion 
        
Roman Catholic 20.8 1,965 
 
30.7 2,675 
 
25.6 4,640 
Lesotho Evangelical 22.4 907 
 
29.7 1,139 
 
25.7 2,046 
Anglican 20.9 343 
 
26.4 463 
 
23.5 806 
Pentecostal 19.3 344 
 
32.1 677 
 
26.6 1,021 
Other Christian 19.3 757 
 
29.6 1,405 
 
25.1 2,162 
Other religion 21.8 306 
 
33.2 531 
 
28.0 837 
Don't know 18.2 114 
 
(37.1) 26 
 
20.7 140          
Pregnancy status 
        
Currently pregnant NA NA 
 
24.5 276 
 
NA NA 
Not currently pregnant NA NA 
 
30.6 6,622 
 
NA NA          
Total 15-59 20.8 4,762 
 
30.4 6,920 
 
25.6 11,682 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 6.3.B HIV prevalence by demographic characteristics: Ages 15-49 years 
Prevalence of HIV among adults aged 15-49 years, by sex and selected demographic characteristics,  LePHIA 2016-2017  
Male 
 
Female 
 
Total 
Characteristic Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number 
Residence 
        
Urban 20.7 1,541 
 
31.2 2,455 
 
26.1 3,996 
Peri-urban 16.8 296 
 
26.9 400 
 
21.8 696 
Rural 18.3 2,362 
 
28.7 3,135 
 
23.2 5,497          
District 
        
Maseru 22.6 1,096 
 
31.1 1,495 
 
26.7 2,591 
Mafeteng 17.9 436 
 
32.2 595 
 
24.8 1,031 
Mohale's Hoek 22.3 288 
 
33.0 440 
 
27.7 728 
Leribe 16.9 715 
 
29.3 1,020 
 
22.9 1,735 
Berea 15.0 539 
 
28.2 772 
 
21.6 1,311 
Quthing 16.8 198 
 
30.9 323 
 
24.4 521 
Butha Buthe  11.5 258 
 
21.6 362 
 
16.4 620 
Mokhotlong 22.9 243 
 
27.1 363 
 
25.0 606 
Qacha's Nek 20.1 146 
 
29.4 236 
 
24.9 382 
Thaba Tseka  20.7 280 
 
28.5 384 
 
24.5 664          
Marital status 
        
Never married / lived together 7.0 2,207 
 
16.6 1,985 
 
10.8 4,192 
Married or living together 27.9 1,644 
 
30.3 3,176 
 
29.2 4,820 
Divorced or separated 49.5 245 
 
52.7 389 
 
51.2 634 
Widowed 59.3 89 
 
67.8 435 
 
66.0 524          
Education 
        
No education 35.4 342 
 
39.5 80 
 
36.0 422 
Primary 24.9 1,752 
 
40.8 2,224 
 
32.3 3,976 
Secondary 13.7 1,740 
 
24.9 3,122 
 
19.8 4,862 
College / University 7.8 326 
 
17.0 498 
 
12.4 824 
Graduate / post-graduate  (11.5) 34 
 
14.7 65 
 
13.2 99          
Wealth quintile 
        
Lowest 21.5 828 
 
27.7 1,162 
 
24.5 1,990 
Second 20.1 894 
 
31.9 1,131 
 
25.5 2,025 
Middle 23.4 855 
 
33.6 1,209 
 
28.4 2,064 
Fourth  18.0 864 
 
31.5 1,215 
 
24.5 2,079 
Highest 13.4 746 
 
25.0 1,257 
 
19.6 2,003          
Religion 
        
Roman Catholic 19.3 1,736 
 
29.7 2,312 
 
24.2 4,048 
Lesotho Evangelical 20.9 799 
 
29.4 964 
 
24.7 1,763 
Anglican 19.8 294 
 
26.3 382 
 
22.9 676 
Pentecostal 17.8 305 
 
31.4 594 
 
25.5 899 
Other Christian 17.2 667 
 
29.4 1,242 
 
24.0 1,909 
Other religion 19.7 279 
 
31.5 471 
 
26.0 750 
Don't know 16.8 97 
 
* 21 
 
19.2 118          
Pregnancy status 
        
Currently pregnant NA NA 
 
24.4 273 
 
NA NA 
Not currently pregnant NA NA 
 
29.9 5,695 
 
NA NA          
Total 15-49 19.1 4,199 
 
29.7 5,990 
 
24.3 10,189 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Figure 6.3.A HIV prevalence by marital status: Ages 15-59 years, LePHIA 2016-2017 
 
 
 
6.4 Adult HIV Prevalence by Age and Sex 
Among adults, HIV prevalence ranged from 4.2% in those aged 15-19 years (older adolescents) to 47.6% 
in those aged 40-44 years. The peak HIV prevalence in women was 49.9%, observed in those aged 35-39 
years, while the peak HIV prevalence in men was 46.9%, observed in those aged 40-44 years. Prevalence 
among women increased sharply, rising from 5.7% in older adolescents to 16.7% in young women aged 
20-24 years, and to 31.4% among women aged 25-29 years. Prevalence among male participants did not 
display a similar pattern of increase, as it was 2.8% in older adolescents aged 15-19 years, 4.0% in young 
men aged 20-24 years, and 12.9% among men aged 25-29 years. Men reached similar levels of HIV 
prevalence as women after the age of 40 years.  The pattern in HIV prevalence mirrored the pattern 
seen in HIV incidence (Table 6.4.A; Figure 6.4.A).   
 
Differences in HIV prevalence between men and women were significant in those aged 15-39 years. 
There were not significant differences by sex above the age of 39 years. Among young people aged 15-
24 years, HIV prevalence was almost three times as high among young women (11.1%) as among young 
men (3.4%), and HIV prevalence among those aged 20-24 years was four times greater in young women 
(16.7%) compared to young men (4.0%) (Table 6.4.A; Figure 6.4.A). 
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Table 6.4.A HIV prevalence by age and sex 
Prevalence of HIV among persons ages 0-59 years, by sex and age, LePHIA 2016-2017  
Male 
 
Female 
 
Total 
Age Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number   Percentage 
HIV positive 
Number 
0-17 months 0.6 157 
 
1.0 158 
 
0.8 315 
18-59 months 0.6 423 
 
1.6 401 
 
1.1 824 
5-9 0.9 663 
 
2.9 676 
 
1.9 1,339 
10-14 3.1 760 
 
3.3 728 
 
3.2 1,488 
         
Total 0-4 0.6 580 
 
1.5 559 
 
1.0 1,139 
Total 0-14 1.5 2,003 
 
2.6 1,963 
 
2.1 3,966 
         
15-19 2.8 921 
 
5.7 1,156 
 
4.2 2,077 
20-24 4.0 769 
 
16.7 1,202 
 
10.4 1,971 
25-29 12.9 707 
 
31.4 1,054 
 
22.0 1,761 
30-34 26.0 611 
 
41.2 857 
 
33.3 1,468 
35-39 33.9 497 
 
49.9 703 
 
41.5 1,200 
40-44 46.9 379 
 
48.3 574 
 
47.6 953 
45-49 43.0 315 
 
44.2 444 
 
43.6 759 
50-54 38.7 261 
 
38.9 459 
 
38.8 720 
55-59 33.3 302 
 
31.0 471 
 
32.0 773          
Total 15-24 3.4 1,690 
 
11.1 2,358 
 
7.2 4,048 
Total 15-49 19.1 4,199 
 
29.7 5,990 
 
24.3 10,189 
Total 15-59 20.8 4,762 
 
30.4 6,920 
 
25.6 11,682 
 
Figure 6.4.A HIV prevalence by age and sex, LePHIA 2016-2017 
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6.5 Adult HIV Prevalence by Ecological Zone and District 
Although there was no difference in prevalence by ecological zone, the burden of HIV varied by district. 
HIV prevalence among adults ranged from 17.8% in Butha Buthe to 29.3% in Mohale’s Hoek (Figures 
6.5.A and 6.5.B, Table 6.3.A). This geographic pattern was similar when disaggregated by sex (Table 
6.3.A), with prevalence ranging from 12.6% to 25.1% in men and 23.3% to 33.0% in women in Butha 
Buthe and Mohale’s Hoek, respectively. 
 
Figure 6.5.A HIV prevalence among adults, by district, LePHIA 2016-2017 (map) 
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Figure 6.5.B HIV prevalence among adults, by district, LePHIA 2016-2017 (bar graph) 
 
 
6.6 Gaps and Unmet Needs 
 
 
 
  
▪ In conjunction with HIV incidence data, the high prevalence of HIV in Lesotho suggests high rates 
of HIV acquisition and indicates the need for more efficient targeted prevention efforts.  
▪ Women are acquiring HIV at a young age, whereas men attain similar levels in their 30s.  
▪ Future prevention campaigns should focus on age-disparate sexual partnerships as data reflected 
younger ages of infection among women compared to men. Other prevention efforts should focus 
on understanding factors driving the epidemic in males. 
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Chapter 7    HIV Testing 
7.1 Key Findings 
 
7.2 Background 
HIV testing is necessary for awareness of HIV status and is a critical component of HIV epidemic control 
targets. Awareness of HIV-positive status is the first step to engagement with HIV care and treatment 
services, accessing ART, prevention counseling for HIV-positive and HIV-negative individuals to reduce 
risk of HIV transmission or acquisition, and access to screening services for other co-morbidities. 
 
In 2016, following the release of WHO 2015 consolidated guidelines, the MOH reviewed and adopted 
the HIV Testing Services Guidelines in order to meet the UNAIDS 90-90-90 global HIV targets. As the first 
target was the diagnosis of 90% of people living with HIV, this supported the MOH recommendation that 
every person, regardless of perceived risk, receive an HIV test every 12 months. HIV testing services 
have since been rolled out to all public health facilities with over 80% of people tested at health facilities 
and the remainder during community campaigns. There has been more than a three-fold increase in the 
number of people tested (including adults, adolescents, and children) per annum between 2011 and 
2016.  
 
In its new National HIV & AIDS Strategic Plan (NSP) 2018/19 – 2022/23, the MOH included the ambitious 
goal of increasing the proportion of people living with HIV who know their HIV status to 95%, for all ages 
by 2023.1 
 
Data presented in this section pertain to participants aged 15-59 years who reported ever receiving an 
HIV test and receiving the test results. Results on HIV testing in the last 12 months and receiving the test 
results are also presented to understand frequent or recent testing and adherence to national 
guidelines. 
 
7.3 Self-Reported HIV Testing Among Adults 
Overall, 86.9% of the adult population reported that they had ever tested for HIV and received their 
results; however, only 56.1% indicated that they had done so in the 12 months preceding the survey. It 
7 HIV TESTING 
▪ In Lesotho, 86.9% of adults (those aged 15-59 years) had ever tested for HIV and received their 
results (91.3% of women and 82.7% of men). The lowest proportion of ever having tested was 
seen among older adolescents (those aged 15-19) at 72.9%. 
▪ The majority (56.1%) of adults reported having HIV testing and receiving results in the 12 months 
preceding the survey (61.7% of women and 50.5% of men). 
▪ Among adults who tested HIV positive in LePHIA, 5.1% reported that they had never been tested 
or that they had never received their results. 
▪ Lower testing rates were associated with having no education among men, and never having been 
married for both sexes. 
▪ There was variation in HIV testing uptake across the districts, with a significantly higher proportion 
of respondents reporting ever having tested for HIV in the lowlands. 
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should be noted that this figure includes those who reported knowing their HIV-positive status for at 
least a year. Significantly more women (91.3%) than men (82.7%) reported past testing, and testing in 
the past year: 61.7% of women and 50.5% of men reported testing for HIV in the 12 months preceding 
the survey (Tables 7.3.A, 7.3.B, and 7.3.C). 
 
Among men of most age groups, over 80% reported ever testing for HIV and receiving their results; 
however, only 73.2% of older adolescent boys aged 15-19 years reported ever testing for HIV and 
receiving results. The percentage of men testing for HIV and receiving results in the year preceding the 
survey ranged from 42.2% among those aged 40-44 years to 58.4% among those aged 25-29 years. HIV 
testing was also low at 43.9% among older adolescent boys aged 15-19 years (Table 7.3.A).  
 
Among women, only 72.5% of older adolescents aged 15-19 years were ever tested compared to 92.2% 
among young women aged 20-24 years and 98.2% among women aged 30-34 years. Over 60% of 
women aged 15-59 years were tested for HIV in the year preceding the survey, ranging from 50.2% 
among women aged 40-44 years to 75.9% among young women aged 20-24 years (Table 7.3.B; Figure 
7.3.A). 
 
Among adults who tested HIV positive in LePHIA, 5.1% reported that they had never been tested or that 
they had never received their results. A significantly higher proportion of HIV-positive men (8.6%) had 
never been tested, compared to women (2.8%).  
 
There was variation in lifetime and recent HIV testing by education status. Overall, among adults, 78.4% 
of those with no education had ever tested for HIV and received their results and 44.0% tested in the 
year preceding the survey. Among adults with secondary education, 88.1% reported ever testing and 
59.5% reported testing in the year preceding the survey. Among men with secondary education, 86.2% 
reported having ever tested for HIV and receiving their results and 54.6% tested in the year preceding 
the survey, compared to 77.1% and 42.3% of men with no education, respectively. There was a similar 
trend among women—among those with secondary education, 89.7% ever tested for HIV and 63.6% 
tested for HIV in the year preceding the survey, slightly higher than the 85.7% and 54.2%, respectively, 
reported by women with no education—though the confidence intervals overlapped (Tables 7.3.A, 
7.3.B, and 7.3.C). 
 
People never married/living together showed a significantly lower ever tested rate (78.5%) compared to 
those who were married/living together (92.5%), divorced or separated (91.0%), and widowed (93.4%). 
Among men, almost nine out of 10 of those who were married or cohabitating, divorced or separated, 
or widowed (87.1%, 85.5%, and 89.8% respectively) reported ever testing for HIV. Percentages of tested 
were even higher among women: 97.1% of married or cohabitating women, 96.2% of divorced or 
separated, and 94.4% of widowed women reported ever testing for HIV. Among both men and women, 
less than 80% of those who were never married or lived together had ever tested (77.9% and 79.4%, 
respectively). When looking at recent testing, people never married/lived together showed a 
significantly lower testing rate (50.2%) compared to people married/living together (62.7%). 
Divorced/separated (51.1%) and widowed (48.3%) adults had similar recent testing rates as those who 
were never married/lived together (Tables 7.3.A, 7.3.B, and 7.3.C). 
 
In rural areas, self-reported HIV testing was lower (84.6%) compared to urban (89.0%) and peri-urban 
(91.1%) areas in adults. However, there was no significant difference in recent testing. The proportion 
reporting ever testing for HIV was significantly higher in the lowlands (88.3%) than in the other zones, and 
varied across the districts where it ranged from 77.4% in Mokhotlong to 89.4% in Berea. A similar pattern 
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was observed for differences by district for recent testing, but there were no significant differences by 
ecological zone (Tables 7.3.A, 7.3.B, and 7.3.C).  
 
Table 7.3.A Self-reported HIV testing: Men 
Percentage of men aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV testing 
and received their test results in the past 12 months, by result of PHIA survey HIV test and selected demographic characteristics,  
LePHIA 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in 
the prior 12 months and received results1 Number 
Result of PHIA survey HIV test 
   
HIV positive 91.4 36.5 1,009 
HIV negative 80.3 54.2 3,735 
Not tested 82.2 51.1 592     
Residence 
   
Urban 87.4 53.3 2,008 
Peri-urban 89.8 56.4 371 
Rural 78.0 47.5 2,957     
Ecological zone 
   
Lowlands 85.0 51.4 3,433 
Foothills 77.9 48.5 500 
Mountains 76.7 49.3 996 
Senqu River Valley 78.0 46.1 407     
District 
   
Maseru 86.5 52.4 1,420 
Mafeteng 80.7 51.0 525 
Mohale's Hoek 78.9 50.5 375 
Leribe 80.2 48.6 883 
Berea 88.4 56.2 685 
Quthing 75.8 44.4 274 
Butha Buthe  76.4 44.0 361 
Mokhotlong 73.0 45.3 287 
Qacha's Nek 75.8 43.4 199 
Thaba Tseka  81.4 48.4 327     
Marital status 
   
Never married / lived together 77.9 47.7 2,519 
Married or living together 87.1 54.3 2,275 
Divorced or separated 85.5 48.4 339 
Widowed 89.8 44.7 186     
Education 
   
No education 77.1 42.3 497 
Primary 77.8 47.9 2,214 
Secondary 86.2 54.6 2,116 
College / University 92.5 52.0 442 
Graduate / post-graduate  87.9 48.7 60     
Wealth quintile 
   
Lowest 73.6 46.1 1,048 
Second 80.9 49.9 1,101 
Middle 83.3 51.6 1,054 
Fourth  85.9 53.0 1,078 
Highest 88.0 51.3 1,042     
Religion 
   
Roman Catholic 82.7 51.2 2,191 
Lesotho Evangelical 84.6 51.8 1,012 
Anglican 83.7 50.6 390 
Pentecostal 81.3 53.9 387 
Other Christian 83.6 49.6 845 
Other religion 81.8 46.9 347 
Don't know 68.7 37.3 131     
Age 
   
15-19 73.2 43.9 993 
20-24 81.3 55.0 874 
25-29 84.0 58.4 827 
30-34 84.8 55.7 690 
35-39 87.6 49.9 572 
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Table 7.3.A Self-reported HIV testing: Men (continued) 
Percentage of men aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV testing 
and received their test results in the past 12 months, by result of PHIA survey HIV test and selected demographic characteristics,  
LePHIA 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in 
the prior 12 months and received results1 Number 
Age (cont.) 
   
40-44 88.6 42.2 426 
45-49 84.3 44.5 350 
50-54 84.8 45.5 283 
55-59 84.8 45.4 321     
Total 15-24 
Total 25-34 
Total 35-49 
77.1 
84.4 
87.1 
49.3 
57.1 
46.2 
1,867 
1,517 
1,348 
Total 15-49 82.4 51.0 4,732 
Total 15-59 82.7 50.5 5,336 
1Relates to PEPFAR HTS_TST. A description of PEPFAR indicators can be found at  
https://www.pepfar.gov/documents/organization/263233.pdf 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has 
been suppressed. 
 
Table 7.3.B Self-reported HIV testing: Women 
Percentage of women aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV 
testing and received their test results in the past 12 months, by result of survey HIV test and selected demographic characteristics,  
LePHIA 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in the 
prior 12 months and received results1 Number 
Result of PHIA survey HIV test 
   
HIV positive 97.2 36.7 2,169 
HIV negative 89.3 72.8 4,731 
Not tested 85.6 64.3 595     
Residence 
   
Urban 90.5 58.3 3,053 
Peri-urban 92.3 66.9 510 
Rural 91.8 63.9 3,932     
Ecological zone 
   
Lowlands 91.5 60.3 4,831 
Foothills 92.6 66.8 604 
Mountains 89.8 65.0 1,456 
Senqu River Valley 91.1 61.7 604     
District 
   
Maseru 92.2 60.0 1,900 
Mafeteng 92.9 61.2 729 
Mohale's Hoek 93.4 64.8 584 
Leribe 91.4 65.2 1,236 
Berea 90.4 60.7 981 
Quthing 89.3 58.4 415 
Butha Buthe  89.6 60.5 453 
Mokhotlong 81.6 55.4 425 
Qacha's Nek 88.7 63.0 309 
Thaba Tseka  94.9 68.4 463     
Marital status 
   
Never married / lived together 79.4 54.0 2,256 
Married or living together 97.1 69.9 3,883 
Divorced or separated 96.2 53.7 488 
Widowed 94.4 49.3 860     
Education 
   
No education 85.7 54.2 121 
Primary 92.9 59.0 3,021 
Secondary 89.7 63.6 3,598 
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Table 7.3.B Self-reported HIV testing: Women (continued) 
Percentage of women aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV 
testing and received their test results in the past 12 months, by result of survey HIV test and selected demographic characteristics,  
LePHIA 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in the 
prior 12 months and received results1 Number 
Education (cont.) 
   
College / University 92.8 63.7 660 
Graduate / post-graduate  97.1 66.1 93     
Wealth quintile 
   
Lowest 90.6 65.7 1,428 
Second 93.8 64.9 1,421 
Middle 91.8 60.8 1,475 
Fourth  92.1 60.9 1,511 
Highest 88.7 57.9 1,640     
Religion 
   
Roman Catholic 91.6 62.9 2,907 
Lesotho Evangelical 91.1 60.8 1,230 
Anglican 90.0 61.1 500 
Pentecostal 92.3 62.7 734 
Other Christian 91.4 61.2 1,514 
Other religion 90.1 58.6 576 
Don't know (83.2) (56.2) 28     
Age 
   
15-19 72.5 53.6 1,246 
20-24 92.2 75.9 1,294 
25-29 97.8 73.7 1,157 
30-34 98.2 62.7 964 
35-39 96.8 55.8 763 
40-44 97.5 50.2 619 
45-49 92.7 52.2 469 
50-54 91.6 53.2 485 
55-59 90.1 55.8 498     
Total 15-24 
Total 25-34 
Total 35-49 
82.2 
98.0 
96.0 
64.6 
68.6 
53.1 
2,540 
2,121 
1,851 
Total 15-49 91.3 62.7 6,512 
Total 15-59 91.3 61.7 7,495 
1Relates to PEPFAR HTS_TST. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. 
 
Table 7.3.C Self-reported HIV testing: Total 
Percentage of adults aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV 
testing and received their test results in the past 12 months, by result of survey HIV test and selected demographic characteristics,  
LePHIA 2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in the 
prior 12 months and received results1 Number 
Result of PHIA survey HIV test 
   
HIV positive 94.9 36.6 3,178 
HIV negative 84.6 63.0 8,466 
Not tested 83.6 56.7 1,187     
Residence 
   
Urban 89.0 55.9 5,061 
Peri-urban 91.1 61.7 881 
Rural 84.6 55.4 6,889     
Ecological zone 
   
Lowlands 88.3 55.9 8,264 
Foothills 84.7 56.9 1,104 
Mountains 83.4 57.3 2,452 
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Table 7.3.C Self-reported HIV testing: Total (continued) 
Percentage of adults aged 15-59 years who ever received HIV testing and received their test results, and percentage who received HIV 
testing and received their test results in the past 12 months, by result of survey HIV test and selected demographic characteristics, LePHIA 
2016-2017 
Characteristic 
Percentage who ever received HIV 
testing and received results 
Percentage who received HIV testing in the 
prior 12 months and received results1 Number 
Ecological zone (cont.) 
   
Senqu River Valley 84.8 54.2 1,011     
District 
   
Maseru 89.3 56.1 3,320 
Mafeteng 86.9 56.2 1,254 
Mohale's Hoek 86.5 58.0 959 
Leribe 85.7 56.8 2,119 
Berea 89.4 58.5 1,666 
Quthing 83.0 51.9 689 
Butha Buthe  82.7 51.8 814 
Mokhotlong 77.4 50.4 712 
Qacha's Nek 82.6 53.7 508 
Thaba Tseka  88.3 58.6 790     
Marital status 
   
Never married / lived together 78.5 50.2 4,775 
Married or living together 92.5 62.7 6,158 
Divorced or separated 91.0 51.1 827 
Widowed 93.4 48.3 1,046     
Education 
   
No education 78.4 44.0 618 
Primary 85.2 53.3 5,235 
Secondary 88.1 59.5 5,714 
College / University 92.7 58.0 1,102 
Graduate / post-graduate  92.8 58.0 153     
Wealth quintile 
   
Lowest 82.0 55.8 2,476 
Second 87.0 57.0 2,522 
Middle 87.5 56.1 2,529 
Fourth  89.0 56.9 2,589 
Highest 88.4 54.8 2,682     
Religion 
   
Roman Catholic 87.0 56.8 5,098 
Lesotho Evangelical 87.6 55.9 2,242 
Anglican 86.7 55.6 890 
Pentecostal 87.6 58.9 1,121 
Other Christian 88.0 56.2 2,359 
Other religion 86.3 53.2 923 
Don't know 70.7 39.8 159     
Age 
   
15-19 72.9 48.7 2,239 
20-24 86.8 65.5 2,168 
25-29 90.8 65.9 1,984 
30-34 91.3 59.1 1,654 
35-39 92.0 52.7 1,335 
40-44 93.0 46.1 1,045 
45-49 88.6 48.5 819 
50-54 88.5 49.7 768 
55-59 87.8 51.4 819     
Total 15-24 
Total 25-34 
Total 35-49 
79.7 
91.0 
91.5 
56.9 
62.7 
49.6 
4,407 
3,638 
3,199 
Total 15-49 86.8 56.8 11,244 
Total 15-59 86.9 56.1 12,831 
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Table 7.3.C Self-reported HIV testing: Total (conclusion) 
1Relates to PEPFAR HTS_TST 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. 
 
Figure 7.3.A Proportion of adults who self-reported having received an HIV test in the last 12 
months, by age and sex, LePHIA 2016-2017 
 
 
 
7.4 Gaps and Unmet Needs 
 
7.5 References 
1. Lesotho Ministry of Health. National HIV & AIDS Strategic Plan 2018/19 – 2022/23. Maseru: Lesotho 
Ministry of Health; 2018. 
 
  
▪ Although the majority of the population tested for HIV at some point in their lives, the frequency 
of recent testing was lower. Approximately 40% of men and women had not received HIV testing 
in the last 12 months. There is need to increase the frequency of testing in the general population.  
▪ There was a significant difference in testing coverage between rural and urban areas and across 
the districts. 
▪ There was an important deficit in reaching men with HIV testing services, with less than half of 
young men having tested in the past year.  
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Chapter 8    HIV Diagnosis and Treatment 
8.1 Key Findings 
 
 
8.2 Background 
Recent studies have proven that treating people living with HIV at higher CD4 counts improves immune 
recovery, decreases the incidence of non-AIDS events and comorbidities and mortality, and reduces 
sexual and vertical transmission through reduction in VL.1 In 2016, after extensive review of evidence of 
both the clinical and population-level benefits of expanding ART, the WHO changed their 
recommendation to support a policy of “Treatment for All,” regardless of CD4 count.1,2 By November 
2017, almost all countries in sub-Saharan Africa had adopted this policy, despite the challenges in 
ensuring uptake and implementation.2  
 
The Government of Lesotho was one of the first to adopt this new strategy, with the publication and 
implementation of the Fifth Edition of the National ART Guidelines in 2016.3 Since these guidelines were 
published, Lesotho has become more ambitious and now aims to provide ART for 95% of those 
diagnosed by 2023.4 This chapter describes HIV diagnosis and treatment status among the population of 
HIV-positive adults by age, sex, region, and other demographic characteristics. 
 
8.3 Self-Reported Diagnosis and Treatment Status Among HIV-Positive Adults 
 
Awareness of HIV-Positive Status 
Among HIV-positive adults, based on self-report, 22.8% were unaware of their HIV-positive status. 
Significantly more men were unaware of their status than women (29.0% of men and 18.5% of women).   
 
Awareness of HIV status increased with age. Among HIV-positive men, the percentage of those who 
were unaware of their HIV status ranged from 54.8% among those aged 25-29 years to 12.8% among 
those aged 55-59 years. Among HIV-positive women, the percentage unaware of their HIV status ranged 
from 39.9% among those aged 20-24 years to only 9.0% among those aged 40-44 years.  
 
Awareness did not differ by urban or rural areas but did differ by district. Among HIV-positive men, the 
percentage of those who were unaware of their HIV status was very high (43.2%) in Mokhotlong, but 
was much lower (19.4%) in Berea. Similar differences across the districts were seen in women: 29.4% 
▪ Among HIV-positive adults (aged 15-59 years), 77.2% reported prior awareness of their HIV status, 
with significantly less awareness in men (71.0%) than women (81.5%). 
▪ Overall, 69.6% of HIV-positive adults reported ART use (63.5% of men; 73.8% of women).  
▪ Awareness of HIV status and ART use increased with age, differed across the districts, and was 
highest among widowed adults. 
▪ Concordance between self-report of ART and detection of ARVs was high, with 94.8% of those who 
reported current ART use having detectable ARVs in the blood. However, self-report of HIV status 
was less accurate, with detection of ARVs among 16.6% of those who reported no previous HIV 
diagnosis. 
8 HIV DIAGNOSIS AND TREATMENT H V DIAGNOSIS AND TREATMENT 
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were unaware of their status in Mokhotlong compared to 10.5% in Thaba Tseka (Tables 8.3.A, 8.3.B, and 
8.3.C).   
 
Among married and cohabitating HIV-positive adults, 21.8% were unaware of their HIV status, while 
among those who had never married/lived together or divorced/separated, 30.4% and 28.0%, 
respectively, were unaware. Very few widowed people (14.0%) living with HIV were not previously 
diagnosed (Table 8.3.C).  
 
Awareness of HIV and ART status 
Overall, 69.6% of HIV-positive adults reported ART use. A significantly lower percentage of men (63.5%) 
reported ART use compared with women (73.8%). Of those aware of their status, only 7.6% were not on 
ART, with no difference between men and women. 
 
Similarly, self-reported ART use increased with age. The percentage of all HIV-positive men who 
reported ART use ranged from 40.8% among those aged 20-29 years to 83.5% among those aged 55-59 
years, while the percentage of HIV-positive women on ART ranged from 54.4% among those aged 20-24 
years to 83.8% among those aged 40-44 years. Overall, only 54.8% of those aged 15-19 years, 51.8% of 
those aged 20-24 years, and 60.9% of those aged 25-29 years, reported ART use.  
 
Among married and cohabitating HIV-positive adults, 70.2% were on ART: 64.2% of men and 75.2% of 
women. Reported ART use was lower among those who were not cohabitating with a partner overall 
and for men, but it was significantly higher in divorced women (70.3%) compared to women who had 
never married (63.8%) (Tables 8.3.A, 8.3.B, and 8.3.C). Widowed participants had the highest reported 
ART use at 79.6%: 76.3% in men and 80.5% in women. The reported use of ART also varied by district, 
with the lowest proportion in Mokhotlong (56.5%) and the highest in Berea (75.0%). 
 
The percentages of those who reported awareness of their status, but not taking ART, were highest in 
urban areas (8.8%), in Maseru (10.2%), among young men aged 20-24 years (17.6%), and women aged 
30-34 years (11.9%).  
 
Table 8.3.A HIV treatment status: Men 
Percent distribution of HIV-positive men aged 15-59 years by self-reported HIV diagnosis and treatment status, by selected demographic 
characteristics, LePHIA 2016-2017 
  
Aware of HIV status 
  
Characteristic 
Unaware of HIV 
status Not on ART On ART1 Total Number 
Residence 
     
Urban 26.9 8.7 64.4 100.0 377 
Peri-urban 26.8 2.4 70.8 100.0 63 
Rural 30.9 7.3 61.8 100.0 577       
District 
     
Maseru 28.5 11.0 60.5 100.0 299 
Mafeteng 21.9 10.3 67.7 100.0 101 
Mohale's Hoek 29.6 4.6 65.8 100.0 91 
Leribe 28.0 3.0 68.9 100.0 153 
Berea 19.4 4.8 75.8 100.0 106 
Quthing 36.3 1.7 62.0 100.0 50 
Butha Buthe  (35.5) (9.0) (55.5) (100.0) 41 
Mokhotlong 43.2 11.3 45.5 100.0 64 
Qacha's Nek (30.0) (4.9) (65.0) (100.0) 38 
Thaba Tseka  40.7 3.5 55.7 100.0 74       
Marital status 
     
Never married / lived together 35.6 4.7 59.6 100.0 168 
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Table 8.3.A HIV treatment status: Men (continued) 
Percent distribution of HIV-positive men aged 15-59 years by self-reported HIV diagnosis and treatment status, by selected demographic 
characteristics, LePHIA 2016-2017 
  
Aware of HIV status 
  
Characteristic 
Unaware of HIV 
status Not on ART On ART1 Total Number 
Marital status (cont.) 
     
Married or living together 27.0 8.8 64.2 100.0 596 
Divorced or separated 36.8 5.5 57.6 100.0 148 
Widowed 15.8 7.9 76.3 100.0 98       
Education 
     
No education 29.7 5.7 64.6 100.0 167 
Primary 29.9 7.8 62.3 100.0 554 
Secondary 26.4 8.9 64.7 100.0 259 
College / University (33.9) (2.7) (63.4) (100.0) 31 
Graduate / post-graduate  * * * * 4       
Wealth quintile 
     
Lowest 32.3 8.2 59.4 100.0 241 
Second 22.8 7.6 69.6 100.0 232 
Middle 36.3 7.2 56.4 100.0 233 
Fourth  30.3 8.0 61.7 100.0 178 
Highest 18.9 6.5 74.6 100.0 132       
Religion 
     
Roman Catholic 28.8 7.5 63.7 100.0 423 
Lesotho Evangelical 30.9 8.9 60.1 100.0 208 
Anglican 29.4 5.6 65.0 100.0 73 
Pentecostal 20.1 10.5 69.3 100.0 68 
Other Christian 29.4 6.8 63.8 100.0 154 
Other religion 24.4 6.2 69.4 100.0 64 
Don't know * * * * 22       
Age 
     
15-19 (46.7) (3.0) (50.3) (100.0) 26 
20-24 (41.5) (17.6) (40.8) (100.0) 32 
25-29 54.8 4.3 40.8 100.0 93 
30-34 39.8 9.6 50.6 100.0 164 
35-39 32.6 8.8 58.6 100.0 176 
40-44 20.2 9.5 70.3 100.0 176 
45-49 15.5 5.4 79.1 100.0 141 
50-54 13.0 4.2 82.8 100.0 105 
55-59 12.8 3.7 83.5 100.0 104       
Total 15-24 43.8 11.3 44.9 100.0 58 
Total 15-49 32.2 8.3 59.5 100.0 808 
Total 15-59 29.0 7.5 63.5 100.0 1,017 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 8.3.B HIV treatment status: Women 
Percent distribution of HIV-positive women aged 15-59 years by self-reported HIV diagnosis and treatment status, by selected demographic 
characteristics, LePHIA 2016-2017 
  Aware of HIV status   
Characteristic 
Unaware of HIV 
status Not on ART On ART1 Total Number 
Residence      
Urban 19.6 8.8 71.6 100.0 900 
Peri-urban 20.9 7.0 72.1 100.0 131 
Rural 17.2 6.6 76.2 100.0 1,141 
      
District      
Maseru 20.3 9.6 70.1 100.0 562 
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Table 8.3.B HIV treatment status: Women (continued) 
Percent distribution of HIV-positive women aged 15-59 years by self-reported HIV diagnosis and treatment status, by selected demographic 
characteristics, LePHIA 2016-2017 
  Aware of HIV status   
Characteristic 
Unaware of HIV 
status Not on ART On ART1 Total Number 
District (cont.)      
Mafeteng 17.4 7.8 74.8 100.0 236 
Mohale's Hoek 15.1 5.7 79.3 100.0 188 
Leribe 15.8 6.3 77.9 100.0 341 
Berea 17.3 8.1 74.6 100.0 271 
Quthing 24.8 1.8 73.4 100.0 125 
Butha Buthe  19.7 9.7 70.6 100.0 104 
Mokhotlong 29.4 5.7 64.9 100.0 122 
Qacha's Nek 19.6 6.0 74.4 100.0 87 
Thaba Tseka  10.5 6.1 83.4 100.0 136 
      
Marital status      
Never married / lived together 27.0 9.2 63.8 100.0 366 
Married or living together 17.4 7.4 75.2 100.0 1,076 
Divorced or separated 20.3 9.3 70.3 100.0 241 
Widowed 13.5 6.0 80.5 100.0 489 
      
Education      
No education (25.8) (8.8) (65.4) (100.0) 45 
Primary 15.1 7.8 77.1 100.0 1,148 
Secondary 23.0 7.1 69.9 100.0 861 
College / University 14.8 9.3 75.8 100.0 106 
Graduate / post-graduate  * * * * 12 
      
Wealth quintile      
Lowest 17.7 6.7 75.6 100.0 411 
Second 15.5 5.7 78.8 100.0 454 
Middle 18.1 7.3 74.6 100.0 483 
Fourth  20.8 8.7 70.5 100.0 438 
Highest 20.1 9.5 70.4 100.0 383 
      
Religion      
Roman Catholic 19.0 8.4 72.7 100.0 852 
Lesotho Evangelical 16.9 5.9 77.2 100.0 347 
Anglican 19.6 8.8 71.6 100.0 129 
Pentecostal 16.8 9.0 74.2 100.0 225 
Other Christian 18.1 7.6 74.4 100.0 431 
Other religion 22.2 5.4 72.4 100.0 177 
Don't know * * * * 10 
      
Age      
15-19 34.6 8.1 57.2 100.0 63 
20-24 39.9 5.7 54.4 100.0 208 
25-29 22.7 7.8 69.4 100.0 340 
30-34 16.9 11.9 71.2 100.0 373 
35-39 13.5 8.0 78.5 100.0 357 
40-44 9.0 7.1 83.8 100.0 291 
45-49 13.9 6.5 79.6 100.0 201 
50-54 16.4 5.5 78.1 100.0 187 
55-59 15.7 1.0 83.3 100.0 152 
      
Total 15-24 38.6 6.3 55.1 100.0 271 
Total 15-49 18.9 8.3 72.8 100.0 1,833 
Total 15-59 18.5 7.6 73.8 100.0 2,172 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable.  Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 8.3.C HIV treatment status: Total 
Percent distribution of HIV-positive persons ages 15-59 years by self-reported HIV diagnosis and treatment status, by selected demographic 
characteristics, LePHIA 2016-2017 
  Aware of HIV status   
Characteristic 
Unaware of HIV 
status Not on ART On ART1 Total Number 
Residence      
Urban 22.5 8.8 68.8 100.0 1,277 
Peri-urban 23.3 5.1 71.6 100.0 194 
Rural 23.0 6.9 70.1 100.0 1,718 
District      
Maseru 23.9 10.2 65.9 100.0 861 
Mafeteng 19.1 8.7 72.1 100.0 337 
Mohale's Hoek 21.0 5.2 73.7 100.0 279 
Leribe 20.7 5.0 74.3 100.0 494 
Berea 18.1 6.9 75.0 100.0 377 
Quthing 29.0 1.8 69.2 100.0 175 
Butha Buthe  25.5 9.4 65.1 100.0 145 
Mokhotlong 35.4 8.1 56.5 100.0 186 
Qacha's Nek 23.7 5.6 70.8 100.0 125 
Thaba Tseka  23.2 5.0 71.7 100.0 210 
Marital status      
Never married / lived together 30.4 7.4 62.2 100.0 534 
Married or living together 21.8 8.0 70.2 100.0 1,672 
Divorced or separated 28.0 7.6 64.4 100.0 389 
Widowed 14.0 6.4 79.6 100.0 587 
Education      
No education 29.1 6.2 64.7 100.0 212 
Primary 21.2 7.8 71.0 100.0 1,702 
Secondary 24.1 7.7 68.2 100.0 1,120 
College / University 21.2 7.1 71.7 100.0 137 
Graduate / post-graduate  * * * * 16 
Wealth quintile      
Lowest 24.3 7.4 68.3 100.0 652 
Second 18.6 6.5 74.8 100.0 686 
Middle 25.9 7.3 66.8 100.0 716 
Fourth  24.5 8.4 67.1 100.0 616 
Highest 19.7 8.5 71.8 100.0 515 
Religion      
Roman Catholic 23.1 8.0 68.9 100.0 1,275 
Lesotho Evangelical 23.5 7.3 69.2 100.0 555 
Anglican 24.1 7.4 68.6 100.0 202 
Pentecostal 17.8 9.5 72.7 100.0 293 
Other Christian 21.9 7.3 70.8 100.0 585 
Other religion 23.0 5.7 71.3 100.0 241 
Don't know (40.1) (1.9) (58.0) (100.0) 32 
Age      
15-19 38.8 6.4 54.8 100.0 89 
20-24 40.2 8.0 51.8 100.0 240 
25-29 32.3 6.8 60.9 100.0 433 
30-34 26.1 11.0 62.9 100.0 537 
35-39 21.7 8.3 70.0 100.0 533 
40-44 14.6 8.3 77.1 100.0 467 
45-49 14.6 6.0 79.4 100.0 342 
50-54 14.9 4.9 80.2 100.0 292 
55-59 14.4 2.2 83.4 100.0 256 
      
Total 15-24 39.8 7.5 52.7 100.0 329 
Total 15-49 24.3 8.3 67.5 100.0 2,641 
Total 15-59 22.8 7.6 69.6 100.0 3,189 
1Relates to Global AIDS Monitoring indicator 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed 
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Figure 8.3.A Proportion of HIV-positive adults reporting awareness of their HIV-positive status and 
antiretroviral therapy (ART) status, by age and sex, LePHIA 2016-2017 
 
 
8.4 Concordance of Self-Reported Treatment Status Versus Laboratory ARV Data 
LePHIA determined the presence of three ARVs in blood samples (efavirenz, nevirapine, and lopinavir) as 
markers of first- and second-line regimens prescribed in the country at the time of the survey. Overall, 
ARVs were detected in 70.9% of all HIV-positive adults (67.9% among men and 73.1% among women). 
Only 5.2% of those who reported current use of ARVs did not have detection of any ARV (3.5% among 
men and 6.1% among women). Of those who reported previous diagnosis, but no ART use, 12.7% had 
detectable ARVs (14.2% of men and 11.6% of women). Among those who reported that they had not 
been previously diagnosed, 16.6% had detectable ARVs (19.1% among men and 14.0% among women) 
(Tables 8.4.A, 8.4.B, and 8.4.C).   
 
Table 8.4.A Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Men 
Percent distribution of HIV-positive men aged 15-59 years by presence of detectable ARVs versus self-reported ARV treatment (ART) status,  
LePHIA 2016-2017 
 ARV status   
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status     
Not previously diagnosed 80.9 19.1 100.0 284 
Previously diagnosed, not on ART 85.8 14.2 100.0 75 
Previously diagnosed, on ART 3.5 96.5 100.0 654 
     
Total 15-24 42.6 57.4 100.0 57 
Total 15-49 36.4 63.6 100.0 805 
Total 15-59 32.1 67.9 100.0 1,014 
1ARV detection assay included only efavirenz, lopinavir, and nevirapine. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
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Table 8.4.B Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Women 
Percent distribution of HIV-positive women aged 15-59 years by presence of detectable ARVs versus self-reported ARV treatment (ART) 
status, LePHIA 2016-2017 
 ARV status   
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status     
Not previously diagnosed 86.0 14.0 100.0 371 
Previously diagnosed, not on ART 88.4 11.6 100.0 155 
Previously diagnosed, on ART 6.1 93.9 100.0 1,619 
     
Total 15-24 45.6 54.4 100.0 269 
Total 15-49 28.4 71.6 100.0 1,815 
Total 15-59 26.9 73.1 100.0 2,150 
1ARV detection assay included only efavirenz, lopinavir, and nevirapine. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
Table 8.4.C Concordance of self-reported treatment status versus presence of antiretrovirals (ARVs): Total 
Percent distribution of HIV-positive adults aged 15-59 years by presence of detectable ARVs versus self-reported ARV treatment (ART) 
status, LePHIA 2016-2017 
 ARV status   
Characteristic Not detectable Detectable Total Number 
Self-reported treatment status     
Not previously diagnosed 83.4 16.6 100.0 655 
Previously diagnosed, not on ART 87.3 12.7 100.0 230 
Previously diagnosed, on ART 5.2 94.8 100.0 2,273 
     
Total 15-24 44.9 55.1 100.0 326 
Total 15-49 31.6 68.4 100.0 2,620 
Total 15-59 29.1 70.9 100.0 3,164 
1ARV detection assay included only efavirenz, lopinavir, and nevirapine. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
8.5 Gaps and Unmet Needs 
 
8.6 References 
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▪ Reaching and diagnosing those living with HIV, particularly men and young people (those aged 15-
24 years) was the major gap found by LePHIA. Almost half of HIV-positive young people were not 
on ART. 
▪ Significant differences were seen across districts in terms of awareness of HIV status and ART use 
once aware of HIV status. Further study is required to understand the disparity in regional 
coverage of key interventions. 
▪ Persistent stigma may have contributed to the discordance between self-reported HIV, treatment 
status and ARVs detected in the blood.  
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Chapter 9    Viral Load Suppression 
9.1 Key Findings  
 
 
9.2 Background 
The MOH has adopted a policy of routine VL monitoring as the preferred approach to monitor the 
treatment response for people living with HIV on ART by increasing laboratory capacity to conduct VL 
testing. VLS is a key indicator of treatment success in HIV-positive individuals. For the purposes of 
LePHIA, VLS is defined as VL less than 1,000 HIV RNA copies per mL of plasma. As per its updated NSP,1 
the Government of Lesotho aims to attain 95-95-95 targets by 2023 with targeted VLS rates increased to 
95% among those receiving ART. This chapter describes VLS among the population of HIV-positive adults 
by age, sex, region, and other demographic characteristics. 
 
9.3 Adult Viral Load Suppression by Select Demographic Characteristics 
Overall, 67.6% of HIV-positive adults had VLS, which was significantly lower in men (63.4%) than in 
women (70.5%). The proportion with VLS was highest among those who reported ART use (88.3%) and 
lowest among those who reported previous diagnosis, but no ART use (17.1%). Twenty-one (21.2%) 
percent of HIV-positive adults who reported no previous HIV diagnosis had VLS (Table 9.3.A). 
 
Although VLS did not differ by urban vs. rural residence, or by ecological zone, there was significant 
variation in VLS by district, ranging from 58.8% in Mokhotlong to 71.7% in Berea. It was particularly low 
among men in Mokhotlong (49.5%). Seventy-eight (78.1%) percent of widowed persons had VLS. This 
was significantly higher than in never-married individuals (61.9%), married or cohabitating persons 
(68.2%), and divorced or separated persons (59.3%) (Table 9.3.A). There were no clear patterns for 
educational attainment, wealth quintile, or religion and VLS (Table 9.3.A, Figures 9.3.A, and 9.3.B). 
 
Table 9.3.A Viral load suppression by demographic characteristics 
Among HIV-positive adults aged 15-59 years, percentage with viral load suppression (VLS) (< 1,000 HIV RNA copies/mL), by sex, self-reported 
diagnosis and treatment status, and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
VLS1 Number   
Percentage 
VLS1 Number   
Percentage 
VLS1 Number 
Self-reported diagnosis and treatment status         
Not previously diagnosed 21.1 285  21.3 378  21.2 663 
Previously diagnosed, not on ART 15.8 75  18.0 157  17.1 232 
Previously diagnosed, on ART 88.4 657  88.2 1,635  88.3 2,292 
Missing * 2  * 8  * 10 
         
Residence         
Urban 62.8 379  68.1 902  66.0 1,281 
Peri-urban 68.5 63  68.8 132  68.7 195 
Rural 63.2 577  73.0 1,144  68.8 1,721 
 
▪ In Lesotho, 67.6% of all HIV-positive adults (aged 15-59 years) had VLS: 63.4% among men and 
70.5% among women. 
▪ As with awareness of HIV status and use of ART, the proportion of those who had VLS varied 
significantly by district.  
▪ After the age of 34 years, VLS increased markedly in both men and women. 
9 VIRAL LOAD SUPPRESSION 
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Table 9.3.A Viral load suppression by demographic characteristics 
Among HIV-positive adults aged 15-59 years, percentage with viral load suppression (VLS) (< 1,000 HIV RNA copies/mL), by sex, self-reported 
diagnosis and treatment status, and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
VLS1 Number   
Percentage 
VLS1 Number   
Percentage 
VLS1 Number 
Ecological zone         
Lowlands 63.6 643  69.4 1,425  67.0 2,068 
Foothills 66.7 95  76.8 171  72.2 266 
Mountains 60.1 211  72.2 396  67.1 607 
Senqu River Valley 66.4 70  72.0 186  70.0 256 
         
District         
Maseru 60.8 301  68.0 562  64.8 863 
Mafeteng 64.4 101  69.6 236  67.6 337 
Mohale's Hoek 61.7 91  74.8 188  69.4 279 
Leribe 65.7 153  74.1 344  70.8 497 
Berea 71.8 106  71.6 273  71.7 379 
Quthing 65.9 50  66.7 126  66.4 176 
Butha Buthe  (68.8) 41  68.4 105  68.5 146 
Mokhotlong 49.5 64  66.2 121  58.8 185 
Qacha's Nek (58.5) 38  76.9 87  69.7 125 
Thaba Tseka  67.3 74  73.5 136  70.9 210 
         
Marital status         
Never married / lived together 64.0 168  60.5 367  61.9 535 
Married or living together 64.3 598  71.4 1,079  68.2 1,677 
Divorced or separated 52.1 148  65.5 241  59.3 389 
Widowed 74.6 98  79.0 491  78.1 589 
         
Education         
No education 65.5 167  (63.4) 45  65.2 212 
Primary 62.3 554  72.4 1,148  68.3 1,702 
Secondary 61.8 260  67.8 866  65.9 1,126 
College / University (77.9) 32  73.7 107  75.2 139 
Graduate / post-graduate  * 4  * 12  * 16 
         
Wealth quintile         
Lowest 63.1 241  70.1 410  67.0 651 
Second 64.5 232  76.5 456  71.4 688 
Middle 56.8 233  70.2 484  64.5 717 
Fourth  63.2 179  68.3 438  66.3 617 
Highest 72.9 133  67.8 387  69.5 520 
         
Religion         
Roman Catholic 64.3 423  70.4 853  67.8 1,276 
Lesotho Evangelical 64.9 209  73.0 349  69.2 558 
Anglican 54.0 73  72.1 129  63.8 202 
Pentecostal 65.5 69  72.5 225  70.3 294 
Other Christian 60.4 154  67.3 434  65.0 588 
Other religion 73.2 64  69.0 177  70.5 241 
Don't know * 22  * 10  (59.5) 32 
         
Total 15-24 51.3 58  50.9 272  51.0 330 
Total 15-49 59.2 810  68.9 1,839  65.0 2,649 
Total 15-59 63.4 1,019  70.5 2,178  67.6 3,197 
1Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Figure 9.3.A Viral load suppression (<1000 copies/mL) among HIV-positive adults, by district, 
LePHIA 2016-2017 (map) 
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Figure 9.3.B Viral load suppression (<1000 copies/mL) among HIV-positive adults, by district, 
LePHIA 2016-2017 (bar graph) 
 
 
9.4 Adult Viral Load Suppression by Age and Sex 
The prevalence of VLS ranged from 50.1% among older adolescents (aged 15-19 years) to 84.3% among 
those aged 55-59 years; it increased sharply for men and women above the age of 34 years. The lowest 
VLS was observed among men aged 25-34 years (46.1%) and in young women aged 15-24 years (50.9%) 
(Tables 9.4.A and 9.4.B; Figure 9.4.A). 
 
Table 9.4.A Viral load suppression by age (5-year age groups) 
Among HIV-positive persons aged 0-59 years, percentage with viral load suppression (VLS) (< 1,000 HIV RNA copies/mL), by sex and age, 
LePHIA 2016-2017 
 Male  Female  Total 
Age 
Percentage 
VLS1 Number   
Percentage 
VLS1 Number   
Percentage 
VLS1 Number 
0-4 * 4  * 8  * 12 
5-9 * 6  * 20  (64.0) 26 
10-14 * 22  * 23  (67.1) 45 
15-19 (48.7) 26  50.8 63  50.1 89 
20-24 (53.2) 32  51.0 209  51.4 241 
25-29 43.6 93  62.2 341  56.7 434 
30-34 47.4 166  66.7 374  58.9 540 
35-39 62.1 176  76.8 359  70.6 535 
40-44 66.1 176  79.1 292  72.6 468 
45-49 77.7 141  79.8 201  78.8 342 
50-54 82.6 105  79.3 187  80.8 292 
55-59 86.6 104  82.4 152  84.3 256          
Total 15-24 51.3 58  50.9 272  51.0 330 
Total 15-49 59.2 810  68.9 1,839  65.0 2,649 
Total 15-59 63.4 1,019  70.5 2,178  67.6 3,197 
1Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 9.4.B Viral load suppression by age (10-to-15-year age groups) 
Among HIV-positive persons in Lesotho, percentage with viral load suppression (VLS) (< 1,000 copies of HIV RNA mL) by sex and age, LePHIA 
2016-2017 
 Male  Female  Total 
Age 
Percentage 
VLS1 Number   
Percentage 
VLS1 Number   
Percentage 
VLS1 Number 
0–14 (51.9) 32  69.3 51  62.7 83 
15–24 51.3 58  50.9 272  51.0 330 
25–34 46.1 259  64.6 715  57.9 974 
35–44 64.1 352  77.8 651  71.5 1,003 
45–59 81.4 350  80.3 540  80.8 890 
         
Total 15-49 59.2 810  68.9 1,839  65.0 2,649 
Total 15-59 63.4 1,019  70.5 2,178  67.6 3,197 
1Relates to Global AIDS Monitoring indicator 1.4: People living with HIV who have suppressed viral loads 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
 
Figure 9.4.A Proportion of viral load suppression (<1000 copies/mL) among people living with HIV, 
by age and sex, LePHIA 2016-2017 
 
 
 
9.5 Gaps and Unmet Needs 
9.6 References 
1. Lesotho Ministry of Health. National HIV & AIDS Strategic Plan 2018/19 – 2022/23. Maseru: Lesotho 
Ministry of Health; 2018. 
 
  
▪ Close to a third of the HIV-positive adults in the country (almost 100,000 people) did not have VLS. 
▪ There is need to prioritize HIV testing to increase diagnosis, to initiate ART once diagnosed, and 
ensure adherence to ART in order to achieve a high level of VLS in the HIV-positive population, 
with special attention for the population younger than the age of 35 years. 
▪  
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Chapter 10    UNAIDS 90-90-90 Targets 
10.1 Key Findings 
 
 
10.2 Background 
To bring the HIV epidemic under control, UNAIDS has set the ambitious target of 90-90-90: by 2020, 90% 
of all HIV-positive people will know their HIV status; 90% of all persons with diagnosed HIV infection will 
receive sustained ART; and 90% of all persons receiving ART will have VLS.1 
 
While the previous chapters on HIV testing and treatment provide results on coverage of HIV testing and 
treatment services, VLS among all HIV-positive individuals is a measure of program impact, irrespective 
of knowledge of status or ART use. This chapter presents the status of the 90-90-90 indicators, which 
reflect program performance. Awareness of HIV-status and ART use are indicators of access to services.  
Viral load suppression among those on treatment not only provides an indication of access to and 
retention in care, but also provides a measure of program success. When VLS among all HIV-positive 
individuals is 73% (90 x 90 x 90) or greater, this is an indication of successful testing and treatment 
services. 
 
The 90-90-90 results in this chapter are presented in two ways. First, Table 10.3.A uses only self-
reported awareness and ARV status. Individuals were defined as ‘aware’ of their HIV-positive status if 
they reported an HIV-positive status before testing as part of the LePHIA survey. Individuals were 
defined as ‘on treatment’ if they reported ART use. Second, Table 10.3.B measures the 90-90-90 
indicators using both self-reported and ARV biomarker data. In this table, ‘aware’ and ‘on treatment’ 
have been adjusted such that individuals were classified as ‘aware’ of their HIV-positive status if they 
reported an HIV-positive status and/or had detectable ARVs in their blood. Individuals were classified as 
‘on treatment’ if they reported that they were taking ART and/or had detectable ARVs in their blood.  
 
It is important to note that in both cascades, individuals who have VLS, but are not aware of their HIV-
positive status or are not on ART, were excluded from the numerator for the third 90 (VLS among those 
who are aware and on ART). 
 
▪ Diagnosed:  Based on self-report and ARV detection data, it is estimated that in Lesotho 81.0% of 
HIV-positive adults (aged 15-59 years) know their HIV status (76.6% of HIV-positive men and 84.0% 
of HIV-positive women). 
▪ On treatment: Based on self-report and ARV detection data, it is estimated that among adults 
living with HIV who know their HIV status, 91.8% were receiving ART (91.6% men and 92.0% of 
women). 
▪ Suppressed viral load: Among adults living with HIV who reported ART use or had detectable 
ARVs, 87.7% had VLS (87.7% of men and women).  
▪ Once men were aware of their status, they achieved the same progress towards ART coverage and 
VLS as women. This underscores the need to focus on expanding opportunities for diagnosis in 
men. 
▪  
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10.3 Status of the UNAIDS 90-90-90 Targets  
 
90-90-90 cascade based on self-reported awareness of HIV Status and ARV use: 
Achievement in diagnosis was below the first 90 target, with 77.2% of HIV-positive adults that were 
aware of their status. However, Lesotho achieved the second and nearly achieved the third of the 90-90-
90 targets: 90.2% of HIV-positive adults who knew their status reported ART use, and 88.3% of those on 
ART had VLS (Table 10.3.A). 
 
90-90-90 cascade based on self-reported awareness of HIV Status and ARV use and detectable ARVs: 
ARV-adjusted awareness of HIV-positive status: After adjusting for the detection of ARVs, 81.0% of HIV-
adults were aware of their status (ARV-adjusted awareness), including 76.6% of men and 84.0% of 
women. ARV-adjusted awareness ranged from 67.6% among young people living with HIV (aged 15-24 
years) (71.3% of young men and 66.4% of young women) to 86.3% among people living with HIV aged 
35-49 years (82.2% of men and 89.8% of women) (Table 10.3.B; Figure 10.3.A). 
 
ARV-adjusted treatment status: Based on either self-reported ARV status or detectable ARVs, 91.8% of 
those with ARV-adjusted awareness status were classified as having ART use (91.6% of men and 92.0% 
of women). This was similar across age groups ranging from 88.8% among those aged 25-34 years to 
92.3% among those aged 35-49 years. The greatest disparity by sex was seen in those aged 15-24 years, 
among whom 84.1% of men and 92.8% of women were on ART (Table 10.3.B; Figure 10.3.A).  
 
Viral suppression: Among persons on ART (ARV-adjusted treatment status), 87.7% had VLS (87.7% of 
men and women), ranging from 77.2% among young people to 89.9% among those aged 35-49 years. 
Across all age bands, VLS among those on ART was similar among men and women (Table 10.3.B; Figure 
10.3.A). 
 
Table 10.3.A Adult 90-90-90 (self-reported antiretroviral therapy (ART) status; conditional percentages) 
90-90-90 targets among adults living with HIV aged 15-59 years, by sex and age, LePHIA 2016-2017 
 Diagnosed 
 Male  Female  Total 
Age 
Percentage 
self-reported 
HIV positive1 Number  
Percentage 
self-reported HIV 
positive1 Number  
Percentage 
self-reported HIV 
positive1 Number 
15-24 56.2 58  61.4 271  60.2 329 
25-34 54.8 257  80.4 713  71.2 970 
35-49 76.3 493  87.8 849  82.5 1,342 
15-49 67.8 808  81.1 1,833  75.7 2,641 
25-59 71.9 959  84.3 1,901  79.0 2,860 
50-59 87.1 209  83.9 339  85.3 548 
15-59 71.0 1,017  81.5 2,172  77.2 3,189 
 On Treatment  
 Male  Female  Total 
Age 
Among those self-
reported as HIV-
positive, 
percentage 
reported on ART Number  
Among those self-
reported as HIV-
positive, 
percentage 
reported on ART Number  
Among those 
self-reported as 
HIV-positive, 
percentage 
reported on ART Number 
15-24 (79.9) 33  89.7 172  87.6 205 
25-34 85.9 139  87.5 579  87.1 718 
35-49 89.3 381  91.6 753  90.6 1,134 
15-49 87.8 553  89.8 1,504  89.1 2,057 
25-59 89.8 699  90.7 1,621  90.4 2,320 
50-59 95.4 179  95.7 289  95.6 468 
15-59 89.4 732  90.6 1,793  90.2 2,525 
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Table 10.3.A Adult 90-90-90 (self-reported antiretroviral therapy (ART) status; conditional percentages) 
90-90-90 targets among adults living with HIV aged 15-59 years, by sex and age, LePHIA 2016-2017 
 Viral Load Suppression (VLS)  
 Male  Female  Total 
Age 
Among those 
self-reported on 
ART, percentage 
with VLS Number  
Among those self-
reported on ART, 
percentage 
with VLS Number   
Among those 
self-reported on 
ART, percentage 
with VLS Number 
15-24 (81.7) 27  76.4 155  77.5 182 
25-34 83.1 120  84.1 509  83.9 629 
35-49 88.5 339  91.8 691  90.4 1,030 
15-49 86.7 486  87.1 1,355  87.0 1,841 
25-59 88.7 630  89.4 1,480  89.1 2,110 
50-59 94.3 171  94.0 280  94.1 451 
15-59 88.4 657  88.2 1,635  88.3 2,292 
 
Table 10.3.B Adult 90-90-90 (self-reported antiretroviral (ART) status and laboratory antiretroviral (ARV) data; conditional 
percentages) 
90-90-90 targets among adults living with HIV aged 15-59 years, by sex and age, LePHIA 2016-2017 
 Diagnosed 
 Male  Female  Total 
Age 
Percentage 
self-reported HIV 
positive or with 
detectable ARVs1 Number   
Percentage 
self-reported HIV 
positive or with 
detectable ARVs1 Number   
Percentage 
self-reported HIV 
positive or with 
detectable ARVs1 Number 
15-24 71.3 58  66.4 272  67.6 330 
25-34 58.7 258  82.5 715  73.9 973 
35-49 82.2 493  89.8 851  86.3 1,344 
15-49 73.5 809  83.5 1,838  79.5 2,647 
25-59 76.9 960  86.5 1,905  82.4 2,865 
50-59 91.6 209  87.2 339  89.2 548 
15-59 76.6 1,018  84.0 2,177  81.0 3,195 
 On Treatment Among Those Diagnosed 
 Male  Female  Total 
Age 
Percentage 
with detectable ARVs 
or who reported 
current ART usage2 Number   
Percentage 
with detectable ARVs 
or who-reported 
current ART usage2 Number   
Percentage 
with detectable ARVs 
or who reported 
current ART usage2 Number 
15-24 (84.1) 41  92.8 186  90.6 227 
25-34 88.3 149  89.0 594  88.8 743 
35-49 91.5 409  92.9 770  92.3 1,179 
15-49 90.2 599  91.3 1,550  90.9 2,149 
25-59 92.0 747  91.9 1,664  91.9 2,411 
50-59 97.2 189  95.8 300  96.4 489 
15-59 91.6 788  92.0 1,850  91.8 2,638 
 Viral Load Suppression (VLS) Among Those on Treatment 
 Male  Female  Total 
Age 
Percentage 
with VLS3  Number   
Percentage 
with VLS3  Number   
Percentage 
with VLS3  Number 
15-24 (78.3) 35  76.8 173  77.2 208 
25-34 83.5 132  83.6 531  83.6 663 
35-49 88.1 373  91.3 716  89.9 1,089 
15-49 86.3 540  86.6 1,420  86.5 1,960 
25-59 88.1 689  88.9 1,538  88.6 2,227 
50-59 92.8 184  93.6 291  93.2 475 
15-59 87.7 724  87.7 1,711  87.7 2,435 
1Relates to Global AIDS Monitoring indicator (GAM) 1.1: People living with HIV who know their HIV status, and PEPFAR DIAGNOSED_NAT; 
2Relates to GAM 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT; 3Relates to GAM 1.4: People 
living with HIV who have suppressed viral loads, and PEPFAR VL_SUPPRESSION_NAT. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
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Figure 10.3.A Adult 90-90-90 (adjusted for laboratory antiretroviral data among adults), LePHIA 
2016-2017 
Note: in LePHIA, antiretroviral (ARV)-adjusted 90-90-90 participants were classified as ‘aware’ or ‘diagnosed’ if they self-
reported HIV positive before testing HIV positive or had detectable ARVs in their blood. Participants were classified as ‘on 
treatment’ if they self-reported that they were on treatment or if they had detectable ARVs in their blood. 
*Inset numbers are conditional proportions. 
 
10.4 Gaps and Unmet Need 
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▪ The major gap was in diagnosis of those living with HIV, especially among men and young adults.  
▪ The lowest coverage of ART among those who were aware of their status was among older 
adolescent boys and young men aged 15-24 years (84.1%). 
▪ Among those on ART, only 77.2% of those aged 15-24 years had achieved VLS, indicating possible 
non-adherence or drug resistance within this priority population. 
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Chapter 11    Clinical Perspectives on People Living with HIV 
11.1 Key Findings  
 
 
11.2 Background 
The quality of HIV care is based on key principles of accessibility, efficiency, and safety. As countries 
implement treatment for all people living with HIV, ensuring a sustainable health system that is people-
centered and innovative requires diligent monitoring and responsiveness.1 Indicators such as CD4 count 
at diagnosis and retention on ART can provide evidence of program coverage, the ability to reach 
individuals with likely HIV infection, and quality of care. The distribution of CD4 counts reflects 
population health and the potential impact of HIV on mortality.  
 
Furthermore, among the challenges associated with implementing the “treat all” strategy is the 
anticipated increase in the number of patients enrolled in HIV care and treatment clinics, possibly 
exhausting the capacity to deliver quality care. Programs are advised to use a differentiated service 
delivery (DSD) model.2 Under the DSD approach, the sickest patients receive intensified care, while 
those with stable or less advanced disease receive appropriate care in the environment best suited to 
their specific needs.1 Thus, although the most recent treatment guidelines in Lesotho no longer use the 
CD4 count as a threshold for ART initiation, the CD4 count continues to be used for clinical staging and 
to determine the clinical package offered to patients.3,4 Late presenters, defined as patients who are 
diagnosed with a CD4 count less than 200 cells/µL, are screened for opportunistic infections such as TB; 
assessed for malnutrition; and provided with cotrimoxazole prophylaxis, isoniazid preventive therapy, 
and food support.  
 
Finally, the measurement of transmitted drug resistance allows optimization of national ART guidelines, 
including second- and third-line therapies. LePHIA provided a unique opportunity to gauge progress in 
the expansion of HIV clinical services in Lesotho, as well as identify gaps and future challenges. 
 
11.3 CD4 Counts and Severe Immunosuppression 
The median CD4 count was 476 cells/microliter (µL) among all HIV-positive adults (397 cells/µL in men 
and 532 cells/µL in women) (Table 11.3.A). Significantly more men (16.0%) were severely 
immunosuppressed (CD4 count less than 200 cells/µL) than women (8.4%).  
 
▪ Among adults (aged 15-59 years) living with HIV, 11.5% had severe immunosuppression with a 
CD4 count less than 200 cells/µL, which was twice as high in men (16.0%) as in women (8.4%).  
▪ Among adults with no previous diagnosis, 17.7% of men and 13.7% of women had severe 
immunosuppression.  
▪ Among adults living with HIV, 98.8% of those who reported initiating ART less than 12 months 
prior to the survey, and 98.0% of those who reported initiating ART more than 12 months prior to 
the survey, reported that they were still taking ART at the time of the survey. 
▪ The prevalence of transmitted drug resistance was 11.4%, with the majority of mutations 
conferring resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
11 CLINICAL PERSPECTIVES ON PEOPLE LIVING 
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Among those who reported no previous diagnosis, the median CD4 count was 383 cells/µL (361 cells/µL 
among men and 413 cells/µL among women). Among previously diagnosed individuals not on ART, the 
median CD4 count was 350 cells/µL (299 cells/µL in men and 377 cells/µL in women); 22.7% had a CD4 
count less than 200 cells/µL (25.9% of men and 20.4% of women). Among those who reported ART use, 
the median CD4 count was 518 cells/µL (424 cells/µL among men and 580 cells/µL among women), with 
less than one in 10 (8.9%) with severe immunosuppression. However, significantly more men on ART 
were severely immunosuppressed than women (14.1% vs 5.8%, respectively) (Figure 11.3.A; Table 
11.3.A). 
 
The percentage of adults with severe immunosuppression was highest in Thaba Tseka (16.2%) and 
lowest in Mafeteng (8.0%). Immunosuppression was highest in those who were divorced or separated 
(13.7%), and in those without any education (14.4%). It did not differ by urban or rural residence, wealth 
quintile, or religion. It was lowest in young adults aged 20-24 years (4.8%) and after the age of 30 years 
there was no difference in the proportion with severe immunosuppression (Table 11.3.A). Almost one in 
four (24.1%) older adolescent boys aged 15-19 years were severely immunosuppressed, although the 
number was very small (n=26), compared to three percent of older adolescent girls (n=64).   
 
 
Figure 11.3.A CD4 count distribution among HIV-positive adults, by antiretroviral therapy (ART) 
status, LePHIA 2016-2017 
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Table 11.3.A Median CD4 count and severe immunosuppression 
Among HIV-positive adults aged 15-59 years, median (Q1, Q3) CD4 count and percentage with severe immunosuppression (< 200 cells/µL), by sex, self-reported diagnosis and ART status, and selected 
demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number  
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number  
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number 
Self-reported diagnosis and treatment status            
Not previously diagnosed 361 (235, 526) 17.7 283  413 (261, 620) 13.7 375  383 (244, 558) 15.8 658 
Previously diagnosed, not on ART 299 (187, 566) 25.9 75  377 (229, 553) 20.4 157  350 (209, 558) 22.7 232 
Previously diagnosed, on ART 424 (268, 606) 14.1 656  580 (404, 754) 5.8 1,635  518 (346, 699) 8.9 2,291 
Missing * * 2  * * 8  * * 10 
            
Residence            
Urban 396 (246, 553) 15.9 378  512 (343, 701) 8.6 900  464 (295, 651) 11.5 1,278 
Peri-urban 374 (210, 646) 16.5 62  498 (392, 726) 7.2 132  481 (322, 690) 10.9 194 
Rural 398 (251, 587) 15.9 576  556 (369, 744) 8.4 1,143  487 (299, 671) 11.6 1,719 
            
District            
Maseru 391 (240, 570) 16.0 300  510 (331, 705) 9.3 562  459 (280, 642) 12.2 862 
Mafeteng 403 (292, 596) 10.7 101  594 (394, 773) 6.3 236  513 (348, 706) 8.0 337 
Mohale's Hoek 404 (259, 571) 13.2 91  565 (406, 746) 5.0 188  519 (338, 689) 8.4 279 
Leribe 415 (247, 567) 18.1 152  520 (348, 728) 7.1 343  472 (307, 677) 11.5 495 
Berea 406 (226, 639) 14.9 106  557 (376, 721) 8.1 271  504 (324, 691) 10.6 377 
Quthing 363 (249, 659) (17.8) 49  470 (327, 717) 6.2 126  464 (295, 697) 10.3 175 
Butha Buthe  365 (220, 549) (21.9) 41  487 (322, 654) 9.4 104  419 (278, 623) 14.0 145 
Mokhotlong 295 (209, 504) 17.9 64  535 (347, 701) 10.4 122  457 (261, 630) 13.7 186 
Qacha's Nek 422 (328, 621) (9.9) 38  550 (401, 723) 9.9 87  520 (361, 678) 9.9 125 
Thaba Tseka  390 (246, 579) 18.8 74  556 (372, 711) 14.3 136  483 (274, 652) 16.2 210 
            
Marital status            
Never married / lived together 409 (265, 578) 10.5 167  518 (357, 717) 9.1 366  472 (316, 675) 9.7 533 
Married or living together 397 (248, 580) 15.4 596  570 (376, 748) 8.2 1,078  485 (299, 676) 11.5 1,674 
Divorced or separated 393 (244, 573) 16.8 148  499 (330, 663) 10.9 240  466 (294, 624) 13.7 388 
Widowed 352 (186, 555) 27.1 98  489 (325, 672) 7.1 491  464 (297, 652) 11.2 589 
            
Education            
No education 402 (244, 574) 16.8 167  472 (293, 668) (1.9) 45  416 (253, 585) 14.4 212 
Primary 397 (250, 574) 15.2 554  520 (348, 722) 9.1 1,148  467 (298, 661) 11.6 1,702 
Secondary 388 (243, 561) 16.7 258  544 (368, 718) 7.7 865  497 (312, 675) 10.6 1,123 
College / University 476 (259, 730) (12.5) 31  554 (380, 709) 10.5 105  540 (330, 716) 11.2 136 
Graduate / post-graduate  * * 4  * * 12  * * 16 
            
Wealth quintile            
Lowest 389 (242, 571) 16.4 241  550 (366, 736) 9.9 411  479 (279, 653) 12.8 652 
Second 398 (255, 567) 17.0 232  562 (392, 748) 7.4 456  480 (314, 675) 11.6 688 
Middle 395 (252, 573) 15.4 232  531 (341, 706) 7.6 483  467 (298, 659) 10.9 715 
Fourth  442 (239, 584) 16.4 178  511 (359, 705) 8.3 437  476 (318, 656) 11.4 615 
Highest 380 (259, 569) 14.4 132  514 (331, 709) 9.3 385  472 (299, 691) 11.0 517 
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Table 11.3.A Median CD4 count and severe immunosuppression (continued) 
Among HIV-positive adults aged 15-59 years, median (Q1, Q3) CD4 count and percentage with severe immunosuppression (< 200 cells/µL), by sex, self-reported diagnosis and ART status, and selected 
demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number  
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number  
Median 
(Q1, Q3) 
Percentage 
< 200 cells/µL Number 
Religion            
Roman Catholic 398 (240, 582) 17.2 421  531 (350, 720) 9.4 851  472 (288, 662) 12.7 1,272 
Lesotho Evangelical 394 (261, 581) 14.4 208  539 (361, 705) 8.5 347  478 (300, 650) 11.2 555 
Anglican 362 (235, 483) 19.8 73  576 (396, 743) 4.8 129  465 (295, 632) 11.7 202 
Pentecostal 405 (238, 580) 17.1 69  532 (358, 736) 6.1 225  485 (321, 706) 9.5 294 
Other Christian 398 (276, 546) 12.1 154  503 (345, 714) 8.4 434  472 (324, 668) 9.6 588 
Other religion 476 (303, 649) 10.7 64  546 (347, 712) 9.3 178  527 (328, 692) 9.8 242 
Don't know * * 22  * * 10  270 (155, 538) (32.2) 32 
            
Age            
15-19 515 (232, 671) (24.1) 26  633 (419, 783) 3.0 64  588 (391, 759) 10.1 90 
20-24 435 (352, 631) (6.9) 31  518 (374, 717) 4.4 207  495 (362, 709) 4.8 238 
25-29 453 (298, 670) 13.1 93  515 (357, 741) 6.8 342  494 (349, 710) 8.7 435 
30-34 383 (238, 535) 15.2 165  529 (315, 746) 10.4 373  461 (270, 657) 12.3 538 
35-39 380 (239, 541) 17.8 176  555 (376, 718) 9.7 359  481 (301, 653) 13.2 535 
40-44 406 (229, 589) 17.9 175  529 (374, 700) 9.2 291  469 (285, 643) 13.5 466 
45-49 390 (250, 570) 14.0 141  510 (324, 706) 8.9 200  446 (269, 638) 11.4 341 
50-54 412 (275, 572) 14.3 105  526 (332, 675) 9.8 187  473 (301, 645) 11.8 292 
55-59 352 (232, 540) 19.1 104  516 (334, 696) 7.8 152  424 (274, 623) 12.8 256 
            
Total 15-24 472 (351, 657) 14.4 57  538 (380, 752) 4.0 271  532 (370, 716) 6.4 328 
Total 15-49 398 (247, 580) 15.9 807  533 (359, 725) 8.3 1,836  478 (301, 670) 11.4 2,643 
Total 15-59 397 (248, 575) 16.0 1,016  532 (356, 719) 8.4 2,175  476 (299, 664) 11.5 3,191 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
 
  
 
 
 
79 
11.4 Late HIV Diagnosis 
Among adults who self-reported an HIV-negative status, but tested HIV positive in LePHIA, 15.7% had a 
CD4 count less than 200 cells/µL (16.5% of men and 15.0% of women) and 44.6% had a CD4 count less 
than 350 cells/µL. The proportion of adults with immunosuppression at diagnosis appeared to increase 
in adults older than the age of 30 years, with severe immunosuppression reaching one in three (35.6%) 
among those aged 55-59 years—however, this estimate is based on a small number of observations (25-
49) and should be interpreted with caution (Table 11.4.A).  
 
Table 11.4.A Late HIV diagnosis 
Among adults aged 15-59 years who tested HIV positive in the PHIA survey, but self-reported HIV negative, percentage who had a CD4 cell 
count < 200 cells/µL and < 350 cells/µL, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
< 200 
 cells/µL1 
Percentage 
< 350 
 cells/µL1 Number   
Percentage 
< 200 
cells/µL1 
Percentage 
< 350 
 cells/µL1 Number   
Percentage 
< 200 
cells/µL1 
Percentage 
< 350 
 cells/µL1 Number 
Residence            
Urban 14.9 41.5 80  15.6 42.3 140  15.3 41.9 220 
Peri-urban * * 14  * * 22  (14.8) (53.9) 36 
Rural 16.3 49.5 134  16.2 40.5 161  16.3 45.5 295 
            
District            
Maseru 15.4 47.3 63  16.7 49.0 87  16.0 48.1 150 
Mafeteng * * 20  (15.6) (41.8) 34  12.6 45.3 54 
Mohale's Hoek (5.9) (38.2) 25  * * 23  (5.2) (31.6) 48 
Leribe (20.5) (48.0) 34  (13.5) (39.3) 45  17.2 43.9 79 
Berea * * 17  (9.3) (34.6) 37  13.8 35.2 54 
Quthing * * 11  (0.0) (29.8) 29  (2.5) (30.2) 40 
Butha Buthe  * * 10  * * 16  (20.7) (55.3) 26 
Mokhotlong * * 23  (25.6) (42.3) 27  22.4 54.9 50 
Qacha's Nek * * 8  * * 12  * * 20 
Thaba Tseka  * * 17  * * 13  (30.1) (56.1) 30 
            
Marital status            
Never married/lived 
together (8.2) (44.1) 43  9.8 36.7 80  9.1 39.9 123 
Married or living  
together 15.7 47.6 130  14.3 34.7 160  15.1 41.8 290 
Divorced or separated (17.9) (46.5) 46  (23.7) (52.1) 35  20.1 48.7 81 
Widowed * * 8  (18.9) (60.9) 48  28.2 65.5 56 
            
Education            
No education (19.1) (43.4) 35  * * 5  (17.1) (42.5) 40 
Primary 18.9 47.9 133  18.2 39.4 149  18.6 44.2 282 
Secondary 9.6 48.6 54  12.9 42.7 158  11.7 44.8 212 
College / University * * 5  * * 9  * * 14 
Graduate / post-
graduate  * * 1  * * 2  * * 3 
            
Wealth quintile            
Lowest 15.1 56.0 57  22.5 42.2 64  18.4 49.9 121 
Second (16.2) (48.4) 46  15.2 38.3 57  15.7 43.8 103 
Middle 15.5 47.0 64  10.9 40.0 67  13.6 44.1 131 
Fourth  (21.9) (40.1) 43  17.7 42.7 77  19.6 41.5 120 
Highest * * 18  9.5 42.2 57  10.0 44.6 75 
            
Religion            
Roman Catholic 12.8 41.4 93  17.9 40.9 125  15.3 41.1 218 
Lesotho Evangelical 18.1 53.2 52  (14.0) (38.6) 44  16.5 47.6 96 
Anglican * * 17  * * 22  (14.5) (48.0) 39 
Pentecostal * * 9  (17.1) (52.3) 29  (14.4) (47.5) 38 
Other Christian (17.4) (49.1) 34  13.5 42.4 68  15.2 45.3 102 
Other religion * * 13  (10.0) (39.0) 35  (18.4) (47.7) 48 
Don't know * * 8  * * 0  * * 8 
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Table 11.4.A Late HIV diagnosis (continued) 
Among adults aged 15-59 years who tested HIV positive in the PHIA survey but self-reported HIV negative, percentage who had a CD4 cell 
count < 200 cells/µL and < 350 cells/µL, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
< 200 
 cells/µL1 
Percentage 
< 350 
 cells/µL1 Number   
Percentage 
< 200 
cells/µL1 
Percentage 
< 350 
 cells/µL1 Number   
Percentage 
< 200 
cells/µL1 
Percentage 
< 350 
 cells/µL1 Number 
Age            
15-19 * * 4  * * 17  * * 21 
20-24 * * 13  5.3 34.5 67  8.0 36.0 80 
25-29 (11.1) (38.4) 47  9.1 36.3 71  10.1 37.4 118 
30-34 14.4 50.0 61  (25.9) (49.7) 49  18.6 49.9 110 
35-39 (17.2) (58.6) 43  (21.4) (37.8) 38  18.8 50.8 81 
40-44 (27.6) (56.8) 27  * * 22  (20.0) (50.7) 49 
45-49 * * 13  * * 20  (20.7) (52.4) 33 
50-54 * * 9  * * 20  (19.6) (53.8) 29 
55-59 * * 11  * * 19  (35.6) (44.3) 30 
            
Total 15-24 * * 17  4.1 32.4 84  6.0 31.9 101 
Total 15-49 15.5 47.9 208  13.7 40.0 284  14.7 44.1 492 
Total 15-59 16.5 47.9 228  15.0 41.2 323  15.7 44.6 551 
1Relates to Global AIDS Monitoring indicator 1.5: Late HIV diagnosis 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
11.5 Retention on Antiretroviral Therapy 
Among adults living with HIV who initiated ART less than 12 months prior to the survey, 98.8% reported 
that they were still taking ART at the time of the survey (Table 11.5.A). Similarly, 98.0% of those who 
initiated ART 12 months or more prior to the survey reported still taking ART. There was little variation 
by sociodemographic characteristics (Table 11.5.B). 
 
Table 11.5.A Retention on antiretroviral therapy (ART): people initiating ART LESS THAN 12 months prior to the survey 
Among HIV-positive adults aged 15-59 years who self-reported initiating ART less than 12 months prior to the survey, percentage who self-
reported still receiving ART, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number 
Presence of detectable ARVs         
Detectable 99.3 136  99.0 358  99.1 494 
Not detectable * 6  (96.4) 32  (95.2) 38 
         
Residence         
Urban 100.0 50  99.2 154  99.5 204 
Peri-urban * 14  * 24  (98.5) 38 
Rural 97.9 79  98.6 215  98.4 294          
District         
Maseru (100.0) 43  99.0 100  99.4 143 
Mafeteng * 16  (100.0) 40  100.0 56 
Mohale's Hoek * 13  (100.0) 28  (96.0) 41 
Leribe * 24  98.3 61  98.9 85 
Berea * 21  97.4 58  98.4 79 
Quthing * 6  * 23  (92.9) 29 
Butha Buthe  * 3  * 20  * 23 
Mokhotlong * 6  * 22  (100.0) 28 
Qacha's Nek * 4  * 16  * 20 
Thaba Tseka  * 7  (100.0) 25  (100.0) 32          
Marital status         
Never married / lived 
together * 18  100.0 63  98.9 81 
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Table 11.5.A Retention on antiretroviral therapy (ART): people initiating ART LESS THAN 12 months prior to the survey (continued) 
Among HIV-positive adults aged 15-59 years who self-reported initiating ART less than 12 months prior to the survey, percentage who self-
reported still receiving ART, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number 
Marital status (cont.)         
Married or living together 99.0 95  99.0 207  99.0 302 
Divorced or separated * 19  (100.0) 43  100.0 62 
Widowed * 10  96.6 80  97.1 90          
Education         
No education * 21  * 5  (100.0) 26 
Primary 98.1 80  99.1 210  98.7 290 
Secondary (100.0) 38  98.2 158  98.7 196 
College / University * 2  * 18  * 20 
Graduate / post-graduate  * 1  * 2  * 3          
Wealth quintile         
Lowest (97.0) 36  98.4 74  97.8 110 
Second (98.2) 34  99.0 88  98.7 122 
Middle (100.0) 27  98.4 98  98.9 125 
Fourth  * 24  98.2 68  98.9 92 
Highest * 22  100.0 65  100.0 87 
         
Religion         
Roman Catholic 98.6 65  99.0 158  98.8 223 
Lesotho Evangelical (97.8) 29  100.0 54  99.0 83 
Anglican * 11  * 19  (100.0) 30 
Pentecostal * 9  (97.4) 43  98.1 52 
Other Christian * 20  97.5 82  98.2 102 
Other religion * 6  (100.0) 34  (100.0) 40 
Don't know * 3  * 3  * 6          
Age         
15-19 * 2  * 12  * 14 
20-24 * 4  (100.0) 48  100.0 52 
25-29 * 19  100.0 99  100.0 118 
30-34 (97.0) 29  98.2 56  97.7 85 
35-39 (98.0) 28  97.6 65  97.7 93 
40-44 * 24  (98.0) 42  99.0 66 
45-49 * 15  * 24  (100.0) 39 
50-54 * 15  (95.1) 27  (97.4) 42 
55-59 * 7  * 20  (100.0) 27 
         
Total 15-24 * 6  100.0 60  100.0 66 
Total 15-49 98.7 121  99.0 346  98.9 467 
Total 15-59 98.9 143  98.8 393  98.8 536 
1Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 11.5.B Retention on antiretroviral therapy (ART): people initiating ART MORE THAN 12 months prior to the survey   
Among HIV-positive adults aged 15-59 years who self-reported initiating ART 12 months or more prior to the survey, percentage who self-
reported still receiving ART, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number 
Presence of detectable ARVs         
Detectable 99.8 466  99.8 1123  99.8 1589 
Not detectable * 22  73.6 83  71.9 105 
         
Residence         
Urban 98.0 190  96.6 504  97.1 694 
Peri-urban (100.0) 29  100.0 68  100.0 97 
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Table 11.5.B Retention on antiretroviral therapy (ART): people initiating ART MORE THAN 12 months prior to the survey (continued) 
Among HIV-positive adults aged 15-59 years who self-reported initiating ART 12 months or more prior to the survey, percentage who self-
reported still receiving ART, by sex and selected demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number   
Percentage 
still receiving 
ART1 Number 
Residence (cont.)         
Rural 98.4 271  98.7 648  98.6 919 
         
District         
Maseru 98.2 137  97.0 301  97.5 438 
Mafeteng (100.0) 45  97.1 138  98.0 183 
Mohale's Hoek (100.0) 43  98.4 118  98.9 161 
Leribe 98.9 80  99.0 200  99.0 280 
Berea 100.0 55  97.6 148  98.4 203 
Quthing * 24  100.0 68  100.0 92 
Butha Buthe  * 23  93.1 57  90.8 80 
Mokhotlong (91.1) 26  100.0 58  96.6 84 
Qacha's Nek * 22  (97.8) 49  98.6 71 
Thaba Tseka  (100.0) 35  100.0 83  100.0 118 
         
Marital status         
Never married / lived together 100.0 80  96.7 170  98.0 250 
Married or living together 98.1 282  97.7 603  97.9 885 
Divorced or separated 98.9 62  96.3 137  97.3 199 
Widowed 96.7 63  99.5 310  98.9 373 
         
Education         
No education 98.8 74  * 23  99.0 97 
Primary 98.2 269  97.9 677  98.0 946 
Secondary 98.1 127  98.2 447  98.2 574 
College / University * 17  94.2 66  95.9 83 
Graduate / post-graduate  * 2  * 7  * 9 
         
Wealth quintile         
Lowest 97.3 103  99.0 232  98.4 335 
Second 99.4 122  98.0 266  98.6 388 
Middle 97.6 105  98.2 263  98.0 368 
Fourth  97.3 86  97.2 247  97.3 333 
Highest 100.0 74  97.0 211  98.0 285 
         
Religion         
Roman Catholic 100.0 196  98.3 471  98.9 667 
Lesotho Evangelical 95.5 97  97.6 217  96.8 314 
Anglican (95.5) 38  100.0 72  98.1 110 
Pentecostal (97.4) 40  98.8 123  98.4 163 
Other Christian 98.7 75  96.4 238  97.1 313 
Other religion (100.0) 34  96.9 94  98.0 128 
Don't know * 8  * 5  * 13 
         
Age         
15-19 * 11  * 22  (97.3) 33 
20-24 * 10  92.5 70  92.6 80 
25-29 * 16  97.9 138  98.2 154 
30-34 (100.0) 49  95.8 219  96.9 268 
35-39 95.6 76  97.9 220  97.1 296 
40-44 97.8 96  99.6 198  98.8 294 
45-49 99.0 92  98.5 134  98.8 226 
50-54 98.9 67  100.0 116  99.5 183 
55-59 100.0 73  100.0 103  100.0 176 
         
Total 15-24 * 21  93.3 92  94.1 113 
Total 15-49 98.0 350  97.4 1001  97.6 1351 
Total 15-59 98.3 490  97.9 1220  98.0 1710 
1Relates to Global AIDS Monitoring indicator 1.3: Retention on antiretroviral therapy at 12 months 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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11.6 Transmitted Resistance to Antiretroviral Therapy 
As indicated in Section 1.3, an objective of LePHIA was to estimate the prevalence of transmitted 
resistance to ARVs, using samples from HIV-positive participants who were identified as recent HIV 
infections using the Recent Infection Testing Algorithm (Figure 2.5.A). 
 
Genotypic resistance testing was done on plasma samples from the 35 adults who were classified as 
recently diagnosed with HIV. The prevalence of transmitted drug resistance was 11.4%, with the most 
common mutations conferring resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
including K103N. Dual-class resistance was seen in 2.9%, where one participant had mutations to the 
nucleoside reverse transcriptase inhibitors (NRTIs), including K65R and M184V, as well as NNRTIs (Table 
11.6.A). Common to the region, all samples that underwent genotyping (n=148) were Subtype C (Table 
11.6.B). 
 
Table 11.6.A Resistance to antiretrovirals (ARVs) 
Among adults aged 15-59 years who were recently infected with HIV, percentage with resistance to ARVs, by class of ARV* resistance, 
LePHIA 2016-2017 
  Percent Number DR Mutations Detected1 
Successfully amplified2 100.0 35  
Any 11.4 4 K103N, K65R, M184V, V106M, V75M 
Nucleoside reverse transcriptase inhibitors 
(NRTIs) 2.9 1 K65R, M184V, V75M 
Non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) 11.4 4 K103N, V106M 
Protease inhibitors (PIs) 0.0 0  
NRTI & NNRTI 2.9 1 K65R, M184V, V106M, V75M 
NRTI, NNRTI & PI 0.0 0  
* Commonly used ARV by class include: NNRTIs nevirapine and efavirenz; NRTIs tenofovir, lamivudine, zidovudine, emtricitabine and PIs 
lopinavir/ritonavir and atazanavir. 
1Based on Stanford Database for HIV Drug Resistance Mutation: 
https://hivdb.stanford.edu/pages/download/resistanceMutations_handout.pdf 
2Unweighted figures, from a total of 35 cases. 
 
 
Table 11.6.B HIV Subtype 
Percent distribution of HIV-positive adults aged 15-59 years that that underwent genotyping, by HIV subtype, LePHIA 2016-2017 
  Total 
  Percent Number 
Subtype A 0.0 0 
Subtype B 0.0 0 
Subtype C 100.0 148 
Subtype D 0.0 0 
Subtype G 0.0 0 
Recombinant 0.0 0 
   
Total 100.0 148 
Unweighted figures 
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11.7 Gaps and Unmet Needs 
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▪ Almost half of adults living with HIV, but previously unaware of their HIV-positive status, had a 
CD4 count less than 350 cells/µL at HIV diagnosis.  
▪ Severe immunosuppression was common among older adolescent boys suggesting long-term 
infection and limited uptake of HIV services. However, numbers were very small and should be 
validated using additional data sources.  
▪ Older people over the age of 55 years appeared vulnerable to late diagnosis with severe 
immunosuppression. There is a need for further investigation within this high-risk population to 
understand this pattern and validate in other cohorts. 
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Chapter 12    Prevention of Mother-to-Child Transmission 
12.1 Key Findings 
 
 
12.2 Background 
Pregnant women living with HIV are at high risk of transmitting HIV to their infants during pregnancy, 
during birth, or through breastfeeding. Over 90% of new infections among infants and young children 
occur through mother-to-child transmission (MTCT). Without any interventions, between 20% and 45% 
of infants may become infected, with an estimated risk of 5-10% during pregnancy, 10-20% during labor 
and delivery, and 5-20% through breastfeeding.1 In 2010, global targets were set to decrease new HIV 
infections in children and reduce mortality among mothers living with HIV, including a 90% reduction in 
child HIV infections, a 50% reduction in AIDS-related maternal deaths, and elimination of MTCT.2 
 
To prevent MTCT, the WHO recommends a comprehensive four-pronged approach including: (1) 
primary prevention of HIV infection among women of childbearing age; (2) preventing unintended 
pregnancies among women living with HIV; (3) preventing HIV transmission from women living with HIV 
to their infants; and (4) providing appropriate treatment, care, and support to mothers living with HIV 
and their children and families.2 Since 2016, WHO/UNICEF guidance has recommended that mothers 
living with HIV should breastfeed for at least 12 months and may continue breastfeeding for 24 months 
or longer while being fully supported for adherence on ART. 
 
In 2013 Lesotho started implementation of Option B+, whereby pregnant women are started on lifelong 
ART as soon as they are diagnosed with HIV.3 Lesotho has established an Elimination of Transmission of 
HIV and Syphilis Plan which outlines strategies for care and treatment.4 This chapter describes antenatal 
care (ANC) attendance; breastfeeding practices; awareness of a woman’s HIV status prior to or during 
pregnancy; use of ART during pregnancy in women who were aware of their HIV-positive status during 
pregnancy; and infant HIV testing to detect HIV infection.   
 
12.3 Antenatal Care Attendance 
Almost all women (97.1%) aged 15-49 years who delivered in the three years preceding the survey 
attended at least one ANC visit for their most recent birth. There was negligible variation by urban/rural 
residence, district, marital status, education, or age, with all above 90.0% (Table 12.3.A). 
 
  
▪ In Lesotho, 97.1% of women aged 15-49 years who delivered in the three years preceding the 
survey attended at least one antenatal care visit for their most recent birth. 
▪ PMTCT: Among women aged 15-49 years who delivered in the 12 months preceding the survey, 
95.6% knew their HIV status, while 98.5% of HIV-positive women who gave birth in the 12 months 
preceding the survey received ART.   
▪ Among infants born in the previous 17 months to HIV-positive mothers, 2.8% were confirmed to be 
HIV positive according to the virologic testing conducted as part of LePHIA. 
12 PREVENTION OF MOTHER-TO-CHILD 
TRANSMISSION 
  
 
 
 
86 
Table 12.3.A Antenatal care 
Among women aged 15-49 years who delivered in the three years preceding the survey, percentage who attended at least one antenatal 
care visit for her most recent birth, by selected demographic characteristics, LePHIA 2016-2017 
Characteristic 
Percentage who attended at least one 
ANC visit Number 
Residence   
Urban 97.5 553 
Peri-urban 100.0 82 
Rural 96.5 894 
   
District   
Maseru 96.1 330 
Mafeteng 96.9 160 
Mohale's Hoek 96.9 123 
Leribe 98.0 259 
Berea 98.3 171 
Quthing 98.8 87 
Butha Buthe  99.0 107 
Mokhotlong 99.0 107 
Qacha's Nek 93.5 103 
Thaba Tseka  98.5 70 
   
Marital status   
Never married / lived together 97.6 209 
Married or living together 97.6 1,165 
Divorced or separated 92.4 95 
Widowed 92.5 59 
   
Education   
No education * 16 
Primary 95.5 597 
Secondary 97.6 779 
College / University 100.0 123 
Graduate / post-graduate  * 14 
   
Wealth quintile   
Lowest 95.2 395 
Second 96.7 345 
Middle 95.9 288 
Fourth  98.4 259 
Highest 100.0 237 
   
Religion   
Roman Catholic 97.2 605 
Lesotho Evangelical 99.1 237 
Anglican 95.8 92 
Pentecostal 95.5 167 
Other Christian 97.0 311 
Other religion 95.7 110 
Don't know * 6 
   
Age   
15-19 97.9 118 
20-24 96.8 508 
25-29 98.6 402 
30-34 96.8 274 
35-39 94.7 158 
40-44 96.9 60 
45-49 * 9 
   
Total 15-24 97.0 626 
Total 15-49 97.1 1,529 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has 
been suppressed. 
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12.4 Breastfeeding 
Almost a quarter of infants (23.9%) were no longer breastfeeding by 9 months, and over a third (35.7%) 
of infants had been weaned before 12 months. Significantly fewer HIV-positive women were 
breastfeeding at the time of the survey; 28.2% of HIV-positive women and 43.3% of HIV-negative 
women. Furthermore, significantly more HIV-positive women (9.8%) had never breastfed their last-born 
child, as compared to HIV-negative women (2.6%) (Table 12.4.A). 
 
Table 12.4.A Breastfeeding status by child’s age and mother’s HIV status  
Percent distribution of last-born children born to women ages 15-49 years in the three years preceding the survey by breastfeeding status, 
by child's age and mother's HIV status, LePHIA 2016-2017 
Characteristic 
Never 
breastfed 
Ever breastfed, but 
not currently 
breastfeeding 
Currently 
breastfeeding Total Number 
Child's age (months)      
0-1 4.6 19.5 75.8 100.0 90 
2-3 3.2 27.4 69.4 100.0 104 
4-5 5.7 21.7 72.6 100.0 97 
6-8 4.5 23.9 71.6 100.0 161 
9-11 7.2 35.7 57.1 100.0 140 
12-17 3.9 50.4 45.7 100.0 259 
18-23 5.2 74.8 20.0 100.0 230 
24-36 5.8 91.2 2.9 100.0 431 
      
Result of mother's PHIA survey HIV test      
HIV positive 9.8 61.9 28.2 100.0 397 
HIV negative 2.6 54.1 43.3 100.0 1,026 
Not tested 12.4 57.3 30.4 100.0 91 
      
Total 5.1 56.4 38.5 100.0 1,514 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
12.5 Awareness of Mother’s HIV Status 
Among all women who delivered within the 12 months preceding the survey, 16.4% reported that they 
were already aware of their HIV-positive status when they went to the ANC, and 4.6% reported that 
they learned that they were HIV-positive when they were tested at their ANC visit (74.7% reported that 
they tested HIV-negative at their ANC visit). Overall, 95.6% reported that they knew their HIV status 
during their pregnancy, ranging from 91.3% in Mohale’s Hoek to 97.1% in Butha Buthe. There was little 
geographic variation in whether they had known their status prior to becoming pregnant or whether 
they were tested as part of ANC. There was no significant variation in awareness across residence, 
marital status, religion, and education (Table 12.5.A).  
 
Table 12.5.A Prevention of mother-to-child transmission: known HIV status  
Among women aged 15-49 years who gave birth within the past 12 months, percentage who were tested for HIV during antenatal care and 
received their results or who already knew they were HIV positive, by selected demographic characteristics, LePHIA 2016-2017 
  Tested for HIV during ANC and received results  
Characteristic 
Percentage 
who tested HIV 
positive 
Percentage who 
tested HIV  
negative 
Percentage 
who already 
knew they 
were HIV 
positive 
Total percentage 
with known HIV 
status1 
Number of 
women who 
gave birth within 
the past 12 
months 
Residence      
Urban 4.6 68.1 21.8 94.5 183 
Peri-urban (9.7) (79.2) (8.6) (97.6) 33 
Rural 4.1 78.0 14.0 96.1 362 
      
District      
Maseru 2.5 71.8 21.2 95.5 127 
Mafeteng 4.8 73.5 18.3 96.6 54 
Mohale's Hoek 8.7 61.6 21.0 91.3 51 
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Table 12.5.A Prevention of mother-to-child transmission: known HIV status (continued)  
Among women aged 15-49 years who gave birth within the past 12 months, percentage who were tested for HIV during antenatal care and 
received their results or who already knew they were HIV positive, by selected demographic characteristics, LePHIA 2016-2017 
  Tested for HIV during ANC and received results  
Characteristic 
Percentage 
who tested HIV 
positive 
Percentage who 
tested HIV  
negative 
Percentage 
who already 
knew they 
were HIV 
positive 
Total percentage 
with known HIV 
status1 
Number of 
women who 
gave birth within 
the past 12 
months 
District (cont.)      
Leribe 6.9 75.1 14.2 96.3 103 
Berea 2.6 82.0 12.6 97.2 70 
Quthing (5.5) (73.2) (15.5) (94.2) 37 
Butha Buthe  (2.9) (82.4) (11.9) (97.1) 35 
Mokhotlong (14.3) (64.6) (15.1) (94.0) 34 
Qacha's Nek * * * * 22 
Thaba Tseka  (0.0) (85.2) (12.4) (97.6) 45 
      
Marital status      
Never married / lived  together 5.3 76.9 11.1 93.3 81 
Married or living together 4.2 76.7 14.8 95.6 454 
Divorced or separated (12.6) (50.0) (37.4) (100.0) 27 
Widowed * * * * 16 
      
Education      
No education * * * * 5 
Primary 5.7 65.9 21.6 93.2 225 
Secondary 4.4 78.2 14.3 96.9 303 
College / University (1.9) (95.4) (2.7) (100.0) 39 
Graduate / post-graduate  * * * * 6 
      
Wealth quintile      
Lowest 4.2 78.2 14.4 96.8 159 
Second 3.2 77.2 14.0 94.4 136 
Middle 7.2 64.4 21.3 92.9 117 
Fourth  5.5 73.8 18.9 98.1 93 
Highest 3.0 79.7 13.9 96.6 71 
      
Religion      
Roman Catholic 4.8 72.2 16.9 93.9 240 
Lesotho Evangelical 3.3 83.7 9.0 96.0 91 
Anglican (2.8) (79.4) (17.8) (100.0) 35 
Pentecostal 7.7 74.9 13.8 96.5 64 
Other Christian 4.8 73.2 19.0 97.0 104 
Other religion (1.4) (68.4) (27.1) (97.0) 40 
Don't know * * * * 3 
      
Age      
15-19 2.3 88.3 4.2 94.8 77 
20-24 3.3 85.4 10.2 98.9 192 
25-29 5.8 71.6 19.0 96.4 147 
30-34 7.4 64.1 23.0 94.5 99 
35-39 (3.7) (48.0) (33.9) (85.7) 48 
40-44 * * * * 12 
45-49 * * * * 3 
      
Total 15-24 3.0 86.2 8.5 97.8 269 
Total 15-49 4.6 74.7 16.4 95.6 578 
1Relates to PEPFAR PMTCT_STAT_NAT / SUBNAT 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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12.6 Antiretroviral Therapy Among HIV-Positive Pregnant Women 
Among HIV-positive women who delivered in the 12 months preceding the survey, 98.5% reported 
receiving ART during their pregnancy: 59.0% were already taking ART at the time of their first ANC visit 
and 39.5% were newly initiated on ART during pregnancy or during labor and delivery (Table 12.6.A).  
 
Table 12.6.A Prevention of mother-to-child transmission: HIV-positive pregnant women who received antiretrovirals (ARVs) 
Among HIV-positive women aged 15-49 years who gave birth within the past 12 months, percentage who received ARVs during pregnancy 
to reduce the risk of MTCT, by selected demographic characteristics, LePHIA 2016-2017 
Characteristic 
Percentage who 
were already on 
ARVs prior to 
pregnancy 
Percentage who were newly 
initiated on ARVs during 
pregnancy or labor and 
delivery 
Total percentage 
who received 
ARVs1 
Number of HIV-positive 
women who gave birth 
within the past  
12 months 
Residence     
Urban (64.3) (35.7) (100.0) 47 
Peri-urban * * * 7 
Rural 57.4 39.6 97.1 68 
     
District     
Maseru (67.2) (32.8) (100.0) 30 
Mafeteng * * * 11 
Mohale's Hoek * * * 16 
Leribe * * * 22 
Berea * * * 11 
Quthing * * * 8 
Butha Buthe  * * * 5 
Mokhotlong * * * 10 
Qacha's Nek * * * 2 
Thaba Tseka  * * * 7 
     
Marital status     
Never married / lived together * * * 14 
Married or living together 61.1 37.8 98.9 85 
Divorced or separated * * * 14 
Widowed * * * 9 
     
Education     
No education * * * 1 
Primary 54.4 44.1 98.5 62 
Secondary 64.1 34.3 98.4 56 
College / University * * * 2 
Graduate / post-graduate  * * * 1 
     
Wealth quintile     
Lowest (53.2) (40.1) (93.3) 31 
Second (66.2) (33.8) (100.0) 25 
Middle (63.1) (36.9) (100.0) 32 
Fourth  * * * 21 
Highest * * * 13 
     
Religion     
Roman Catholic 63.1 35.2 98.3 54 
Lesotho Evangelical * * * 11 
Anglican * * * 7 
Pentecostal * * * 13 
Other Christian * * * 24 
Other religion * * * 12 
Don't know * * * 1 
     
Age     
15-19 * * * 5 
20-24 (52.7) (43.7) (96.4) 27 
25-29 (62.6) (37.4) (100.0) 36 
30-34 (50.9) (46.2) (97.1) 31 
35-39 * * * 18 
40-44 * * * 4 
45-49 * * * 1 
     
Total 15-24 (52.3) (44.7) (97.0) 32 
Total 15-49 59.0 39.5 98.5 122 
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Table 12.6.A Prevention of mother-to-child transmission: HIV-positive pregnant women who received antiretrovirals (ARVs) 
(conclusion) 
1Relates to Global AIDS Monitoring indicator 2.3: Preventing the mother-to-child transmission of HIV, and PMTCT_ARV_NAT / SUBNAT 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
12.7 Mother-to-Child Transmission 
Among infants born in the 17 months preceding the survey to HIV-positive mothers aged 15-49 years 
and alive at the time of the survey, 2.8% tested positive for infection by HIV TNA PCR. Among those 
whose mothers reported ever breastfeeding, 2.1% were HIV positive. Among last-born infants of women 
who were already on ART at their first ANC visit, 2.6% were HIV positive—however, this estimate should 
be interpreted with caution as it was based upon a small number (n=35). At the time of the survey, 
20.9%, (19/91) of all mothers who had delivered 17 months preceding the survey did not have VLS. 
(Table 12.7.A.) 
 
Table 12.7.A Mother-to-child transmission of HIV  
Among infants born in the last 17 months to HIV-positive women aged 15-49 years, percentage confirmed positive for HIV infection, by 
mother's self-reported ARV and breastfeeding status, LePHIA 2016-2017 
Characteristic 
Percentage of infants 
confirmed HIV-positive1, 2 
Number of infants born 
to HIV-positive women3, 4 
Mother's self-reported ARV status   
Mother unaware of HIV status during pregnancy * 17 
Already on ARVs at first antenatal visit (2.6) 35 
Newly initiated on ARVs during pregnancy or labor and delivery * 22 
Did not receive ARVs during pregnancy * 3 
Missing self-reported ARV status * 14 
    
Maternal viral load in LePHIA   
Suppressed 2.3 72 
Unsuppressed * 19 
    
Mother's self-reported breastfeeding status   
Ever breastfed the infant 2.1 80 
Never breastfed the infant * 4 
Missing self-reported breastfeeding status * 7 
    
Total 0-11 months 2.6 63 
Total 0-17 months 2.8 91 
1Relates to Global AIDS Monitoring indicator 2.2: Mother-to-child transmission of HIV; 2Includes only infants who were tested for HIV during 
the PHIA survey. 
2Infants confirmed as HIV positive by virological testing (virological testing was only conducted among infants who had a reactive screening 
test). 
3Includes only infants who were tested for HIV during the PHIA survey. 
4Women who tested HIV positive during the PHIA survey. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable.  
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution.  
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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12.8 Gaps and Unmet Needs 
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▪ Contrary to the current PMTCT National Guidelines,3 HIV-positive women less frequently 
breastfed compared to HIV-negative women. However, these pregnancies preceded the change 
in guidelines on breastfeeding for HIV-positive women. More recent data can allow an 
assessment of breastfeeding in the era of universal treatment.  
▪ Despite progress on PMTCT in Lesotho, one in 36 infants born to HIV-positive mothers has 
become HIV positive. Although a large proportion of these infants were born to a mother already 
on ART prior to ANC, one in five (20.9%) of the infants’ mothers did not have VLS at the time of 
the survey (although this might not reflect their status during pregnancy and labor). 
▪ The prevalence of early weaning suggests that WHO guidelines on breastfeeding for a minimum 
of 12 months should be reinforced in ANC. 
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Chapter 13    Young People 
13.1 Key Findings  
 
 
13.2 Background 
One-third of the population of sub-Saharan Africa is aged between 10-24 years, a phenomenon often 
referred to as the youth bulge.1 Studies have shown that young people aged 15-24 years are more likely 
to engage in risky sexual behaviors than older adults and have less frequent contact with the healthcare 
system. Control of HIV in this demographic is critical for long-term epidemic control but is also 
particularly challenging.  
 
The PEPFAR DREAMS program (Determined, Resilient, Empowered, AIDS-free, Mentored and Safe) was 
rolled out in two key districts (Maseru and Berea) in Lesotho in 2016.2,3 This private-public partnership 
was designed to empower adolescent girls and young women by providing them with long-term skills by 
supporting education; strengthening families and communities to counteract harmful local gender 
norms; and improving coverage of contraception, condoms, and HIV testing services.  
 
This chapter presents the prevalence of early sexual debut, defined as sexual intercourse before the age 
of 15 years, among young people by marital status, region, and socio-demographic characteristics. It 
also describes their knowledge of HIV prevention. These data were measured by asking participants to 
agree or disagree with both accurate and inaccurate statements about HIV prevention. This chapter also 
describes HIV incidence, prevalence, and the 90-90-90 cascade for young people. 
 
13.3 Sexual Intercourse Before the Age of 15 Years 
Among young people, 12.7% reported early sexual debut; this was four times higher among young men 
(20.6%) than among young women (4.7%). The percentage reporting early sexual debut was higher in 
certain districts, with over one in four young men reporting early sexual debut in the districts of 
▪ Among young people, including older adolescents and young adults aged 15-24 years, 12.7% 
reported having sexual intercourse before the age of 15 years; it was far more commonly reported 
by young men (20.6%) than young women (4.7%). (Note: in this chapter, the terms young men and 
women include older adolescents, unless an age bracket is specifically indicated). 
▪ Only 28.3% of young people correctly responded to all questions in a set that assessed knowledge 
of HIV transmission and prevention (26.0% of young men and 30.7% of young women).  
▪ Annual incidence of HIV infection among young people was estimated at 0.78% (95% CI 0.31- 
1.25%), and was high in young women (1.49%). 
▪ HIV prevalence in older adolescents (those aged 15-19 years) was 4.2% (2.8% in older adolescent 
boys and 5.7% in older adolescent girls) and 10.4% in young adults aged 20-24 years (4.0% in 
young men and 16.7% in young women).  
▪ Based on self-report and detection of ARVs in blood, 67.6% of young people living with HIV had 
been diagnosed with HIV (71.3% of young men and 66.4% of young women), and among those 
who had been previously diagnosed, 90.6% were on ART.  Only 77.2% of young people on ART had 
VLS. 
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93 
Quthing, Mokhotlong, Qacha’s Nek, and Thaba Tseka. Among those who attended secondary school, a 
significantly lower percentage (10.6%) reported early sexual debut compared to those who had only 
attended primary school (18.3%). There was no difference between the proportion reporting early 
sexual debut by geographic residence, wealth quintile, religion, or age (Table 13.3.A). 
 
Table 13.3.A Sex before the age of 15 years 
Percentage of young people aged 15–24 years who have had sexual intercourse before the age of 15 years; by sex and selected 
demographic characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
who had sex 
before age 15 Number  
Percentage 
who had sex 
before age 15 Number  
Percentage 
who had sex 
before age 15 Number 
Residence         
Urban 19.7 606  4.6 985  11.5 1,591 
Peri-urban 19.4 161  1.0 186  10.6 347 
Rural 21.4 1,067  5.4 1,320  13.9 2,387          
District         
Maseru 18.4 467  4.1 619  11.3 1,086 
Mafeteng 23.6 217  2.8 244  14.1 461 
Mohale's Hoek 20.3 114  6.1 184  12.6 298 
Leribe 18.0 291  5.0 407  11.6 698 
Berea 19.0 269  4.4 342  12.0 611 
Quthing 28.3 110  11.9 130  20.4 240 
Butha Buthe  20.9 133  3.2 153  12.8 286 
Mokhotlong 27.1 75  5.7 166  13.9 241 
Qacha's Nek 32.1 65  4.5 110  17.4 175 
Thaba Tseka  25.6 93  4.2 136  14.5 229          
Marital status         
Never married / lived together 20.6 1,675  3.6 1,607  13.5 3,282 
Married or living together 18.6 137  6.3 811  8.8 948 
Divorced or separated * 17  15.0 54  22.1 71 
Widowed * 1  * 16  * 17          
Education         
No education (20.5) 46  * 24  16.3 70 
Primary 23.7 652  10.0 585  18.3 1,237 
Secondary 19.5 1,039  3.3 1,714  10.6 2,753 
College / University 13.7 96  1.9 164  7.2 260 
Graduate / post-graduate  * 1  * 4  * 5          
Wealth quintile         
Lowest 25.0 294  6.6 486  15.0 780 
Second 21.3 389  5.1 490  13.5 879 
Middle 19.8 410  6.3 554  13.1 964 
Fourth  19.6 410  3.2 500  11.9 910 
Highest 19.2 323  2.6 454  10.7 777          
Religion         
Roman Catholic 21.4 757  4.5 973  13.3 1,730 
Lesotho Evangelical 22.4 321  3.3 367  13.6 688 
Anglican 19.8 120  4.4 161  12.0 281 
Pentecostal 21.4 132  7.3 235  13.5 367 
Other Christian 18.2 297  4.8 556  10.4 853 
Other religion 19.4 150  5.5 186  12.8 336 
Don't know (12.8) 44  * 12  11.9 56          
Age         
15-19 21.0 987  4.8 1,242  13.0 2,229 
20-24 20.3 847  4.6 1,249  12.4 2,096          
Total 15-24 20.6 1,834  4.7 2,491  12.7 4,325 
 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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13.4 Knowledge About HIV Prevention 
LePHIA also collected information on knowledge of HIV prevention, by asking two questions about 
prevention of sexual transmission of HIV and three questions related to common misconceptions about 
contracting HIV. Comprehensive knowledge of HIV was defined as knowing that having just one HIV-
negative, faithful partner and using condoms during each sexual act can reduce the chances of acquiring 
HIV, and that a healthy-looking person can have HIV, and rejecting that a person can get HIV from 
mosquito bites and sharing food with someone who is HIV positive.  
 
Among young people, only 28.3% displayed comprehensive knowledge of HIV; 26.0% of young men 
answered all five HIV knowledge questions correctly and 30.7% of young women. Young people in urban 
areas had a higher proportion (32.1%) with comprehensive knowledge of HIV, compared to those in 
rural areas (24.9%). Geographically, the highest proportion that responded to all five questions correctly 
was in Berea (31.6%) and the lowest proportion was in Mohale’s Hoek (22.8%). The percentage of those 
with comprehensive knowledge varied in terms of education and wealth, where 18.2% of those with a 
primary education answered correctly compared to 31.4% of those with a secondary education, and 
22.8% of those in the lowest wealth quintile answered correctly compared to 36.4% of those in the 
highest wealth quintile. It did not vary by age group. Most young people (86.3%) answered correctly 
about the protective use of condoms, whereas only 52.8% answered correctly that you could not 
acquire HIV from a mosquito bite (Tables 13.4.A, 13.4.B, and 13.4.C). 
 
Table 13.4.A Young people, knowledge about HIV prevention: Young men 
Among older adolescent boys and young men aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of 
HIV and reject major misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having 
sex with only one 
uninfected partner 
who has no other 
partners? 
Can a person 
reduce the risk of 
getting HIV by 
using a condom 
every time they 
have sex? 
Can a 
healthy-
looking 
person 
have HIV? 
Can a 
person get 
HIV from 
mosquito 
bites? 
Can a person 
get HIV by 
sharing food 
with someone 
who is 
infected? 
All five 
questions Number2 
Residence        
Urban 77.4 90.9 83.1 56.0 84.3 33.0 319 
Peri-urban 84.1 92.8 90.6 42.0 83.8 25.4 81 
Rural 72.3 84.3 71.1 47.5 73.4 21.6 551         
District        
Maseru 78.9 89.6 81.4 53.5 77.6 30.1 249 
Mafeteng 74.8 85.5 73.3 38.7 71.8 20.0 112 
Mohale's Hoek 74.1 84.9 69.9 54.9 82.4 24.7 60 
Leribe 72.3 85.9 77.9 45.1 78.5 20.6 154 
Berea 77.7 88.9 80.9 52.7 84.5 31.9 134 
Quthing 78.0 84.4 78.3 59.6 70.9 28.8 57 
Butha Buthe  63.2 93.1 70.6 38.6 84.7 19.9 67 
Mokhotlong (64.9) (89.6) (82.7) (47.8) (80.4) (28.6) 41 
Qacha's Nek (73.1) (75.2) (71.7) (51.8) (69.0) (23.3) 35 
Thaba Tseka  (75.7) (79.3) (50.9) (61.2) (69.8) (15.8) 42         
Marital status        
Never married / lived  
 together 75.0 87.5 76.1 51.3 78.8 26.2 855 
Married or living together 76.8 86.9 87.6 37.1 70.4 23.4 82 
Divorced or separated * * * * * * 11 
Widowed * * * * * * 1         
Education        
No education (56.5) (72.6) (70.8) (30.5) (64.2) (15.7) 25 
Primary 66.8 79.2 60.0 49.4 64.2 16.5 344 
Secondary 80.3 92.2 87.1 50.2 86.6 30.8 534 
College / University (83.5) (96.2) (85.0) (62.2) (86.3) (42.4) 47 
Graduate / post-graduate  * * * * * * 1 
Wealth quintile        
Lowest 67.0 81.2 65.0 54.2 67.8 23.1 164 
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Table 13.4.A Young people, knowledge about HIV prevention: Young men (continued) 
Among older adolescent boys and young men aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of 
HIV and reject major misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having 
sex with only one 
uninfected partner 
who has no other 
partners? 
Can a person 
reduce the risk of 
getting HIV by 
using a condom 
every time they 
have sex? 
Can a 
healthy-
looking 
person 
have HIV? 
Can a 
person get 
HIV from 
mosquito 
bites? 
Can a person 
get HIV by 
sharing food 
with someone 
who is 
infected? 
All five 
questions Number2 
Wealth quintile (cont.)        
Second 76.6 85.3 71.8 45.4 74.9 20.8 200 
Middle 75.4 86.3 74.5 44.3 72.8 17.0 201 
Fourth  78.3 90.3 83.6 48.0 86.6 30.2 210 
Highest 76.5 93.0 87.6 59.3 85.6 37.7 172         
Religion        
Roman Catholic 74.8 88.4 76.4 50.0 77.5 23.3 394 
Lesotho Evangelical 77.6 85.4 80.2 52.3 77.8 30.9 163 
Anglican 72.2 82.4 79.7 52.3 83.6 30.6 54 
Pentecostal 69.7 89.8 73.3 44.3 70.5 22.3 75 
Other Christian 75.8 87.1 77.5 51.8 82.0 28.4 158 
Other religion 84.8 89.7 80.8 51.5 79.0 29.0 71 
Don't know (69.4) (88.3) (75.0) (35.2) (74.4) (22.1) 28         
Age        
15-19 72.3 85.0 72.2 53.8 75.9 26.0 486 
20-24 78.3 90.0 82.4 45.8 80.6 25.9 465         
Total 15-24 75.2 87.4 77.1 49.9 78.2 26.0 951 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention; 2Includes only participants who answered all five 
questions. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. An asterisk 
indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 13.4.B Young people, knowledge about HIV prevention: Young women 
Among older adolescent girls and young women aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission 
of HIV and reject major misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of 
HIV 
transmission be 
reduced by 
having sex with 
only one 
uninfected 
partner who has 
no other 
partners? 
Can a 
person 
reduce the 
risk of 
getting HIV 
by using a 
condom 
every time 
they have 
sex? 
Can a 
healthy-
looking 
person have 
HIV? 
Can a person 
get HIV from 
mosquito 
bites? 
Can a person get 
HIV by sharing 
food with 
someone who is 
infected? 
All five 
questions Number2 
Residence        
Urban 76.1 87.1 84.0 55.5 91.1 31.3 507 
Peri-urban 82.2 88.0 87.0 65.2 85.9 42.2 88 
Rural 75.7 83.4 79.3 54.5 84.4 28.5 708 
        
District        
Maseru 73.8 85.6 84.5 59.2 91.1 32.7 307 
Mafeteng 76.6 90.8 83.2 52.9 86.2 26.2 126 
Mohale's Hoek 71.9 79.9 72.8 54.7 84.5 21.3 100 
Leribe 80.2 88.4 87.3 51.5 89.5 32.7 219 
Berea 80.3 85.4 84.5 55.7 86.9 31.3 181 
Quthing 69.5 76.1 74.3 61.7 71.3 29.4 76 
Butha Buthe  76.6 85.0 81.1 51.7 85.5 34.2 79 
Mokhotlong 77.7 82.7 68.5 46.6 84.1 25.0 85 
Qacha's Nek 76.1 76.9 83.7 57.2 85.7 32.4 54 
Thaba Tseka  76.1 85.3 69.7 63.7 83.7 32.3 76         
Marital status        
Never married / lived together 73.2 83.7 80.1 58.2 87.1 29.5 840 
Married or living together 83.4 88.1 85.1 50.7 87.9 33.4 422 
Divorced or separated (68.5) (93.6) (81.7) (47.7) (85.1) (25.4) 31 
Widowed * * * * * * 7 
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Table 13.4.B Young people, knowledge about HIV prevention: Young women (continued) 
Among older adolescent girls and young women aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission 
of HIV and reject major misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of 
HIV transmission 
be reduced by 
having sex with 
only one 
uninfected 
partner who has 
no other 
partners? 
Can a 
person 
reduce the 
risk of 
getting HIV 
by using a 
condom 
every time 
they have 
sex? 
Can a 
healthy-
looking 
person have 
HIV? 
Can a person 
get HIV from 
mosquito 
bites? 
Can a person get 
HIV by sharing 
food with 
someone who is 
infected? 
All five 
questions Number2 
        
Education        
No education * * * * * * 14 
Primary 67.6 78.8 68.2 52.9 79.4 20.9 311 
Secondary 78.9 87.0 86.2 54.6 89.4 31.9 893 
College / University 83.0 89.4 83.8 73.8 93.2 52.7 83 
Graduate / post-graduate  * * * * * * 2 
        
Wealth quintile        
Lowest 70.1 77.5 72.2 52.0 80.3 22.5 262 
Second 76.0 86.4 77.2 57.0 87.7 32.6 253 
Middle 79.9 83.9 86.2 56.3 89.5 31.6 300 
Fourth  77.4 89.2 87.2 50.5 88.6 31.6 270 
Highest 77.2 88.9 84.8 63.2 89.0 35.0 216 
        
Religion        
Roman Catholic 76.4 86.3 80.7 57.3 87.8 31.5 492 
Lesotho Evangelical 78.4 85.3 88.3 59.8 86.2 34.1 180 
Anglican 75.6 83.7 77.6 53.6 88.5 27.6 85 
Pentecostal 77.7 81.5 87.5 50.9 86.2 30.5 131 
Other Christian 75.7 85.9 78.2 56.2 87.6 30.5 306 
Other religion 76.2 84.5 82.6 45.5 85.4 23.9 101 
Don't know * * * * * * 8 
        
Age        
15-19 70.0 82.4 77.1 58.0 86.2 27.8 660 
20-24 83.0 88.2 86.6 53.4 88.3 33.8 643 
        
Total 15-24 76.4 85.3 81.8 55.7 87.2 30.7 1,303 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention  
2Includes only participants who answered all five questions 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 13.4.C Young people, knowledge about HIV prevention: Total 
Among young people aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of HIV and reject major 
misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having 
sex with only one 
uninfected partner 
who has no other 
partners? 
Can a person 
reduce the 
risk of getting 
HIV by using 
a condom 
every time 
they have 
sex? 
Can a 
healthy-
looking 
person have 
HIV? 
Can a person 
get HIV from 
mosquito 
bites? 
Can a person 
get HIV by 
sharing food 
with 
someone 
who is 
infected? 
All five 
questions Number2 
Residence        
Urban 76.7 88.9 83.6 55.7 87.9 32.1 826 
Peri-urban 83.2 90.7 89.0 52.5 84.7 33.0 169 
Rural 74.0 83.9 75.1 50.8 78.7 24.9 1,259         
District        
Maseru 76.5 87.7 82.9 56.2 84.1 31.3 556 
Mafeteng 75.6 87.9 77.8 45.2 78.4 22.9 238 
Mohale's Hoek 72.9 82.1 71.5 54.8 83.6 22.8 160 
Leribe 76.2 87.1 82.6 48.3 84.0 26.6 373 
Berea 79.0 87.2 82.7 54.2 85.7 31.6 315 
Quthing 73.7 80.2 76.3 60.7 71.1 29.1 133 
Butha Buthe  69.4 89.4 75.4 44.6 85.1 26.5 146 
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Table 13.4.C Young people, knowledge about HIV prevention: Total (continued) 
Among young people aged 15-24 years, percentage who correctly identify both ways of preventing the sexual transmission of HIV and reject major 
misconceptions about HIV transmission,1 by selected demographic characteristics, LePHIA 2016-2017 
 Percentage who correctly answered the questions:  
Characteristic 
Can the risk of HIV 
transmission be 
reduced by having 
sex with only one 
uninfected partner 
who has no other 
partners? 
Can a person 
reduce the 
risk of getting 
HIV by using 
a condom 
every time 
they have 
sex? 
Can a 
healthy-
looking 
person have 
HIV? 
Can a person 
get HIV from 
mosquito 
bites? 
Can a person 
get HIV by 
sharing food 
with 
someone 
who is 
infected? 
All five 
questions Number2 
District (cont.)        
Mokhotlong 72.6 85.4 74.2 47.0 82.6 26.4 126 
Qacha's Nek 74.7 76.1 77.8 54.5 77.5 27.9 89 
Thaba Tseka  76.0 82.7 61.7 62.6 77.8 25.2 118         
Marital status        
Never married / lived together 74.2 85.9 77.8 54.2 82.3 27.6 1,695 
Married or living together 82.0 87.9 85.7 47.9 84.2 31.3 504 
Divorced or separated (68.9) (89.1) (78.3) (50.3) (86.9) (28.6) 42 
Widowed * * * * * * 8         
Education        
No education (57.8) (75.0) (70.1) (40.8) (66.7) (14.9) 39 
Primary 67.1 79.0 63.2 50.7 70.2 18.2 655 
Secondary 79.6 89.4 86.6 52.6 88.1 31.4 1,427 
College / University 83.2 92.3 84.3 68.8 90.2 48.3 130 
Graduate / post-graduate  * * * * * * 3         
Wealth quintile        
Lowest 68.6 79.2 68.9 53.0 74.5 22.8 426 
Second 76.3 85.8 74.4 51.0 81.1 26.4 453 
Middle 77.8 85.0 80.7 50.6 81.6 24.6 501 
Fourth  77.9 89.8 85.3 49.2 87.5 30.9 480 
Highest 76.9 91.0 86.3 61.2 87.2 36.4 388         
Religion        
Roman Catholic 75.5 87.4 78.4 53.4 82.3 27.1 886 
Lesotho Evangelical 78.0 85.3 83.9 55.7 81.6 32.4 343 
Anglican 74.0 83.1 78.6 53.0 86.2 29.0 139 
Pentecostal 74.1 85.2 81.2 47.9 79.2 26.9 206 
Other Christian 75.7 86.4 77.9 54.4 85.3 29.6 464 
Other religion 80.5 87.1 81.7 48.5 82.2 26.5 172 
Don't know (65.3) (88.1) (75.2) (41.4) (76.5) (23.3) 36         
Age        
15-19 71.1 83.7 74.6 55.9 81.0 26.9 1,146 
20-24 80.7 89.1 84.5 49.6 84.5 29.9 1,108         
Total 15-24 75.8 86.3 79.4 52.8 82.7 28.3 2,254 
1Relates to Global AIDS Monitoring indicator 5.1: Young people: Knowledge about HIV prevention; 2Includes only participants who answered all five 
questions. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. An asterisk 
indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
13.5 HIV Incidence and Prevalence 
Annual incidence among young people was estimated at 0.93% (95% CI 0.42-1.44%): 0.13% in young 
men and 1.81% in young women (Table 5.3.A). The annual incidence estimate, including ARV detection, 
was 0.78% (95% CI 0.31-1.25%): 0.13% in young men and 1.49% in young women (Table 5.3.B).   
 
HIV prevalence among young people was 7.2% and almost three-fold higher in young women (11.1%) 
than in young men (3.4%). HIV prevalence was 2.8% and 4.0% in older adolescent boys and young men 
aged 20-24 years, respectively; and 5.7% and 16.7% in older adolescent girls and young women aged 20-
24 years, respectively (Table 6.4.A).  
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13.6 HIV Testing, Treatment, and Viral Load Suppression 
Among young people, 79.7% reported that they had ever tested for HIV and received their results, with 
a similar proportion of young men (77.1%) and young women (82.2%), and no difference between older 
adolescents and young adults. However, recent testing was less common, with 56.9% reporting testing 
in the 12 months preceding the survey (49.3% among young men and 64.6% among young women) 
(Tables 7.3.A, 7.3.B, and 7.3.C).   
  
Among HIV-positive young people, 39.8% reported no previously diagnosis, while 52.7% reported taking 
ART, and 7.5% reported awareness of HIV status, but denied taking ART. There were more young men 
who reported awareness without ART (11.3%) than young women (6.3%) (Tables 8.3.A, 8.3.B, and 8.3.C). 
VLS was observed in only 51.0% of young people; there was no difference by age group or by sex, as VLS 
was documented in 51.3% of young men and 50.9% of young women (Tables 9.4.A and 9.4.B). 
 
13.7 Status of the UNAIDS 90-90-90 Targets  
Based on self-report and detection of ARVs in blood, it was estimated that 67.6% of young people living 
with HIV had previous HIV diagnosis (71.3% of young men and 66.4% of young women), and that among 
those who had been previously diagnosed, 90.6% were on ART (84.1% of young men and 92.8% of 
young women). Among those on treatment, only 77.2% had VLS (Table 10.3.B and Figure 13.7.A). 
 
Figure 13.7.A Young people 90-90-90 (laboratory ARV-adjusted data among young people aged 15-
24 years), LePHIA 2016-2017 
 
1In the antiretroviral (ARV)-adjusted 90-90-90, participants were classified as ‘aware’ or ‘diagnosed’ if they self-reported HIV 
positive before testing HIV positive in LePHIA or had detectable ARVs in their blood. Participants were classified as ‘on 
treatment’ if they self-reported that they were on treatment or if they had detectable ARVs in their blood.  
*Inset numbers are conditional proportions. Estimates in parentheses are based on a small number (25 to 49) of unweighted 
cases and should be interpreted with caution. 
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13.8 Gaps and Unmet Needs 
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▪ Among young people, 72% lacked comprehensive knowledge about HIV transmission and 
prevention, with one in four not knowing that monogamy with an HIV-negative partner may 
reduce risk of transmission.   
▪ Annual incidence was high among young women, indicating a need for improved prevention 
efforts in this population. 
▪ Among young people living with HIV, almost forty percent (39.8%) had not been diagnosed, and 
among those diagnosed, 7.5% had not initiated ART. Among those on treatment, 22.8% did not 
have VLS. Of all young people living with HIV, almost half (49.0%) did not have VLS.  
  
 
 
 
100 
Chapter 14    Children 
14.1 Key Findings  
 
 
14.2 Background 
Estimates of HIV prevalence in children, the number of children living with HIV, and VLS among children 
are most commonly derived indirectly from clinic-based data or epidemiologic models. LePHIA provided 
direct measurements of these estimates among children, which are critical for meeting the needs of 
pediatric HIV treatment; planning for HIV prevention, care, and treatment services for children; 
evaluating PMTCT programs; and addressing specific needs of young adolescents (those aged 10-14 
years). 
 
This chapter presents results on the UNAIDS 90-90-90 cascade in children, using both parent/guardian-
reported data (on awareness of child’s HIV status and ARV use) and data on detectable ARVs. Analyses 
for the 90-90-90 tables for children were similar to that described for adults in Chapter 10. Parents or 
guardians were asked about a child’s HIV status and ART use. Data on detectable ARVs were used in 
combination with self-reported ARV use to correct awareness of HIV-positive status and ARV status of 
the child. The presence of detectable ARVs among children who were reported as HIV negative was used 
to reclassify the child as aware.    
 
14.3 HIV Prevalence 
Overall, 2.1% of children were living with HIV (1.5% of boys and 2.6% of girls). HIV prevalence was 1.0% 
among those under the age of five years, 1.9% among those aged 5-9 years, and 3.2% among young 
adolescents. Prevalence was significantly higher among girls (2.9%) than boys aged 5-9 years (0.9%) 
(Table 6.4.A). 
 
14.4 Status of the UNAIDS 90-90-90 Targets  
 
90-90-90 cascade based on guardian-reported HIV status and ART use in children: 
Among all HIV-positive children, parents/guardians reported 74.0% as known HIV positive, 97.7% as 
receiving ARV, and 74.2% as having VLS (Table 14.4.A).   
 
 
 
 
▪ The estimated HIV prevalence among children (aged 0-14 years) was 2.1%.  
▪ Diagnosed:  Based on parents’ report and ARV detection data, it was estimated that in Lesotho, 
81.1% of children living with HIV were aware of their status. 
▪ On treatment: Based on parents’ report and ARV detection data, it was estimated that 98.2% of 
HIV-positive children who had been previously diagnosed were on ART.  Lesotho appeared to have 
achieved almost universal treatment of diagnosed HIV-positive children. 
▪ Suppressed viral load: Among children who were on ART, 73.9% had VLS.  
14 CHILDREN 
  
 
 
 
101 
90-90-90 cascade based on guardian-reported HIV status and ART use and/or detectable ARV children: 
ARV-adjusted awareness of HIV-positive status:  Based on guardian-reported HIV-positive status of the 
child and/or presence of detectable ARV, 81.1% of HIV-positive children were classified as aware (ARV-
adjusted awareness) (Table 14.4.B).   
 
ARV-adjusted treatment status: Using guardian-reported ARV status of the child and/or detectable 
ARVs, 98.2% of children with awareness of HIV-positive status (ARV-adjusted awareness) were classified 
as being on ART. 
 
Viral load suppression: Among children with ARV-adjusted treatment status, 73.9% had VLS (Table 
14.4.B, Figure 14.4.A).   
 
Table 14.4.A Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data; conditional percentages)  
90-90-90 targets among children living with HIV aged 0-14 years, by age LePHIA 2016-2017 
 Diagnosed  On Treatment  Viral Load Suppression (VLS) 
 
Total  
Among children whose parent 
reported that the child is HIV positive  
Among children whose parent 
reported that the child is on ART 
Age 
Percentage 
whose parent 
reported that  
the child is HIV 
positive Number  
Percentage 
whose parent 
reported that 
the child is on 
ART Number  
Percentage 
with VLS Number 
0-17 months * 2  * 2  * 2 
18-59 months * 9  * 4  * 4 
0-4 years * 11  * 6  * 6 
5-9 years * 21  * 18  * 18 
10-14 years (72.3) 33  * 24  * 23 
0-14 years 74.0 65  (97.7) 48  (74.2) 47 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 14.4.B Pediatric 90-90-90 (parent-reported antiretroviral therapy (ART) data and laboratory antiretroviral (ARV) data; 
conditional percentages)   
90-90-90 targets among children living with HIV aged 0-14 years, by age LePHIA 2016-2017 
 Diagnosed  On Treatment  Viral Load Suppression (VLS) 
 Total  Total  Total 
Age 
Percentage 
whose parent 
reported that the child 
is HIV positive 
AND/OR with 
detectable ARVs1 Number  
Percentage 
with detectable ARVs 
AND/OR whose parent 
reported current ARV 
usage for the child2 Number  
Percentage 
with VLS 3 Number 
0-17 months * 2  * 2  * 2 
18-59 
months * 9  * 4  * 4 
0-4 years * 11  * 16  * 6 
5-9 years * 23  * 22  * 22 
10-14 years (79.6) 44  (96.7) 35  (81.9) 34 
0-14 years 81.1 78  98.2 63  73.9 62 
1Relates to Global AIDS Monitoring indicator (GAM) 1.1: People living with HIV who know their HIV status, and PEPFAR DIAGNOSED_NAT; 
2Relates to GAM 1.2: People living with HIV on antiretroviral therapy, and PEPFAR TX_CURR_NAT / SUBNAT; 3Relates to GAM 1.4: People 
living with HIV who have suppressed viral loads, and PEPFAR VL_SUPPRESSION_NAT 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Figure 14.4.A Pediatric 90-90-90 (laboratory antiretroviral (ARV)-adjusted data among children aged 
0-14 years), LePHIA 2016-2017 
 
1In the antiretroviral (ARV)-adjusted 90-90-90, children were classified as ‘aware’ or ‘diagnosed’ if their parents or guardian 
reported that they were HIV positive before testing HIV positive in LePHIA or if they had detectable ARVs in their blood. 
Children were classified as ‘on treatment’ if their guardian reported that they were on treatment or if they had detectable ARVs 
in their blood.  
*Inset numbers are conditional proportions. 
 
14.5 Gaps and Unmet Needs 
  
▪ Almost one in five children living with HIV had not been diagnosed. Programs should prioritize 
more efficient case finding strategies, including systematic infant HIV exposure screening and 
virologic testing throughout breastfeeding and index testing strategies that target biologically at-
risk children or siblings of ART patients who have unknown HIV status. 
▪ Among children living with HIV on ART, close to 30% had not achieved VLS. This indicates a need to 
strengthen adherence support and drug resistance screening for the pediatric population in 
Lesotho. 
▪  
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Chapter 15    HIV Risk Factors 
15.1 Key Findings 
 
 
15.2 Background 
The overarching goal of the Lesotho MOH HIV/AIDS program is to ensure universal access to prevention, 
care, and treatment for HIV/AIDS. The MOH targets are zero new infections and to reduce AIDS-related 
deaths by 50% by 2023. As part of the National Strategic Plan, the National AIDS Committee developed 
strategies to facilitate promotion and distribution of condoms, in an effort to increase condom use 
during high-risk sexual encounters by 80% by 2023.1 Strategies to achieve this goal include distributing 
condoms at hotspots and meeting locations (health centers, shops, hotels/lodges, etc.), educational 
campaigns on the benefits of female condoms, and integrating condom provision into HIV testing and 
treatment services.  
 
Since 2007, WHO and UNAIDS have recommended voluntary medical male circumcision (VMMC) as a 
strategy to lower risk of HIV transmission from women to men. Traditional male circumcision in Lesotho 
is often a rite of passage that young men participate in as part of initiation schools, but does not confer 
the same protective benefit as VMMC as there is not complete removal of the foreskin. In 2012, the 
MOH adopted VMMC as a preventive strategy for HIV/AIDS by providing no cost services to male 
participants who came to clinics.2 Initiatives developed by the VMMC program include Role Kati, which 
aimed to educate male participants on the differences and benefits of VMMC compared to traditional 
circumcision, while still acknowledging the cultural sensitivities of traditional circumcision.  
 
This chapter describes the prevalence of sexual behaviors that elevate risk of HIV. Questions about high-
risk behaviors, including early sexual debut, lifetime and recent sexual partnerships, condom use at last 
sexual intercourse, engagement in paid sexual intercourse, and condom use at last sexual intercourse 
with a non-marital, non-cohabitating partner were asked in LePHIA 2016-2017 for adults (those aged 15-
59 years). With this information, programs can identify and target interventions for individuals most in 
need of information and most at risk for HIV infection.  
▪ HIV prevalence among those who reported an early sexual debut (before 15 years of age) was 
21.4%, but was nearly three times as high for women (41.6%) as for men (14.4%). 
▪ HIV prevalence in women who reported ever engaging in paid sexual intercourse was 48.2% and 
46.2% in those who reported paid intercourse in the 12 months preceding the survey. 
▪ Among sexually active participants, 49.6% reported having sex with a non-marital or non-
cohabitating partner in the 12 months preceding the survey; this was reported by significantly 
more men (59.8%) than women (38.9%). Among married participants, 27.1% of men had an extra-
marital partner in the past 12 months compared to 11.9% of women.  
▪ Among adults who reported having sex with a non-marital or non-cohabitating partner in the 12 
months preceding the survey, there was a higher proportion of men who reported using a condom 
with that partner (72.6%) than women (65.0%).  
▪ Among men, 36.0% reported having undergone medical circumcision, 31.6% non-medical 
circumcision, and 30.7% reported that they were uncircumcised. 
15 HIV RISK FACTORS 
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15.3 HIV Prevalence by Sexual Behavior 
One in four (25.6%) adults were found to be HIV positive (20.8% in men and 30.4% in women). HIV 
prevalence among those who reported an early sexual debut (below the age of 15 years) was 21.4%, but 
was nearly three times as high for women (41.6%) as for men (14.4%), indicating that its role as a risk 
factor for HIV acquisition is primarily in women. Later sexual debut (above the age of 24 years) was 
associated with high prevalence in both men (31.6%) and women (38.8%). 
 
The lifetime number of sexual partners was strongly associated with HIV prevalence; 29.8% of those 
with two or more partners were HIV positive, compared to 19.4% of those with only one partner. Of 
those who reported never having sex, 7.9% were HIV positive, which was significantly higher in men 
(10.8%) than in women (4.6%). Among persons reporting two or more sexual partners in the last 12 
months, HIV prevalence was almost twice as high among women (37.6%) as among men (19.8%). HIV 
prevalence was higher among those who used a condom at last sexual intercourse during the previous 
12 months (30.5%) than among those who did not use a condom (22.9%). This may be due to people 
who know that they are HIV-positive implementing prevention with positives steps to protect their 
partners (Table 15.3.A). 
 
Almost half of women (48.2%) who reported ever having engaged in paid sexual intercourse were HIV 
positive, compared to 32.9% of women who had never engaged in paid sex. This pattern was also 
observed in men, where 30.1% who had engaged in paid sex were HIV positive, compared to 20.9% of 
those who had not. HIV prevalence in women who reported engaging in paid sexual intercourse in the 
12 months preceding the survey was 46.2%. Of those reporting recent paid sexual intercourse, the 
prevalence of HIV was higher for those who did not use condom at the last time of paid sexual 
intercourse (42.2%) compared to those who did (28.0%) (Table 15.3.A), although not significantly higher.  
 
Table 15.3.A HIV prevalence by sexual behavior 
Prevalence of  HIV among adults aged 15-59 years, by sex and sexual behavior characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
HIV positive Number  
Percentage 
HIV positive Number  
Percentage 
HIV 
positive Number 
Age at first sexual intercourse         
<15 14.4 628  41.6 328  21.4 956 
15-19 19.5 2,234  33.6 3,991  27.0 6,225 
20-24 31.4 702  30.4 1,344  30.8 2,046 
≥25 31.6 283  38.8 247  34.4 530          
Lifetime number of sexual partners         
0 (never had sex) 10.8 671  4.6 785  7.9 1,456 
1 14.8 464  20.9 2,052  19.4 2,516 
≥ 2 22.0 3,233  39.7 3,724  29.8 6,957          
Number of sexual partners in the past 12 months         
0 24.7 500  42.3 1,007  35.0 1,507 
1 22.5 2,307  31.4 4,378  27.5 6,685 
≥2 19.8 1,195  37.6 633  24.5 1,828          
Condom use at last sexual intercourse in the past  
12 months         
Used condom 23.2 1,967  40.2 2,199  30.5 4,166 
Did not use condom 19.5 1,513  25.6 2,783  22.9 4,296          
Ever had paid sexual intercourse          
Yes1 30.1 394  48.2 217  34.8 611 
Used condom at last paid sexual intercourse 26.9 268  47.5 132  31.9 400 
Did not use condom at last paid sexual  
 intercourse 35.5 89  47.0 78  39.7 167 
No2 20.9 3,487  32.9 5,697  27.2 9,184 
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Table 15.3.A HIV prevalence by sexual behaviour (continued) 
Prevalence of  HIV among adults aged 15-59 years, by sex and sexual behavior characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
HIV positive Number  
Percentage 
HIV positive Number  
Percentage 
HIV 
positive Number          
Paid sexual intercourse in the past 12 months         
Yes1 24.1 154  46.2 132  31.9 286 
Used condom at last paid sexual intercourse 20.4 114  42.8 87  28.0 201 
Did not use condom at last paid sexual  
 intercourse (36.3) 39  (51.4) 42  42.2 81 
No2 21.0 3,144  31.3 4,746  26.2 7,890          
Total 15-24 3.4 1,690  11.1 2,358  7.2 4,048 
Total 15-49 19.1 4,199  29.7 5,990  24.3 10,189 
Total 15-59 20.8 4,762  30.4 6,920  25.6 11,682 
1Includes persons who paid or received money for sexual intercourse. 
2Among those who had sexual intercourse during the relevant time period. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. 
 
15.4 Condom Use at Last Sex with a Non-Marital, Non-Cohabitating Partner 
Among adults who reported having sex in the past 12 months, 49.6% reported having sex with a non-
marital, non-cohabitating partner, which was significantly more common in men (59.8%) than in women 
(38.9%). Only 69.7% used a condom the last time they had sex with such a partner. Among married 
participants, 27.1% of men had an extra-marital partner in the past 12 months compared to 11.9% of 
women; 66.8% of men and 61.5% of women reported using a condom at last sex with that partner. 
Approximately 95% of never married/lived together adults reported having a non-marital, non-
cohabitating partner in the past 12 months. Of those, 74.1% reported condom use at last sex with this 
partner. Condom use at last sex with a non-marital, non-cohabitating partner was highest amongst older 
adolescents (aged 15-19 years) and lowest among older adults aged 50-59 years (78.3% and 55.6%, 
respectively) (Tables 15.4.A, 15.4.B, and 15.4.C).  
 
Table 15.4.A Condom use at last sex with a non-marital, non-cohabitating partner: Men 
Among men aged 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating 
partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage 
who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, 
LePHIA 2016-2017. 
 
Among men who reported having sex 
in the past 12 months  
Among men who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having 
sex with a non-marital, non-
cohabitating partner in the past  
12 months Number  
Percentage who reported using a 
condom the last time they had sex 
with a non-marital, non-
cohabitating partner1 Number 
Residence      
Urban 57.6 1,581  76.0 931 
Peri-urban 65.0 284  73.7 185 
Rural 60.9 2,111  69.8 1,277       
District      
Maseru 59.0 1,105  75.6 650 
Mafeteng 60.4 382  70.1 229 
Mohale's Hoek 61.9 266  63.0 168 
Leribe 58.6 651  77.1 384 
Berea 62.4 504  74.8 320 
Quthing 69.2 183  70.7 127 
Butha Buthe  65.8 270  76.5 180 
Mokhotlong 56.4 237  57.6 131 
Qacha's Nek 66.0 148  63.2 96 
Thaba Tseka  47.8 230  60.2 108 
 
  
 
 
 
106 
Table 15.4.A Condom use at last sex with a non-marital, non-cohabitating partner: Men (continued) 
Among men aged 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating 
partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage 
who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, 
LePHIA 2016-2017. 
 
Among men who reported having sex 
in the past 12 months  
Among men who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having 
sex with a non-marital, non-
cohabitating partner in the past  
12 months Number  
Percentage who reported using a 
condom the last time they had sex 
with a non-marital, non-
cohabitating partner1 Number 
      
Marital status      
Never married / lived together 96.9 1,555  76.6 1,501 
Married or living together 27.1 2,059  66.8 555 
Divorced or separated 91.8 246  64.0 225 
Widowed 96.2 105  66.2 101       
Education      
No education 51.9 358  57.7 182 
Primary 56.1 1,628  67.4 913 
Secondary 66.3 1,545  78.4 1,048 
College / University 58.2 385  77.1 224 
Graduate / post-graduate  46.9 54  (78.4) 26       
Wealth quintile      
Lowest 55.6 743  59.3 415 
Second 62.9 791  69.9 496 
Middle 61.3 771  76.9 483 
Fourth  63.1 827  76.4 520 
Highest 56.1 838  76.6 475       
Religion      
Roman Catholic 59.9 1,643  72.1 982 
Lesotho Evangelical 58.3 780  76.3 462 
Anglican 62.7 298  75.0 188 
Pentecostal 57.6 280  66.7 163 
Other Christian 60.1 609  72.6 367 
Other religion 62.4 254  70.7 162 
Don't know 58.0 87  66.0 51       
Age      
15-19 97.3 422  79.3 408 
20-24 85.5 709  80.4 603 
25-29 65.2 685  69.8 446 
30-34 50.0 607  68.4 313 
35-39 46.7 468  67.0 218 
40-44 37.3 356  68.4 139 
45-49 38.7 284  64.4 111 
50-54 37.2 217  55.2 83 
55-59 29.4 228  65.3 72       
Total 15-24 89.7 1,131  79.9 1,011 
Total 15-49 62.5 3,531  73.4 2,238 
Total 15-59 59.8 3,976  72.6 2,393 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 15.4.B Condom use at last sex with a non-marital, non-cohabitating partner: Women 
Among women aged 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating 
partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage 
who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner, by selected demographic characteristics, 
LePHIA 2016-2017. 
 Among women who reported having sex 
in the past 12 months  
Among women who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported having 
sex with a non-marital, non-
cohabitating partner in the past  
12 months Number  
Percentage who reported using a 
condom the last time they had sex with 
a non-marital, non-cohabitating 
partner1 Number 
Residence      
Urban 44.3 2,207  67.0 962 
Peri-urban 43.7 365  67.8 152 
Rural 33.4 2,873  62.1 940       
District      
Maseru 44.5 1,386  64.6 602 
Mafeteng 33.4 521  67.7 172 
Mohale's Hoek 38.4 422  61.9 159 
Leribe 33.5 895  70.9 292 
Berea 42.4 696  68.5 293 
Quthing 37.9 297  55.2 114 
Butha Buthe  34.6 346  76.0 116 
Mokhotlong 39.6 320  49.7 124 
Qacha's Nek 41.9 219  50.5 92 
Thaba Tseka  26.8 343  58.2 90       
Marital status      
Never married / lived together 92.0 1,094  69.0 993 
Married or living together 11.9 3,599  61.5 412 
Divorced or separated 87.9 347  58.5 299 
Widowed 88.1 402  63.1 347       
Education      
No education 44.6 82  (63.5) 34 
Primary 31.9 2,201  57.5 687 
Secondary 42.3 2,538  68.5 1,048 
College / University 46.8 542  68.7 248 
Graduate / post-graduate  47.5 80  (70.0) 36       
Wealth quintile      
Lowest 30.2 1,033  53.4 309 
Second 36.7 1,016  61.2 366 
Middle 39.4 1,047  63.8 405 
Fourth  42.1 1,121  68.3 464 
Highest 43.0 1,212  70.5 505       
Religion      
Roman Catholic 39.2 2,115  65.0 807 
Lesotho Evangelical 38.5 905  68.9 340 
Anglican 37.5 363  68.9 133 
Pentecostal 35.2 545  54.8 182 
Other Christian 40.6 1,075  64.1 426 
Other religion 38.4 424  66.0 156 
Don't know * 14  * 8       
Age      
15-19 67.4 430  76.6 282 
20-24 45.9 1,095  69.0 489 
25-29 35.6 1,042  61.5 350 
30-34 31.8 849  62.6 267 
35-39 36.5 642  61.6 233 
40-44 34.8 526  63.2 179 
45-49 35.7 345  60.4 119 
50-54 26.2 297  56.3 76 
55-59 28.4 219  42.7 59       
Total 15-24 52.2 1,525  71.9 771 
Total 15-49 40.0 4,929  65.9 1,919 
Total 15-59 38.9 5,445  65.0 2,054 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. An asterisk indicates that 
an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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Table 15.4.C Condom use at last sex with a non-marital, non-cohabitating partner: Total 
Among adults aged 15-59 years who reported having sex in the past 12 months, percentage who reported having a non-marital, non-cohabitating 
partner in the past 12 months; among those who reported having sex with a non-marital, non-cohabitating partner in the past 12 months, percentage 
who reported using a condom the last time they had sex with a non-marital, non-cohabitating partner; by selected demographic characteristics, 
LePHIA 2016-2017. 
 
Among adults who reported having sex 
in the past 12 months  
Among adults who reported having sex 
with a non-marital, non-cohabitating partner 
in the past 12 months 
Characteristic 
Percentage who reported 
having sex with a non-
marital, non-cohabitating 
partner in the past 12 
months Number  
Percentage who reported 
using a condom the last time 
they had sex with a non-
marital, non-cohabitating 
partner1 Number 
Residence      
Urban 51.0 3,788  72.1 1,893 
Peri-urban 54.6 649  71.4 337 
Rural 47.5 4,984  67.2 2,217       
District      
Maseru 52.2 2,491  71.2 1,252 
Mafeteng 46.8 903  69.2 401 
Mohale's Hoek 49.5 688  62.6 327 
Leribe 46.4 1,546  74.9 676 
Berea 52.5 1,200  72.3 613 
Quthing 52.1 480  64.6 241 
Butha Buthe  50.9 616  76.3 296 
Mokhotlong 48.3 557  54.5 255 
Qacha's Nek 53.6 367  58.0 188 
Thaba Tseka  36.9 573  59.5 198       
Marital status      
Never married / lived together 95.2 2,649  74.1 2,494 
Married or living together 18.8 5,658  65.0 967 
Divorced or separated 89.8 593  61.2 524 
Widowed 90.2 507  64.0 448       
Education      
No education 50.9 440  58.4 216 
Primary 44.4 3,829  63.9 1,600 
Secondary 53.5 4,083  74.2 2,096 
College / University 52.6 927  73.4 472 
Graduate / post-graduate  47.2 134  74.0 62       
Wealth quintile      
Lowest 43.1 1,776  57.2 724 
Second 50.6 1,807  66.9 862 
Middle 50.7 1,818  72.0 888 
Fourth  52.8 1,948  73.3 984 
Highest 49.5 2,050  73.9 980       
Religion      
Roman Catholic 50.1 3,758  69.5 1,789 
Lesotho Evangelical 49.5 1,685  73.7 802 
Anglican 51.1 661  73.0 321 
Pentecostal 44.7 825  61.3 345 
Other Christian 49.2 1,684  68.8 793 
Other religion 49.5 678  68.8 318 
Don't know 58.4 101  67.1 59       
Age      
15-19 84.1 852  78.3 690 
20-24 65.2 1,804  76.3 1,092 
25-29 50.1 1,727  66.8 796 
30-34 41.2 1,456  66.2 580 
35-39 41.8 1,110  64.8 451 
40-44 36.0 882  66.0 318 
45-49 37.3 629  62.5 230 
50-54 31.8 514  55.6 159 
55-59 29.0 447  55.6 131       
Total 15-24 71.3 2,656  77.1 1,782 
Total 15-49 51.5 8,460  70.5 4,157 
Total 15-59 49.6 9,421  69.7 4,447 
  
  
 
 
 
109 
Table 15.4.C Condom use at last sex with a non-marital, non-cohabitating partner: Total (conclusion) 
1Relates to Global AIDS Monitoring indicator 3.18: Condom use at last high-risk sex. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
15.5 Male Circumcision 
Among men, 36.0% reported having been medically circumcised. A lower percentage of HIV-positive 
men (18.7%) were medically circumcised compared to HIV-negative men (38.9%). Men in urban areas 
reported significantly higher rates of medical circumcision (49.8%) compared to rural areas (23.4%), and 
in the lowlands (43.6%) compared to the foothills (20.6%), mountains (18.1%) or Senqu River Valley 
(19.3%), where traditional circumcision was more common, particularly in the mountainous districts 
(54.9%). Medical circumcision was conducted for almost half the men in Berea (47.8%) and Maseru 
(46.1%).  
 
Higher rates of medical circumcision were found among those never married (45.8%). Education was 
also strongly associated with medical circumcision, with only 9.8% of men without any education 
reporting medical circumcision compared to 52.0% of those with secondary education, and 69.1% of 
those with a tertiary education. Coverage of medical circumcision also varied substantially by 
socioeconomic status, ranging from 10.6% among those in the lowest wealth quintile to 61.3% among 
those in the highest wealth quintile. Older adolescents were far more likely to report having been 
medically circumcised, with more than half (53.6%) medically circumcised, compared to less than 20% of 
men above 45 years of age (Table 15.5.A). 
 
Table 15.5.A Male circumcision 
Percent distribution of men aged 15-59 years by self-reported circumcision status, by result of PHIA survey HIV test and selected 
demographic characteristics, LePHIA 2016-2017 
 Circumcised1 
Uncircumcised Unknown Total Number Characteristic 
Medical 
circumcision 
Non-medical 
circumcision 
Result of PHIA survey HIV test       
HIV positive 18.7 44.8 33.8 2.7 100.0 1,019 
HIV negative 38.9 29.6 30.2 1.4 100.0 3,743 
Not tested 46.9 22.5 28.7 1.9 100.0 599        
Residence       
Urban 49.8 18.3 30.2 1.7 100.0 2,019 
Peri-urban 49.8 19.4 28.2 2.6 100.0 371 
Rural 23.4 43.6 31.4 1.6 100.0 2,971        
Ecological zone       
Lowlands 43.6 23.8 30.9 1.8 100.0 3,450 
Foothills 20.6 38.8 39.0 1.6 100.0 503 
Mountains 18.1 54.9 25.4 1.6 100.0 1,000 
Senqu River Valley 19.3 49.5 30.0 1.3 100.0 408        
District       
Maseru 46.1 18.0 34.0 1.9 100.0 1,430 
Mafeteng 31.0 38.1 29.8 1.0 100.0 528 
Mohale's Hoek 23.4 44.0 30.5 2.1 100.0 376 
Leribe 28.6 36.7 32.9 1.8 100.0 886 
Berea 47.8 23.5 26.9 1.8 100.0 688 
Quthing 19.6 53.3 25.4 1.8 100.0 275 
Butha Buthe  34.1 29.7 34.1 2.1 100.0 361 
Mokhotlong 20.7 59.1 18.6 1.6 100.0 289 
Qacha's Nek 20.6 50.5 28.0 0.9 100.0 200 
Thaba Tseka  21.9 50.8 26.3 1.1 100.0 328        
Marital status       
Never married / lived together 45.8 21.8 31.2 1.3 100.0 2,530 
Married or living together 29.1 38.6 30.2 2.2 100.0 2,288 
Divorced or separated 21.6 45.7 31.4 1.3 100.0 340 
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Table 15.5.A Male circumcision 
Percent distribution of men aged 15-59 years by self-reported circumcision status, by result of PHIA survey HIV test and selected 
demographic characteristics, LePHIA 2016-2017 
 Circumcised1 
Uncircumcised Unknown Total Number Characteristic 
Medical 
circumcision 
Non-medical 
circumcision 
Marital status (cont.)       
Widowed 14.8 54.9 28.8 1.5 100.0 186        
Education       
No education 9.8 58.2 28.1 3.8 100.0 501 
Primary 17.0 47.4 34.1 1.5 100.0 2,227 
Secondary 52.0 17.2 29.4 1.4 100.0 2,121 
College / University 69.1 4.6 24.4 1.9 100.0 445 
Graduate / post-graduate  71.9 4.1 22.3 1.8 100.0 60        
Wealth quintile       
Lowest 10.6 56.8 30.5 2.1 100.0 1,054 
Second 22.7 44.8 31.2 1.3 100.0 1,105 
Middle 33.0 31.5 34.1 1.4 100.0 1,058 
Fourth  46.3 21.9 30.2 1.6 100.0 1,081 
Highest 61.3 9.0 27.5 2.2 100.0 1,050        
Religion       
Roman Catholic 36.3 30.4 31.6 1.8 100.0 2,198 
Lesotho Evangelical 36.3 30.7 31.1 1.9 100.0 1,020 
Anglican 38.0 32.6 28.1 1.3 100.0 392 
Pentecostal 30.3 35.0 33.5 1.2 100.0 390 
Other Christian 36.9 33.4 28.1 1.6 100.0 848 
Other religion 40.5 29.7 28.0 1.7 100.0 348 
Don't know 25.6 38.8 33.3 2.3 100.0 132 
Age       
15-19 53.6 10.2 35.2 1.1 100.0 1,001 
20-24 47.6 25.0 26.3 1.1 100.0 875 
25-29 35.9 35.6 26.6 1.9 100.0 827 
30-34 31.0 39.7 28.0 1.3 100.0 697 
35-39 27.6 38.0 33.0 1.5 100.0 573 
40-44 30.1 37.6 30.4 1.9 100.0 427 
45-49 19.7 42.9 34.3 3.1 100.0 352 
50-54 18.6 42.7 35.4 3.3 100.0 285 
55-59 14.7 45.6 36.2 3.6 100.0 324        
Total 15-24 50.7 17.3 30.9 1.1 100.0 1,876 
Total 15-49 38.0 30.3 30.1 1.5 100.0 4,752 
Total 15-59 36.0 31.6 30.7 1.7 100.0 5,361 
1Relates to Global AIDS Monitoring indicator 3.16: Prevalence of male circumcision and PEPFAR VMMC_TOTALCIRC NAT / SUBNAT. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
15.6 Gaps and Unmet Needs 
 
▪ Extra-marital sexual partnerships were relatively common among married and cohabitating men in 
Lesotho. More than one in three married and cohabitating adults who engaged in extra-marital 
partnerships reported not using a condom. This suggests that knowledge, access, and acceptability 
of condoms needs further promotion. 
▪ The low percentage of reported condom use suggests the need to promote knowledge, access and 
acceptability of condoms. 
▪ Among young men aged 15-24 years, only half were medically circumcised. Further efforts to 
achieve greater coverage of this effective intervention should be sought, particularly in areas of 
traditional circumcision in the mountainous districts, and in populations with less access to 
education.  
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Chapter 16    Violence, Including Gender-Based Violence 
16.1 Key Findings  
 
 
16.2 Background 
In the World Report on Violence and Health (WRVH), WHO defined violence as "the intentional use of 
physical force or power, threatened or actual, against oneself, another person, or against a group or 
community, that either results in or has a high likelihood of resulting in injury, death, psychological 
harm, maldevelopment, or deprivation."1,2 Two forms of violence in particular have been associated 
with an increased risk of HIV: gender-based violence (GBV) and intimate partner violence (IPV).3 
  
GBV is defined as “acts perpetrated against women, men, girls, and boys on the basis of their sex, which 
cause or could cause them physical, sexual, psychological, emotional, or economic harm, including the 
threat to take such acts, or to undertake the imposition of arbitrary restrictions on or deprivation of 
fundamental freedoms in private or public life, in peace time, and during situations of armed and other 
forms of conflict.”4 Much of this violence targets girls and women, and whether sexual or not, it occurs 
within the context of their subordinate status in society, and serves to perpetuate gender inequality. 5 
Such violence is often associated with an increased risk of psychological and behavioral problems, 
including depression, alcohol abuse, anxiety, and suicidal behavior. Other common health-related 
outcomes of GBV and sexual violence include unintended pregnancy, and infection with HIV and/or 
other sexually transmitted infections.1   
 
IPV is defined as physical violence, sexual violence, stalking, or psychological aggression (including 
coercive tactics) by a current or former intimate partner (i.e., spouse, boyfriend/girlfriend, dating 
partner, or ongoing sexual partner).6 Exposure to IPV has been implicated in increased risk of contracting 
HIV in women, through mechanisms such as forced sex with an HIV-positive partner, an increase in risky 
sexual behaviors, and reduced ability to negotiate forms of safe sex (e.g., condom use).7,8  Children and 
adolescents girls also suffer from GBV including sexual violence. Long term effects of childhood sexual 
abuse can include development of obesity, early puberty, and psychiatric conditions such as depression, 
post-traumatic stress disorder, and suicidal behaviors in young adulthood.9,10  
 
Data from LePHIA helped fill gaps in information on subnational prevalence estimates and demographic 
characteristics of women and young adolescents who experienced violence, including GBV and IPV.  
This chapter reports the prevalence of severe forms of sexual violence reported by women aged 15-59 
years, including forced sex perpetrated by a live-in partner in the last 12 months among ever married or 
partnered women. Here, severe forms of sexual violence included having been physically forced or 
pressured to have sex. The association between sexual violence and women’s HIV status was also 
assessed.  
 
▪ In all women, a history of having been physically forced to have sex was associated with a 
significantly higher prevalence of HIV (39.3%).  
▪ More than one in ten (11.8%) young adolescent girls aged 13-14 years reported sexual harassment 
or violence, and one in four (25.7%) reported physical violence. Young adolescent girls who lived in 
urban areas experienced more physical violence than those in rural areas.  
 
16 VIOLENCE, INCLUDING GENDER-BASED 
VIOLENCE 
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The chapter also reports on the prevalence of violence among young adolescents aged 13-14 years, 
including physical violence (by any perpetrator), sexual harassment, and forced sex. Physical violence is 
defined as getting punched, kicked, whipped, beaten with an object, choked, smothered, drowned, or 
burned. It also includes getting threatened with a knife, gun, or other weapon.  Sexual harassment has 
been defined as any form of unwanted verbal, non‐verbal, or physical conduct of a sexual nature that 
occurs “with the purpose or effect of violating the dignity of a person, in particular when creating an 
intimidating, hostile, degrading, humiliating, or offensive environment.”11 The prevalence of recent 
violence is also broken down by age, education, region, and sociodemographic characteristics.   
 
Violence questionnaires were administered to one randomly selected female participant aged 13-59 
years in each household. Questions were adapted from the Demographic and Health Surveys, and the 
Violence Against Children Surveys, which measure lifetime experience of physical, emotional, and sexual 
violence among those aged 13-24 years. Women and adolescents reporting violence were offered 
referral to social services. 
 
16.3 Recent Sexual Violence Characteristics of Adult Women 
Among ever-married or partnered women, 1.0% reported having been physically forced to have sex in 
the past 12 months. Three times as many divorced women (3.0%) had recently experienced physically 
forced sex as had married women (0.9%). Women who had attended tertiary school also reported 
higher prevalence of recent forced sex (2.9%) compared to women with primary (0.8%) and secondary 
(0.9%) education. Physically forced sex was most commonly reported by older adolescents aged 15-19 
years (1.8%), who also reported higher prevalence of pressured sex (4.0%) (Table 16.3.A). 
 
Table 16.3.A Recent sexual violence among ever partnered women aged 15-59 years, by demographic characteristics 
Among ever-partnered women aged 15-59 years, percentage who experienced sexual violence in the past 12 months, by woman's HIV status and 
selected demographic characteristics, LePHIA 2016-2017 
Characteristic 
 Self-reported experience of sexual harassment / violence 
Pressured to have 
sex 
Physically forced to 
have sex 
Physically forced by 
partner to have sex 
Number of ever-married 
or partnered women 
Result of PHIA survey HIV test     
HIV positive 0.9 1.1 0.8 1,369 
HIV negative 1.1 1.1 0.9 2,366 
Not tested 0.2 0.0 0.0 301 
     
Residence     
Urban 1.0 1.1 1.0 1,569 
Peri-urban 1.5 1.7 1.7 236 
Rural 0.9 0.8 0.4 2,231 
     
District     
Maseru 1.6 1.4 1.2 974 
Mafeteng 0.2 0.2 0.2 400 
Mohale's Hoek 0.1 0.0 0.0 359 
Leribe 1.0 1.0 0.4 667 
Berea 1.1 1.3 1.1 482 
Quthing 0.7 1.4 1.1 220 
Butha Buthe  0.7 1.3 1.0 238 
Mokhotlong 1.0 1.0 0.6 221 
Qacha's Nek 0.0 0.5 0.5 157 
Thaba Tseka  0.2 0.5 0.2 318 
     
Marital status     
Never married / lived together * * * 0 
Married or living together 1.0 0.9 0.8 3,075 
Divorced or separated 2.0 3.0 1.9 334 
Widowed 0.5 0.4 0.0 622 
     
Education     
No education 0.0 0.0 0.0 64 
Primary 0.7 0.8 0.4 1,919 
Secondary 0.9 0.9 0.8 1,681 
College / University 2.6 2.9 2.6 316 
Graduate / post-graduate  1.5 1.5 1.5 55 
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Table 16.3.A Recent sexual violence among ever partnered women aged 15-59 years, by demographic characteristics 
Among ever-partnered women aged 15-59 years, percentage who experienced sexual violence in the past 12 months, by woman's HIV status and 
selected demographic characteristics, LePHIA 2016-2017 
Characteristic 
 Self-reported experience of sexual harassment / violence 
Pressured to have 
sex 
Physically forced to 
have sex 
Physically forced by 
partner to have sex 
Number of ever-married 
or partnered women 
Wealth quintile     
Lowest 0.5 0.4 0.2 848 
Second 1.3 0.9 0.6 789 
Middle 1.1 1.2 1.1 794 
Fourth  0.8 1.0 0.5 811 
Highest 1.3 1.4 1.3 786 
     
Religion     
Roman Catholic 1.4 1.3 1.1 1,601 
Lesotho Evangelical 0.3 0.6 0.3 659 
Anglican 1.7 1.3 1.1 256 
Pentecostal 0.9 1.0 0.8 413 
Other Christian 0.8 0.9 0.5 777 
Other religion 0.5 0.5 0.3 316 
Don't know * * * 11 
     
Age     
15-19 4.0 1.8 0.0 114 
20-24 1.1 1.2 1.1 581 
25-29 0.9 1.3 1.1 744 
30-34 1.2 1.0 0.8 697 
35-39 0.8 1.0 0.9 514 
40-44 0.9 0.9 0.4 404 
45-49 0.0 0.0 0.0 318 
50-54 1.5 1.5 1.5 327 
55-59 0.1 0.3 0.0 337 
     
Total 15-24 1.6 1.3 0.9 695 
Total 15-49 1.0 1.0 0.8 3,372 
Total 15-59 1.0 1.0 0.8 4,036 
1Relates to Global AIDS Monitoring indicator 4.3: Prevalence of recent intimate partner violence. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
16.4 HIV Prevalence by Experience of Sexual Violence 
HIV prevalence among women who reported ever having experienced forced sex was 39.3%, 
significantly higher than in those who did not report a history of forced sex (31.0%). HIV prevalence was 
higher in older adolescent girls and young women, aged 15-24 years, reporting a history of forced sex 
(18.9% vs 12.1% in those who do not report a history of forced sex), and was very high in women aged 
25-59 years who reported forced sex (47.2%). The prevalence of HIV also appeared to be higher among 
women who reported a greater exposure to sexual violence, although this was not significant. More 
than one third (36.4%) of women who reported having experienced physically forced sex in the 12 
months before the survey were HIV positive.  
 
Table 16.4.A HIV prevalence by experience of sexual violence 
Prevalence of HIV among women aged 15-59 years by self-reported experience of sexual harassment/violence  
 Women 
Characteristic 
Percentage 
HIV positive Number 
Ever physically forced to have sex 
    15-24 
      No 
      Yes 
    25-59 
     No 
     Yes 
39.3 
 
12.1 
18.9 
 
39.0 
47.2 
521 
 
1,329 
153 
 
3,111 
368 
In lifetime, number of times physically forced to have sex   
0 31.0 4,440 
1-2 38.7 454 
3-5 45.4 55 
>5 * 12 
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Table 16.4.A HIV prevalence by experience of sexual violence (continued) 
Prevalence of HIV among women aged 15-59 years by self-reported experience of sexual harassment/violence  
 Women 
Characteristic 
Percentage 
HIV positive Number 
Physically forced to have sex in the last 12 months   
In the past 12 months, physically forced to have sex  36.4 61 
In the past 12 months, physically forced by partner to have sex  (39.0) 35    
Total 15-24 12.8 1,482 
Total 15-49 31.4 4,295 
Total 15-59 31.9 4,961 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
16.5 Sexual and Physical Violence among Young Adolescent Girls 
More than one tenth (11.8%) of young adolescent girls aged 13-14 years reported experiencing sexual 
harassment or sexual violence. Approximately a quarter (25.7%) of adolescent girls aged 13-14 years 
reported the experience of physical violence, which was more common in girls in urban (30.6%) than in 
rural areas (23.0%). Wealth quintile did not appear to be associated with risk of physical violence.  
 
Table 16.5.A Experience of sexual and physical violence among girls aged 13-14 years 
Among young adolescent girls aged 13-14 years, percentage who experienced physical or sexual violence in their lifetime, by HIV status and 
selected demographic characteristics, LePHIA 2016-2017 
Characteristic 
Self-reported experience of sexual harassment / violence and 
physical violence  
Physically forced / 
pressured into having 
first time sex 
Physical 
violence 
Sexual harassment 
/ violence 
Number of young 
adolescent girls aged  
13-14 years 
Result of PHIA survey HIV test     
HIV positive * * * 8 
HIV negative 1.6 25.8 11.3 156 
Not tested * * * 11      
Residence     
Urban 2.1 30.6 10.2 55 
Peri-urban * * * 11 
Rural 1.3 23.0 12.1 109      
District     
Maseru (0.0) (23.1) (9.8) 38 
Mafeteng * * * 19 
Mohale's Hoek * * * 17 
Leribe (4.9) (8.7) (20.2) 25 
Berea * * * 16 
Quthing * * * 15 
Butha Buthe  * * * 14 
Mokhotlong * * * 13 
Qacha's Nek * * * 6 
Thaba Tseka  * * * 12      
Education     
Currently attending school 1.5 26.5 11.8 170 
Not currently attending school * * * 5      
Wealth quintile     
Lowest (0.0) (19.6) (9.2) 49 
Second (5.8) (32.1) (13.6) 43 
Middle (0.0) (25.4) (20.0) 30 
Fourth  (0.0) (28.7) (4.0) 29 
Highest * * * 24      
Total 13-14 1.4 25.7 11.8 175 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
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16.6 Gaps and Unmet Needs 
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▪ HIV prevalence was significantly higher in women who reported a history of sexual violence, 
including in young women.  
▪ Worryingly, many girls aged 13-14 years reported already having experienced of some form of 
violence. Identification of those most likely to perpetrate abuse is critical in designing appropriate 
violence prevention interventions. 
▪ Social support services should be promoted to women affected by violence to provide counseling 
and support, and mitigate consequences of abuse which appear to lead to increased HIV risk.  
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Chapter 17    Discriminatory Attitudes Towards People Living with HIV 
17.1 Key Findings  
 
 
17.2 Background 
Previous research has shown an association between stigma and treatment non-adherence.1 Stigma and 
discrimination are two of the greatest challenges to curbing the spread of HIV in Lesotho. Stigma is 
defined as all unfavorable attitudes and beliefs directed toward people living with HIV, and toward their 
significant others and communities. Discrimination refers to treatment given to individuals or groups 
with prejudice. In Lesotho, stigma and discrimination of people living with HIV include social exclusion, 
denial of health insurance, and loss of employment due to HIV status.2 Loss of insurance and 
employment may have a negative impact on treatment adherence, as it becomes difficult to access 
treatment and care. Strategies to combat stigma in Lesotho include training of health workers, media 
campaigns, enactment and enforcement of laws, and implementation of a new stigma index.3 
 
This chapter presents data from LePHIA 2016-2017 on discriminatory attitudes towards HIV-positive 
people. Participants were asked two questions to assess discriminatory attitudes. The first question was 
whether the participant would buy fresh vegetables from a shopkeeper or vendor if he or she knew that 
this person had HIV, and the second was if the participant thought that children living with HIV should 
be able to attend school with children who are HIV negative. Discriminatory attitudes were present if 
the participants responded to either question with “No.”   
 
17.3 Discriminatory Attitudes towards People Living with HIV 
Among adults who have heard of HIV, 17.4% showed discriminatory attitudes towards people living with 
HIV. One tenth (11.3%) reported that they did not feel children living with HIV should be allowed to 
attend school with HIV-negative children. A higher proportion of those in rural areas (21.4%) had 
discriminatory attitudes compared to those in urban areas (13.1%), with the highest proportion in 
Mokhotlong (23.4%). Discriminatory attitudes also varied across educational groups, where those with 
no (35.8%) or primary education (22.5%) had a higher prevalence of discriminatory attitudes than those 
with secondary (13.4%) or tertiary education (7.2%). Discriminatory attitudes decreased with increasing 
wealth, with the largest proportion in the lowest quintile (27.7%). They were also highest in the 
youngest age group, at 29.0% of older adolescents (ages 15-19 years).  
 
  
▪ Among adults (aged 15-59 years) who had ever heard of HIV, 17.4% reported discriminatory 
attitudes towards people living with HIV.  
▪ More adults in rural areas (21.4%) reported discriminatory attitudes towards HIV-positive people, 
compared to those in urban areas (13.1%). 
▪ The largest variation in discriminatory attitudes occurred across different levels of educational 
attainment: 35.8% of those with no education reported discriminatory attitudes in contrast to 
13.4% among those with secondary education. 
17 DISCRIMINATORY ATTITUDES TOWARDS 
PEOPLE LIVING WITH HIV 
  
 
 
 
118 
Table 17.3.A Discriminatory attitudes toward people living with HIV 
Among adults aged 15-59 years who have heard of HIV, percentage who report discriminatory attitudes towards people living with HIV, by 
selected demographic characteristics, LePHIA 2016-2017 
  
Would you buy fresh 
vegetables from a 
shopkeeper or vendor if 
you knew that this 
person had HIV?  
Do you think that 
children living with HIV 
should be able to attend 
school with children 
who are HIV negative?  Both questions   
Characteristic 
Percentage who 
responded "No"  
Percentage who 
responded "No"  
Percentage who 
responded "No" to 
either of the two 
questions1  Number
2 
Residence        
Urban 8.0  8.4  13.1  2,475 
Peri-urban 10.3  7.6  14.5  408 
Rural 14.7  14.2  21.4  3,348         
District        
Maseru 9.8  9.5  15.0  1,615 
Mafeteng 12.3  11.0  17.5  603 
Mohale's Hoek 13.4  12.5  19.4  460 
Leribe 11.8  12.0  18.1  1,035 
Berea 9.8  9.4  15.4  816 
Quthing 15.6  13.2  19.8  341 
Butha Buthe  12.4  11.2  18.9  409 
Mokhotlong 14.1  16.0  23.4  335 
Qacha's Nek 17.5  13.8  22.3  234 
Thaba Tseka  14.2  16.8  22.5  383         
Marital status        
Never married / lived together 16.4  13.2  22.1  2,317 
Married or living together 8.0  9.6  14.1  3,005 
Divorced or separated 9.8  12.1  16.0  384 
Widowed 10.7  10.8  15.6  512         
Education        
No education 24.5  25.6  35.8  291 
Primary 15.8  15.4  22.5  2,512 
Secondary 8.4  7.7  13.4  2,813 
College / University 3.4  4.1  7.2  549 
Graduate / post-graduate  5.3  8.7  10.4  63         
Wealth quintile        
Lowest 18.1  19.4  27.7  1,196 
Second 13.9  13.0  19.0  1,212 
Middle 10.4  9.4  15.6  1,233 
Fourth  10.1  9.4  15.6  1,296 
Highest 7.0  7.3  11.6  1,278         
Religion        
Roman Catholic 11.9  12.7  18.3  2,445 
Lesotho Evangelical 9.2  9.5  14.6  1,075 
Anglican 13.1  8.4  16.5  414 
Pentecostal 11.7  12.7  18.5  555 
Other Christian 11.8  9.9  16.9  1,169 
Other religion 10.3  10.9  17.1  461 
Don't know 23.1  18.3  30.1  96 
Age        
15-19 22.0  17.8  29.0  1,093 
20-24 11.5  9.4  16.5  1,084 
25-29 8.3  9.6  14.2  964 
30-34 8.5  8.8  13.4  786 
35-39 6.5  8.3  12.2  662 
40-44 10.3  11.1  16.2  493 
45-49 8.0  11.2  14.0  372 
50-54 11.6  13.5  18.5  377 
55-59 12.6  11.5  18.3  400         
Total 15-24 16.8  13.7  22.9  2,177 
Total 15-49 11.5  11.1  17.3  5,454 
Total 15-59 11.6  11.3  17.4  6,231 
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Table 17.3.A Discriminatory attitudes toward people living with HIV (continued) 
1Relates to Global AIDS Monitoring indicator 4.1: Discriminatory attitudes towards people living with HIV; 2Includes only participants who 
answered both questions. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. 
 
17.4 Gaps and Unmet Needs 
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▪ Discriminatory attitudes are more common in rural areas, and among socio-economically 
disadvantaged populations. They are also most common among older adolescents, which could 
have far-reaching consequences due to their demographic importance. Interventions to reduce 
discrimination should consider hard-to-reach populations, and target venues where these young 
people are found, including schools and youth groups.   
  
 
 
 
120 
Chapter 18    Tuberculosis 
18.1 Key Findings 
 
 
18.2 Background 
People living with HIV are at risk for acquiring other diseases, including TB. Despite being preventable 
and curable, TB remains the leading cause of death for people living with HIV in sub-Saharan Africa. 
Lesotho has the second highest incidence of TB in the world, estimated at 665 cases per 100,000 per 
year in 2017.1 The estimated HIV prevalence among TB incident cases is 71% (63–78%). The above rates, 
when translated into absolute numbers, are equivalent to 15,000 (9,600-21,000) estimated new TB 
cases in 2017, of whom 11,000 (6,700-15,000) are living with TB and HIV. 2 In order to gain a better 
understanding of the TB burden, the MOH plans to conduct a TB Prevalence Survey in 2019.  
 
Lesotho’s TB control is guided by The National TB and Leprosy Control Strategic Plan 2013-2018, which 
had the goals of reducing TB prevalence and mortality rates by 25% and 50%, respectively.3 The Joint 
Review of HIV, TB, and Hepatitis Programs conducted by the MOH with support from the WHO during 
23 October-3 November 2017 noted a 40% decrease in TB mortality (i.e., from 477 in 2008 to 287 
deaths/100 000 population in 2016), which is still far from the mortality target; the limitations in 
estimating a TB prevalence makes the achievement of the first target uncertain. The joint review also 
highlighted that only 46% of the estimated TB incident cases were registered for treatment in 2016 and 
only 74% and 64% of the new/relapse TB cases and previously treated TB cases, respectively, were 
successfully treated in 2015.4  
 
In its new (draft) National Tuberculosis Strategic Plan 2018-2022, Lesotho adopted two goals of the End 
TB Strategy, with reference to the baseline of 2016 and to be achieved by 2022; to reduce TB mortality 
and incidence by 75% and 50%, respectively.  
 
This chapter describes the prevalence of ever having received a diagnosis of TB by certain demographic 
characteristics, as well as the TB clinical care cascade for HIV-positive individuals: received care at a TB 
clinic, TB diagnoses among those receiving care, and treatment among those diagnosed with TB. 
 
18.3 Tuberculosis 
Overall, 7.1% of adults reported having been diagnosed with TB during their lifetime. A higher 
proportion of men (8.1%) had been diagnosed with TB than women (6.0%). This number was 
significantly higher in those who tested HIV positive during the survey (20.6%) than in those who tested 
▪ Among all adults (those aged 15-59 years), 7.1% reported a history of TB—with a higher 
proportion among those who tested HIV positive (20.6%) than those who tested HIV negative 
(2.3%). 
▪ TB was more common in men, in those without any education, and in older people.  
▪ More people were diagnosed with TB in urban areas and the lowlands.  
▪ Among self-reported HIV-positive adults, 51.9% reported having visited a clinic for TB diagnosis, 
46.6% of whom were diagnosed with TB, and 97.9% of those who were diagnosed were treated 
for TB. 
18 TUBERCULOSIS 
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negative (2.3%), or in those with no HIV test result (5.9%). More than one out of three people (36.2%) 
who visited a TB clinic were diagnosed with TB, ranging from 46% in HIV-positive to 22.6% in HIV-
negative persons. The majority of people with a TB diagnosis reported having been treated (96.8%). 
Among those diagnosed with TB, only individuals not tested for HIV during the PHIA survey had a lower 
percentage (87.3%) of not being treated for TB compared to those who did get tested during the survey 
(Table 18.3.A).  
 
Significantly more people in urban areas (8.1%) had been diagnosed with TB than in rural areas (6.3%), 
and significantly less in the mountains (4.3%) compared to the lowlands (7.9%), as significantly fewer 
persons in the mountains had ever visited a TB clinic (15.9% compared to 20.6% in the lowlands). The 
highest percentage of persons diagnosed with TB was in Maseru district (8.6%), and the lowest in 
Mokhotlong (4.4%). Diagnosis of TB decreased with increasing education, with 11.4% of those with no 
education reporting a history of TB, compared to 5.4% of those with a secondary education, and 4.9% of 
those with a tertiary education. It also increased rapidly with age, with only 1.5% of those aged 15-19 
years reporting a TB diagnosis compared to 16.0% of those aged 55-59 years (Table 18.3.A). 
 
Among self-reported HIV-positive adults, 51.9% reported ever visiting a TB clinic (60.9% of HIV-positive 
men compared to 46.6% of HIV-positive women). Among those who ever visited a TB clinic, 46.6% were 
diagnosed with TB (57.6% of HIV-positive men compared to 38.1% of HIV-positive women). Among 
those diagnosed with TB, 97.9% reported receiving TB treatment (99.0% of men and 96.7% of women) 
(Table 18.3.B). 
 
Table 18.3.A Tuberculosis (TB) diagnoses and treatment characteristics of the population aged 15-59 years 
Among adults aged 15-59 years, percentage who were ever diagnosed with TB or who had ever visited a TB clinic; among those who had ever visited 
a TB clinic, percentage who were diagnosed for TB; and among those diagnosed with TB, percentage who were treated for TB, LeP HIA 2016-2017 
  
Among all adults  
Among adults who ever 
visited a TB clinic  
Among adults who 
were diagnosed with 
TB 
Characteristic 
Percentage 
diagnosed 
with TB 
Percentage 
who ever 
visited a  
TB clinic Number  
Percentage 
who were 
diagnosed 
with TB Number  
Percentage 
who were 
treated for 
TB Number 
Result of PHIA survey HIV test          
HIV positive 20.6 44.8 3,193  46.0 1,402  97.7 623 
HIV negative 2.3 10.3 8,466  22.6 865  97.4 190 
Not tested 5.9 19.7 1,201  29.9 230  87.3 64           
Sex          
Male 8.1 19.1 5,349  42.7 1,023  96.8 441 
Female 6.0 19.9 7,511  29.9 1,474  96.7 436           
Residence          
Urban 8.1 21.5 5,078  37.7 1,086  96.9 389 
Peri-urban 6.1 19.3 880  31.4 166  94.1 51 
Rural 6.3 17.8 6,902  35.5 1,245  97.0 437           
Ecological zone          
Lowlands 7.9 20.6 8,286  38.1 1,710  96.5 635 
Foothills 6.3 18.6 1,111  34.0 213  98.6 70 
Mountains 4.3 15.9 2,453  26.8 397  96.3 108 
Senqu River Valley 6.3 17.2 1,010  36.8 177  98.7 64           
District          
Maseru 8.6 21.6 3,328  40.1 713  96.3 280 
Mafeteng 6.6 19.9 1,261  33.2 256  100.0 84 
Mohale's Hoek 6.7 20.5 961  32.8 205  97.2 64 
Leribe 6.6 20.2 2,127  32.5 438  96.1 139 
Berea 7.1 17.7 1,667  40.1 297  97.9 119 
Quthing 6.4 16.3 689  39.3 112  (98.0) 42 
Butha Buthe  5.8 19.4 816  29.7 159  (88.8) 46 
Mokhotlong 4.4 15.5 714  28.3 115  (94.7) 33 
Qacha's Nek 5.9 12.7 507  46.4 65  (100.0) 30 
Thaba Tseka  4.9 17.3 790  28.5 137  (100.0) 40           
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Table 18.3.A Tuberculosis (TB) diagnoses and treatment characteristics of the population aged 15-59 years 
Among adults aged 15-59 years, percentage who were ever diagnosed with TB or who had ever visited a TB clinic; among those who had ever visited 
a TB clinic, percentage who were diagnosed for TB; and among those diagnosed with TB, percentage who were treated for TB, LePHIA 2016-2017 
  
Among all adults  
Among adults who ever 
visited a TB clinic  
Among adults who 
were diagnosed with 
TB 
Characteristic 
Percentage 
diagnosed 
with TB 
Percentage 
who ever 
visited a  
TB clinic Number  
Percentage 
who were 
diagnosed 
with TB Number  
Percentage 
who were 
treated for 
TB Number 
Marital status          
Never married / lived  together 3.3 10.3 4,784  32.5 493  96.2 154 
Married or living together 8.0 22.6 6,170  35.3 1,337  96.6 451 
Divorced or separated 12.9 31.8 829  40.5 264  96.0 104 
Widowed 16.3 38.4 1,052  42.3 396  98.2 166           
Education          
No education 11.4 26.6 620  42.8 161  96.6 71 
Primary 8.9 21.4 5,248  41.6 1,124  96.9 452 
Secondary 5.4 17.1 5,722  31.6 967  97.9 290 
College / University 4.9 18.9 1,109  26.1 213  95.1 55 
Graduate / post-graduate  5.9 20.1 152  (29.2) 29  * 7           
Wealth quintile          
Lowest 5.7 16.9 2,479  34.0 416  97.9 142 
Second 7.0 19.9 2,526  35.3 506  96.3 174 
Middle 8.3 19.7 2,537  41.9 510  97.0 206 
Fourth  7.0 20.3 2,594  34.6 518  95.9 170 
Highest 7.1 20.1 2,692  35.0 543  96.9 184 
Religion          
Roman Catholic 6.7 18.7 5,105  35.9 956  99.2 340 
Lesotho Evangelical 7.5 21.0 2,254  35.7 462  96.5 160 
Anglican 7.2 20.9 892  34.7 188  95.1 63 
Pentecostal 8.1 20.2 1,123  40.2 226  88.8 84 
Other Christian 6.8 18.9 2,366  36.0 447  98.4 152 
Other religion 7.6 21.1 921  35.9 191  92.6 66 
Don't know 5.7 13.1 160  * 22  * 10           
Age          
15-19 1.5 4.9 2,243  30.9 106  (91.5) 29 
20-24 1.6 10.0 2,170  16.3 220  (97.6) 35 
25-29 3.5 14.8 1,985  23.8 301  94.7 66 
30-34 7.3 22.9 1,660  32.0 388  96.9 116 
35-39 11.0 27.3 1,340  40.3 363  97.8 143 
40-44 14.8 35.3 1,048  42.0 356  95.4 148 
45-49 14.2 31.5 820  45.1 247  94.4 111 
50-54 14.7 33.7 773  43.6 251  99.2 104 
55-59 16.0 33.3 821  48.0 265  100.0 125           
Total 15-24 1.6 7.4 4,413  21.3 326  94.5 64 
Total 15-49 6.1 17.8 11,266  34.0 1,981  95.9 648 
Total 15-59 7.1 19.5 12,860  36.2 2,497  96.8 877 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification 
variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with caution. 
An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 18.3.B Tuberculosis (TB) clinic attendance and services among HIV-positive adults 
Among self-reported HIV-positive adults aged 15-59 years, percentage who ever visited a TB clinic; among those who had ever visited a TB 
clinic, percentage who were diagnosed for TB; and among those diagnosed with TB, percentage who were treated for TB, by sex, LePHIA 
2016-2017 
  
Among HIV-positive adults  
Among HIV-positive adults who ever 
visited a TB clinic  
Among HIV-positive adults who 
were diagnosed with TB 
Characteristic 
Percentage who ever 
visited a TB clinic Number  
Percentage who were 
diagnosed with TB Number  
Percentage who were 
treated for TB Number 
Sex         
Male 60.9 785  57.6 477  99.0 280 
Female 46.6 1,861  38.1 857  96.7 322          
Total 15-59 51.9 2,646  46.6 1,334  97.9 602 
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18.4 Gaps and Unmet Needs 
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▪ TB diagnoses were relatively common in Lesotho, with one in five people living with HIV, and 
almost one in ten of all adults reporting a history of TB.  
▪ The reasons for fewer clinical assessments and TB diagnoses in the mountains are not clear, 
therefore, access to appropriate services in these remote areas should be assessed. 
▪ These data are limited in terms of their accuracy and completeness as they are based on self-
report.  The planned TB prevalence survey should provide more rigorous data on risk factors for 
TB, including occupational risks and barriers to accessing care. 
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Chapter 19    External Migration 
19.1 Key Findings 
 
 
19.2 Background 
Migration has been shown as a potential bridge to HIV acquisition, due to familial disruption and 
increases in sexual risk behavior. HIV prevalence is often higher among migrant populations, but the 
exact pathway between mobility and HIV acquisition is unclear. Mobility can also lead to interruptions in 
treatment and care, with decreasing access to HIV testing and clinical services due to local restrictions 
on treating non-citizens, or stigmatization of ‘outsiders.’ Patterns of migration in Lesotho and their 
association with HIV infection are important to understand to determine what gaps in prevention or 
linkage to care currently exist, and what interventions are needed for this population. 
 
19.3 External Migration Characteristics and HIV 
Migration plays an important role in Lesotho’s social organization; among adults (those aged 15-59 
years), 30.9% of men and 17.8% of women reported having lived outside Lesotho during their lifetime. 
Six percent (6.0%) of participants reported that they lived outside the country for a month or more 
during the last 12 months. This temporary out-migration was more common in men (7.2%) than in 
women (4.8%). Ninety-five percent of respondents who were out of the country for a month or more 
during the past 12 months reported South Africa as their place of residence while away, and 84.4% of 
men and 58.9% of women reported “work” as their primary reason for travel. Among men travelling for 
work, two in five reported working in construction, followed by mining and agriculture. One in four 
women reported “family” as the primary reason that they were away from home for more than a 
month. Among women who travelled for work, retail sales, manufacturing, and agriculture were 
mentioned as their primary work activity (Table 19.3.A). 
 
HIV prevalence was significantly higher in those who reported ever having lived outside Lesotho, with 
39.1% of women and 27.5% of men testing HIV-positive, compared to 28.5% of women and 17.8% of 
men who had never lived outside Lesotho. The number of times participants had lived outside Lesotho 
did not appear to be associated with HIV risk, nor did recent migration (Table 19.3.B).  
 
Table 19.3.A External migration characteristics of the population: Ages 15-59 years 
Percent distribution of the population aged 15-59 years, by sex and selected migration characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic Percent Number  Percent Number  Percent Number 
Ever lived outside Lesotho         
Yes 30.9 1,658  17.8 1,339  24.3 2,997 
No 69.1 3,698  82.2 6,185  75.7 9,883          
Away from home >1 month in last 12 months          
Yes 7.2 358  4.8 367  6.0 725 
No 21.1 1,106  10.6 768  15.9 1,874 
Never lived outside Lesotho 71.7 3,698  84.5 6,185  78.2 9,883          
19 EXTERNAL MIGRATION 
▪ Nearly one-quarter of all respondents had lived outside of Lesotho; 30.9% of men and 17.8% of 
women reported having lived outside of Lesotho.  
▪ HIV prevalence was significantly higher in those who had ever lived outside Lesotho than those 
who had not. 
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Table 19.3.A External migration characteristics of the population: Ages 15-59 years (continued) 
Percent distribution of the population aged 15-59 years, by sex and selected migration characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic Percent Number  Percent Number  Percent Number 
Reason away from home (> 1 month)         
Work 6.1 304  2.8 218  4.4 522 
School * 12  * 19  (0.3) 31 
Family * 17  1.1 85  0.7 102 
Medical care * 2  * 3  * 5 
Travel * 7  * 20  (0.2) 27 
Other  * 16  * 22  (0.3) 38 
Not away from home > 1 month in last 12 months 21.1 1,106  10.6 768  15.9 1,874 
Never lived outside Lesotho 71.7 3,698  84.5 6,185  78.2 9,883          
In what country, away from home         
South Africa 6.8 344  4.7 357  5.7 701 
Swaziland * 1  * 0  * 1 
Mozambique * 2  * 0  * 2 
Namibia * 0  * 0  * 0 
Botswana * 1  * 1  * 2 
Zimbabwe * 2  * 3  * 5 
Other * 7  * 6  * 13 
Not away from home > 1 month in last 12 months 21.1 1,106  10.6 768  15.9 1,874 
Never lived outside Lesotho 71.7 3,698  84.5 6,185  78.2 9,883          
Main product/ service / activity last time outside Lesotho         
Did not work (0.7) 37  1.0 76  0.8 113 
Agriculture (0.6) 34  * 17  0.4 51 
Fishing * 1  * 0  * 1 
Mining (0.7) 37  * 3  (0.4) 40 
Manufacturing * 19  * 19  (0.3) 38 
Electricity * 3  * 0  * 3 
Construction 2.7 133  * 2  1.4 135 
Wholesale * 16  * 22  (0.3) 38 
Household goods Hotels * 3  * 8  * 11 
Transport and communication * 9  * 1  * 10 
Financial * 2  * 1  * 3 
Real estate * 5  * 0  * 5 
Social * 4  * 1  * 5 
Other 1.0 50  2.8 209  1.9 259 
Not away from home > 1 month in last 12 months 21.1 1,106  10.7 768  15.9 1,874 
Never lived outside Lesotho 71.8 3,698  84.6 6,185  78.2 9,883          
Total 15-59 100.0 5,361  100.0 7,526  100.0 12,887 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. Estimates in parentheses are based on a small number (25 to 49) of unweighted cases and should be interpreted with 
caution. An asterisk indicates that an estimate is based on a very small number (less than 25) of unweighted cases and has been suppressed. 
 
Table 19.3.B HIV prevalence by external migration characteristics: Ages 15-59 years 
Prevalence of  HIV among adults aged 15-59 years, by sex and selected migration characteristics, LePHIA 2016-2017 
 Male  Female  Total 
Characteristic 
Percentage 
HIV positive Number  
Percentage 
HIV positive Number  
Percentage 
HIV positive Number 
Ever lived outside Lesotho 27.5 1,440  39.1 1,224  31.8 2,664          
Ever lived outside Lesotho         
Never 17.8 3,318  28.5 5,695  23.6 9,013 
1 time 27.0 735  38.9 694  31.6 1,429 
2-3 times 25.4 300  40.5 236  30.7 536 
4 times or more  31.4 338  40.6 226  34.3 564          
Away from home >1 month in last 12 months          
Yes 23.0 309  39.6 339  29.8 648 
No 28.9 966  40.4 700  32.8 1,666 
Never lived outside Lesotho 17.8 3,318  28.5 5,695  23.6 9,013          
Total 15-24 3.4 1,690  11.1 2,358  7.2 4,048 
Total 15-49 19.1 4,199  29.7 5,990  24.3 10,189 
Total 15-59 20.8 4,762  30.4 6,920  25.6 11,682 
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Table 19.3.B HIV prevalence by external migration characteristics: Ages 15-59 years (conclusions) 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the 
classification variable. 
 
19.4 Gaps and Unmet Needs 
  
▪ Migration was relatively common in the survey population during the survey period, although it is 
likely an underestimate as only those who had returned to Lesotho during the survey were 
interviewed. 
▪ The role of mobility in HIV acquisition should be further examined to determine how to diminish 
risk to migrants and how to encourage access to care. 
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Discussion and Conclusions  
LePHIA provides an important snapshot of the state of the HIV epidemic in a country with one of the 
highest burdens of HIV in the world. HIV continues to greatly affect the people of Lesotho, with 25.6% of 
HIV-positive adults (those aged 15-59 years), corresponding to an estimated 306,000 people in 2017. Over 
the last decade, Lesotho has made great efforts to combat this epidemic, with innovative HIV testing 
campaigns, improved linkage to care, as well as increased ART coverage. By quantifying national 
population-level HIV incidence and VLS for the first time in Lesotho, LePHIA has contributed to the 
understanding of the epidemic. The results demonstrate that there has been remarkable progress in 
epidemic control as Lesotho has made considerable gains toward the achievement of the UNAIDS 90-90-
90 targets in adults, with 81.0% of those living with HIV diagnosed, 91.8% of those diagnosed receiving 
ART, and 87.7% of those on ART had VLS. 
  
There are persistent gaps in achievements. The LePHIA national estimate of HIV incidence in adults was 
amongst the highest in the world (HIV incidence: 1.1%), resulting in almost 10,000 new HIV infections in 
2017.  
 
In addition, the high prevalence of households having at least one HIV-positive member, including 36.0% 
with an HIV-positive head, could have economic and psycho-social impacts on other household members, 
as well as long-term consequences for the family structure, the health system and the economy. 
  
Increasing coverage of diagnosis and improving adherence to treatment to improve the proportion of 
sexually active adults who have VLS are critical to reduce HIV incidence. However, prevention efforts such 
as improving condom use, limiting the number of sexual partners, increasing coverage medical male 
circumcision, improving HIV education in young people, and promoting pre-exposure prophylaxis (PrEP) 
for those at high risk should also be included in any national strategy for HIV prevention. 
 
Priority Populations in Lesotho 
Young People (ages 15-24 years) and HIV 
▪ There are disparities by sex in HIV burden in young people, with young women acquiring HIV at a 
much faster rate than young men the same age, with an HIV incidence of 1.5% in young women 
compared to 0.1% in young men. Although this disparity subsides by the time they age into their 
40s, young women were three times more likely to be living with HIV (11.1% vs 3.4% prevalence) 
than young men in the same age group.  
▪ This disparity in risk was seen despite the fact that far fewer young women reported early sexual 
debut than young men (4.7% vs 20.6%), although there is possible reporting bias due to gender 
norms around sexuality. We also see that girls aged 13-14 years had already experienced high rates 
of sexual and physical abuse, with implications for HIV acquisition in the future, as the prevalence of 
HIV was higher in women with a history of sexual violence. 
▪ The high rate of infection at young ages in the female population has consequences for both the 
individual as well as the health system. It has negative consequences for their own health due to the 
higher risk of comorbidities associated with long-term infection and the potential cumulative toxicity 
of treatment due to more years of ART exposure. Furthermore, as older adolescent girls and young 
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women had the lowest rates of VLS amongst women, with almost half without VLS, they are at 
higher likelihood of onward vertical and sexual transmission. 
▪ Despite their lower prevalence of HIV, young men had established behavioral patterns which would 
put them at risk of HIV acquisition when they are older. This includes one in five (20.6%) reporting 
early sexual debut. Furthermore, despite having the highest frequency of non-marital, non-
cohabitating partners in the past year (89.7%), only 79.9% reported using condoms and less than 
half (49.3%) reported HIV testing in the past year. And although more young men had been 
medically circumcised than their older counterparts, approximately half were not.  
▪ For young men living with HIV, almost half (48.7%) did not have VLS, and, unlike young women, this 
low rate of VLS continues in those aged 25-34 years, where 53.9% did not have VLS. Older 
adolescent boys aged 15-19 also had the highest proportion who were severely immunosuppressed 
(24.1%), which could indicate long-standing undiagnosed HIV. However, it should be noted that the 
number of males in this age band was small, suggesting the need for further research in this 
population. 
▪ Surprisingly, in a country with the second highest burden of HIV in the world, only 26.0% of young 
men and 27.8% of young women had complete and correct knowledge of HIV. Older adolescents 
aged 15-19 years also had the highest rates of discriminatory attitudes. Despite apparent gains in 
epidemic control, if this key demographic ages without an improved basic understanding of HIV 
transmission, additional barriers to prevention could arise.  
▪ There were no risk factors clearly explaining the disparity in HIV in young men vs women, although 
in both sexes education was associated with lower prevalence of HIV. It is recommended to target 
this population with interventions addressing both structural and individual risk factors. 
Interventions in terms of sexual mores and gender norms should address some of the factors 
encouraging early adoption of high-risk behaviors in young men. School attendance should also be 
encouraged in both boys and girls. Furthermore, low rates of VLS in their male sexual partners are 
likely key drivers of HIV in young women, requiring further investment to determine how to best 
engage men in earlier testing and treatment. Finally, encouraging uptake of medical circumcision in 
HIV-negative young men before peak sexual activity should reduce HIV acquisition in men, 
interrupting the transmission cycle between men and women. 
 
Children and HIV 
▪ With one of the highest global burdens of HIV among children (those aged 0-14 years) (HIV 
prevalence of 2.1%), Lesotho has done very well in achieving almost universal treatment coverage 
(98.2%) amongst children whose parents or guardians are aware of their status. However, it is 
worrisome that 20% of children had not been previously diagnosed, reflecting gaps in infant and 
child HIV testing services. Lesotho is currently evaluating different strategies to improve yield and 
efficiency of pediatric testing to identify those children living with HIV who have not yet been 
identified. Another concern is that almost 30% of children on treatment did not have VLS. Current 
pediatric ART in Lesotho is predominantly NNRTI-based and access to more optimal ART regimens 
and tailored support for medication administration will be critical to address the low prevalence of 
VLS in this population. 
▪ HIV prevalence was 24.5% in pregnant women in LePHIA. Although Lesotho began implementing 
Option B+ in 2013, and has achieved high coverage of the key intervention to reduce vertical 
transmission of HIV (98.5% of HIV-positive women aged 15-49 years who gave birth during the 12 
months preceding the survey reported that they had received ART during pregnancy or labor and 
delivery), 2.8% of HIV exposed infants younger than 18 months were HIV positive.  
▪ Furthermore, 20.9% of the HIV-positive mothers of infants tested in the survey did not have VLS at 
the time of the survey.  Increasing coverage of virological testing continues to be a national priority. 
  
 
 
 
129 
Several system-level interventions could be useful. In the laboratory, facilitating access to testing 
with the potential use of POC technologies, and, in facilities, through service quality improvement 
initiatives, training of healthcare personnel, and additional points of entry to testing, such as 
immunization clinics. Furthermore, strengthening existing laboratory systems to improve access to 
DNA PCR testing for EID (e.g., specimen transport), maximizing lab capacity/efficiency, and 
implementing efficient systems to return results back to clinics could all be useful in addressing this 
gap. 
 
Sex workers and their clients 
▪ Data on sex work in Lesotho is relatively limited. LePHIA found that 3.7% of women reported ever 
having engaged in paid sexual intercourse, and 10.1% of men. HIV prevalence was significantly 
higher in this population, with almost 1 in 2 women (48.2%) reporting lifetime sex work testing HIV 
positive, and 46.2% of those who reported recent sex work. HIV prevalence was 51.4% in women 
who reported recent paid intercourse where they did not use a condom at their last paid sex act; 
this has serious implications for onward transmission if they did not have VLS.  
▪ Men who had ever paid for sex were also more likely to be HIV positive, with an HIV prevalence of 
30.1% in male clients and 36.3% in those who reported recent paid intercourse and who did not use 
a condom at their last paid sex act. 
▪ This demonstrates that even though this is a generalized epidemic in Lesotho, there are still 
populations at even greater risk of HIV acquisition, who also tend to be harder to reach by many 
common prevention interventions. Interventions such as PrEP, cash transfers to vulnerable young 
women, and re-energized condom promotion should be explored within this context. 
 
Men and HIV  
▪ There was very high HIV incidence in men above the age of 25 years, with 1.4% of men aged 25-34 
years and 2.7% of men aged 35-49 years acquiring HIV in 2017. This was also apparent in the tripling 
of prevalence in men aged 25-44 years (from 12.9% in adults aged 25-29 years to 46.9% in adults 
aged 40-44 years).  
▪ It is difficult to ascertain exactly which risk factors are driving this later acquisition. Migration was 
very common in men, with 30.9% reporting having lived outside Lesotho, mainly for work purposes, 
with HIV prevalence significantly higher in migrants. Migrant men have been shown to engage in 
more high-risk partnerships, including paid sexual intercourse. Furthermore, over a quarter of 
married men reported having an extra-marital partner in the past year, with only 66.8% reporting 
condom use at last sex with that partner. 
▪ The coverage of key care interventions such as testing, diagnosis, and ART was lower for men than 
for women. As a consequence, the prevalence of VLS was low in HIV-positive men (63.4%), in 
contrast to women (70.5%). This is likely a consequence of poor health-seeking behaviors among 
men, reflective of gender norms defining masculinity in ways that affect health behaviors, 
encourage multiple and concurrent partnerships, and promote alcohol and drug use, particularly in 
those away from their families for long periods.  
▪ It is important to note though that men who were aware of their status were clearly adhering to 
medication, as demonstrated by high levels of VLS, and good concordance between self-reported 
ART use and detectable ARVs.  
▪ To address the gap in awareness of HIV, various interventions should be considered at different life 
stages. Male-friendly testing and care clinics are recommended in order to better provide services 
geared to male health concerns and sensitivities. The intersection of employment, migration, and 
risky sexual behaviors should also be evaluated in older men, to generate targeted policies to better 
serve mobile populations. 
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Older people and HIV 
▪ Although prevalence was slightly lower in those aged 50 years and older compared to those aged 
40-49 years, as people living with HIV age into this range comorbidities will become more common 
and will increase the burden on the health system. Furthermore, although the numbers were small, 
a high proportion of those aged 55-59 years had severe immunosuppression (CD4 count <200 
cells/µL) at diagnosis. As close to half had not tested for HIV in the past year, it is likely that many 
older people do not consider themselves at risk for HIV. Considering the slow immune recovery 
often seen in older people living with HIV, testing campaigns and HIV services, which include 
screening for other chronic diseases such as hypertension or diabetes mellitus, might encourage 
older patients to access services more regularly. 
▪ This underestimate of risk appears to pertain to widowed people living with HIV who have lower 
rates of awareness, and to divorced or separated people living with HIV who have lower rates of VLS 
than their married counterparts, with only 52.1% of divorced men and 65.5% of women with VLS, 
even though they tended to be older and rates of VLS increase with age. Innovative methods to 
identify people living with HIV in groups, that are traditionally thought of as lower risk should be 
developed.  
 
HIV services in Lesotho 
▪ The Lesotho National HIV Program needs to implement evidence-based HIV prevention packages of 
interventions carefully selected to suit the epidemic setting and the target populations.   
▪ The considerable variation observed in prevalence of HIV and in coverage of testing and male 
circumcision across districts, with rural areas and mountainous districts often performing less well 
than other regions, highlights the need to ensure accessibility and quality of services in all regions. 
Both geographic topography and human resource constraints contribute to the disparity in service 
coverage, accessibility, and uptake. Targeting additional resources to the lower performing districts 
should include assessments of current staffing, as well as capacity-building for monitoring, 
evaluation, and supervision, and should aim to address any current shortcomings and ensure more 
equitable distribution of resources. 
 
HIV Testing and Counseling 
▪ As in many other countries, the key gap in achieving the 90-90-90 targets is really in terms of 
awareness of status, particularly among young people overall and men aged 25-34 years. Although 
the majority of the population have tested for HIV at some point in their lives, the frequency of 
recent testing was lower than desired, particularly among young people. Identification of people 
living with HIV is crucial, as young men living with HIV had achieved high rates of VLS once on 
treatment, and there was very little discordance between reporting ART use and having detectable 
ARVs. Understanding barriers to testing in key populations should be prioritized, and addressing 
mobility and misperceptions of HIV as a female disease need to be addressed to encourage 
participation in testing campaigns.  
▪ Innovative methods for improving community-based testing yield, with differentiated HIV testing 
services, including self-testing and decentralization of care, with task shifting of some key HIV 
interventions to community health workers and other cadres, might assist in reaching hard to reach 
populations. 
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Condom Promotion 
▪ Condoms remain a key low-cost intervention for the prevention of HIV. According to our data, 72.6% 
of men and 65.0% of women who had a non-marital partner in the last 12 months, used a condom 
the last time they had sex with that partner. Although this suggests improvement in condom use for 
higher risk partners, there are still key demographics who are not using condoms regularly. For 
instance, women aged 50-59 years were less likely to use condoms with non-marital partners than 
their younger counterparts, suggesting that females still consider condoms primarily for pregnancy 
prevention, and decrease their use after ageing out of reproductive ages. 
 
Antiretrovirals 
▪ Lesotho has achieved enormous gain in coverage of ART, and VLS was high in those on ART. This is a 
credit to the adoption of the Test and Treat policy in 2016. However, there were still some gaps 
identified. Among adults previously diagnosed with HIV, but not on ART, the median CD4 count was 
350 cells/µL and 22.7% were severely immunosuppressed. This finding highlights the need to 
identify pre-ART patients and prioritize initiation of treatment in this group, including through active 
tracking of those not engaged in care. Among those adults living with HIV but not previously 
diagnosed, the median CD4 count was 383 cells/µL (361 cells/µL in men and 413 cells/µL in women); 
15.8% had a CD4 count less than 200 cells/µL (17.7% of men and 13.7% of women). However, the 
median CD4 count was over 500 cells/µL for people on ART, demonstrating that drug efficacy and 
adherence are very good in terms of the suppression of viremia as well as immune reconstitution. 
▪ Almost one in eight (11.4%) adults had transmitted resistance to NNRTIs, the most commonly used 
class of ARVs. This pattern suggests that a significant portion of those who are newly diagnosed with 
HIV and initiating ART will fail treatment due to pre-existing drug resistance. However, the total 
number of genotyped samples was small, and further genotyping should be done on both newly 
diagnosed and treated individuals to assess the prevalence of primary and secondary drug 
resistance in Lesotho, to provide further evidence to support the shift of first-line regimens to 
integrase or protease inhibitor-based therapies. 
 
Conclusions 
▪ The fact that over one in three people in Lesotho above 30 years of age is HIV positive indicates a 
substantial economic burden on the country’s health system. The peak HIV prevalence in adults 
aged 40-44 years is likely a reflection of both diagnoses of new cases of HIV and decreased mortality 
due to the expanded access to ART during the past 10 years. As this population ages, it is important 
to address the double burden of HIV and non-communicable diseases. This calls for transitioning the 
response from an emergency response to a chronic disease management model, including the 
development of differentiated care models that include the integration of non-communicable 
disease management in HIV care.  
▪ Despite encouraging results in terms of VLS and approaching the 90-90-90 goals, there remain 
challenges in achievements. LePHIA should provide actionable policy goals for targeting of evidence-
based, high-impact interventions. 
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Appendix A    Sample Design and Implementation 
Appendix A provides a high-level overview of sampling and weighting procedures for LePHIA 2016-2017. 
In-depth details are provided in the LePHIA 2016-2017 Sampling and Weighting Technical Report, which 
may be found online on the PHIA Project website. 
 
A.1 Sample Design 
Overview 
The sample design for the LePHIA 2016-2017 was a stratified multistage probability sample design, with 
strata defined by the 10 districts of the country, first-stage sampling units defined by enumeration areas 
(EAs) within strata, second-stage sampling units defined by households within EAs, and finally eligible 
persons within households. Within each, the first-stage sampling units (also referred to as primary 
sampling units or PSUs) were selected with probabilities proportionate to the number of households in 
the PSU based on preliminary results of the 2016 Lesotho Population and Housing Census. The allocation 
of the sample PSUs to the 10 districts was made in a manner designed to achieve specified precision 
levels for (1) a national estimate of the HIV incidence rate and (2) district estimates of VLS. 
 
The second-stage sampling units were selected from lists of dwelling units/households compiled by 
trained staff for each of the sampled PSUs. Upon completion of the listing process, a random systematic 
sample of dwelling units/households was selected from each PSU at rates designed to yield self-
weighting (i.e., equal probability) samples within each district to the extent feasible. 
 
Within the sampled households, all eligible adolescents and adults aged 15-59 years were included in 
the study sample for data collection. All eligible children aged 0-14 years in half of the sampled 
households were included in the study for data collection. 
 
Population of Inference 
The population of inference for the LePHIA 2016-2017 was comprised of the de facto household 
population. The de facto population is comprised of individuals who were present in households (i.e., 
slept in the household) on the night prior to the household interview. In contrast, the de jure population 
is comprised of individuals who are usual residents of the household, irrespective of whether or not they 
slept in the household on the night prior to the household interview.  
 
Precision Specifications and Assumptions 
The following specifications were used to develop the sample design for the LePHIA 2016-2017. 
▪ The number of first-stage sampling units (EAs) to be selected was 418, with an average of 25 
occupied dwelling units per EA. 
▪ The total sample of 10,450 occupied dwelling units were allocated to the ten strata (districts) as 
follows: The minimum number of EAs for each stratum was determined by estimating the minimum 
number of HIV-positive respondents and blood tests needed (accounting for response and testing 
rates from previous surveys) to provide sub-national estimates of VLS with a maximum 95% CI of +/- 
10.0% in each stratum.  Since the denominator used for estimating VLS was HIV-positive individuals, 
the required minimum number of blood draws in a stratum was inversely proportional to the 
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expected HIV prevalence rate in that stratum. The total sample size also had to be sufficient to 
produce a national annual HIV incidence rate with a relative standard error (RSE) of 30% or less for 
persons aged 15-49 years, as well as a national annual HIV incidence rate for women aged 15-24 
with an RSE of 30% or less. Based on the sample allocation given in (c) above, the RSE of the 
estimated incidence rate was expected be approximately 33%. 
 
The following assumptions were used to develop the sample design for the LePHIA 2016-2017. 
▪ An overall HIV prevalence rate of 0.23 (23%) that varies by district. 
▪ An annual HIV incidence rate for adults aged 15-49 years of 𝑃𝑎 = 0.0185 (1.85%). 
▪ An MDRI of 130 days, yielding an annualization rate of 365/130= 2.8077. Hence, the estimated 
incidence rate for MDRI = 130 days is 𝑃𝑚 = 0.0185/2.8077=0.0066 (0.66%). 
▪ A VLS rate among HIV-positive adults aged 15-49 years in each district of Pvh = 50%. This conservative 
assumption overstates the actual variance of the VLS rate. 
▪ An intra-cluster correlation (ICC) of = 0.05 for both prevalence and incidence. The ICC provides an 
average measure of the homogeneity of responses within the first-stage sampling units. This 
assumption is conservative. 
▪ An occupancy rate of 96.0% for sampled dwellings. Note that this is not included in the calculation 
of the overall survey RR, but does determine the initial number of dwelling units to be sampled. A 
sample of 10,887 dwelling units will yield a sample of about 10,450 occupied dwelling units 
(households). 
▪ The average number of persons aged 15-49 years in a household is 1.33. 
▪ The percentage of persons in households who are aged 0-14 years is 32.9%. 
▪ The percentage of persons in households who are aged 50-59 years is 5.9%. 
▪ Among the individuals aged 15-59 years, an overall biomarker RR of 80.9%, reflecting sample loss 
due to any of the following reasons: nonparticipation (refusal) of some sample households, 
nonresponse to the individual interview, refusal to provide a blood sample, or providing a non-
analyzable blood sample. 
▪ Among the children in the eligible responding households, an overall biomarker RR of 75.9% for 
children aged 0-14 years. This value is the comparable RR for adults minus 5%. 
 
Selection of the Primary Sampling Units 
The PSUs for the LePHIA 2016-2017 were defined to be the EAs created for the 2016 Lesotho Census. 
The sampling frame consisted of approximately 6,000 EAs containing an estimated 570,000 households 
and 2,000,000 persons. The EAs varied in size from 80 to 150 households with approximately 400 
persons per EA. 
 
A stratified sample of 418 EAs was selected from the sampling frame. The ten strata specified for 
sampling were the ten districts of Lesotho. The EA samples were selected systematically and with 
probabilities proportionate to a measure of size (MOS) equal to the number of households in the EA 
based on preliminary results of the 2016 Lesotho Census. Prior to selection, the EAs were sorted by EA 
code within each stratum (district). The sorting of the EAs prior to sample selection induced an implicit 
geographic stratification, which included constituency, community or town council, ecological zone and 
type of residence. To select the sample from a particular stratum, the cumulative MOS was determined 
for each EA in the ordered list of EAs, and the sample selections were designated using a sampling 
interval equal to the total MOS of the EAs in the stratum divided by the number of EAs to be selected 
and a random starting point. The resulting sample had the property that the probability of selecting an 
EA within a particular stratum was proportional to the MOS of the EA in the stratum. 
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Details regarding EA substitution and segmentation may be found in the LePHIA 2016-2017 Sampling 
and Weighting Technical Report on the PHIA Project website. 
 
Selection of Households 
For both sampling and analysis purposes, a household is defined as a group of individuals who reside in 
a physical structure such as a house, apartment, compound, or homestead, and share in housekeeping 
arrangements. The physical structure in which people reside is referred to as the dwelling unit, which 
may contain more than one household meeting the above definition. Households were eligible for 
participation in the survey if they are located within the sampled EA. 
 
The selection of households for the LePHIA 2016-2017 involved the following steps: (1) listing the 
dwelling units/households within the sampled EAs; (2) assigning eligibility codes to the listed dwelling 
unit/household records; (3) selecting the samples of dwelling units/households; and (4) designating a 
subsample of households for data collection for children. 
 
A description of the household listing process as well as a summary of household eligibility may be 
found in the LePHIA 2016-2017 Sampling and Weighting Technical Report on the PHIA Project website. 
 
Selection of households utilized an equal probability design. In order to achieve equal probability 
samples of households within each of the 10 districts of Lesotho, the sampling rates required to select 
dwelling units/households within an EA depended on the difference between the MOS used in sampling 
and the actual number of dwelling units/households found at the time of listing. Thus, application of 
these within-EA sampling rates yielded more or less than the desired 30 households in EAs where the 
sampling MOS differed from the actual listing count. The LePHIA 2016-2017 Sampling and Weighting 
Technical Report provides an in-depth description of the equal probability sample design, as well as a 
detailed summary of the results of the household selection. 
 
Table A.1 Number of sampled dwelling units/households and expected unequal weighting design effects by stratum  
Stratum 
(District) 
Number of sample 
PSUs (clusters) 
Number of 
sampled dwelling 
units/house-holds 
Number of dwelling 
units/house-holds 
flagged for child data 
collection 
Minimum PSU 
sample size 
Maximum PSU 
sample size 
UEW DEFF for 
LEPHIA household 
sample after 
capping 
Butha-Buthe 27 703 352 15 34 1.00 
Leribe 65 1,693 846 15 35 1.00 
Berea 51 1,328 664 15 35 1.06 
Maseru 102 2,657 1,329 15 35 1.02 
Mafeteng 41 1,059 529 15 35 1.02 
Mohale's Hoek  39 1,031 516 15 35 1.02 
Quthing 26 676 338 16 35 1.01 
Qacha's Nek  20 521 260 21 34 1.00 
Mokhotlong 21 547 273 18 35 1.00 
Thaba-Tseka 26 677 339 15 35 1.03 
Total 418 10,892 5,446 15 35 1.05* 
 
*Reflects variation in weights within and across strata.  
PSU: Primary sampling unit  
UEW: Unequal weighting  
DEFF: Design effect 
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Selection of Individuals 
The selection of individuals for the LePHIA 2016-2017 involved the following steps: (1) compiling a list of 
all individuals known to reside in the household or who slept in the household during the night prior to 
data collection; (2) identifying those rostered individuals who are eligible for data collection; and (3) 
selecting for the study those individuals meeting the age and residency requirements of the study. 
However, only those individuals who slept in the household the night before the household interview 
(i.e., the de facto population) were retained for subsequent weighting and analysis. 
 
The LePHIA 2016-2017 Sampling and Weighting Technical Report on the PHIA Project website provides a 
brief description of the process for listing and selecting individuals for participation in the LePHIA 2016-
2017, and also presents detailed summaries of the distributions of eligible individuals and participants in 
individual interviews and HIV testing by strata and age. 
 
A.2 Weighting 
Overview 
In general, the purpose of weighting survey data from a complex sample design is to (1) compensate for 
variable probabilities of selection, (2) account for differential nonresponse rates within relevant subsets 
of the sample, and (3) adjust for possible under-coverage of certain population groups. Weighting is 
accomplished by assigning an appropriate sampling weight to each responding sampled unit (e.g., a 
household or person), and using that weight to calculate weighted estimates from the sample. The 
critical component of the sampling weight is the base weight, which is defined as the reciprocal of the 
probability of including a household or person in the sample. The base weights are used to inflate the 
responses of the sampled units to population levels and are generally unbiased (or consistent) if there is 
no nonresponse or noncoverage in the sample. When nonresponse or noncoverage occurs in the survey, 
weighting adjustments are applied to the base weights to compensate for both types of sample 
omissions. 
 
Nonresponse is unavoidable in virtually all surveys of human populations. For LePHIA 2016-2017, 
nonresponse can occur at different stages of data collection, for example, (1) before the enumeration of 
individuals in the household, (2) after household enumeration and selection of persons but before 
completion of the individual interview, and (3) after completion of the interview, but before collection 
of a viable blood sample. 
 
Noncoverage arises when some members of the survey population have no chance of being selected for 
the sample. For example, non-coverage can occur if the field operations fail to enumerate all dwelling 
units during the listing process, or if certain household members are omitted from the household 
rosters. To compensate for such omissions, post-stratification procedures are used to calibrate the 
weighted sample counts to available population projections. For LePHIA 2016-2017, the weights were 
calibrated to the 2016 Population and Housing Census. 
 
Methods 
The overall weighting approach for LePHIA 2016-2017 included several steps. Methods and results for 
each of the steps below are detailed in the LePHIA 2016-2017 Sampling and Weighting Technical Report. 
 
▪ Initial checks: Checks of the data files were carried out as part of the survey and data QC, and the 
probabilities of selection for PSUs and households were calculated and checked. 
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▪ Creation of jackknife replicates: The variables needed to create the jackknife replicates for variance 
estimation were then established. This step can be implemented immediately after the PSU sample 
has been selected. All of the subsequent weighting steps described below were applied to the full 
sample, and to each of the jackknife replicates. 
 
▪ Calculation of PSU base weights: The weighting process began with the calculation and checking of 
the sample PSU (EA) base weights as the reciprocals of the overall PSU probabilities of selection. 
 
▪ Calculation of household weights: The next step was to calculate household weights. The household 
base weights were calculated as the PSU weights times the reciprocal of the within-PSU household 
selection probabilities. The household base weights were adjusted first to account for dwelling units 
for which it could not be determined whether the dwelling unit contained an eligible household and 
then the responding households had their weights adjusted to account for nonresponding eligible 
households. This adjustment was made based on the EA the households were in, and the resulting 
weight was the final household weight. 
 
▪ Calculation of person-level interview weights: Once the household weights were determined, they 
were used to calculate the individual base weights. The individual base weights were then adjusted 
for nonresponse among the eligible individuals, with a final adjustment for the individual weights to 
compensate for under-coverage in the sampling process by post-stratifying (i.e., weighting up) to 
2016 Population and Housing Census. 
 
▪ Calculation of person-level HIV testing weights: The individual weights adjusted for nonresponse 
were in turn the initial weights for the HIV testing data sample, with a further adjustment for 
nonresponse to HIV testing, and a final post-stratification adjustment to compensate for under-
coverage. 
 
▪ Application of weighting adjustments to jackknife replicates: All of the adjustment processes were 
applied to the full sample and the replicate samples so that the final set of full sample and replicate 
weights could be used for variance estimation that accounted for the complex sample design and 
every step of the weighting process. 
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Appendix B    HIV Testing Methodology 
B.1 Specimen Collection and Handling 
Blood was collected by qualified survey staff from consenting participants: 14 milliliters (mL) of venous 
blood from adults (those aged 15-59 years), 6 mL of venous blood from children aged 2-14 years and 1 
mL of capillary blood from children aged 0-2 years using finger-stick for children aged 6-23 months and 
heel-stick for children less than age six months. 1 mL using a finger prick was also collected for 
individuals aged 2 years and older where venous collection was not possible. 
 
Blood samples were labeled with a unique bar-coded participant identification number and stored in 
temperature-controlled cooler boxes. At the end of each day, samples were transported to a satellite 
laboratory for registration in a laboratory information management system, processing into plasma and 
dried blood spots (DBS), and storage at -20oC within 24 hours of blood collection. Approximately weekly, 
samples were transported to the Lesotho National Reference Laboratory (NRL) for additional testing and 
long-term storage at -80C. 
 
B.2 Household-Based Procedures 
HIV Rapid Testing 
HIV rapid testing was conducted in each household in accordance with Lesotho’s national guidelines 
(Figure B.2.A). HIV-positive samples underwent additional testing at a satellite laboratory, as described 
in Section B.3. For participants who self-reported an HIV-positive status but tested HIV negative during 
the survey, additional testing was conducted at NRL, as described in Section B.3. For children aged less 
than 18 months, only the initial rapid test was performed. If the test was reactive, the sample 
underwent additional testing at NRL, as described in Section B.3. 
 
APPENDIX B HIV TESTING METHODOLOGY 
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Figure B.2.A  Household-based HIV testing algorithm, LePHIA 2016-2017 
 
 
 
CD4 Testing  
All participants who tested HIV positive and a random sample of two percent of participants who tested 
HIV negative received a CD4 T-cell count measurement in the field by qualified survey staff. The 
measurement was performed using a Pima™ Analyzer and Pima™ CD4 Cartridge (Abbott Molecular Inc., 
Chicago, IL, United States of America [USA], formerly Alere). 
 
Counseling, Referral to Care, and Active Linkage to Care 
Pre- and post-test counseling were conducted in each household in accordance with Lesotho’s national 
guidelines. For participants age 12 years or older, results were communicated directly to the participant, 
while for participants aged less than 12 years, results were communicated to the participant’s parent or 
guardian. All participants who consented to HIV testing were asked to share contact information and to 
select a referral health facility prior to testing. Participants with an HIV-positive test result were referred 
to HIV care and treatment at the health facility of their choice, while participants with an HIV-
indeterminate test result were advised to seek repeated testing at the health facility of their choice in 
two weeks. Further, HIV-positive participants were asked to consent to be contacted by qualified 
healthcare personnel, in order to facilitate active linkage to HIV care and treatment in Lesotho’s 
healthcare system. 
 
In rare cases where participants were provided an incorrect HIV test result, self-reported an HIV-positive 
status but tested HIV negative during the survey, or required additional collection of blood to complete 
testing, households were revisited by qualified personnel to provide participants with correct 
information and guidance on appropriate actions. 
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Quality Assurance and Control 
To control the quality of the performance of HIV rapid tests, field staff conducted testing of a panel of 
HIV-positive and HIV-negative dried tube specimens on a weekly basis. To assure the quality of the 
performance of field staff conducting HIV testing, proficiency testing using a panel of blinded HIV-
positive and HIV-negative dried tube specimens was evaluated twice during the course of fieldwork. 
Additionally, sample retesting was conducted at a satellite lab for (1) the first 50 samples tested by each 
field staff member, (2) a random sample of five percent of HIV-negative specimens, and (3) all HIV-
indeterminate specimens. 
 
The potential limitations of rapid tests in detecting HIV antibodies among people in the serological 
window of infection, or in HIV-infected patients on antiretroviral therapy (ART), and in detecting 
maternal HIV antibodies among infants older than four months are all inherent limitations of the study. 
Participants in the first two categories are not expected to be a significant source of bias. Further 
analysis will identify how many infants born to HIV-positive women were not identified by a rapid test. 
 
B.3 Laboratory-Based Procedures 
Three survey satellite laboratories were established in existing health facility laboratories across the 
country. An additional two mobile satellite labs were also utilized. One central laboratory was 
established at NRL in Maseru, Lesotho.  
 
Geenius Testing  
All HIV-positive samples, as well as samples with discrepant or indeterminate results, were tested using 
the Geenius™ HIV 1/2 Supplemental Assay (Bio-Rad, Hercules, CA, USA) (Figure B.3.A). Testing was 
conducted at the satellite and mobile laboratories in accordance with the manufacturer’s protocol. 
 
HIV TNA Polymerase Chain Reaction  
HIV total nucleic acid (TNA) PCR was conducted for children aged less than 18 months who had a 
reactive HIV test result during household-based testing (Figure B.3.B). Additionally, HIV TNA PCR was 
evaluated for participants who self-reported an HIV-positive status but tested HIV negative during the 
survey, as well as for samples that were HIV positive by the rapid testing algorithm but were HIV 
negative or indeterminate by Geenius testing (Figure B.3.A). HIV TNA PCR was conducted on the Roche 
COBAS® AmpliPrep Instrument and COBAS® TaqMan 96 Analyzer using the COBAS® AmpliPrep/COBAS® 
TaqMan HIV-1 qualitative test (Roche Molecular Diagnostics, Branchburg, NJ, USA). 
 
Classification of Final HIV Status 
For participants aged 18 months or older, the algorithm for classification of final HIV status included 
results from HIV rapid testing, Geenius testing, and HIV TNA PCR (Figure B.3.A). For participants of ages 
less than 18 months, the algorithm for classification of final HIV status included results from HIV rapid 
testing and HIV TNA PCR (Figure B.3.B). Classification of final HIV status was used to determine 
estimates for HIV prevalence and to inform estimates for HIV incidence. 
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Figure B.3.A  Final HIV Status Classification Algorithm (ages 18 months and older), LePHIA 2016-2017 
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Figure B.3.B  Final HIV Status Classification Algorithm (<18 months), LePHIA 2016-2017 
 
 
Viral Load Testing 
HIV-1 viral load from confirmed HIV-1 positive participants was measured using the COBAS® 
AmpliPrep/COBAS® TaqMan HIV-1 Test, version 2.0 (v2.0) (Roche Molecular Systems, Branchburg, NJ, 
USA). The COBAS® Ampliprep instrument was used to prepare plasma samples for nucleic acid 
amplification and detection of HIV-1 RNA. The Abbott RT-PCR m2000 system (Abbott Molecular, 
Wiesbaden, Germany) was used to measure HIV-1 VL from DBS samples from children and from adults 
with insufficient volume of plasma. The DBS VL tests were performed at the National Institute of 
Communicable Diseases (NICD) in South Africa in accordance with the manufacturer’s protocol.    
 
VL results were returned to the health facility chosen by each HIV-positive participant. Participants were 
provided with a referral form during home-based testing and counseling for subsequent retrieval of 
their results. Survey staff also contacted participants who provided contact information, informing them 
that their VL results were available at the chosen facility and further advising them to seek care and 
treatment. 
 
HIV Recency Testing 
Estimation of HIV incidence was based on the classification of confirmed HIV-positive cases as recent or 
long-term HIV infections. The survey used two laboratory-based testing algorithms to estimate 
incidence. The first estimate used an algorithm that employed a combination of the HIV-1 Limiting 
Antigen (LAg) Avidity enzyme immunoassay (Sedia Biosciences Corporation, Portland, OR, USA) and VL 
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results (Figure B.3.C). Antiretroviral (ARV) detection results were added to that algorithm for the second 
estimate (Figure B.3.D). The HIV recent infection testing algorithms were applied to repository 
specimens from all confirmed HIV-positive participants aged 18 months and older. 
 
LAg testing was performed twice, with an initial screening test followed by a confirmatory process: 
specimens with an ODn > 2.0 during initial testing were classified as long-term infections, while those 
with ODn ≤ 2.0 underwent further testing of the specimen in triplicate. Specimens with median ODn > 
1.5 in confirmatory testing were classified as long-term infections. Specimens with median ODn < 0.4 
were retested using the HIV diagnostic testing algorithm to confirm HIV-1 seropositivity, and samples 
identified as HIV-1 seronegative were excluded from the total number of HIV positives and incorporated 
into the total number of negative specimens for incidence estimation. 
 
Specimens with median ODn ≤ 1.5 were classified as potential HIV-recent infections, and their VL results 
were assessed. For the first incidence testing algorithm, specimens with VL < 1,000 copies/mL were 
classified as long-term infections, while those with VL ≥ 1,000 copies/mL were classified as recent 
infections. For the updated incidence algorithm, those classified as recent infections by the first 
algorithm were reclassified using ARV detection data.  Those specimens in which efavirenz (EFV), 
lopinavir (LPV), and nevirapine (NVP) were detected were classified as long-term infections and those in 
which no ARVs were detected remained classified as recent infections. 
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Figure B.3.C HIV-1 Recent Infection Testing Algorithm (LAg/VL algorithm), LePHIA 2016-2017 
 
 
1ODn: normalized optical density; 2mL: milliliter 
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Figure B.3.D  HIV-1 Recent Infection Testing Algorithm (LAg/VL/ARV algorithm), LePHIA 2016-2017 
 
 
1ODn: normalized optical density; 2mL: milliliter 
 
HIV Incidence Estimation 
 
Incidence estimates were obtained using the formula recommended by the WHO Incidence Working 
Group and Consortium for Evaluation and Performance of Incidence Assays. Weighted counts for HIV-
negative persons (N); HIV-positive persons (P); numbers tested on the LAg assay (Q); and numbers HIV 
recent (R) are provided for use in incidence calculations or the United Nations Joint Programme on 
HIV/AIDS Spectrum models (Tables B.3.A, B.3.B). Incidence estimates were calculated using the 
following parameters: mean duration recent infection (MDRI) = 130 days (95% CI: 118-142 days); PFR = 
0.00; T = 1 year. In-depth details are provided in the LePHIA Technical Report on the PHIA Project 
website.
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Table B.3.A: Annual HIV incidence auxiliary data: N, P, Q, R (LAg/VL algorithm) 
Annual incidence of HIV among persons aged 15-49 and 15-59 years, by sex and age, using the limiting antigen (LAg)+viral load (VL) algorithm LePHIA 2016-2017 
 Male  Female  Total 
Age 
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R)  
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R)  
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R) 
15-24 1632.88 57.12 57.12 0.73  2096.34 261.66 260.32 13.58  3755.62 292.38 291.23 12.48 
25-34 1066.02 251.98 251.98 7.16  1224.49 686.51 685.40 5.15  2347.44 881.56 880.64 13.24 
35-49 712.72 478.28 478.28 7.75  896.43 824.57 824.57 8.83  1631.78 1280.22 1280.22 16.97 
15-49 3395.71 803.29 803.29 16.14  4211.47 1778.53 1776.06 27.36  7710.09 2478.91 2476.84 42.79 
15-59 3772.51 989.49 989.49 16.55  4819.57 2100.43 2097.91 30.14  8696.30 2985.70 2983.58 45.73 
1Weighted number 
Note: mean duration recent infection (MDRI) = 130 days (95% confidence interval: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year 
Weighted figures calculated using (normalized) btwt0. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
Table B.3.B:  Annual HIV incidence auxiliary data: N, P, Q, R (LAg/VL/ARV algorithm) 
Annual incidence of HIV among persons aged 15-49 and 15-59 years, by sex and age, using the limiting antigen (LAg)+viral load (VL)+antiretroviral (ARV) algorithm, LePHIA 2016-2017 
 Male  Female  Total 
Age 
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R)  
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R)  
Number 
HIV 
negative1 
(N) 
Number 
HIV 
positive1 
(P) 
Number 
tested on 
LAg assay1 
(Q) 
Number 
HIV 
recent1 
(R) 
15-24 1632.88 57.12 57.12 0.73  2096.34 261.66 260.32 11.15  3755.62 292.38 291.23 10.41 
25-34 1066.02 251.98 251.98 5.33  1224.49 686.51 685.40 5.15  2347.44 881.56 880.64 10.94 
35-49 712.72 478.28 478.28 6.81  896.43 824.57 824.57 3.58  1631.78 1280.22 1280.22 11.45 
15-49 3395.71 803.29 803.29 13.23  4211.47 1778.53 1776.06 19.82  7710.09 2478.91 2476.84 32.90 
15-59 3772.51 989.49 989.49 13.57  4819.57 2100.43 2097.91 21.00  8696.30 2985.70 2983.58 34.36 
1Weighted number 
Note: mean duration recent infection (MDRI) = 130 days (95% confidence intervaI: 118-142 days); proportion false recent (PFR) = 0.00; time cutoff (T) = 1 year 
Weighted figures calculated using (normalized) btwt0. 
The sum of the sample sizes for a given classification may be less than the total sample size because of missing responses to the classification variable. 
 
  
 
 
 
146 
Detection of Antiretrovirals 
To understand recent exposure to ARVs and hence level of ART coverage, samples from all confirmed 
HIV-positive participants were evaluated for the presence of selected ARVs, using high-resolution liquid 
chromatography coupled with tandem mass spectrometry to detect ARVs from DBS specimens.1 Three 
ARVs—two NNRTIs, EFV and NVP, and one PI, LPV—were used as markers for both first- and second-line 
regimens, based on  Lesotho’s national treatment guidelines. The ARVs were selected based on their 
long half-lives, allowing for a longer window period from drug exposure to detection. 
 
To qualitatively detect ARVs, a single DBS was eluted, and chromatographic separation carried out on a 
Luna 5μm PFP column (110 Å, 50 x 2 mm) (Phenomonex, Torrance, CA, USA). Each ARV was detected 
using an API 4000 LC/MS/MS instrument (Applied Biosystems, Foster City, CA, USA). Internal standards 
and in-house QC cut-off samples including negative controls were utilized in each run. This qualitative 
method used a limit of detection of 0.02 μg/mL for each ARV, with a signal-to-noise ratio of at least 5:1 
for all ARVs. Samples with concentrations above 0.02 μg/mL were considered positive for each ARV. 
Testing was conducted at University of Cape Town in South Africa. 
 
Genotyping for Detection of Antiretroviral Drug Resistance and HIV Subtyping 
To determine the extent of transmitted HIV-1 drug resistance mutations among participants in LePHIA 
2016-2017, samples from confirmed HIV-positive participants aged less than 18 months and HIV-positive 
participants aged 18 months or older who were classified as recent infections as well as an equal or 
greater number of who were classified as long-term infections were evaluated using an HIV-1  
Genotyping Kit (Applied Biosystems) to identify mutations within the HIV-1 pol gene region, which 
encodes amino acid substitutions known to be responsible for resistance to ARVs. 
 
Viral TNA from plasma or DBS was extracted using the NucliSENS® easyMAG® (bioMérieux, Marcy 
l’Etoile, France) platform. The HIV pol gene was amplified by one-step reverse transcription (RT)-PCR 
(Invitrogen), which was followed by nested PCR. Sequencing of the approximately one-kilobase 
amplicons was performed on the ABI 3730 DNA Analyzer (Applied Biosystems).4,5,6 
 
The customized RECall software program was used to edit raw sequences and generate consensus 
sequences.2 Mutations in the protease and reverse transcriptase genes were classified as potentially 
associated with drug resistance, according to the Stanford University HIV Drug Resistance Database.3 
Internal QA measures and in-house QC samples were included in each run to validate the testing process 
and results. The assay’s sensitivity has been established at 1000 copies/mL for plasma and DBS.4 
Sequences with >98% homology were flagged for potential cross-contamination or possible 
epidemiological links. Sequences were also analyzed for potential cross-contamination by phylogenetic 
analysis from codon 6 of the protease gene to codon 251 of the reverse transcriptase gene. 
 
Subtyping of each sample was performed using the REGA HIV-1 & 2 Automated Subtyping Tool.5,6 This 
BioAfrica viral subtyping tool is designed to use phylogenetic methods in order to identify the HIV-1 
subtype of a specific sequence. The sequence is analyzed for recombination using boot-scanning 
methods. 
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Appendix C    Estimates of Sampling Errors 
Estimates from sample surveys are affected by two types of errors: non-sampling errors and sampling 
errors. Non-sampling errors result from mistakes made during data collection (e.g., misinterpretation of 
an HIV test result) and data management (e.g., transcription errors in data entry). While LePHIA 2016-
2017 implemented numerous QA and QC measures minimize non-sampling errors, these errors are 
impossible to avoid and difficult to evaluate statistically. 
 
In contrast, sampling errors can be evaluated statistically. The sample of respondents selected for 
LePHIA 2016-2017 is only one of many samples that could have been selected from the same 
population, using the same design and expected size. Each of these samples would yield results that 
differ somewhat from the results of the actual sample selected. Sampling errors are a measure of the 
variability between all possible samples. Although the degree of variability is not known exactly, it can 
be estimated from the survey results. 
 
The standard error, which is the square root of the variance, is the usual measurement of sampling error 
for a particular statistic (e.g., proportion, mean, rate, count). In turn, the standard error can be used to 
calculate confidence intervals within which the true value for the population can reasonably be assumed 
to fall. For example, for any given statistic calculated from a sample survey, the value of that statistic will 
fall within a range of approximately plus or minus two times the standard error of that statistic in 95 
percent of all possible samples of identical size and design. 
 
LePHIA 2016-2017 utilized a multi-stage stratified sample design, which required complex calculations to 
obtain sampling errors. Specifically, a variant of the Jackknife replication method was implemented in 
SAS to estimate variance for proportions (e.g., HIV prevalence), rates (e.g., annual HIV incidence), and 
counts (e.g., numbers of people living with HIV). Each replication considered all but one cluster in the 
calculation of the estimates. Pseudo-independent replications were thus created. In LePHIA 2016-2017 a 
Jackknife replicate was created by randomly deleting one cluster from each variance-estimation stratum 
and retaining all of the clusters in the remaining strata. A total of 206 variance-estimation strata were 
created by pairing (or occasionally tripling) the sample clusters in the systematic order in which they had 
been selected . Hence, 206 replications were created. The variance of a sample-based statistic, y, was 
calculated as follows: 
 
var(y) = ∑  𝐾𝑘=1 (yk - y)
2 
 
where y is the full-sample estimate, and yk is the corresponding estimate for jackknife replicate k (k = 1, 
2, ..., K).  
 
In addition to the standard error, the design effect for each estimate was also calculated. The design 
effect is defined as the ratio of the standard error using the given sample design to the standard error 
that would result if a simple random sample had been used. A design effect of 1.0 indicates that the 
sample design is as efficient as a simple random sample, while a value greater than 1.0 indicates the 
APPENDIX C ESTIMATES OF SAMPLING ERRORS 
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increase in the sampling error due to the use of a more complex and less statistically efficient design. 
Confidence limits for the estimates, which are calculated as  
 
y  ±  t(0.975; K) √𝑣𝑎𝑟(𝑦) , 
 
where t(0.975; K) is the 97.5th percentile of a t-distribution with K degrees of freedom, were also 
computed.  
 
Sampling errors for selected variables from the LePHIA 2016-2017 are presented in tables C.1 through 
C.8, and sampling errors for all survey estimates may be found online on the PHIA website. For each 
variable, sampling error tables include the weighted estimate, unweighted denominator, standard error, 
design effect, and lower and upper 95 percent confidence limits. 
 
 
Table C.1  Sampling errors: Annual HIV incidence by age, LePHIA 2016-2017 
Age (years) 
Weighted 
estimate (%) 
Design 
effect 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 0.78 0.93 0.31 1.25 
25-34 1.30 1.09 0.53 2.07 
35-49 1.95 1.23 0.82 3.07 
15-49 1.19 1.22 0.77 1.61 
15-59 1.10 1.23 0.72 1.48 
MALE 
15-24 0.13 0.72 0.00 0.41 
25-34 1.39 1.14 0.22 2.56 
35-49 2.65 1.11 0.66 4.59 
15-49 1.09 1.16 0.50 1.67 
15-59 1.00 1.19 0.47 1.54 
FEMALE 
15-24 1.49 1.10 0.62 2.35 
25-34 1.18 0.70 0.16 2.18 
35-49 1.11 0.95 0.00 2.26 
15-49 1.31 0.94 0.73 1.90 
15-59 1.22 0.95 0.69 1.74 
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Table C.2  Sampling errors: HIV prevalence by age, LePHIA 2016-2017 
Ages 
Weighted 
estimate (%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
0-17 months 0.8  315  0.5 0.0 1.7 
18-59 months 1.1  824  0.3 0.4 1.8 
5-9 1.9  1,339  0.3 1.2 2.6 
10-14 3.2  1,488  0.5 2.1 4.2       
Total 0-4 1.0  1,139  0.3 0.5 1.6 
Total 0-14 2.1  3,966  0.3 1.5 2.6       
15-19 4.2  2,077  0.5 3.3 5.2 
20-24 10.4  1,971  0.7 9.0 11.8 
25-29 22.0  1,761  1.0 19.9 24.0 
30-34 33.3  1,468  1.3 30.6 36.0 
35-39 41.5  1,200  1.5 38.3 44.7 
40-44 47.6  953  2.0 43.5 51.6 
45-49 43.6  759  1.8 40.0 47.2 
50-54 38.8  720  2.0 34.8 42.9 
55-59 32.0  773  1.8 28.3 35.7       
Total 15-24 7.2  4,048  0.4 6.4 8.0 
Total 15-49 24.3  10,189  0.4 23.4 25.2 
Total 15-59 25.6  11,682  0.4 24.7 26.4 
MALE 
0-17 months 0.6  157  0.6 0.0 1.7 
18-59 months 0.6  423  0.4 0.0 1.3 
5-9 0.9  663  0.4 0.1 1.6 
10-14 3.1  760  0.6 1.7 4.4       
Total 0-4 0.6  580  0.3 0.0 1.2 
Total 0-14 1.5  2,003  0.3 1.0 2.1       
15-19 2.8  921  0.5 1.8 3.8 
20-24 4.0  769  0.6 2.7 5.3 
25-29 12.9  707  1.3 10.2 15.6 
30-34 26.0  611  1.9 22.0 30.0 
35-39 33.9  497  2.1 29.5 38.3 
40-44 46.9  379  2.9 40.9 52.9 
45-49 43.0  315  2.6 37.7 48.3 
50-54 38.7  261  3.2 32.1 45.3 
55-59 33.3  302  2.8 27.6 39.1       
Total 15-24 3.4  1,690  0.4 2.6 4.2 
Total 15-49 19.1  4,199  0.6 18.0 20.3 
Total 15-59 20.8 4,762 0.6 19.6 22.0  
FEMALE 
0-17 months 1.0  158  0.7 0.0 2.5 
18-59 months 1.6  401  0.6 0.5 2.8 
5-9 2.9  676  0.6 1.7 4.1 
10-14 3.3  728  0.7 1.8 4.8       
Total 0-4 1.5  559  0.5 0.5 2.4 
Total 0-14 2.6  1,963  0.4 1.8 3.3       
15-19 5.7  1,156  0.8 4.1 7.2 
20-24 16.7  1,202  1.1 14.4 19.0 
25-29 31.4  1,054  1.5 28.3 34.4 
30-34 41.2  857  1.8 37.5 44.9 
35-39 49.9  703  1.9 46.0 53.8 
40-44 48.3  574  2.3 43.5 53.1 
45-49 44.2  444  2.3 39.4 49.0 
50-54 38.9  459  2.2 34.5 43.4 
55-59 31.0  471  2.3 26.2 35.7       
Total 15-24 11.1  2,358  0.7 9.7 12.5 
Total 15-49 29.7  5,990  0.6 28.5 30.9 
Total 15-59 30.4  6,920  0.5 29.2 31.5 
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Table C.3  Sampling errors: HIV prevalence by residence and region, ages 15-59 years, LePHIA 2016-2017 
Characteristic 
Weighted 
estimate (%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
Residence      
Urban 26.9  4,438  0.7 25.4 28.3 
Peri-urban 23.1  781  1.9 19.1 27.1 
Rural 24.9  6,463  0.6 23.6 26.2 
      
Region      
Maseru 27.8  2,899  0.8 26.1 29.4 
Mafeteng 26.3  1,199  1.2 23.9 28.8 
Mohale's Hoek 29.3  889  1.6 26.0 32.5 
Leribe 23.7  1,955  1.0 21.6 25.7 
Berea 23.0  1,477  1.4 20.2 25.8 
Quthing 26.5  642  2.3 21.7 31.2 
Butha Buthe  17.8  715  1.5 14.8 20.8 
Mokhotlong 26.1  679  2.1 21.8 30.5 
Qacha's Nek 25.9  458  3.2 19.4 32.4 
Thaba Tseka  26.2  769  1.8 22.5 29.9 
MALE 
Residence      
Urban 21.7  1,709  1.0 19.7 23.8 
Peri-urban 19.0  328  2.9 13.0 25.1 
Rural 20.3  2,725  0.8 18.7 21.9 
      
Region      
Maseru 24.0  1,215  1.1 21.7 26.2 
Mafeteng 19.8  498  1.9 15.9 23.8 
Mohale's Hoek 25.1  341  2.7 19.6 30.7 
Leribe 18.5  803  1.5 15.3 21.7 
Berea 16.8  599  1.5 13.7 19.9 
Quthing 21.1  243  3.3 14.3 27.8 
Butha Buthe  12.6  299  1.8 9.0 16.2 
Mokhotlong 23.2  274  2.5 18.1 28.3 
Qacha's Nek 21.5  174  3.3 14.8 28.2 
Thaba Tseka  22.1  316  2.5 17.0 27.3 
FEMALE 
Residence      
Urban 31.6  2,729  0.9 29.7 33.4 
Peri-urban 27.1  453  1.5 24.0 30.3 
Rural 29.8  3,738  0.8 28.2 31.4 
      
Region      
Maseru 31.7  1,684  1.2 29.2 34.2 
Mafeteng 32.9  701  1.4 30.0 35.8 
Mohale's Hoek 33.0  548  2.0 29.0 37.1 
Leribe 29.1  1,152  1.1 26.8 31.4 
Berea 29.1  878  1.7 25.6 32.6 
Quthing 31.0  399  3.1 24.6 37.3 
Butha Buthe  23.3  416  1.8 19.6 27.1 
Mokhotlong 29.0  405  3.3 22.2 35.8 
Qacha's Nek 29.7  284  4.0 21.5 37.9 
Thaba Tseka  30.3  453  2.2 25.7 34.9 
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Table C.4  Sampling errors: Viral load suppression by age, LePHIA 2016-2017 
Age (years) 
Weighted 
estimate (%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
0-14 62.7  83  5.9 50.6 74.8 
15-24 51.0  330  2.7 45.5 56.5 
25-34 57.9  974  1.8 54.3 61.6 
35-44 71.5  1,003  1.5 68.3 74.7 
45-59 80.8  890  1.3 78.1 83.6 
Total 15-24 51.0  330  2.7 45.5 56.5 
Total 15-49 65.0  2,649  1.0 62.9 67.1 
Total 15-59 67.6  3,197  0.9 65.7 69.5 
MALE 
0-14 51.9  32  9.2 33.0 70.8 
15-24 51.3  58  6.7 37.4 65.1 
25-34 46.1  259  3.3 39.4 52.8 
35-44 64.1  352  2.6 58.7 69.4 
45-59 81.4  350  2.1 77.1 85.8 
Total 15-24 51.3 58 6.7 37.4 65.1 
Total 15-49 59.2 810 1.7 55.8 62.6 
Total 15-59 63.4 1,019 1.5 60.4 66.4 
FEMALE 
0-14 69.3  51  7.3 54.3 84.4 
15-24 50.9  272  3.0 44.8 57.1 
25-34 64.6  715  2.1 60.3 69.0 
35-44 77.8  651  1.7 74.3 81.2 
45-59 80.3  540  1.7 76.9 83.7 
Total 15-24 50.9 272 3.0 44.8 57.1 
Total 15-49 68.9 1,839 1.2 66.4 71.3 
Total 15-59 70.5 2,178 1.1 68.3 72.7 
 
 
Table C.5  Sampling errors: Viral load suppression by residence and region, ages 15-59 years, LePHIA 2016-2017 
Characteristic 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
Residence      
Urban 66.0 1281 1.4 63.2 68.9 
Peri-urban 68.7 195 3.1 62.3 75.1 
Rural 68.8 1721 1.3 66.1 71.6 
      
Region      
Maseru 64.8 863 1.6 61.4 68.2 
Mafeteng 67.6 337 2.5 62.4 72.9 
Mohale's Hoek 69.4 279 3.9 61.3 77.6 
Leribe 70.8 497 2.0 66.7 74.8 
Berea 71.7 379 2.9 65.8 77.6 
Quthing 66.4 176 2.8 60.7 72.1 
Butha Buthe  68.5 146 3.1 62.1 74.9 
Mokhotlong 58.8 185 5.3 47.9 69.8 
Qacha's Nek 69.7 125 3.0 63.5 75.9 
Thaba Tseka  70.9 210 3.8 63.2 78.6 
MALE 
Residence      
Urban 62.8 379 2.4 57.9 67.6 
Peri-urban 68.5 63 4.6 59.0 78.0 
Rural 63.2 577 2.1 58.9 67.5 
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Table C.5  Sampling errors: Viral load suppression by residence and region, ages 15-59 years, LePHIA 2016-2017 (continued) 
Characteristic 
Weighted 
estimate (%)  
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
MALE (cont.) 
Region      
Maseru 60.8 301 2.6 55.4 66.2 
Mafeteng 64.4 101 4.2 55.7 73.1 
Mohale's Hoek 61.7 91 6.1 49.2 74.2 
Leribe 65.7 153 3.5 58.5 72.9 
Berea 71.8 106 5.2 61.2 82.5 
Quthing 65.9 50 4.6 56.4 75.4 
Butha Buthe  68.8 41 5.5 57.5 80.1 
Mokhotlong 49.5 64 7.1 34.9 64.1 
Qacha's Nek 58.5 38 5.8 46.6 70.4 
Thaba Tseka  67.3 74 5.2 56.5 78.0 
FEMALE 
Residence      
Urban 68.1 902 1.8 64.3 71.9 
Peri-urban 68.8 132 4.0 60.5 77.0 
Rural 73.0 1144 1.3 70.2 75.7 
 0.0 0 0.0 0.0 0.0 
Region      
Maseru 68.0 562 2.1 63.6 72.3 
Mafeteng 69.6 236 2.9 63.6 75.6 
Mohale's Hoek 74.8 188 3.6 67.4 82.2 
Leribe 74.1 344 2.9 68.1 80.2 
Berea 71.6 273 2.5 66.4 76.9 
Quthing 66.7 126 4.2 58.0 75.3 
Butha Buthe  68.4 105 3.7 60.7 76.1 
Mokhotlong 66.2 121 5.3 55.3 77.1 
Qacha's Nek 76.9 87 4.3 68.0 85.7 
Thaba Tseka  73.5 136 3.9 65.6 81.4 
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Table C.6  Sampling errors: ARV-adjusted 90-90-90 by age (conditional percentages), LePHIA 2016-2017 
 Diagnosed  On Treatment  Viral Load Suppression 
Age (years) 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%)  
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%)  
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 67.6 330 2.2 62.3 72.8  90.6 227 2.2 86.1 95.2  77.2 208 2.9 71.1 83.2 
25-34 73.9 973 1.3 71.0 76.9  88.8 743 1.3 86.2 91.4  83.6 663 1.6 80.3 86.9 
35-49 86.3 1344 0.9 84.2 88.4  92.3 1179 0.9 90.4 94.2  89.9 1089 1.0 87.7 92.0 
15-49 79.5 2647 0.7 77.9 81.1  90.9 2149 0.7 89.4 92.4  86.5 1960 0.9 84.6 88.4 
15-59 81.0 3195 0.6 79.5 82.5  91.8 2638 0.6 90.5 93.1  87.7 2435 0.8 86.1 89.3 
MALE 
15-24 71.3 58 6.3 58.4 84.2  84.1 41 6.8 70.1 98.1  78.3 35 6.4 65.1 91.6 
25-34 58.7 258 3.2 52.1 65.3  88.3 149 2.3 83.6 93.1  83.5 132 3.3 76.7 90.2 
35-49 82.2 493 1.8 78.5 85.8  91.5 409 1.5 88.4 94.6  88.1 373 1.7 84.5 91.7 
15-49 73.5 809 1.4 70.6 76.5  90.2 599 1.2 87.7 92.7  86.3 540 1.6 83.0 89.5 
15-59 76.6 1018 1.2 74.0 79.1  91.6 788 1.0 89.5 93.6  87.7 724 1.3 85.0 90.3 
FEMALE 
15-24 66.4 272 3.0 60.2 72.6  92.8 186 2.0 88.8 96.8  76.8 173 3.2 70.1 83.5 
25-34 82.5 715 1.5 79.4 85.6  89.0 594 1.4 86.2 91.8  83.6 531 1.8 80.0 87.2 
35-49 89.8 851 1.2 87.4 92.3  92.9 770 1.1 90.6 95.1  91.3 716 1.1 89.1 93.5 
15-49 83.5 1838 1.0 81.5 85.5  91.3 1550 0.8 89.6 93.1  86.6 1420 1.0 84.6 88.7 
15-59 84.0 2177 0.9 82.3 85.8  92.0 1850 0.7 90.4 93.5  87.7 1711 0.9 85.9 89.5 
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Table C.7  Sampling errors: ARV-adjusted 90-90-90 by age (unconditional percentages), LePHIA 2016-2017 
 Diagnosed  On Treatment  Viral Load Suppression 
Age 
(years) 
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%)  
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%)  
Weighted 
estimate 
(%) 
Unweighted 
number 
Standard 
error (%) 
Lower 
confidence 
limit (%) 
Upper 
confidence 
limit (%) 
TOTAL 
15-24 67.6 330 2.6 62.3 72.8  61.2 330 2.9 55.4 67.1  47.3 330 2.8 41.4 53.1 
25-34 73.9 973 1.4 71.0 76.9  65.7 973 1.7 62.2 69.1  54.9 973 1.9 51.1 58.7 
35-49 86.3 1344 1.0 84.2 88.4  79.6 1344 1.2 77.1 82.1  71.6 1344 1.3 68.8 74.3 
15-49 79.5 2647 0.8 77.9 81.1  72.3 2647 1.0 70.3 74.3  62.5 2647 1.1 60.3 64.8 
15-59 81.0 3195 0.7 79.5 82.5  74.4 3195 0.9 72.6 76.2  65.2 3195 1.0 63.2 67.2 
MALE 
15-24 71.3 58 6.3 58.4 84.2  60.0 58 8.1 43.2 76.8  47.0 58 8.1 30.3 63.7 
25-34 58.7 258 3.2 52.1 65.3  51.8 258 3.2 45.3 58.4  43.3 258 3.2 36.6 49.9 
35-49 82.2 493 1.8 78.5 85.8  75.2 493 2.0 71.2 79.2  66.2 493 2.1 61.9 70.6 
15-49 73.5 809 1.4 70.6 76.5  66.3 809 1.6 63.1 69.5  57.2 809 1.7 53.7 60.7 
15-59 76.6 1018 1.2 74.0 79.1  70.1 1018 1.4 67.3 72.9  61.5 1018 1.5 58.4 64.5 
FEMALE 
15-24 66.4 272 3.0 60.2 72.6  61.6 272 3.0 55.5 67.7  47.3 272 2.9 41.3 53.4 
25-34 82.5 715 1.5 79.4 85.6  73.4 715 1.7 69.8 77.0  61.4 715 2.1 57.0 65.8 
35-49 89.8 851 1.2 87.4 92.3  83.5 851 1.4 80.6 86.4  76.2 851 1.5 73.2 79.2 
15-49 83.5 1838 1.0 81.5 85.5  76.3 1838 1.1 74.0 78.5  66.1 1838 1.2 63.6 68.6 
15-59 84.0 2177 0.9 82.3 85.8  77.3 2177 1.0 75.2 79.3  67.8 2177 1.1 65.5 70.1 
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Table C.8  Sampling errors: Number of new infections annually and number of people living with HIV (ages 15-59 years) LePHIA 2016-2017 
  
Weighted 
estimate 
Standard 
error 
Lower 
confidence 
limit 
Upper 
confidence 
limit 
Number of new infections annually (using the limiting antigen 
[LAg]/viral load [VL] algorithm) 13,066 2,259 8,405 17,727 
Number of new infections annually (using LAg/VL/antiretroviral 
[ARV] algorithm) 9,835 1,827 6,066 13,605 
Number of people living with HIV 305,853 5,101 295,347 316,359 
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Appendix D    Survey Personnel
Her Majesty Queen 
‘Masenate Mohato Seeiso 
 
Ministry of Health 
Baroane Phenethi 
Keletso Ntene Sealiete 
Kyaw Thin 
Limpho Maile 
Mahlape Ramoseme 
‘Masebeo Koto 
Mosilinyane Letsie 
Quality Assurence Officers 
Monkoe Leqheka 
Kolisang Phatšoane 
Laboratory Director 
Tsietso Motšoane 
NRL Lab Managers 
David Mothabeng 
‘Mathabo Mareka 
Central Lab supervision 
Mamakhetha Phalatse 
Kellelo Mapolosi 
Lag Avidity Testing 
Lula Budiaki 
Lilyan Tlapana 
Satellite Lab Supervisors 
Thuso Mphokoro 
Moroesi Masoaka 
Posi Napo 
 
ICAP in Lesotho 
Koen Frederix 
Lavert Remhunga 
Lenao Mohapi  
Maema Ramaema 
Moeketsi Ntoane (RIP)    
Moipone Mashale 
Molibeli Lethoko 
Mphonyane Tuoane 
Reaboka Maraisane 
Sakhile Sithole 
Salome Manyau 
Tlotliso Moshoeshoe 
Makhate Makhate 
Moeti Mphoso 
Mamontsi Manyeli 
Seema Maleke 
Thato Mosaase 
 
CDC Lesotho 
Amee Schwitters 
Stefania Davia 
Yohannes Eshete 
Martha Conkling 
Andy Pelletier 
 
Bureau of Statistics in 
Lesotho 
‘Malehloa Molato 
Lehlohonolo Takalimane 
Mothoweso Lefosa 
Tšiu Litšiba 
 
Ministry of Development 
Planning 
Mpho Mosili 
 
National University Lesotho 
Sunny Aiyuk 
 
UNAIDS 
Puleng Letsie 
 
EGPAF 
Morongoe Masilo 
 
Jhpiego 
Nkomile Mpooa 
 
CDC Atlanta 
Bharat Parekh 
Carin Molchan 
Carole Moore 
Christine West 
Daniel Williams   
Drew Voetsch 
Hetal Patel 
Katina Pappas-Deluca  
Katrina Sleeman 
Kristin Brown 
Laura Porter 
Linda Fleming 
Melissa Cates 
Mervi Dattorio 
Nikhil Kothegal 
Paul Stupp 
Sehin Birhanu 
Stephen McCracken 
Steven Kinchen 
Trudy Dobbs 
William Levine 
Wolfgang Hladik 
 
ICAP in New York 
Andrea Low 
Chelsea Solmo 
David Hoos 
Elizabeth Radin 
Hannah Chung 
Jessica Justman 
Joseph Elias 
Katherine Johnson 
Kiwon Lee 
Larkin Callaghan 
Melissa Metz 
Nahima Ahmed  
Neena Philip 
Sally Findley 
Stephen Arpadi  
Stephen Delgado 
Suzue Saito 
Theo Smart 
Yen Pottinger 
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ICAP in South Africa 
Belete Tegbaru Erkyhun 
Blanche Pitt 
Bright Phiri 
Charles Wentzel 
Herbert Longwe 
Oliver Murangandi 
Pule Mphohle 
Takura Kupamupindi 
Yvonne Mavengere 
 
Laboratory Team Lesotho 
Satellite and Mobile Lab 
Staff 
Bonang Sylvia Ntsielo 
Kamohelo Sello 
Kekeletso Elliot Mofoka 
Lebohang Nteso 
Lerato Motseki 
Liteboho Letumanyane 
Malichaba Catheine Moseli 
Mamello Mary-patience 
Motlomelo 
Mojabeng Adelaide 
Mokoaleli 
Moliehi Lerotholi 
Mosa Nephtali Lefoka 
Nkhala Rose Makhetha 
Refuoe Ramoroke 
Rethabile Leseeka 
Selloane Motaba 
Teba David Tšepang 
Tefo Ebenezer Libate 
Thabiso Azael Matšoha 
 
Central Lab Staff 
Lerato Joyce Moteane 
Mahlape Khaketla 
   Moletsane Lincoln 
Mokokoane  
 
Field Teams 
‘Mabokang Tšehla 
‘Machere Seutloali 
‘Mafusi Boopa 
‘Mafusi Motlomelo 
‘Mahopolang Lehata 
‘Maleaooa Chaole 
‘Malehloa Mahooana 
‘Malehlohonolo Kolobe 
‘Malereko Moffman 
‘Maleronti Mafisa 
‘Malesiamo Mathata 
‘Maletsatsi Lejakane 
‘Maliakae Lekhula 
‘Malinkeng Mohale 
‘Malithlong Seisa 
‘Mamakoli Senauoane 
‘Mamatlatse Mochecha 
‘Mamofelehetsi Moerane 
‘Mamokoli Sekantši 
‘Mamosa Semelane 
‘Mamotšoane Lekhoele 
‘Mankoe Makakane 
‘Mankoe Mphokoro 
‘Mankuebe Nkuebe 
‘Mantaoleng Kocha 
‘Mantebete Lerotholi 
‘Mantila Khaahloe 
‘Manyalleng Letsie 
‘Mapalo Mahloane 
‘Maphoka Qhobela 
‘Mareentseng Lerotholi 
‘Maretšepile Ntsau  
‘Maseabata Machai 
‘Maseabata Mochochoko 
‘Masehloho Moahloli 
‘Masenate Mohale 
‘Masentle Makhetha 
‘Mashale Rabeleng 
‘Matlhalefo Sekhonyana 
‘Mazwakala Zwakala 
‘Neuoe Maqache 
Arabang Motjolopane 
Arabang Nkhabu 
Atang Tlopo 
Balekile Adontsi 
Belice Thato 
Bokang Lebatama 
Bokang Monare Maloisane  
Bonang Mohapi 
Bulane Lebohang 
Dora Kaaba 
Emily Hlalele 
Felleng Joele 
Fusi Maseru 
Hlatsi Thetsane 
Hlomisi Maleshoane 
Hlomohang Letsie 
Kamohelo Maoela 
Kananelo Maanela 
Kasa Matekane 
Katleho Makautse 
Katleho Makhaba 
Katleho Ramalefane 
Kekeletso Mahula 
Keneuoe Melato 
Ketjane Matseliso 
Khahliso Khabo 
Khahliso Tšoaeli 
Khantši Lineo 
Khetheng Tšele 
Khoete Relebohile 
Khopotso Majara 
Khotso Tšenyeletso 
Khunyane Mohapi 
Leah Masia 
Lefalamang Koaleli 
Lefulesele Tjellane 
Lehana Sehleke 
Lehlohonolo Kotseli 
Lehlohonolo Matekane 
Lehlohonolo Sootho 
Lekolantšo Remaketse 
Leloko Khoiti 
Leloko Lisanyane 
Lerata Lerata 
Lerato Mote 
Lesia Seetsetsa 
Letšikhoana Nkeka 
Libuseng Marekimane 
Lieketseng Pholoana 
Likhapa Libete 
Limakatso Seboka 
Limpho Leche 
Limpho Makhele 
Limpho Rantsiane 
Limpho Sethabathaba 
Lindiwe Qhojeng 
Lineo Masaile 
Linkeng Monkhi 
Litšoanelo Makoa 
Mahloane 
Lomile Ramalefane 
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Field Teams (continued) 
Losholopina Motsamai 
Mabula Khetheng 
Mafika Matlotlo 
Mafonase Phakoe 
Mahlatsinyane Lesaoana 
Mahloli Majara 
Mahou Malefane 
Maile Phoofolo 
Makuili Zwane 
Malebane Lesihla 
Malebohang Matekane 
Malefetsane Masasa 
Maleshoane Seutloali 
Mamello Khetheng 
Masesi Paulina 
Mngomezulu 
Masingoaneng Lekhooana 
Matla Lesala 
Matobako Makhabane 
Meisi Sootho 
Metsing Tšehla 
Mofoleng Mokopotsa 
Mohapi Seemiso 
Mohapi Tšolo 
Mohlomi Sello 
Mokete Ranyali 
Mokhantšo Mokhothu 
Mokheseng Mpooa 
Moleboheng ‘Neko 
Moliehi Motsatse 
Montšeng Mohasi 
Monyane Mohale 
Mookho Maabe 
Mookho Ntšoeu 
Morapeli Kompi 
Moroesi Mohlomi 
Mosa Thamae 
Mothebesoane Thato 
Motheo Majoro 
Motjoboko Lindiwe 
Motlatsi Kose 
Motlatsi Rampa 
Motloi Moleli 
Motsatsi Molapo 
Motselisi Tšita 
Mpeli Moshoeshoe 
Mpho Seephephe 
Mphoko Matete 
Mphokoletse Makhetha  
Mphonyane Mahlako 
Mphoroane Malise 
Mphunyetsane 
Mphunyetsane 
Mpinane Malekhokolo  
Mpopo Mariti-Kutloano 
Mporoane Motloheloa 
Mthandazo Magadela 
Nana Molise 
Ndlobo Leteka 
Ndombikayese Moloi 
Neo Motsiba 
Neoa Phoofolo 
Nkemele Nkemele 
Nomhle Spelemane 
Nomthetho Thafene 
Notembiso Matooane  
Nteboheleng Molise 
Nteboheleng Ramoshabe 
Nthabeleng Liphoto 
Nthuseng Sehlala 
Ntona Maphomene 
Ntsejoa Tšukulu 
Ntšekhe Mokhesi 
Ntšeliseng Nyabela 
Ntsoaki Mabohla 
Ntsoaki Monyamane 
Paballo Khama 
Paballo Maphea 
Palesa Jasong 
Palesa Sello 
Paulinah Moreira 
Pelaelo Majara 
Phole Taole 
Poloko Hloele 
Poloko Mosito 
Puleng Kamele 
Puleng Lenkoane 
Puleng Likhale 
Puseletso Ntomane 
Ramorena Pulane 
Rapelang Lethoko 
Reabetsoe Motloi 
Refiloe Keketsi 
Refiloe Mohale 
Reitumetse Sekorobele 
Relebohile Mphole 
Relebohile Putsoane 
Relebohile Sebusi 
Renang Lieta 
Rethabile Lebusa 
Rethabile Mponye 
Rethabile Phomane 
Rethabile Ramabolu 
Rethusitsoe Mphokoro 
Retšelitsoe Polane 
Rorisang Mpharoe 
Sebili Maoatsa 
Selloane Pitso 
Seme Tšoepho 
Sempe Lerotholi 
Senate Mokobocho 
Senate Moshoeshoe 
Senekane Sehloho 
Site Khomo-ea-Majoe 
Kinela 
Tebello Mokonyana 
Teboho Maqoabikane 
Teboho Mojaki 
Teboho Pitso 
Tefo ‘Malane 
Thabang Damazene 
Thabang Mokobocho 
Thabelang Raboholo 
Thabiso Mochesane 
Thabo Makholela 
Thabo Mosebekoa 
Thapelo Molete  
Thato Mosese 
Thelisi Lenoesa 
Thembile Badela 
Thulo Ramalebo 
Thuso Makhorole 
Thuso Makoko 
Tiisetso Sekhonyana 
Tipe Seetsi 
Tlali Mothobi 
Tlalinyane Tapisa 
Tokelo Nyelele 
Tsebo Lehloa 
Tšehla Tšepiso 
Tseki Bokang 
Tselane Pule 
Tselanyane Moeti 
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Field Teams (continued) 
Tšepang Thahanyane 
Tšepiso Pule 
Tšepo Napo 
Tšobotsi Mokatsanyane 
Tšolo Thabana 
Tumisang Mathafeng 
 
Drivers 
Bokang Bernard Motumi 
Bulara Ntsalong 
Chaka Mahooana 
Fokoane Makhakhe 
Halejoetsoe Polisa 
Hlomelang J Lebona 
Kalinyane Ramolibeli 
Kantoro C Rampai 
Katiso Moleko 
Kemelo V Lebesa 
Khabane Lepatoa 
Khoase Mphuthing 
Khutlang Mokone 
Kolotsane Ntsapi 
Lebohang Makosholo 
Lefa Mahlomola 
Lehlohonolo Hlongwane 
Lekhotla Matela 
Letsika Maofane 
Lisema Moahloli 
Machabe Matsau 
Maethola Mapepesa 
Maisa Maope 
Malefane Stephen Wall 
Malefetsane Baji 
Maranzo Mavumengwane 
Masupha D Nena 
Matona Rantekoa 
Mohale Mohale 
Mohlomi Ramakatsa 
Mojari John Kojoana 
Mokhele Mokhele 
Mokhoele Mahao 
Molahlehi C Tlali 
Mopeli S Ramakhula 
Morero Mahooana 
Mosoeu Mabote 
Mosoeunyane Thapelo 
Motaba Ndlela 
Motebang Ramokoatsi 
Motlalepula Phuthehang 
Motsomi Makhalanyane 
Mphafi Lebina 
Neo Ntsau 
Njabulo Moshabesha 
Pitso E Mothobi 
Pule Mosunkuthu 
Qobete Mopeli 
Ramajake Leoli 
Reitumetse Liefo 
Seetsi Kabi 
Sekaleli Koloko 
Seleso Lephosa 
Sello Lempe 
Seutloali Seitlheko 
Tekano Kolobe 
Thabang Molelle 
Thabelo Mohapi 
Thabiso Makhetha 
Thato Adoro 
Theko Raphael Molapo 
Thoola Tseko 
Tšepo Letsika Matela 
Tšepo Makepe 
Tumisang Rantlo 
Tumo Motšoene 
 
Final Report Workshop 
Contributors 
Amee Schwitters 
Andrea Low 
Felix Ndagije 
Keletso Ntene Sealiete 
Koen Frederix 
Kyaw Thin 
Limpho Maile 
Martha Conkling 
Nahima Ahmed 
Refiloe Mpholo 
Stephen McCracken 
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Appendix E    Household Questionnaire 
ENGLISH 
 
CONFIDENTIAL 
MINISTRY OF HEALTH 
LESOTHO POPULATION-BASED  
HIV IMPACT ASSESSMENT  
(LePHIA 2016-2017) 
HOUSEHOLD QUESTIONNAIRE 
TICK IF HOUSEHOLD SELECTED FOR        
CHILDREN’S SURVEY 
HOUSEHOLD IDENTIFICATION 
[THIS PAGE AUTOPOPULATED WITH HOUSEHOLD LISTING INFORMATION]  
   
DISTRICT CODE 
 
ZONE  CODE 
 
WARD NUMBER 
 
HH NUMBER 
 
DISTRICT NAME:  _________________________________________ 
ZONE NAME:  _________________________________________ 
 
WARD  NAME: _________________________________________ 
 
CONSTITUENCY  NAME: _________________________________________ 
 
NAME OF HOUSEHOLD HEAD: _________________________________________ 
 
TOTAL PERSONS 
IN HOUSEHOLD 
 
 
TOTAL ELIGIBLE  
WOMEN: 
 
TOTAL ELIGIBLE  
MEN: 
 
 
TOTAL ELIGIBLE 
CHILDREN: 
 
 
LINE NO. OF RESPONDENT TO 
HOUSEHOLD QUESTIONNAIRE 
LANGUAGE OF INTERVIEW:  
NATIVE LANGUAGE OF RESPONDENT: 
TRANSLATOR USED? (Y/N)  
LANGUAGE CODES: 
(01) ENGLISH 
(02) SESOTHO 
 
  
 
SUPERVISOR:  ______________________________ 
 
DATE OF COMPLETING QUESTIONNAIRE:   
 
__________________________________________ 
 
SUPERVISOR CODE: 
 
OFFICE EDITOR: 
 
KEYED BY: 
* RESULTS CODES: 
(1) COMPLETED 
(2) NO HOUSEHOLD MEMBER AT HOME OR NO COMPETENT 
RESPONDENT AT HOME AT TIME OF VISIT 
(3) ENTIRE HOUSEHOLD ABSENT FOR EXTENDED PERIOD OF TIME 
(4) POSTPONED 
 
(5) REFUSED 
(6) DWELLING VACANT OR ADDRESS NOT A DWELLING 
(7) DWELLING DESTROYED 
(8) DWELLING NOT FOUND 
(9) PARTLY COMPLETED 
(96) OTHER (SPECIFY) 
 
APPENDIX E HOUSEHOLD QUESTIONNAIRE 
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START TIME 
 
START 
 
Record the start time. 
USE 24-HOUR TIME.  
 
IF START TIME IS 3:12 PM, 
RECORD 15 HOURS, 12 MINUTES, 
NOT 03 HOURS, 12 MINUTES.  
 
 
HOUR:  
 
MINUTES:   
 
 
HOUSEHOLD SCHEDULE 
LINE 
NO. USUAL RESIDENTS AND VISITORS 
RELATIONSHIP 
TO HEAD OF 
HOUSEHOLD SEX RESIDENCE AGE 
  
Please give me the names of the 
persons who usually lives in your 
household or guests of the 
household who stayed here last 
night, starting with the head of the 
household. 
 
AFTER LISTING THE NAME AND 
RECORDING THE RELATIONSHIP 
AND SEX FOR EACH PERSON ASK 
QUESTIONS 2A-2C BELOW TO BE 
SURE THAT THE SCHEDULE IS 
COMPLETE. 
What is the 
relationship of 
(NAME) to the 
head of the 
household? 
 
SEE CODES 
BELOW 
Is (NAME) 
Male or 
Female? 
Does 
(NAME) 
usually 
live 
here? 
Did 
(NAME) 
sleep here 
last night? 
IF LESS THAN 2 YEARS, RECORD 
IN MONTHS. 
How old is 
(NAME)? 
Is age of 
(NAME) 
recorded in 
MONTHS/ 
YEARS? 
(1) (2) (3) (4) (5) (6) (7) (8) 
1  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
2  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
3  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
4  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
5  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
6  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
7  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
8  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
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9  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
10  
 
M       F Y       N Y       N 
 MONTHS 
YEARS 
TICK HERE IF CONTINUATION SHEET USED   CODES FOR COLUMN 3: RELATIONSHIP TO HOUSEHOLD HEAD 
2A) Just to make sure I have a complete listing, are 
there any other persons such as small children or 
infants that we have not listed? 
YES    NO 01 = HEAD 
02 = WIFE/HUSBAND/PARTNER 
03 = SON OR DAUGHTER 
04 = SON-IN-LAW/ 
        DAUGHTER-IN-LAW 
05 = GRANDCHILD 
06 = PARENT 
07 = PARENT-IN-LAW 
08 = BROTHER/SISTER 
09 = CO-WIFE 
10 = OTHER RELATIVE 
11 = ADOPTED/ 
        FOSTER/STEPCHILD 
12 =  NOT RELATED 
98 = DON’T KNOW 
2B) Are there any other people who may not be 
members of your household such as domestic 
servants, lodgers, of friends who usually live here? 
YES    NO 
2C) Are there any guests or temporary visitors 
staying here, or anyone else who stayed here last 
night who we have not seen? 
YES 
 
ADD TO 
SCHEDULE 
   NO 
 
HOUSEHOLD SCHEDULE 
LINE 
NO. 
IF (NAME) IS 0-17 YEARS IF (NAME) 
IS 0-14 
YEARS 
   
EMANC 
STATUS 
ORPHAN STATUS/PARENT OR 
GUARDIAN 
 
  
 
Is (NAME) 
emancipated? 
 
[INSERT 
DEFINITION 
OF 
EMANCIPATE
D MINOR] 
Is 
(NAME)’s 
natural 
mother 
alive? 
Does 
(NAME)’s 
natural 
mother 
usually live in 
this 
household or 
was a guest 
last night? 
 
IF YES:  
RECORD 
MOTHER’S 
LINE 
NUMBER. 
 
IF NO: 
RECORD 
FEMALE 
GUARDIAN’S 
LINE NUMBER 
OR ‘00’ IF 
FEMALE 
PARENT OR 
GUARDIAN 
NOT PRESENT 
IN HH. 
Is (NAME)’s 
natural 
father alive? 
Does 
(NAME)’s 
natural 
father 
usually live 
in this 
household 
or was a 
guest last 
night? 
 
IF YES:  
RECORD 
FATHER’S 
LINE 
NUMBER. 
 
IF NO: 
SKIP TO 
QUESTION 
14.   
 
 
Does 
(NAME*) have 
a male 
guardian who 
usually lives in 
this 
household or 
was a guest 
last night?  
 
IF YES:  
RECORD 
MALE 
GUARDIAN’S 
LINE 
NUMBER. 
IF NO: 
Skip to 
question 17.   
 
 
 
RECORD LINE 
NUMBER OF 
PARENT/GUA
RDIAN WHO 
WILL FILL OUT 
CHILDREN’S 
MODULE FOR 
(NAME) 
You said that 
(NAME*) 
does not have 
a parent or 
guardian 
living in the 
household.  Is 
this correct? 
DO NOT READ: 
 
IS (NAME) 
ELIGIBLE 
FOR SURVEY? 
(1) (9) (10) (11) (12) (13) (14) (16) (17) (18) 
1 
Y    N   DK 
 
Y  N       DK  
   
 
   12 
 
Y  N        DK 
        
     
 16 
  
Y       N Y       N Y       N 
2 Y    N   DK 
Y  N       DK 
        
     
   12 
 
Y  N        DK 
        
     
  16 
  
Y       N Y       N Y       N 
3 Y    N   DK 
Y  N       DK 
        
     
   12 
 
Y  N        DK 
        
     
  16 
  
Y       N Y       N Y       N 
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4 Y    N   DK 
Y  N     DK 
        
   
  12 
 
Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
5 Y    N   DK 
Y  N       DK 
        
     
     12 
 
Y  N        DK 
        
     
   16 
  Y       N Y       N Y       N 
6 Y    N   DK 
Y  N       DK 
        
     
     12 
 Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
7 Y    N   DK 
Y  N       DK 
        
     
     12 
 
Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
8 Y    N   DK 
Y  N       DK 
        
     
     12 
 
Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
9 Y    N   DK 
Y  N       DK 
        
     
     12 
 
Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
10 Y    N   DK 
Y  N       DK 
        
     
     12 
 
Y  N        DK 
        
     
   16 
  
Y       N Y       N Y       N 
 
 
TOTAL ELIGIBLE MEN (ADULTS 15+ YEARS AND EMANCIPATED MINORS) 
TOTAL ELIGIBLE WOMEN (ADULTS 15+ YEARS AND EMANCIPATED MINORS) 
TOTAL ELIGIBLE CHILDREN (10 TO 14 YEARS) 
TOTAL ELIGIBLE CHILDREN (0 MONTHS TO 9 YEARS) 
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HOUSEHOLD SCHEDULE 
LINE 
NO. 
IF (NAME) is 
18+ 
IF (NAME) is 0-17 years 
SICK PERSON 
SICKNESS AND RESIDENCE OF BIOLOGICAL PARENTS 
MOTHER 
DEAD OR 
SICK 
FATHER 
DEAD OR 
SICK 
 
 
CHECK 
COLUMNS 7 
AND 8, IF 
UNDER 18  
 17 
  
IF 18 YEARS OR 
MORE:  
 
Has (NAME) 
been very sick 
for at least 3 
months during 
the past 12 
months, that is 
(NAME) was 
too sick to work 
or do normal 
activities? 
CHECK COLUMN 
10, IF COLUMN 10 
‘N’ OR ‘DK’  21 
 
IF COLUMN 10 ‘Y’: 
 
Has (NAME)’s 
natural mother 
been very sick for 
at least 3 months 
during the past 
12 months, that is 
she was too sick 
to work or do 
normal activities? 
IF MOTHER SICK: 
 
 
 
Does (NAME)’s 
natural mother 
have HIV/AIDS?* 
CHECK COLUMN 
12, IF COLUMN 12 
‘N’ OR ‘DK’  23 
 
IF COLUMN 12 ‘Y’: 
 
Has (NAME)’s 
natural father 
been very sick for 
at least 3 months 
during the past 
12 months, that is 
he was too sick to 
work or do 
normal activities? 
IF FATHER SICK: 
 
 
 
Does (NAME)’s 
natural father have 
HIV/AIDS?* 
 
IF CHILD’S 
NATURAL 
MOTHER 
HAS DIED 
(COLUMN 
10 ‘N’) OR 
BEEN SICK 
(COLUMN 
18 ‘Y’), 
SELECT Y. 
 
IF CHILD’S 
NATURAL 
FATHER 
HAS DIED 
(COLUMN 
12‘N’) OR 
BEEN SICK 
(COLUMN 
20 ‘Y’), 
SELECT Y. 
(1) (19) (20) (21) (22) (23) (24) (25) 
1 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
2 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
3 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
4 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
5 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
6 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
7 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
8 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
9 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
 
10 
 
Y    N    DK 
 
Y     N     DK 
        
         22 
 
Y    N    DK 
 
Y     N     DK 
        
         24 
 
Y    N    DK 
 
 
Y       N 
 
 
Y       N 
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HOUSEHOLD SCHEDULE 
Thank you for completing the questions regarding the Household members who are 0-17 years old.  The next step will be to answer some 
additional questions regarding the men who live in the household. 
LINE 
NO. 
SPOUSES AND CO-HABITATING PARTNERS 
 Does (NAME) 
have a 
spouse or co-
habitating 
partner who 
usually lives 
in the 
household or 
was a guest 
last night? 
How many 
spouses or co-
habitating 
partners (those 
who usually 
live in the 
household or 
stayed here 
last night) does 
(NAME) have? 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If 
no spouse or 
partner 
leave blank. 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If 
no spouse or 
partner 
leave blank. 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If 
no spouse or 
partner 
leave blank. 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If 
no spouse or 
partner 
leave blank. 
Record the 
LINE 
NUMBER 
(NAME)’s of 
spouse or 
partner. If no 
spouse or 
partner leave 
blank. 
(1) (26) (27) (28a) (28b) (28c) (28d) (28e) (28f) 
1 Y    N    DK 
 
      
2 Y    N    DK 
 
      
3 Y    N    DK 
 
      
4 Y    N    DK 
 
      
5 Y    N    DK 
 
      
6 Y    N    DK 
 
      
7 Y    N    DK 
 
      
8 Y    N    DK 
 
      
9 Y    N    DK 
 
      
10 Y    N    DK 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS 
 
➢ INTERVIEWER SAYS: “Thank you for completing the questions for the household's women.  The next 
step will be to complete some additional questions regarding the household itself. Now I would like 
to ask you more questions about your household.” 
 
201 
 
What is the main source of drinking 
water for members of your household? 
 
PIPED WATER 
PIPED INTO DWELLING………………11 
PIPED TO YARD/PLOT………………..12 
PUBLIC TAP/STANDPIPE…………….13 
TUBE WELL OR BOREHOLE……..……..21 
DUG WELL 
   PROTECTED WELL……….……………….31 
   UNPROTECTED WELL……………….....32 
WATER FROM SPRING 
   PROTECTED SPRING…………………….41 
   UNPROTECTED SPRING……………….42 
RAINWATER…………………………………..51 
TANKER TRUCK……………………………...61 
CART WITH SMALL TANK…….………….71 
SURFACE WATER (RIVER / DAM / LAKE/     
POND / STREAM/CANAL)……………......81 
BOTTLED WATER…………………………...91 
OTHER……………………………...…………...96 
_____________________________ 
(SPECIFY) 
 
 
202  
 
Do you do anything to the water to make 
it safer to drink? 
 
YES…………………………………….……......…1 
NO………………………………………………..…2 
DON’T KNOW..……………..……..…….……8 
 
NO, DK→204 
 
203  
 
What do you do to make your water safe 
for drinking? 
 
BOILING………………………………………..…1 
FILTRATION (CHARCOAL FILTER….…...2 
SEDIMENTATION………………………….….3 
DISINFECTION  (WATERGUARD, 
CHLORINE)…………………………………...….4 
USE BOTTLED WATER…………………......5 
OTHER……………………………….……..…...96 
_____________________________ 
(SPECIFY) 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS (continued) 
 
204 
 
What kind of toilet facility do members of 
your household usually use? 
 
FLUSH OR POUR FLUSH TOILET…….11 
TRADITIONAL PIT LATRINE…………...21 
VENTILATED IMPROVED PIT LATRINE    
(VIP)…………………………………………....22 
NO FACILITY/BUSH/FIELD………......61 
OTHER………………………………………….96 
_____________________________ 
(SPECIFY) 
 
NO FACILITY, 
OTHER → 207 
 
205 
 
Do you share this toilet facility with other 
households? 
 
YES………………………………………........…1 
NO…………………………………….………..…2 
 
NO→207 
 
206 
 
How many households use this toilet 
facility? 
 
NO. OF HOUSEHOLD IF LESS THAN 10 
________ 
10 OR MORE HOUSEHOLDS 
…………………………………………………..…96 
DON’T KNOW ………………………..…….98 
 
PREFACE BEFORE QUESTIONS 207-214:  
Does your household have: 
 
207 
 
Electricity? 
 
YES…………………………………..………...…1 
NO…………………………………..………..….2 
 
 
208 
 
A radio? 
 
YES………………………………………….....…1 
NO…………………………………………………2 
 
 
209 
 
A television? 
 
YES…………………………………………....…1 
NO……………………………………………..…2 
 
 
210 
 
A telephone/mobile telephone 
 
YES……………………………………….......…1 
NO……………………………………….…….…2 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS (continued) 
 
211 
 
A refrigerator 
 
YES….………………………………………....…1 
NO……………………………………………..…2 
 
 
212 
 
Battery/Generator? 
 
YES…………………………………………....…1 
NO……………………………………….…....…2 
 
 
213 
 
A computer? 
 
YES……………………………………….......…1 
NO……………………………………………..…2 
 
 
214 
 
Internet access? 
 
YES…………………………………………....…1 
NO……………………………………………..…2 
 
 
215 
 
What type of fuel does your household 
mainly use for cooking? 
 
ELECTRICITY……………………………..……1 
LPG / NATURAL GAS…………………..….2 
BIOGAS………………………………………....3 
PARAFFIN / KEROSENE…………………..4 
COAL, LIGNITE………………………….…...5 
CHARCOAL FROM WOOD…………..….6 
FIREWOOD / STRAW……………………..7 
DUNG…………………………………….……..8 
NO FOOD COOKED IN  
HOUSEHOLD………………………………..95 
OTHER………………………………………...96 
____________________________ 
(SPECIFY) 
 
 
216 
 
MAIN MATERIAL OF FLOOR 
 
RECORD OBSERVATION. 
 
NATURAL FLOOR 
   EARTH / SAND………………………………11 
DUNG……………….………………………….12 
RUDIMENTARY FLOOR 
   WOOD PLANKS……………...…………….21 
…PALM / BAMBOO………..………….……22 
FINISHED FLOOR 
PARQUET OR POLISHED WOOD……31 
VINYL OR ASPHALT STRIP….………….32 
CERAMIC TILES……….…………………....33 
CEMENT/TERAZO……………………..….34 
CARPET………………………………………...35 
OTHER…………………………………………….96 
_______________________________ 
(SPECIFY) 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS (continued) 
 
217 
 
MAIN MATERIAL OF THE ROOF 
 
RECORD OBSERVATION. 
 
NATURAL ROOFING 
   NO ROOF……………………………………...11 
   THATCH/PALM LEAF (MAKUTI)..…...12 
   DUNG / MUD………………………………..13 
RUDIMENTARY ROOFING 
   CORRUGATED IRON (MABATI)…..…21 
   TIN CANS………………………………………22 
FINISHED ROOFING 
   ASBESTOS SHEET…………………………..31 
   CONCRETE……………………………….……32 
   TILES………………………………………..…...33 
OTHER…………………………………..………...96 
_______________________________ 
(SPECIFY)    
 
 
218 
 
MAIN MATERIAL OF THE EXTERIOR 
WALLS 
 
RECORD OBSERVATION. 
 
NATURAL WALLS 
   NO WALLS…………………………………….11 
   CANE/PALM/TRUNKS…………………..12 
   DUNG / MUD……………………………..…13 
RUDIMENTARY WALLS 
   BAMBOO WITH MUD…………………...21 
   STONE WITH MUD………………………..22 
   PLYWOOD/CARDBOARD…………….…23 
   CARTON…………………………………….....24 
   REUSED WOOD…………………………..…25 
FINISHED WALLS 
CEMENT………………………………….…….…31 
STONE WITH LIME/CEMENT……………32 
BRICKS…………………………………...……...33 
CEMENT BLOCKS……………………..…..…34 
WOOD PLANKS/SHINGLES………….....35 
OTHER………………………………………..…...96 
_______________________________ 
(SPECIFY) 
 
 
219 
 
How many rooms are used for sleeping? 
 
NUMBER OF ROOMS: 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS (continued) 
PREFACE BEFORE QUESTIONS 220-223:  
Does any member of your household own: 
 
220 
 
A bicycle? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
221 
 
A motorcycle or motor scooter? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
222 
 
A car or truck? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
223 Scotch cart?  
YES………………………………………....…1 
NO…………………………………………..…2 
 
PREFACE BEFORE QUESTIONS 219-223:  
Does any member of your household own: 
 
224 
 
Does any member of your household own 
any agricultural land? 
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
 
225 
 
Does your family own any livestock, herds, 
other farm animals, or poultry?  
 
YES………………………………………....…1 
NO…………………………………………..…2 
 
IF NO → skip 
these questions 
 
226 
 
How many cows does your family own? 
 
## 
 
 
227 
 
Goats? 
 
## 
 
 
228 
 
Sheep? 
 
## 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
HOUSEHOLD CHARACTERISTICS (continued) 
 
229 
 
Poultry (e.g., ducks, chickens)? 
 
## 
 
 
230 
 
Pigs? 
 
## 
 
 
231 
 
Horses? 
 
## 
 
 
232 
 
Donkeys? 
 
## 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
FOOD SECURITY 
 
233* 
 
In the past 4 weeks, was there ever no 
food to eat of any kind in your household 
because of lack of resources to get food? 
 
YES…………………………………………………1 
NO………………………………………….……..2 
DON’T KNOW………………………………..8 
 
NO, DK→235 
 
 
234* 
 
How often did this happen in the past 4 
weeks? 
 
RARELY (1-2 TIMES)……………….………1 
SOMETIMES (3-10 TIMES)……………..2 
OFTEN (MORE THAN 10 
TIMES)……………………………………..…...3 
 
 
235* 
 
In the past 4 weeks, did you or any 
household member go to sleep at night 
hungry because there was not enough 
food? 
 
YES…………………………………………………1 
NO………………………………………….……..2 
DON’T KNOW………………………………..8 
 
NO, DK→237 
 
 
236* 
 
How often did this happen in the past 4 
weeks? 
 
RARELY (1-2 TIMES)……………………….1 
SOMETIMES (3-10 TIMES)……………..2 
OFTEN (MORE THAN 10 TIMES)…….3 
 
 
237* 
 
In the past four weeks, did you or any 
household member go a whole day and 
night without eating anything because 
there was not enough food? 
 
YES…………………………………………….……1 
NO………………………………………..………..2 
DON’T KNOW…………………….…………..8 
 
NO, DK→301 
 
 
238* 
 
How often did this happen in the past 4 
weeks? 
 
RARELY (1-2 TIMES)………………………..1 
SOMETIMES (3-10 TIMES)………….…..2 
OFTEN (MORE THAN 10 TIMES)…....3 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
ECONOMIC SUPPORT 
Now I will ask you questions on economic support you have received. 
 
301 
 
Has your household received any of the 
following forms of external economic support in 
the last 12 months? 
 
SELECT ALL THAT APPLY. 
 
NOTHING………………………………………………A 
CASH TRANSFER (E.G. PENSIONS, 
DISABILITY GRANTS, CHILD GRANT)….…..B 
ASSISTANCE FOR SCHOOL FEES……..........C 
MATERIAL SUPPORT FOR EDUCATION (E.G. 
UNIFORMS, SCHOOL BOOKS, EDUCATION, 
TUITION SUPPORT, BURSARIES)…….……..D 
INCOME GENERATION SUPPORT IN CASH 
OR KIND (E.G. AGRICULTURAL INPUTS)….E 
FOOD ASSISTANCE PROVIDED AT THE 
HOUSEHOLD OR EXTERNAL 
INSTITUTION….........................................F 
MATERIAL OR FINANCIAL SUPPORT FOR 
SHELTER……………………....................……...G 
SOCIAL PENSION……………………....………...H 
REMITTANCES………………………………..…….I 
OTHER……………………………………………......X 
_________________________________ 
(SPECIFY) 
DON’T KNOW …………………….……….……...Y 
REFUSED………………….………………….………Z 
 
NOTHING, DON’T 
KNOW→END OF 
SECTION 
 
302 
 
Has your household received any of the 
following forms of external economic support in 
the last 3 months? 
 
SELECT ALL THAT APPLY. 
 
NOTHING…………………………………..………..A 
CASH TRANSFER (E.G. PENSIONS, 
DISABILITY GRANTS, CHILD GRANT) .……B 
ASSISTANCE FOR SCHOOL FEES……........C 
MATERIAL SUPPORT FOR EDUCATION (E.G. 
UNIFORMS, SCHOOL BOOKS, EDUCATION, 
TUITION SUPPORT, BURSARIES)…………..D 
INCOME GENERATION SUPPORT IN CASH 
OR KIND (E.G. AGRICULTURAL INPUTS)..E 
FOOD ASSISTANCE PROVIDED AT THE 
HOUSEHOLD OR EXTERNAL 
INSTITUTION…………………………...……..…...F 
MATERIAL OR FINANCIAL SUPPORT FOR 
SHELTER…………………………………….…...…..G 
SOCIAL PENSION……………………….....……..H 
REMITTANCES………………………….………..…I 
OTHER…………………………………………….…..X 
_________________________________ 
(SPECIFY) 
DON’T KNOW ………………………………….....Y 
REFUSED……………………………………..….…..Z 
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NO. QUESTIONS AND INSTRUCTIONS CODING CATEGORIES SKIP 
MOBILITY AND MIGRATION 
Now I will ask you questions about individuals who are part of your household, but may not be living with you 
right now. 
 
401 
 
Are there any members of your 
household who are not in the country 
right now because of work? 
 
YES…………………………………………..….1 
NO……………………………………………...2 
DON’T KNOW  …………………………..-8 
 
YES → 402 
NO, DON’T 
KNOW→END 
OF SECTION 
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HOUSEHOLD SCHEDULE – MIGRATION AND MOBILITY 
IF (NAME) IS USUAL MEMBER BUT DID NOT SLEEP IN HOUSEHOLD AND IS 18 YEARS OR OLDER 
LINE NUMBER AND 
NAME  
When was the 
last time 
(NAME) slept 
the night in 
the 
household? 
 
 
IF < 30 DAYS: 
ASK 
When do you 
expect 
(NAME) to 
return? 
 
IF 401 plus 
402 < 30 
DAYS, skip TO 
405. If >30 
days 403-404: 
 
 
Is (NAME) in 
another 
district or 
country 
Which district or country 
is (NAME) in currently? 
 
BUTHA-BUTHE=01 
LERIBE=02 
BEREA=03 
MASERU=04 
MAFETENG=05 
MOHALE’S HOEK=06 
QUTHING=07 
QACHA’S NEK=08 
MOKHOTLONG=09 
THABA-TSEKA=10 
SOUTH AFRICA=11 
SWAZILAND = 12 
MOZAMBIQUE = 13 
NAMIBIA = 14 
BOTSWANA = 15 
ZIMBABWE = 16 
OTHER = 96 
 
What is (NAME’s) primary  
activity while away? 
NONE= 0 
AGRICULTURE=1 
FISHING= 2 
MINING/QUARRYING= 3 
MANUFACTURING/PROCESSI
NG= 4 
ELECTRICITY= 5 
CONSTRUCTION= 6 
WHOLESALE & RETAIL, REPAIR 
OF MOTOR VEHICLES & 
PERSONAL & HOUSEHOLD 
GOODS= 7 
HOTELS & RESTAURANTS= 8 
TRANSPORT, STORAGE, & 
COMMUNICATION= 9 
FINANCIAL INTERMEDIATION= 
10 
REAL ESTATE, RENDING & 
BUSSINESS ACTIVITIES= 11 
PUBLIC ADMIN, DEFENCE, 
COMP. SOCIAL SERVICE= 12 
EDUCATION= 13 
HEALTH & SOCIAL WORK= 14 
OTHER COMMUNITY, SOCIAL 
& PERS. SERVICES= 15 
PRIVATE HOUSEHOLD= 16 
EXTRA TERRITORIAL 
ORGANISATIONS BODIES= 17 
OTHER (SPECIFY)= 96 
DON’T KNOW= -8 
REFUSED= -9 
 
(1) (401) (402) (403) (404) (405) 
__ 
 
______ 
Name 
 
DAYS 
WEEKS 
MONTHS 
 
DAYS 
WEEKS 
MONTHS 
Y     N     DK 
 
     Next Line 
  
__ 
 
______ 
Name 
 
DAYS 
WEEKS 
MONTHS 
 
DAYS 
WEEKS 
MONTHS 
Y     N     DK 
 
     Next Line 
  
__ 
 
______ 
Name 
 
DAYS 
WEEKS 
MONTHS 
 
DAYS 
WEEKS 
MONTHS 
Y     N     DK 
 
     Next Line 
  
__ 
 
______ 
Name 
 
DAYS 
WEEKS 
MONTHS 
 
DAYS 
WEEKS 
MONTHS 
Y     N     DK 
 
     Next Line 
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LINE 
NO. 
HOUSEHOLD MEMBERS 
WHO LIVE ABROAD 
(OUTSIDE LESOTHO) 
RELATIONS
HIP TO 
HEAD OF 
HOUSEHOL
D SEX 
LENGTH OF  
TIME AWAY PLACE / COUNTRY PRIMARY ACTIVITY 
  
Please give me the 
names of the any other 
persons (not noted 
above) who have lived 
with you (as household 
members) during the 
past 3 years who 
currently live outside 
the country.  
 
What is the 
relationship 
of (NAME) 
to the head 
of the 
household? 
 
SEE CODES 
BELOW 
 
Is 
(NAME) 
Male or 
Female? 
 
How long has 
he/she been 
away? 
(MONTHS) 
 
Where (What 
country) does (NAME) 
live? 
 
 
 
What is (NAME’s) primary activity 
while away? 
 
(406) (407) (408) (409) (410) (411) (412) 
1  
 
M       F 
   
2  
 
M       F 
   
3  
 
M       F 
   
4  
 
M       F 
   
 
 
CODES FOR COLUMN 3: RELATIONSHIP TO HOUSEHOLD HEAD 
01 = HEAD   09 = CO-WIFE 
02 = WIFE/HUSBAND/PARTNER 10 = OTHER RELATIVE 
03 = SON OR DAUGHTER  11 = 
ADOPTED/FOSTER/STEPCHILD 
04 = SON/DAUGHTER-IN-LAW 12 =  NOT RELATED 
05 = GRANDCHILD 
06 = PARENT   -8 = DON’T KNOW 
07 = PARENT-IN-LAW 
08 = BROTHER/SISTER 
 
 
SOUTH AFRICA=11 
SWAZILAND = 12 
MOZAMBIQUE = 13 
NAMIBIA = 14 
BOTSWANA = 15 
ZIMBABWE = 16 
OTHER = 96 
 
 
NONE= 0 
AGRICULTURE= 1 
FISHING= 2 
MINING/QUARRYING= 3 
MANUFACTURING/PROCESSING= 
4 
ELECTRICITY= 5 
CONSTRUCTION= 6 
WHOLESALE & RETAIL, REPAIR OF 
MOTOR VEHICLES & PERSONAL & 
HOUSEHOLD GOODS= 7 
HOTELS & RESTAURANTS= 8 
TRANSPORT, STORAGE, & 
COMMUNICATION= 9 
FINANCIAL INTERMEDIATION= 10 
REAL ESTATE, RENDING & 
BUSSINESS ACTIVITIES= 11 
PUBLIC ADMIN, DEFENCE, COMP. 
SOCIAL SERVICE= 12 
EDUCATION= 13 
HEALTH & SOCIAL WORK= 14 
OTHER COMMUNITY, SOCIAL & 
PERS. SERVICES= 15 
PRIVATE HOUSEHOLD= 16 
EXTRA TERRITORIAL 
ORGANISATIONS BODIES= 17 
OTHER (SPECIFY)= 96 
DON’T KNOW= -8 
REFUSED= -9 
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END OF HOUSEHOLD INTERVIEW 
➢ INTERVIEWER SAY: “This is the end of the household survey. Thank you very much for your time and 
for your responses. Do you have any questions for me at this time?” 
END TIME 
 
END 
 
Record the end time.  
 
USE 24 HOUR TIME.  
 
IF START TIME IS 3:12 PM, RECORD 15 
HOURS, 12 MINUTES, NOT 03 HOURS, 12 
MINUTES.  
 
 
HOUR:  
 
MINUTES:   
 
 
 
INTERVIEWER OBSERVATIONS: 
TO BE COMPLETED AFTER THE INTERVIEW: 
 
 
COMMENTS ABOUT RESPONDENT:  
 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
COMMENTS ABOUT SPECIFIC QUESTIONS:  
 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
ITEMS FOR THE ATTENTION OF THE SUPERVISOR:  
 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________ 
GENERAL QUESTIONS:  
 
______________________________________________________________________________________________
______________________________________________________________________________________________
______________________________________________________________________________________________  
  
 
179 
Appendix F    Adult Questionnaire 
NO QUESTIONS CODING CATEGORIES SKIPS 
MODULE 1:  RESPONDENT BACKGROUND 
Interviewer says: “Thank you for agreeing to participate in this survey.  The first set of questions is about your life in 
general. Afterwards, we will move on to other topics.” 
L1 DO NOT READ:  
LANGUAGE OF QUESTIONNAIRE 
SESOTHO = 1 
ENGLISH = 2 
 
L2 DO NOT READ:  
LANGUAGE OF INTERVIEW 
SESOTHO = 1 
ENGLISH = 2 
OTHER = 96 
SPECIFY: ____________________ 
 
L3 DO NOT READ:  
NATIVE LANGUAGE OF PARTICIPANT 
SESOTHO = 1 
ENGLISH = 2 
OTHER = 96 
SPECIFY: ____________________ 
 
L4 DO NOT READ:  
TRANSLATION USED 
YES = 1 
NO = 2 
 
101  DO NOT READ:  
IS THE RESPONDENT MALE OR FEMALE? 
MALE = 1 
FEMALE = 2 
 
102  What is your religion? ROMAN CATHOLIC = 1 
LESOTHO EVANGELICAL = 2 
ANGLICAN = 3 
PENTECOSTAL = 4 
OTHER CHRISTIAN = 5 
OTHER RELIGION = 96 
SPECIFY: _______________ 
DON’T KNOW = -8 
REFUSED = -9 
 
103  Have you ever attended school? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED 
→113 
104  What is the highest level of school you 
attended: primary, secondary, or higher? 
PRIMARY = 1 
VOCATIONAL/TECHNICAL 
TRAINING AFTER PRIMARY = 2 
SECONDARY/HIGH = 3 
VOCATIONAL/TECHNICAL 
TRAINING AFTER 
SECONDARY/HIGH = 4 
COLLEGE/UNIVERSITY = 5 
GRADUATE/POST GRADUATE = 6 
DON’T KNOW = -8 
REFUSED = -9 
 
 
  
APPENDIX F ADULT QUESTIONNAIRE 
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NO QUESTIONS CODING CATEGORIES SKIPS 
105 What is the highest [standard/form/year] 
you completed at that level? 
 
(IF ATTENDING FORM 1 OF SECONDARY 
SCHOOL AND HAS/DID NOT COMPLETE 
THE SCHOOL YEAR, ENTER “0”) 
STANDARD/FORM/YEAR _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
 FOLLOWING QUESTIONS ON SCHOOLING 
ARE FOR ADOLESCENT/YOUNG ADULTS 
AGES 15-18 
 IF > 18, GO TO 113 
106 Are you enrolled in school? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
DK, REFUSED → 113 
107 What grade/form/year are you in now? STANDARD/FORM/YEAR _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
108 During the last school week, did you miss 
any school days for any reason? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
107 
109 Why did you miss school? I HAVE BEEN SICK = 1 
I DON’T FEEL SAFE TRAVELING TO 
SCHOOL = 2 
I DON’T FEEL SAFE WHILE IN 
SCHOOL = 3 
I DON’T LIKE SCHOOL = 4 
I HAVE TO LOOK AFTER MY FAMILY 
= 5 
THERE’S NOT ENOUGH MONEY TO 
SEND ME TO SCHOOL = 6 
SCHOOL IS TOO FAR AWAY = 7 
I HAVE TO WORK = 8 
I HAVE A CHILD OR I AM 
PREGNANT (GIRLS ONLY) = 9 
I MISSED TOO MUCH SCHOOL 
BECAUSE OF MY PERIOD 
(MENSTRUATION) (GIRLS ONLY) = 
10 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
110 What grade/form/year were you in last 
year? 
STANDARD/FORM/YEAR _______ 
DON’T KNOW = -8 
REFUSED = -9 
ALL → 113 
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111 Why do you NOT go to school? I HAVE BEEN SICK = 1 
I DON’T FEEL SAFE TRAVELING TO 
SCHOOL = 2 
I DON’T FEEL SAFE WHILE IN 
SCHOOL = 3 
I DON’T LIKE SCHOOL = 4 
I HAVE TO LOOK AFTER MY FAMILY 
= 5 
THERE’S NOT ENOUGH MONEY TO 
SEND ME TO SCHOOL = 6 
SCHOOL IS TOO FAR AWAY = 7 
I HAVE TO WORK = 8 
I HAVE A CHILD OR I AM 
PREGNANT (GIRLS ONLY) = 9 
I MISSED TOO MUCH SCHOOL 
BECAUSE OF MY PERIOD 
(MENSTRUATION) (GIRLS ONLY) = 
10 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
112 When was the last time you regularly 
attended school? Would you say it was 
less than a year ago or more than a year 
ago? 
LESS THAN 1 YEAR = 1 
1 YEAR OR LONGER = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
113 Have you done any work in the last 12 
months for which you received cash or 
goods as payment? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
114 Have you done any work in the last seven 
days for which you received cash or goods 
as payment? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
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NO QUESTIONS CODING CATEGORIES SKIPS 
115 What is your main 
product/service/activity of your place of 
work?  
AGRICULTURE = 1 
FISHING = 2 
MINING/QUARRYING = 3 
MANUFACTURING/PROCESSING = 
4 
ELECTRICITY = 5 
CONSTRUCTION = 6 
WHOLESALE & RETAIL, REPAIR OF 
MOTOR VEHICLES & PERSONAL & 
HOUSEHOLD GOODS = 7 
HOTELS & RESTAURANTS = 8 
TRANSPORT, STORAGE, & 
COMMUNICATION = 9 
FINANCIAL INTERMEDIATION = 10 
REAL ESTATE, RENDING & 
BUSINESS ACTIVITIES = 11 
PUBLIC ADMIN, DEFENCE, COMP. 
SOCIAL SERVICE = 12 
EDUCATION = 13 
HEALTH & SOCIAL WORK = 14 
OTHER COMMUNITY, SOCIAL & 
PERS. SERVICES = 15 
PRIVATE HOUSEHOLD = 16 
EXTRA TERRITORIAL 
ORGANISATIONS BODIES = 17 
OTHER = 96 
SPECIFY = ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
 
MODULE 2: MOBILITY/MIGRATION 
Interviewer says: “Now I would like to ask you questions about where you have lived.” 
201 How long have you lived in Lesotho? 
 
ONLY ONE OPTION MAY BE SELECTED.  
FOR EXAMPLE, ANSWER ONLY IN 
MONTHS OR IN YEARS. 
 
CODE ‘0’ IN MONTHS IF LESS THAN 1 
MONTH. 
MONTHS _____ 
YEARS _____ 
MY ENTIRE LIFE/BORN HERE= 96 
DON’T KNOW = -8 
REFUSED=-9 
ENTIRE LIFE/BORN 
HERE/DK/REF → 
OUTSIDE 
202 What was your main reason for moving to 
Lesotho? 
 
TO JOIN FAMILY= 1 
FOR MARRIAGE = 2 
TO FIND WORK = 3 
TO GO TO SCHOOL = 4 
TO ESCAPE INSECURITY/CONFLICT 
= 5 
TO ESCAPE DROUGHT, FLOOD, 
ETC= 6 
TO ESCAPE VIOLENCE IN 
HOUSEHOLD = 7 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
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NO QUESTIONS CODING CATEGORIES SKIPS 
203 Have you ever lived outside Lesotho? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
IF NO, DK, REFUSED 
→ END OF MODULE 
204 How old were you the first time you lived 
outside Lesotho? 
AGE IN YEARS ___ ___ 
DON’T KNOW = -8 
REFUSED = -9 
 
205 How many times in your life have you ever 
lived outside of Lesotho? 
NUMBER OF TIMES ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
206 What was the longest period of time you 
spent living outside Lesotho since you 
were 18 years old? 
WEEKS __ __ 
MONTHS __ __ 
YEARS __ __  
DON’T KNOW = -8 
REFUSED = -9 
 
207 In the last 12 months, have you been 
away from home for more than one 
month at a time? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
END OF MODULE 
208 For what reason were you away from 
home for longer than one month? 
WORK = 1 
SCHOOL = 2 
FAMILY OBLIGATIONS = 3 
MEDICAL CARE = 4 
TRAVEL = 5 
OTHER = 6 
SPECIFY = _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
209 In what country/countries did you spend 
more than one month living in during the 
past year? 
SOUTH AFRICA = A 
SWAZILAND = B 
MOZAMBIQUE = C 
NAMIBIA = D 
BOTSWANA = E 
ZIMBABWE = F 
OTHER = G 
SPECIFY = ______ 
DON’T KNOW = Y 
REFUSED = Z 
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NO QUESTIONS CODING CATEGORIES SKIPS 
210 What was your main 
product/service/activity of your place of 
work the last time you lived outside of 
Lesotho? 
DID NOT WORK = 0 
AGRICULTURE = 1 
FISHING = 2 
MINING/QUARRYING = 3 
MANUFACTURING/PROCESSING = 
4 
ELECTRICITY = 5 
CONSTRUCTION = 6 
WHOLESALE & RETAIL, REPAIR OF 
MOTOR VEHICLES & PERSONAL & 
HOUSEHOLD GOODS = 7 
HOTELS & RESTAURANTS = 8 
TRANSPORT, STORAGE, & 
COMMUNICATION = 9 
FINANCIAL INTERMEDIATION = 10 
REAL ESTATE, RENDING & BUSS. 
ACTIVITIES = 11 
PUBLIC ADMIN, DEFENCE, COMP. 
SOCIAL SERVICE = 12 
EDUCATION = 13 
HEALTH & SOCIAL WORK = 14 
OTHER COMMUNITY, SOCIAL & 
PERS. SERVICES = 15 
PRIVATE HOUSEHOLD = 16 
EXTRA TERRITORIAL 
ORGANISATIONS BODIES = 17 
OTHER = 96 
SPECIFY = ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
 
MODULE 3: MARRIAGE 
Interviewer says: “Now I would like to ask you about your current and previous relationships and/or marriages.” 
301 Have you ever been married or lived 
together with a [man/woman] as if 
married? 
YES = 1 
NO = 2 
DON’T KNOW =-8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
302 How old were you the first time you 
married or started living with a 
[man/woman] as if married?  
AGE IN YEARS ___ ___ 
DON’T KNOW = -8 
REFUSED = -9 
 
303 What is your marital status now: are you 
married, living together with someone as 
if married, widowed, divorced, or 
separated? 
 
MARRIED = 1 
LIVING TOGETHER = 2 
WIDOWED = 3 
DIVORCED = 4 
SEPARATED = 5 
DON’T KNOW = -8 
REFUSED = -9 
WIDOWED, 
DIVORCED, 
SEPARATED, DK, 
REFUSED → SKIP TO 
END OF MODULE 
304 Altogether, how many wives or live-in 
partners do you have? 
NUMBER OF WIVES OR LIVE-IN 
PARTNERS _____ 
DON’T KNOW = -8 
REFUSED = -9 
DK, REFUSED → SKIP 
TO END OF MODULE 
SKIP IF FEMALE 
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NO QUESTIONS CODING CATEGORIES SKIPS 
305 The Household Schedule listed [INSERT 
NUMBER OF REPORTED PARTNERS] 
household members as your 
wives/partners.  Please review the list 
below.  Are all of the listed household 
members your wives/partners who live in 
the household? 
YES = 1 
NO = 2 
NO → 308  
SKIP IF FEMALE 
 
306 Is [HHRNAME**] your wife/partner? YES = 1 
NO = 2 
SKIP IF FEMALE 
 
307 Does [HHRNAME**] live in the 
household? 
YES = 1 
NO = 2 
SKIP IF FEMALE 
 
308 Do you have additional 
spouse(s)/partner(s) that live with you? 
YES = 1 
NO = 2 
SKIP IF FEMALE 
 
309 How many additional 
spouse(s)/partners(s) live with you? 
NUMBER OF SPOUSES OR LIVE-IN 
PARTNERS _ _  
SKIP IF FEMALE 
 
310 Please enter the name of your 
spouse/partner that lives with you. 
NAME OF SPOUSE/PARTNER ____ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF FEMALE 
 
311 How many wives or live-in partners do 
you have who live elsewhere? 
NUMBER OF ADDITIONAL 
SPOUSE(S)/PARTNERS ____ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF FEMALE 
 
312 Is your husband or partner living with you 
now or is he staying elsewhere? 
LIVING TOGETHER = 1 
STAYING ELSEWHERE = 2 
DON’T KNOW = -8 
REFUSE TO ANSWER = -9 
STAYING ELSEWHERE, 
DK, REFUSED →316 
 
STAYING ELSEWHERE 
& LISTED PARTNER IN 
HH ROSTER→ 313 
 
SKIP IF MALE 
313 The household schedule listed [NAME OF 
HUSBAND/PARTNER] as your 
husband/partner who is living here.  Is 
that correct? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES 
DK, REF→316 
SKIP IF MALE 
314 Please select the spouse/partner that 
lives with you. 
[LIST OF PERSONS ON HH ROSTER] 
NOT LISTED IN HOUSEHOLD = 96 
LISTED →316 
 
SKIP IF MALE 
315 Please enter the name of your 
spouse/partner that lives with you. 
NAME OF SPOUSE/PARTNER ____ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF MALE 
 
316 Does your husband or partner have other 
wives or does he live with other women 
as if married? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSE TO ANSWER = -9 
NO, DK, REFUSED→  
SKIP TO END OF 
MODULE 
SKIP IF MALE 
317 Including yourself, in total, how many 
wives or live-in partners does your 
husband or partner have? 
 
NUMBER OF WIVES OR LIVE-IN 
PARTNERS _ _  
DON’T KNOW = -8 
REFUSE TO ANSWER = -9 
SKIP IF MALE 
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MODULE 4: REPRODUCTION 
Interviewer says: “Now I would like to ask you questions about your pregnancies and your 
children.” 
IF MALE SKIP TO 439. 
401 How many times have you been pregnant 
including a current pregnancy? 
 
CODE ‘00’ IF NONE. 
NUMBER OF TIME(S) ____ 
DON’T KNOW = -8 
REFUSED = -9 
NONE, DK, REFUSED 
→ 439 
 
402 Have you ever had a pregnancy that 
resulted in a live birth? 
 
A live birth is when the baby shows signs 
of life, such as breathing, beating of the 
heart or movement. 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
438 
 
403 In total, how many children have you 
given birth to who were born alive? 
 
These include children who were born 
alive but later died.  They could have 
been children who have lived with you or 
have not lived with you.   
NUMBER OF CHILDREN ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
NONE, DK, REFUSED 
→  
404 
404 How many live births have you had since 
the 1st of January, 2013?  
 
CODE ‘00’ IF NONE. 
NUMBER OF CHILDREN ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
NONE, DK, REFUSED 
→ 438 
YEAR IS SURVEY YEAR 
– 3 YEARS 
405 Did your last pregnancy result in birth to 
twins or more? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REF → 406 
 What is the name of the [BIRTHORDER*] 
born child from your last pregnancy that 
resulted in a live birth? 
A live birth is when the baby shows signs 
of life, such as breathing, beating of the 
heart or movement. 
 
DO NOT READ: IF THE CHILD WAS NOT 
NAMED BEFORE DEATH, INPUT BIRTH 
AND THE BIRTH ORDER NUMBER. FOR 
EXAMPLE, "BIRTH 1". 
 
DO NOT READ: WAS THERE ANOTHER 
MULTIPLE BORN ALIVE? 
NAME ________ 
 
WILL BE REPEATED 
FOR EACH MULTIPLE 
BIRTH 
406 What is the name of the child from your 
last pregnancy that resulted in a live 
birth?  
 
A live birth is when the baby shows signs 
of life, such as breathing, beating of the 
heart or movement. 
  
IF THE CHILD WAS NOT NAMED BEFORE 
DEATH, INPUT BIRTH 1. 
NAME ______ 
ID NUMBER______ 
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407 When you were pregnant with 
[CHILDLAST/PRGTWINNAME*], did you 
plan to get pregnant at that time? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES, NO, DK, REFUSED 
→ 408 
408 When you were pregnant with 
[CHILDLAST/PRGTWINNAME*], did you 
visit a health facility for antenatal care? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
410 
409 At what months in your pregnancy 
[CHILDLAST/PRGTWINNAME*] did you 
first attend the antenatal clinic? 
 
DO NOT READ: SELECT ALL THAT APPLY. 
SHOW AID IF UNSURE 
0-3 MONTHS/1ST TRIMESTER = A 
4-6 MONTHS/2ND TRIMESTER = B 
7-9 MONTHS/3RD TRIMESTER = C 
DON’T KNOW = Y 
REFUSED = Z 
ELECTRONIC AID IF 
DON’T KNOW 
410 What is the main reason you did not visit 
a clinic for antenatal care when you were 
pregnant with 
[CHILDLAST/PRGTWINNAME*]? 
 
CLINIC WAS TOO FAR AWAY = 1 
COULD NOT TAKE TIME OFF 
WORK/TOO BUSY = 2 
COULD NOT AFFORD TO PAY FOR 
THE VISIT = 3 
DID NOT TRUST THE CLINIC STAFF 
= 4 
RECEIVED CARE AT HOME = 5 
DID NOT WANT AN HIV TEST DONE 
= 6 
HUSBAND/FAMILY WOULD NOT 
LET ME GO = 7 
USED TRADITIONAL BIRTH 
ATTENDANT/HEALER = 8 
COST OF TRANSPORT = 9 
RELIGIOUS REASONS = 10 
OTHER = 96  
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→ 420 
 
ADAPT RESPONSES TO 
LOCAL CONTEXT. 
411 Have you ever tested for HIV before your 
pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
414 
412 Did you test positive for HIV before your 
pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
414 
 
413 At the time of your first antenatal care 
visit when you were pregnant with 
[CHILDLAST/PRGTWINNAME*], were you 
taking ARVs, that is, antiretroviral 
medications to treat HIV? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
YES → BIRTHWHR 
NO, DK, REFUSED → 
418 
 
ELECTRONIC AID IF 
DON’T KNOW 
414 During any of your visits to the antenatal 
care clinic when you were pregnant with 
[CHILDLAST/PRGTWINNAME*], were you 
offered an HIV test? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
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415 Were you tested for HIV during any of 
your antenatal care clinic visits when you 
were pregnant with 
[CHILDLAST/PRGTWINNAME*]? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES →417 
DK, REFUSED →420 
416 What is the main reason you were not 
tested for HIV during antenatal care with 
[CHILDLAST/PRGTWINNAME*]? 
 
DID NOT WANT AN HIV TEST DONE 
/ DID NOT WANT TO KNOW MY 
STATUS = 1 
DID NOT RECEIVE PERMISSION 
FROM SPOUSE/FAMILY = 2 
AFRAID OTHERS WOULD KNOW 
ABOUT TEST RESULTS = 3 
DID NOT NEED TEST/LOW RISK = 4 
OTHER = 96 
SPECIFY: ___________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→SKIP TO 420 
 
ADAPT RESPONSES 
BASED ON LOCAL 
CONTEXT. 
417 What was the result of your last HIV test 
during your pregnancy with 
[CHILDLAST/PRGTWINNAME*]? 
POSITIVE = 1 
NEGATIVE = 2 
UNKNOWN/INDETERMINATE = 3 
DID NOT RECEIVE RESULTS = 4 
DON’T KNOW = -8 
REFUSED = -9 
NEGATIVE, UNK, NO 
RESULTS, DK, REF → 
420 
 
418 Did you take ARVs during your pregnancy 
with [NAME] to stop 
[CHILDLAST/PRGTWINNAME*] from 
getting HIV? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES, DK, REFUSED → 
420 
419 What was the main reason you did not 
take ARVs while you were pregnant with 
[CHILDLAST/PRGTWINNAME*]? 
WAS NOT PRESCRIBED = 1 
I FELT HEALTHY/NOT SICK = 2 
COST OF MEDICATIONS = 3 
COST OF TRANSPORT = 4 
RELIGIOUS REASONS = 5 
WAS TAKING TRADITIONAL 
MEDICATIONS = 6 
MEDICATIONS OUT OF STOCK = 7 
DID NOT WANT PEOPLE TO KNOW 
HIV STATUS = 8 
DID NOT RECEIVE PERMISSION 
FROM SPOUSE/FAMILY = 9 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
420 Where did you give birth to 
[CHILDLAST/PRGTWINNAME*]? 
AT HOME = 1 
AT A HEALTH FACILITY = 2 
IN TRANSIT = 3 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
HOME, TRANSIT, OTH, 
DK, REFUSED → 429 
421 What health facility or hospital did you 
deliver [CHILDLAST/PRGTWINNAME*] at? 
PICK FROM LIST 
ENTER NAME _________________ 
DON’T KNOW = -8 
REFUSED = -9 
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422 Were you offered an HIV test during 
labor? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
423 Did you test for HIV during labor? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
429 
 
SKIP IF HIV POSITIVE 
424 What was the result of that test? POSITIVE = 1 
NEGATIVE = 2 
UNKNOWN/INDETERMINATE = 3 
DID NOT RECEIVE RESULTS = 4 
DON’T KNOW = -8 
REFUSED = -9 
NEG, UNK/INDET, NO 
RESULTS, DK, 
REFUSED → 429 
 
SKIP IF HIV POSITIVE 
425 During labor, were you offered ARVs to 
protect [NAME] against HIV? 
 
DO NOT READ: SHOW ARV GRAPHIC IF 
PARTICIPANT IS UNSURE 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
SKIP IF ALREADY ON 
ARVS 
426 During labor, did you take ARVs to protect 
[CHILDLAST/PRGTWINNAME*] against 
HIV? 
 
DO NOT READ: SHOW ARV GRAPHIC IF 
PARTICIPANT IS UNSURE 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → CHILDBDATE 
ADAPT BASED ON COUNTRY 
CONTEXT  
ELECTRONIC AID IF DON’T KNOW 
SKIP IF ALREADY ON ARVS 
 
427 Did you continue to take ARVs after 
delivery? 
YES = 1 
NO= 2 
DON’T KNOW =8 
REFUSED = -9 
ADAPT TO LOCAL 
COUNTRY CONTEXT. 
 
SKIP IF ALREADY ON 
ARVS. 
428 For how many months after delivery did 
you continue to take ARVs? 
 
MONTH __ __ 
STILL TAKING ARVS = 95 
 
DON’T KNOW = -8 
REFUSED = -9 
 
429 When did you give birth to 
[CHILDLAST/PRGTWINNAME*]? Please 
give your best guess. 
DAY __ __ 
DON’T KNOW DAY= -8 
REFUSED DAY= -9 
 
MONTH __ __ 
DON’T KNOW MONTH= -8 
REFUSED MONTH= -9 
 
YEAR __ __ __ __ 
DON’T KNOW YEAR=-8 
REFUSED YEAR= -9 
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430 Is [CHILDLAST/PRGTWINNAME*] still 
alive? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES, DK, REFUSED 
→433 
NO→431 
431 How old was 
[CHILDLAST/PRGTWINNAME*] when 
he/she died? 
 
KEY ‘0’ IF CHILD WAS LESS THAN ONE 
YEAR OLD   
COMPLETED YEARS _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
>0, DK, REF →432 
432 How old was 
[CHILDLAST/PRGTWINNAME*] in months 
when he/she died? 
 
KEY ‘0’ IF LESS THAN ONE MONTH OLD. 
COMPLETED MONTHS ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
 
433 Is [CHILDLAST/PRGTWINNAME*] living 
with you? 
YES = 1 
NO = 2 
NO →435 
434 Please select 
[CHILDLAST/PRGTWINNAME*] that lives 
with you. 
 
RECORD ‘0’ IF CHILD NOT LISTED IN 
HOUSEHOLD 
[LIST OF CHILDREN IN 
HOUSEHOLD] 
NOT LISTED IN HOUSEHOLD = 96 
 
435 Did you ever breastfeed 
[CHILDLAST/PRGTWINNAME*]? 
YES = 1 
NO, NEVER BREASTFED = 2 
 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
438 
436 For how long did you breastfeed 
[CHILDLAST/PRGTWINNAME*]? 
 
ONLY ONE OPTION MAY BE SELECTED.  
FOR EXAMPLE, ANSWER ONLY IN WEEKS 
OR IN MONTHS. 
 
CODE ‘00’ IF LESS THAN 1 WEEK. 
WEEKS ____ 
MONTHS ____ 
STILL BREASTFEEDING = 96 
DON’T KNOW = -8 
REFUSED = -9 
 
437 Thank you for the information regarding 
[CHILDLAST/PRGTWINNAME*]. 
 
 IF 405 = 1 
RETURN TO 
CHILDALIVE* FOR 
EACH VALUE OF 
PRGTWINNAME* 
438 Are you pregnant now? 
 
YES = 1 
NO = 2 
DON’T KNOW/UNSURE = -8 
REFUSED = -9 
YES → SKIP TO END 
OF MODULE 
439 Are you or your partner currently doing 
something or using any method to delay 
or avoid getting pregnant? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, 
REFUSED→SKIP TO 
END OF MODULE 
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440 Which method are you or your partner 
using? 
 
SELECT ALL THAT APPLY. 
FEMALE STERILIZATION = A 
MALE STERILIZATION = B 
PILL = C 
IUD/”COIL” = D 
INJECTIONS = E 
IMPLANT = F 
CONDOM = G 
FEMALE CONDOM = H 
RHYTHM/NATURAL METHODS = I 
WITHDRAWAL = J 
NOT HAVING SEX = K 
OTHER = X  
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
 
 
MODULE 5: CHILDREN 
Interviewer says: “I am going to ask you a number of questions about your child/children regarding their health and 
where they get their health services. I will begin with your youngest child.” 
 LIST OF CHILDREN < 14 ASSIGNED TO 
[INNAME] 
  
 Now I am going to ask you questions for 
[CHILD*]. 
  
501 How old is [CHILD*] in years? 
 
IF [CHILD*] IS LESS THAN 1 YEAR OLD, KEY 
0 HERE AND KEY AGE IN MONTHS ON 
NEXT SCREEN.   
YEARS ___ 
DON’T KNOW =-8 
REFUSED = -9 
>5, DK, REF →504 
1-5 → 503 
 
AGE CANNOT BE 
GREATER THAN 14 
YEARS.  
502 How old is [CHILD*] in months? 
 
 
MONTHS ___ 
DON’T KNOW =-8 
REFUSED = -9 
ALL → 504 
503 You said that [CHILD*] was [KIDAGEY]. 
How many months over [KIDAGEY] is 
[CHILD*]. 
MONTHS ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
504 Is [CHILD*] a boy or girl? 
 
BOY = 1 
GIRL = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
505 Is [CHILD*] enrolled in school? YES = 1 
NO, CURRENTLY NOT IN SCHOOL = 
2 
NO, TOO YOUNG TO BE IN SCHOOL 
= 3 
DON’T KNOW = -8 
REFUSED = -9 
NO, CURR NOT IN 
SCHOOL→  508 
NO, TOO YOUNG, DK, 
REFUSED → 510 
506 What is the highest level of school 
[CHILD*] has attended: primary or 
secondary? 
NURSERY = 1 
PRIMARY = 2 
SECONDARY = 3 
DON’T KNOW = -8 
REFUSED = -9 
NURSERY, DK, REF → 
510 
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507 What standard/form/year is [CHILD*] in 
now? 
STANDARD/FORM/YEAR _____ 
DON’T KNOW = -8 
REFUSED = -9 
ALL → 510 
508 Was [CHILD*] enrolled in school during 
the previous school year? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REF → 510 
509 What standard/form/year was [CHILD*] 
during the previous school year? 
STANDARD/FORM/YEAR _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
510 Is [CHILD*] circumcised? 
 
Circumcision is the complete removal of 
the foreskin from the penis.  If you feel 
comfortable, I can show you a picture of a 
completely circumcised penis. 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REF → 511 
SKIP IF FEMALE CHILD. 
 
ELECTRONIC AID IF 
REQUESTED. 
511 Why is [CHILD*] not circumcised? DON'T KNOW WHERE TO GET 
CIRCUMCISED = A 
HAD TO TRAVEL TOO FAR TO GET 
CIRCUMCISED = B 
CHILD WAS AFRAID TO GET 
CIRCUMCISED = C 
DO NOT HAVE A REASON TO 
CIRCUMCISE THE CHILD = D 
WAITING UNTIL CHILD IS OLDER 
TO GET HIM CIRCUMCISED = E 
RELIGIOUS REASONS = F 
OTHER = G 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
 
512 Who circumcised [CHILD*]? DOCTOR, CLINICAL OFFICER, OR 
NURSE = 1 
TRADITIONAL PRACTITIONER / 
CIRCUMCISER =2 
MIDWIFE = 3 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSE TO ANSWER=-9 
SKIP IF FEMALE CHILD. 
 
ADAPT RESPONSES 
BASED ON COUNTRY 
CONTEXT 
513 Has [CHILD*] ever been tested for HIV? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES → 515 
DK, REFUSED → 532 
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514 Why has [CHILD*] never been tested for 
HIV? 
 
SELECT ALL THAT APPLY. 
 
DON'T KNOW WHERE TO TEST = A 
TEST COSTS TOO MUCH = B 
TRANSPORT COSTS TOO MUCH = C 
TOO FAR AWAY = D 
AFRAID OTHERS WILL KNOW 
ABOUT TEST RESULTS = E 
DON'T NEED TEST/LOW RISK = F 
DID NOT RECEIVE PERMISSION 
FROM SPOUSE/FAMILY = G 
AFRAID SPOUSE/PARTNER/FAMILY 
WILL KNOW RESULTS = H 
DON’T WANT TO KNOW CHILD 
HAS HIV = I 
CANNOT GET TREATMENT FOR HIV 
= J 
TEST KITS NOT AVAILABLE = K 
RELIGIOUS REASONS = L 
OTHER = X 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
ALL-> 532 
515 What month and year was [CHILD*]’s last 
HIV test done? 
 
MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
YEAR ___ ___ ___ ____  
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
DATE RESTRAINTS 
516 What was [CHILD*]’s last HIV test result? POSITIVE = 1 
NEGATIVE = 2 
UNKNOWN/INDETERMINATE = 3 
DID NOT RECEIVE RESULTS = 4 
DON’T KNOW = -8 
REFUSED = -9 
IF NEG, UNK/INDET, 
DID NOT RECEIVE, DK, 
REFUSED → 
532  
 
517 What was the month and year of 
[CHILD*]’s first HIV positive test result? 
Please give your best guess. 
 
This will be the very first HIV-positive test 
result that you have received. 
 
PROBE TO VERIFY DATE. 
MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
YEAR ___ ___ ___ ____  
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
518 Has [CHILD*] ever received HIV medical 
care from a doctor, clinical officer or 
nurse? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
YES → 520  
DK, REFUSED → 523 
 
ADAPT HEALTHCARE 
PROVIDER TERMS 
BASED ON LOCAL 
CONTEXT. 
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519 What is the main reason why [CHILD*] 
has never seen a doctor, clinical officer, or 
nurse for HIV medical care? 
 
FACILITY IS TOO FAR AWAY = 1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE FOR CHILD = 2 
COST OF CARE = 3 
COST OF TRANSPORT = 4 
I DON’T THINK CHILD NEEDS IT, 
HE/SHE IS NOT SICK = 5 
I FEAR PEOPLE WILL KNOW THAT 
CHILD HAS HIV IF I TAKE HIM/HER 
TO A CLINIC = 6 
RELIGIOUS REASONS = 7 
CHILD IS TAKING TRADITIONAL 
MEDICINE = 8 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→ 523 
 
ADAPT RESPONSES TO 
LOCAL CONTEXT. 
 
ADAPT HEALTHCARE 
PROVIDER TERMS 
BASED ON LOCAL 
CONTEXT. 
520 What month and year did [CHILD*] first 
see a doctor, clinical officer or nurse for 
HIV medical care? 
 
PROBE TO VERIFY DATE. 
MONTH __________ 
DON’T KNOW MONTH = -8 
REFUSED MONTH= -9 
 
YEAR ____________ 
DON’T KNOW YEAR =-8 
REFUSED YEAR = -9 
 
521 What month and year did [CHILD*] last 
see a doctor, clinical officer or nurse for 
HIV medical care? 
MONTH __________ 
DON’T KNOW MONTH = -8 
REFUSED MONTH= -9 
 
YEAR ____________ 
DON’T KNOW YEAR =-8 
REFUSED YEAR = -9 
IF <7 MONTHS, DK, 
REFUSED, MISSING 
DATE → 523 
 
522 What is the main reason for [CHILD*] not 
seeing a doctor, clinical officer or nurse 
for HIV medical care for more than 6 
months? 
 
FACILITY IS TOO FAR AWAY = 1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE FOR CHILD = 2 
COST OF CARE = 3 
COST OF TRANSPORT = 4 
I DON’T THINK CHILD NEEDS IT, 
HE/SHE IS NOT SICK = 5 
I FEAR PEOPLE WILL KNOW THAT 
CHILD HAS HIV IF I TAKE HIM/HER 
TO A CLINIC = 6 
RELIGIOUS REASONS = 7 
CHILD IS TAKING TRADITIONAL 
MEDICINE = 8 
NO APPOINTMENT 
SCHEDULED/DID NOT MISS MOST 
RECENT APPOINTMENT= 9 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
523 Has [CHILD*] ever had a CD4 count test? 
The CD4 count tells you how sick you are 
with HIV and if you need to take any HIV 
medications. All HIV infected people need 
to take ARVs. 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
525 
 
NO, DK, REFUSED & 
NEVER IN HIV CARE → 
532 
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524 What month and year was [CHILD*] last 
tested for his/her CD4 count? 
MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
YEAR ___ ___ ___ ___ 
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
SKIP TO 532 IF NEVER 
IN HIV CARE. 
525 Has [CHILD*] ever taken ARVs, that is, 
antiretroviral medications to treat his/her 
HIV infection? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
YES → 527 
DK, REFUSED → 531 
 
ELECTRONIC AID IF 
DON’T KNOW 
526 What is the main reason [CHILD*] has 
never taken ARVs? 
 
CHILD IS NOT ELIGIBLE FOR 
TREATMENT=1 
HEALTH CARE PROVIDER DID NOT 
PRESCRIBE = 2 
HIV MEDICINES NOT AVAILABLE = 
3 
DO NOT THINK CHILD NEEDS IT, 
HE/SHE IS NOT SICK = 4 
COST OF MEDICATIONS = 5 
COST OF TRANSPORT = 6 
RELIGIOUS REASONS = 7 
CHILD IS TAKING TRADITIONAL 
MEDICATIONS = 8 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→SKIP TO 531 
 
ADAPT RESPONSES 
BASED ON COUNTRY 
CONTEXT. 
527 What month and year did [CHILD*] first 
start taking ARVs? 
PROBE TO VERIFY DATE. 
MONTH = ____ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
YEAR = ____ 
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
528 Is [CHILD*] currently taking ARVs, that is, 
antiretroviral medications? 
 
By currently, I mean that [CHILD*] may 
have missed some doses but [CHILD* is 
still taking ARVs. 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES → 530 
DK, REFUSED → 531 
 
  
  
 
196 
NO QUESTIONS CODING CATEGORIES SKIPS 
529 Can you tell me the main reason why 
[CHILD*] is not currently taking ARVs? 
 
I HAVE TROUBLE GIVING CHILD A 
TABLET EVERYDAY = 1 
CHILD HAD SIDE EFFECTS/RASH = 2 
FACILITY/PHARMACY TOO FAR 
AWAY TO GET MEDICATION 
REGULARLY = 3 
COST OF MEDICATIONS = 4 
COST OF TRANSPORT = 5 
 CHILD IS HEALTHY/HE/SHE IS NOT 
SICK = 6 
FACILITY WAS OUT OF  
STOCK = 7 
RELIGIOUS REASONS= 8 
CHILD IS TAKING TRADITIONAL 
MEDICATIONS = 9 
OTHER =96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL →531 
 
ADAPT RESPONSES 
BASED ON COUNTRY 
CONTEXT. 
530 People sometimes forget to take all their 
ARVs every day. In the last 30 days, how 
many days has [CHILD*] missed taking 
any ARV pills? 
CODE ‘00’ IF NONE. 
DAYS ___ ___ 
DON’T KNOW = -8 
REFUSED = -9 
 
531 Is [CHILD*] currently taking Septrin, 
Dapsone or cotrimoxazole?  
 
Septrin, Dapsone or cotrimoxazole is a 
medicine recommended for people with 
HIV, even if they have not started 
treatment for HIV.  It helps prevent 
certain infections but it is not treatment 
for HIV. 
 
By currently, I mean that [ CHILD*] may 
have missed some doses but is still taking 
Septrin, Dapsone or cotrimoxazole. 
YES = 1 
NO = 2 
I DON’T KNOW WHAT IT IS = 3 
REFUSED = -9 
ADAPT TERM 
‘SEPTRIN’ BASED ON 
COUNTRY CONTEXT. 
 
ELECTRONIC AID IF 
DON’T KNOW 
 
532 Has [CHILD*] ever visited a clinic for 
tuberculosis for TB diagnosis or 
treatment? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
533 Have you ever been told by a doctor, 
clinical officer or nurse that [CHILD*] had 
TB? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
 
ADAPT TERMS FOR 
HEALTHCARE 
PROVIDER TO 
COUNTRY CONTEXT. 
534 Was [CHILD*] ever treated for TB? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
  
  
 
197 
NO QUESTIONS CODING CATEGORIES SKIPS 
535 Is [CHILD*] currently on treatment for TB? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
537 
536 The last time [CHILD*] was treated for TB, 
did [CHILD*] complete at least 6 months 
of treatment?  
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
537 Thank you for the information about 
[CHILD*].   
 
DOES THE RESPONDENT HAVE ANOTHER 
CHILD AGED 0-14 YEARS? 
YES = 1 
NO = 2 
YES→RETURN TO 
START OF MODULE 5 
 
MODULE 6: MALE CIRCUMCISION 
Interviewer says: “I will be asking a few questions about circumcision.  Circumcision is the 
removal of the foreskin from the penis.  If you feel comfortable, I can show you a picture of 
circumcised penis.” 
ELECTRONIC AID IF 
REQUESTED. 
 
IF FEMALE → 609 
601 Some men are uncomfortable talking 
about circumcision but it is important for 
us to have this information.   Some men 
are circumcised. Are you circumcised? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED=9 
YES→604 
NO → 606 
DK, REF → 609  
 
602 If so, were you medically circumcised, 
traditionally circumcised, or both? 
 
By medically, we mean that your 
circumcision was done at the hospital or 
clinic, while traditional circumcision is 
done by a traditional doctor at the 
initiation school. 
MEDICAL = 1 
TRADITION = 2 
BOTH = 3 
DON’T KNOW = -8 
REFUSED = -9 
DK, REF → 609 
603 Are you completely or partially 
circumcised? 
 
In partial circumcision, a small part of the 
foreskin is removed from the penis while 
in complete circumcision, the entire 
foreskin is removed. 
 
If you allow me, I can show you a picture 
that shows a partially and a completely 
circumcised penis. 
COMPLETELY = 1 
PARTIALLY = 2 
DON’T KNOW = -8 
REFUSED = -9 
DK, REF → 609 
604 How old were you when you were 
medically circumcised?  Please give your 
best guess. 
 
How old were you when you were 
traditionally circumcised?  Please give 
your best guess. 
 
IF LESS THAN ONE YEAR, CODE ‘00’. 
MEDICAL: 
COMPLETED AGE IN YEARS _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
TRADITIONAL: 
COMPLETED AGE IN YEARS _____ 
DON’T KNOW = -8 
REFUSED= -9 
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605 Who did the circumcision? DOCTOR, CLINICAL OFFICER, OR 
NURSE = 1 
RELIGIOUS LEADER = 2 
TRADITIONAL PRACTITIONER, 
CIRCUMCISER/INITIATION 
SCHOOL PERSONNEL = 3 
MIDWIFE = 4 
FAMILY MEMBER/RELATIVE = 5 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
606 Are you planning to get circumcised? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED= -9 
YES → 607  
NO → 608 
DK, REF → 609 
607 What type of circumcision are you 
planning to get? 
MEDICAL = 1 
TRADITIONAL = 2 
DON’T KNOW = -8 
REFUSED = -9 
ALL → 609 
608 Why are you not planning to get 
circumcised? 
DON'T KNOW WHERE TO GET 
CIRCUMCISED = A 
HAD TO TRAVEL TOO FAR TO GET 
CIRCUMCISED = B 
AFRAID TO GET CIRCUMCISED = C 
DO NOT HAVE A REASON TO GET 
CIRCUMCISED = D 
RELIGIOUS REASONS = E 
NO REASON = F 
OTHER = X 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
 
609 Does male circumcision alone reduce the 
risk, or chance, of a man getting HIV 
completely, somewhat or not at all? 
PROTECTS COMPLETELY = 1 
PROTECTS SOMEWHAT = 2 
NOT AT ALL = 3 
DON’T KNOW = 4 
REFUSED = -9 
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MODULE 7: SEXUAL ACTIVITY 
Interviewer says: “In this part of the interview, I will be asking questions about your sexual relationships and practices.  
These questions will help us have a better understanding of how they may affect your life and risk for HIV.  
 
Let me assure you again that your answers are completely confidential and will not be shared with anyone.  If there are 
questions that you do not want to answer, we can go to the next question.”  
701 How old were you when you had vaginal 
sex for the very first time? 
 
Vaginal sex is when a penis enters a 
vagina. 
 
IF UNSURE, ASK THEM TO MAKE A BEST 
GUESS USING OTHER EVENTS IN THEIR 
LIFE THAT HAPPENED AROUND THE SAME 
TIME. 
 
IF THE PARTICIPANT HAS NEVER HAD SEX, 
REFUSES, OR DOES NOT KNOW, SWIPE 
THROUGH WITHOUT ENTERING ANY 
RESPONSE. YOU WILL BE ABLE TO 
RECORD THESE RESPONSES ON THE 
SCREEN THAT FOLLOWS. 
AGE IN YEARS _ _ 
NEVER HAD VAGINAL SEX = 96 
DON’T KNOW = -8 
REFUSED = -9 
IF NEVER HAD 
VAGINAL SEX → SKIP 
TO 704 
702 The first time you had vaginal sex was a 
condom used? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
703 The first time you had vaginal sex, was it 
because you wanted to or because you 
were forced? 
WANTED TO = 1 
FORCED = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
704 People have sex in different ways.  Some 
have vaginal sex.  Some have anal sex.  
Anal sex is when a penis enters a person’s 
anus.  Have you ever had anal sex? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED  
 
NEVER ANAL SEX __> 
708 
 
NEVER VAGINAL OR 
ANAL SEX__> NEXT 
MODULE 
705 How old were you when you had anal sex 
for the very first time? 
 
AGE IN YEARS _ _ 
DON’T KNOW = -8 
REFUSED = -9 
 
706 The first time you had anal sex was a 
condom used? 
YES = 1  
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
707 The first time you had anal sex, was it 
because you wanted to or because you 
were forced? 
WANTED TO = 1 
FORCED = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
708 How old was the person you first had 
vaginal or anal sex with? Please give your 
best guess. 
AGE IN YEARS _____ 
DON’T KNOW = -8 
REFUSED = -9 
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709 People often have sex with different 
people over their lifetime.  In total, with 
how many different people have you had 
vaginal or anal sex in your lifetime?  
Please give your best guess. 
 
IF NUMBER OF PARTNERS IS  
GREATER THAN 100, WRITE ' 100'. 
NUMBER OF SEXUAL PARTNERS IN 
LIFETIME ____ 
 
DON’T KNOW = -8 
REFUSED = -9 
 
710 People often have sex with different 
partners over their lifetime. In total, with 
how many different people have you had 
vaginal or anal sex in the last 12 months? 
 
IF NONE CODE ‘00’. 
 
IF NUMBER OF PARTNERS IS  
GREATER THAN 100, WRITE ' 100'. 
NUMBER OF SEXUAL PARTNERS IN 
LAST 12 MONTHS ______ 
 
DON’T KNOW = -8 
REFUSED = -9 
IF 00 PARTNERS IN 
LAST 12 MONTHS → 
SKIP TO 728 
711 Does [INITIALS] live in this household? YES = 1 
NO = 2 
NO→713 
 
712 DO NOT READ: HOUSEHOLD LINE NO. for 
[INITIALS] 
CODE ‘0’ IF NOT LISTED IN HOUSEHOLD 
ROSTER. 
[LIST OF PERSONS FROM 
HOUSEHOLD] 
NOT LISTED IN HOUSEHOLD = 96 
LISTED → 714 
713 I would like to ask you for the initials of 
this person so I can keep track.  They do 
not have to be the actual initials of this 
person. 
INITIALS 
 
____ ____ 
 
714 What is your relationship with (INITIALS)? 
 
HUSBAND/WIFE = 1 
LIVE-IN PARTNER = 2 
PARTNER, NOT LIVING WITH 
RESPONDENT = 3 
EX-SPOUSE/EX-PARTNER = 4 
FRIEND/ACQUAINTANCE = 5 
SEX WORKER = 6 
SEX WORKER CLIENT =7 
STRANGER = 8 
OTHER = 96 
SPECIFY: ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
715 Is (INITIALS) male or female? MALE = 1 
FEMALE = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
716 How old is (INITIALS)? Please give your 
best guess. 
 
AGE IN YEARS ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
717 The last time you had sex with (INITIALS) 
was a condom used? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
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NO QUESTIONS CODING CATEGORIES SKIPS 
718 Did you enter into a sexual relationship 
with (INITIALS) because (INITIALS) 
provided you with or you expected that 
(INITIALS) would provide you gifts, help 
you to pay for things, or help you in other 
ways? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
720 
 
SKIP IF SEX WORKER 
OR CLIENT 
719 In the last 12 months, what have you 
received from (INITIALS)?  
 
READ RESPONSES ALOUD.  
 
SELECT ALL THAT APPLY. 
 
DID NOT RECEIVE ANYTHING = A 
MONEY = B 
FOOD = C 
SCHOOL FEES = D 
EMPLOYMENT = E 
GIFTS/FAVORS = F 
TRANSPORT = G 
SHELTER/RENT = H 
PROTECTION = I 
OTHER = X 
SPECIFY: ______ 
DON’T KNOW = Y 
REFUSED = Z 
SKIP IF SPOUSE, LIVE-
IN PARTNER, SEX 
WORKER OR CLIENT 
720 Do you expect to have sex with (INITIALS) 
again? 
YES =1 
NO =2 
DON’T KNOW = -8 
REFUSED = -9 
 
721 Does (INITIALS) know your HIV status? 
HIV status could mean you are HIV 
negative or HIV positive. 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
722 What is the HIV status of (INITIALS)?  
 
READ RESPONSES ALOUD 
 
I THINK (INITIALS) IS POSITIVE = 1 
(INTIALS) TOLD ME HE/SHE IS 
POSITIVE = 2 
(INITIALS) IS POSITIVE, TESTED 
TOGETHER = 3 
I THINK (INITIALS) IS NEGATIVE = 4 
(INITIALS) TOLD ME HE/SHE IS 
NEGATIVE = 5 
(INITIALS) IS NEGATIVE, TESTED 
TOGETHER=6 
DON’T KNOW STATUS = 7 
REFUSED = -9 
 
723 How long has it been since you last had 
sex with (INITIALS)? 
 
DO NOT READ: IF LESS THAN ONE WEEK 
RECORD IN DAYS, IF LESS THAN ONE 
MONTH, RECORD IN WEEKS, OTHERWISE 
RECORD IN MONTHS. 
DAYS _ _ 
WEEKS _ _ 
MONTHS _ _ 
DON’T KNOW = -8 
REFUSED = -9 
 
724 How long has it been since you first had 
sex with (INITIALS)? 
 
DO NOT READ: IF LESS THAN ONE WEEK 
RECORD IN DAYS, IF LESS THAN ONE 
MONTH, RECORD IN WEEKS.  IF LESS 
THAN ONE YEAR, RECORD, IN MONTHS, 
OTHERWISE RECORD IN YEARS. 
DAYS _ _ 
WEEKS _ _ 
MONTHS _ _ 
YEARS _ _ 
DON’T KNOW = -8 
REFUSED = -9 
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725 In the last 4 weeks, what is the total 
number of times you had sex with 
(INITIALS)? By “times” we mean number 
of sex acts.  For example, you could have 
sex 5 times with the same partner.  
 
CODE ‘00’ IF NONE. 
NUMBER OF TIMES ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
726 In the last 12 months, how often did you 
use condoms with (INITIALS) when having 
vaginal sex?  Was it always, most of the 
time, sometimes, rarely or never? 
ALWAYS = 1 
MOST OF THE TIME = 2 
SOMETIMES = 3 
RARELY = 4 
NEVER = 5 
NO VAGINAL SEX IN THE LAST 12 
MONTHS = 3 
DON’T KNOW = -8 
REFUSED = -9 
 
SKIP IF NEVER HAD VAGINAL SEX. 
 
727 DOES THE RESPONDENT HAVE ANOTHER 
PARTNER IN THE LAST 12 MONTHS? 
 
I will now ask you about the person you 
have had sex with previous to (initials). 
YES = 1 
NO = 2 
YES → 711 
728 Have you ever had sex for money and/or 
gifts? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
731 
729 In the last 12 months, have you had sex 
for money and/or gifts? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
731 
 
730 The last time you had sex for money 
and/or gifts, was a condom used? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
731 Have you ever paid money or given gifts 
for sex? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED →  
 
ENDOFMODULE 
732 In the last 12 months, have you paid 
money or given gifts for sex? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
 
ENDOFMODULE 
729 The last time you paid money or gave 
gifts for sex, was a condom used? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
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MODULE 8: HIV KNOWLEDGE 
Interviewer says: “Now I will ask you questions on your knowledge of HIV.” SELECT A SUBSET (I.E. 
HALF) OF 
PARTICIPANTS 
801 Can the risk of HIV transmission be 
reduced by having sex with only one 
uninfected partner who has no other 
partners? 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
802 Can a person get HIV from mosquito 
bites? 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
803 Can a person reduce their risk of getting 
HIV by using a condom every time they 
have sex? 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
804 Can a person get HIV by sharing food with 
someone who has HIV? 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
805 Can a healthy-looking person have HIV? YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
806 Would you buy fresh vegetables from a 
shop keeper or vendor if you knew the 
person had HIV? 
YES = 1 
NO = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
807 Do you think children living with HIV 
should be allowed to attend school with 
children who do not have HIV? 
YES = 1 
NO = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
808 Do you think people hesitate to take an 
HIV test because they are afraid of how 
other people will react if the test result is 
positive for HIV? 
YES = 1 
NO = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
809 Do people talk badly about people who 
are living with HIV, or who are thought to 
be living with HIV? 
YES = 1 
NO = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
810 Do people living with HIV, or thought to 
be living with HIV, lose the respect of 
other people? 
YES = 1 
NO = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
811 Do you fear that you could get HIV if you 
come into contact with the saliva of a 
person living with HIV? 
YES = 1 
NO =2 
ALREADY HAS HIV = 3 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
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812 Do you agree or disagree with the 
following statement: I would be ashamed 
if someone in my family had HIV. 
AGREE = 1 
DISAGREE = 2 
DON’T KNOW/NOT 
SURE/DEPENDS = -8 
REFUSED = -9 
 
 
MODULE 9: HIV TESTING 
Interviewer says: “I would now like to ask you some questions about HIV testing.” 
901 Have you ever tested for HIV? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
YES →  
903 
DK, REFUSED→SKIP 
TO END OF MODULE 
 
CONSTRAINT IF 
REPORTED TESTING 
902 Why have you never been tested for HIV? 
 
SELECT ALL THAT APPLY. 
READ ALL RESPONSE CATEGORIES 
DON'T KNOW WHERE TO TEST = A 
TEST COSTS TOO MUCH = B 
TRANSPORT COSTS TOO MUCH = C 
TOO FAR AWAY = D 
AFRAID OTHERS WILL KNOW 
ABOUT TEST RESULTS = E 
DON'T NEED TEST/LOW RISK = F 
DID NOT RECEIVE PERMISSION 
FROM SPOUSE/FAMILY = G 
AFRAID SPOUSE/PARTNER/FAMILY 
WILL KNOW RESULTS = H 
DON’T WANT TO KNOW I HAVE 
HIV = I 
CANNOT GET TREATMENT FOR HIV 
= J 
TEST KITS NOT AVAILABLE = K 
RELIGIOUS REASONS = L 
OTHER = X 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
 
903 In your lifetime, how many times have 
you been tested for HIV? 
 
NUMBER OF TIMES TESTED FOR 
HIV __ __ 
 
DON’T KNOW = -8 
REFUSED = -9 
CONSTRAINT SHOULD 
BE >=1 
904 What month and year was your last HIV 
test? 
CALENDER MONTH _____ _____ 
DON’T KNOW MONTH= -8 
REFUSED MONTH= -9 
 
CALENDER YEAR ____ 
DON’T KNOW YEAR = -8 
REFUSED YEAR= -9 
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905 Where was your last test done? VCT FACILITY = 1 
MOBILE VCT = 2 
AT HOME = 3 
HEALTH CLINIC/FACILITY = 4 
HOSPITAL OUTPATIENT CLINIC = 5 
TB CLINIC = 6 
STI CLINIC = 7 
HOSPITAL INPATIENT WARDS = 8 
BLOOD DONATING CENTER = 9 
ANC CLINIC = 10 
OTHER = 96 
SPECIFY: _____________________ 
DON’T KNOW = -8 
REFUSED = -9 
 
906 What was the result of that HIV test? 
 
POSITIVE = 1 
NEGATIVE = 2 
UNCERTAIN/INDETERMINATE = 3 
DID NOT RECEIVE THE RESULT = 4 
DON’T KNOW = -8 
REFUSED = -9 
NEG, 
UNCERTAIN/IND, NO 
RESULT, DK, 
REF→SKIP TO END OF 
MODULE 
 
907 What was the month and year of your 
first HIV-positive test result? Please give 
your best guess. 
 
This will be the very first HIV-positive test 
result that you have received. 
 
DO NOT READ; PROBE TO VERIFY DATE. 
CALENDER MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
CALENDER YEAR ___ ___ ___ ____  
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
908 Of the following people, to whom have 
you told that you are HIV positive?   
 
CHECK ALL THAT APPLY. READ ALL 
RESPONSE CATEGORIES ALOUD. 
NO ONE = A 
SPOUSE/SEX PARTNER = B 
DOCTOR = C 
FRIEND = D 
FAMILY MEMBER = E 
OTHER = X 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
SKIP TO NEXT 
QUESTION IF NO ONE, 
DK OR REFUSED. 
   SKIP TO END OF 
MODULE IF NOT HIV 
POSITIVE. 
 
909 In the last 12 months, when you sought 
health care in a facility where your HIV 
status is not known, did you feel you 
needed to hide your HIV status? 
 
YES = 1 
NO, NO NEED TO HIDE = 2 
NO, DID NOT ATTEND HEALTH 
FACILITY IN LAST 12 MONTHS =3 
DON’T KNOW = -8 
REFUSED = -9 
NO, DID NOT ATTEND 
HEALTH 
FACILITY→SKIP TO 
NEXT MODULE 
910 In the last 12 months, have you been 
denied health services including dental 
care, because of your HIV status? 
 
YES = 1 
NO = 2 
NO ONE KNOWS MY STATUS = 3 
DON’T KNOW = -8 
REFUSED = -9 
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MODULE 10: HIV STATUS, CARE AND TREATMENT 
Interviewer says: “Now I’m going to ask you more about your experience with HIV support, care 
and treatment.” 
SKIP TO NEXT 
MODULE IF NOT HIV 
POSITIVE 
1001 After learning you had HIV, have you ever 
received HIV medical care from a doctor, 
clinical officer or nurse? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES → 1003 
DK, REFUSED → SKIP 
TO END OF MODULE 
 
ADAPT HEALTHCARE 
PROVIDER TERMS TO 
LOCAL CONTEXT. 
1002 What is the main reason why you have 
never received HIV medical care from a 
doctor, clinical officer, or nurse? 
 
FACILITY IS TOO FAR AWAY = 1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE = 2 
COST OF CARE = 3 
COST OF TRANSPORT = 4 
I DO NOT NEED IT/I FEEL 
HEALTHY/NOT SICK = 5 
I FEAR PEOPLE WILL KNOW THAT I 
HAVE HIV IF I GO TO A CLINIC = 6 
RELIGIOUS REASONS = 7 
I’M TAKING TRADITIONAL 
MEDICINE= 8 
DO NOT TRUST THE 
STAFF/QUALITY OF CARE = 9 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP TO 1006 
1003 What month and year did you first see a 
doctor, clinical officer or nurse for HIV 
medical care? 
 
DO NOT READ; PROBE TO VERIFY DATE. 
CALENDER MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
CALENDER YEAR ___ ___ ___  
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
1004 What month and year did you last see a 
doctor, clinical officer or nurse for HIV 
medical care? 
CALENDER MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH= -9 
 
CALENDER YEAR ___ ___ ___  
DON’T KNOW YEAR = -8 
REFUSED = -9 
IF <7 MONTHS, DK, 
REFUSED → 1006 
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1005 What is the main reason for not seeing a 
doctor, clinical officer or nurse for HIV 
medical care for more than 6 months? 
 
THE FACILITY IS TOO FAR AWAY = 
1 
I DON’T KNOW WHERE TO GET HIV 
MEDICAL CARE = 2 
COST OF CARE = 3 
COST OF TRANSPORT = 4 
I DO NOT NEED IT/I FEEL 
HEALTHY/NOT SICK = 5 
I FEAR PEOPLE WILL KNOW THAT I 
HAVE HIV IF I GO TO A CLINIC = 6 
I’M TAKING TRADITIONAL 
MEDICINE = 7 
RELIGIOUS REASONS = 8 
NO APPOINTMENT 
SCHEDULED/DID NOT MISS MOST 
RECENT APPOINTMENT = 9 
OTHER = 96  
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ADAPT TIME BASED 
ON COUNTRY LOST-
TO-FOLLOW-UP FOR 
PRE-ART HIV CARE. 
1006 Have you ever had a CD4 count test?  
 
The CD4 count tells you how sick you are 
with HIV and if you need to take ARVs or 
other HIV medications. 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
1008 
 
NO, DK, REFUSED & 
NEVER IN HIV CARE → 
SKIP TO END OF 
MODULE 
1007 What month and year were you last 
tested for your CD4 count? 
CALENDAR MONTH ___ ___ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
CALENDAR YEAR ___ ___ ___  
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
1008 Have you ever taken ARVs, that is, 
antiretroviral medications to treat HIV 
infection? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
YES→ 1010 
 
DK, REFUSED → SKIP 
TO END OF MODULE 
1009 What is the main reason you have never 
taken ARVs? 
NOT ELIGIBLE FOR TREATMENT=1 
HEALTH CARE PROVIDER DID NOT 
PRESCRIBE = 2 
HIV MEDICINES NOT AVAILABLE = 
3 
I FEEL HEALTHY/NOT SICK = 3 
COST OF MEDICATIONS = 4 
COST OF TRANSPORT = 5 
RELIGIOUS REASONS = 6 
TAKING TRADITIONAL 
MEDICATIONS = 7 
NOT ATTENDING HIV CLINIC = 8 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→SKIP TO END OF 
MODULE 
 
ADAPT RESPONSES 
BASED ON COUNTRY 
CONTEXT. 
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1010 What month and year did you first start 
taking ARVs? 
 
DO NOT READ; PROBE TO VERIFY DATE. 
 
CALENDER MONTH _____ 
DON’T KNOW MONTH = -8 
REFUSED MONTH = -9 
 
CALENDER YEAR _____ 
DON’T KNOW YEAR = -8 
REFUSED YEAR = -9 
 
1011 Are you currently taking ARVs, that is, 
antiretroviral medications? 
 
By currently, I mean that you may have 
missed some doses but you are still taking 
ARVs. 
YES = 1 
NO=2 
DON’T KNOW = -8 
REFUSED = -9 
YES→1013  
DK, REFUSED → SKIP 
TO END OF MODULE 
1012 Can you tell me the main reason why you 
are not currently taking ARVs? 
I HAVE TROUBLE TAKING A TABLET 
EVERYDAY = 1 
I HAD SIDE EFFECTS = 2 
FACILITY TOO FAR AWAY FOR ME 
TO GET MEDICINE REGULARLY = 3 
COST OF MEDICATIONS = 4 
COST OF TRANSPORT = 5 
I FEEL HEALTHY/NOT SICK =6 
FACILITY WAS OUT OF STOCK = 7 
RELIGIOUS REASONS = 8 
TAKING TRADITIONAL 
MEDICATIONS = 9 
OTHER = 96 
SPECIFY: ____________________   
DON’T KNOW = -8 
REFUSED = -9 
ALL → SKIP TO END 
OF MODULE 
 
ADAPT RESPONSES 
BASED ON COUNTRY 
CONTEXT. 
 
 
1013 People sometimes forget to take all of 
their ARVs every day. In the last 30 days, 
how many days have you missed taking 
any of your ARV pills? 
 
DO NOT READ; CODE ‘00’ IF NONE. 
NUMBER OF DAYS ______ 
DON’T KNOW = -8 
REFUSED = -9 
 
 
 
MODULE 11: TUBERCULOSIS AND OTHER HEALTH ISSUES 
Interviewer says: “Now we will ask you about tuberculosis or TB.” 
1101 Have you ever visited a clinic for TB 
diagnosis or treatment? 
YES = 1 
NO=2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
 
1102 Have you ever been told by a doctor, 
clinical officer or nurse that you had TB? 
YES = 1 
NO=2 
DON’T KNOW = -8 
REFUSED = -9 
 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
 
ADAPT TERMS FOR 
HEALTHCARE 
PROVIDER TO 
COUNTRY CONTEXT. 
1103 Were you ever treated for TB? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
SKIP TO END OF 
MODULE 
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NO QUESTIONS CODING CATEGORIES SKIPS 
1104 Are you currently on treatment for TB? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
YES →SKIP TO END OF 
MODULE 
1105 The last time you were treated for TB, did 
you complete at least 6 months of 
treatment?  
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
 
MODULE 12: GENDER NORMS 
Interviewer says: “Now I would like to ask you questions on attitudes and decision-making in your home.” 
1201 Who usually makes decisions about 
health care for yourself: you, your 
(spouse/partner), you and your 
(spouse/partner) together, or someone 
else? 
I DO = 1 
SPOUSE/PARTNER = 2 
WE BOTH DO = 3 
SOMEONE ELSE = 4 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF NOT 
MARRIED/LIVING 
TOGETHER 
1202 Who generally decides about how the 
money you receive is spent? 
 
READ ANSWER CHOICES ALOUD. 
I DO = 1 
SPOUSE/PARTNER = 2 
WE BOTH DO = 3 
SOMEONE ELSE = 4 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF NOT 
MARRIED/LIVING 
TOGETHER 
1203 Who usually makes decisions about 
making major household purchases: you, 
your (spouse/partner), you and your 
(spouse/partner) together or someone 
else? 
I DO = 1 
SPOUSE/PARTNER = 2 
WE BOTH DO = 3 
SOMEONE ELSE = 4 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF NOT 
MARRIED/LIVING 
TOGETHER 
1204 Do you believe it is right for a man to hit 
or beat his wife if she goes out without 
telling him? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
1205 Do you believe a person should tolerate 
violence from a spouse/partner to keep 
the family together? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
1206 Who should decide when to have sex—
only the man, only the woman, or the 
man and woman together? 
 
MEN ONLY = 1 
WOMEN ONLY = 2 
TOGETHER = 3 
DON’T KNOW = -8 
REFUSED = -9 
 
1207 Do you believe women who carry 
condoms have sex with a lot of men? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
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NO QUESTIONS CODING CATEGORIES SKIPS 
MODULE 13: VIOLENCE 
Interviewer says: “You have been selected to be asked questions on other important aspects of a 
person’s life.  I know that some of these questions are very personal.  However, your answers are 
important for helping to understand the condition of men and women in Lesotho.  You will be 
the only person in your household who is asked these questions.  Let me assure you that your 
answers are completely confidential and will not be told to anyone and no one in your household 
will know that you were asked these questions. 
 
By sex, I mean vaginal, anal, oral sex or the insertion of an object into your vagina or anus.  
Vaginal sex is when a penis enters a vagina.  Anal sex is when a penis enters an anus (butt).  Oral 
sex is when a partner puts his/her mouth on his/her partner’s penis or vagina.” 
SELECT ONLY 1 
PERSON PER 
HOUSEHOLD. 
 
SHOULD ALWAYS BE 
LAST MODULE IN 
QUESTIONNAIRE 
1301 How many times in your life has someone 
pressured you to have sex through 
harassment, threats and tricks and did 
succeed?   
 
Being pressured can include being worn 
down by someone who repeatedly asks 
for sex, feeling pressured by being lied to, 
being told promises that were untrue, 
having someone threaten to end a 
relationship or spread rumors or sexual 
pressure due to someone using their 
influence or authority.  
 
CODE ‘00’ IF NONE. 
NUMBER OF TIMES____ 
DON’T KNOW = -8 
REFUSED = -9 
NONE, DK, 
REFUSED→ END OF 
MODULE 
1302 How old were you the first time someone 
pressured you to have sex and did 
succeed? 
AGE IN YEARS ____ 
DON’T KNOW = -8 
REFUSED = -9 
 
1303 In the last 12 months, did someone 
pressure you to have sex and did 
succeed? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
1305 
1304 What was this person’s relationship to 
you? If it was more than one person, 
what was your relationship with the 
person you knew the best? 
BOYFRIEND/GIRLFRIEND/LIVE-IN 
PARTNER/SPOUSE = 1 
EX-
BOYFRIEND/GIRLFRIEND/PARTNE
R/SPOUSE = 2 
RELATIVE/FAMILY MEMBER = 3 
CLASSMATE/SCHOOLMATE = 4 
TEACHER = 5 
POLICE/SECURITY 
OFFICER/MILITARY= 6 
EMPLOYER = 7 
NEIGHBOR = 8 
COMMUNITY/  
RELIGIOUS LEADER = 9 
FRIEND = 10 
STRANGER = 11 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF ONLY 
HAPPENED ONCE. 
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NO QUESTIONS CODING CATEGORIES SKIPS 
1305 How many times in your life have you 
been physically forced to have sex? 
 
CODE ‘00’ IF NONE. 
NUMBER OF TIMES ____ 
DON’T KNOW = -8 
REFUSED = -9 
NONE, DK, 
REFUSED→ 
1307 
1306 How old were you the first time someone 
physically forced you to have sex? 
AGE IN YEARS _____ 
DON’T KNOW = -8 
REFUSED = -9 
 
1307 In the last 12 months, did someone 
physically force you to have sex? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
NO, DK, REFUSED → 
1309 
1308 What was this person’s relationship to 
you? If it was more than one person, 
what was the relationship with the 
person you knew the best? 
BOYFRIEND/GIRLFRIEND/LIVE-IN 
PARTNER/SPOUSE = 1 
EX-
BOYFRIEND/GIRLFRIEND/PARTNE
R/SPOUSE = 2 
RELATIVE/FAMILY MEMBER = 3 
CLASSMATE/SCHOOLMATE = 4 
TEACHER = 5 
POLICE/SECURITY 
OFFICER/MILITARY= 6 
EMPLOYER = 7 
NEIGHBOR = 8 
COMMUNITY/  
RELIGIOUS LEADER = 9 
FRIEND = 10 
STRANGER = 11 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF ONLY 
HAPPENED ONCE. 
1309 In the last 12 months, did a partner 
physically force you to have sex? 
 
By partner, I mean a live-in partner 
whether or not you were married at the 
time.   
YES =1  
NO, DID NOT FORCE = 2 
NO, DID NOT HAVE A LIVE-IN 
PARTNER IN THE LAST 12 
MONTHS = 3 
DON’T KNOW = -8 
REFUSED = -9 
 
1310 After any of these unwanted sexual 
experiences, did you try to seek 
professional help or services from any of 
the following? 
 
SELECT ALL THAT APPLY. 
I DID NOT TRY TO SEEK HELP = A 
HEALTHCARE PROFESSIONAL = B  
POLICE OR OTHER SECURITY 
PERSONNEL = C 
SOCIAL WORKER, COUNSELOR OR 
NON-GOVERNMENTAL 
ORGANIZATION = D 
RELIGIOUS LEADER = E  
OTHER = X 
SPECIFY: ____________________ 
DON’T KNOW = Y 
REFUSED = Z 
DID NOT TRY TO SEEK 
HELP → END OF 
MODULE 
 
SKIP IF NEVER 
EXPERIENCED SEXUAL 
VIOLENCE. 
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NO QUESTIONS CODING CATEGORIES SKIPS 
1311 What was the main reason that you did 
not try to seek professional help or 
services? 
 
DID NOT KNOW SERVICES WERE 
AVAILABLE = 1 
SERVICES NOT AVAILABLE = 2 
AFRAID OF GETTING IN TROUBLE 
= 3 
ASHAMED FOR SELF/FAMILY = 4 
COULD NOT AFFORD SERVICES = 5 
DID NOT THINK IT WAS A 
PROBLEM = 6 
FELT IT WAS MY FAULT = 7 
AFRAID OF BEING ABANDONED = 
8 
DID NOT NEED/WANT SERVICES = 
9 
AFRAID OF MAKING SITUATION 
WORSE = 10 
OTHER = 96 
SPECIFY: ____________________ 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF NEVER 
EXPERIENCED SEXUAL 
VIOLENCE. 
 Thank you for sharing your personal 
experiences with me. I know it may have 
been difficult for you to talk about your 
experiences with me. If you would like to 
talk further about these experiences, I 
can refer you to a place that can provide 
you with help.  
 
PROVIDE PARTICIPANT WITH LIST OF 
ORGANIZATIONS. 
 SKIP IF NEVER 
EXPERIENCED SEXUAL 
OR PHYSICAL 
VIOLENCE. 
 You mentioned earlier that you have sold 
sex for money.  Thank you for sharing 
your personal experiences with me.  If 
you want to talk further about these 
experiences, I can refer you to a place 
that can provide you with help. 
 
FILL OUT REFERRAL FORM FOR CHILDREN 
IDENTIFIED AS TRAFFICKED MINORS.  FILL 
OUT SUMMARY OF REFERRED 
TRAFFICKED MINORS. PROVIDE 
PARTICIPANT WITH LIST OF 
ORGANIZATIONS, IF NOT ALREADY GIVEN. 
 SKIP IF >18 YEARS OLD 
 
SKIP IF NEVER SOLD 
SEX 
 
 
  
  
 
213 
Appendix G    Young Adolescent Questionnaire 
THIS QUESTIONNAIRE IS ADMINISTERED TO ELIGIBLE YOUNG ADOLESCENTS AGED BETWEEN 10-14 YEARS AFTER INFORMED 
PARENTAL/GUARDIAN CONSENT AND MINOR ASSENT.  
 
NO QUESTIONS CODING CATEGORIES SKIPS 
MODULE 1: SOCIO-DEMOGRAPHIC CHARACTERISTICS 
101 
  
IS THE RESPONDENT MALE OR 
FEMALE? 
MALE =1 
FEMALE =2  
  
  
102 How old were you at your last 
birthday? 
  
AGE IN COMPLETED YEARS=integer 
DON’T KNOW AGE =-8 
REFUSED =-9  
  
  
103 
  
  
  
Are you enrolled in school? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9  
IF NO, DK, 
REFUSED→109 
104 
  
   
During the last school week, did you 
miss any school days for any reason? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9  
NO, DK, REFUSED 
→107 
105 
  
  
  
  
Why did you miss school? 
  
I HAVE BEEN SICK=1 
I DON'T FEEL SAFE TRAVELING TO 
SCHOOL=2 
I DON'T FEEL SAFE WHILE IN SCHOOL=3 
I DON'T LIKE SCHOOL=4 
I HAVE TO LOOK AFTER MY FAMILY=5 
THERE'S NOT ENOUGH MONEY TO SEND ME 
TO SCHOOL =6 
SCHOOL IS TOO FAR AWAY=7 
I HAVE TO WORK=8 
I HAVE A CHILD OR I AM PREGNANT =9 
I MISSED TOO MUCH SCHOOL BECAUSE OF 
MY PERIOD (MENSTRUATION) =10 
OTHER (SPECIFY)=96 
DON'T KNOW=-8 
REFUSED =-9  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
106 
  
  
  
  
What is the highest level of school 
you attended: primary or secondary? 
  
PRIMARY = 1 
SECONDARY = 2 
DON’T KNOW = -8 
REFUSED = -9 
  
  
107 
  
  
What standard/form/year are you in 
now?  
STANDARD/FORM/YEAR ____ 
DON’T KNOW = -8 
REFUSED = -9  
 
NO QUESTIONS CODING CATEGORIES SKIPS 
108 
  
   
What standard/form/year were you 
in last year? 
  
STANDARD/FORM/YEAR ____ 
DON’T KNOW = -8 
REFUSED = -9 
ALL→MODULE 2, HIV 
PREVENTION 
INTERVENTIONS   
APPENDIX G YOUNG ADOLESCENT QUESTIONNAIRE 
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109 
  
  
  
Why do you NOT go to school? 
  
I HAVE BEEN SICK = 1 
I DON’T FEEL SAFE TRAVELING TO SCHOOL = 
2 
I DON’T FEEL SAFE WHILE IN SCHOOL = 3 
I DON’T LIKE SCHOOL = 4 
I HAVE TO LOOK AFTER MY FAMILY= 5 
THERE’S NOT ENOUGH MONEY TO SEND ME 
TO SCHOOL = 6 
SCHOOL IS TOO FAR AWAY = 7 
I HAVE TO WORK = 8 
I HAVE A CHILD OR I AM PREGNANT (GIRLS 
ONLY) = 9 
I MISSED TOO MUCH SCHOOL BECAUSE OF 
MY PERIOD (MENSTRUATION) (GIRLS ONLY) 
= 10 
OTHER (SPECIFY) = 96 
DON’T KNOW = -8    
REFUSED = -9 
 
110 
  
  
  
Have you ever attended school? 
  
YES = 1 
NO = 2 
DON’T KNOW =-8 
REFUSED = -9 
NO, DK, 
REFUSED→ADHIVPRE
V 
111 
  
  
  
  
  
When was the last time you regularly 
attended school? Would you say it 
was less than a year ago or more 
than a year ago?  
LESS THAN 1 YEAR = 1 
1 YEAR OR LONGER = 2 
DON’T KNOW =-8 
REFUSED = -9 
  
  
112 
   
What is the highest 
standard/form/year that you have 
completed? 
STANDARD/FORM/YEAR ____ 
DON’T KNOW = -8 
REFUSED = -9 
  
MODULE 2:  HIV PREVENTION INTERVENTIONS 
Interviewer says: “Now I would like to ask you some questions about what you know about health.” 
201 
  
  
  
 Have you ever heard of HIV?  
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED = -9 
IF NO, DK, 
REFUSED→207 
  
202 
  
  
  
  
  
  
  
  
  
  
  
  
From where have you heard about 
HIV?  
PROBE: "Anywhere else?" 
RECORD ALL MENTIONED 
SCHOOLS / TEACHERS =A 
PARENTS / GUARDIAN / FAMILY =B  
FRIENDS =C 
RELIGIOUS LEADERS =D 
INTERNET =E 
MOBILE PHONE =F 
HEALTH PROVIDERS / DOCTORS / NURSES / 
CLINICAL OFFICERS =G 
TELEVISION / FILM  =H 
RADIO =I 
COMMUNITY HEALTH WORKERS =J 
OTHER (SPECIFY) =X 
DON’T KNOW =Y 
REFUSED =Z 
 
NO QUESTIONS CODING CATEGORIES SKIPS 
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204 
  
  
  
  
  
  
  
  
  
  
  
  
Which HIV prevention measures have 
you heard of? 
 
DO NOT READ ANSWER ALOUD, LET 
PARTICIPANT GIVE ANSWERS AND IF 
THEY ARE UNABLE TO, PROBE.  
ABSTINENCE = A 
BEHAVIOR CHANGE/FAITHFUL TO ONE 
PARTNER = B 
CONDOMS = C 
PMTCT = D 
PRE- AND POST-EXPOSURE PROPHYLAXIS = 
E 
SAFE BLOOD = F 
CIRCUMCISION = G 
OTHER (SPECIFY) = H 
DON’T KNOW = Y 
 
205 
  
  
How did you hear about the 
prevention measures? 
 
PROBE: "Anywhere else?" 
RECORD ALL MENTIONED   
SCHOOLS/TEACHERS = A 
PARENTS/GUARDIAN/FAMILY = B 
FRIENDS = C 
RELIGIOUS LEADERS = D 
INTERNET = E 
MOBILE PHONE = F 
HEALTH 
PROVIDERS/DOCTORS/NURSES/CLINICAL 
OFFICERS = G 
TELEVISION/FILM = H 
RADIO = I 
COMMUNITY HEALTH WORKERS = J 
OTHER (SPECIFY) = X 
DON’T KNOW = Y 
REFUSED = Z 
 
206  Do you know what a condom is?  YES =1  
NO =2 
REFUSED =-9 
NO, REFUSED →301 
207 
 
Do you know where to get a 
condom? 
 
  
YES = 1 
NO = 2 
REFUSED = -9 
NO, REFUSED →211 
DK →301   
208  Where can a person go to get a 
condom? 
 
SELECT ALL THAT APPLY 
CLINIC/HOSPITAL = A 
KIOSK/SHOP = B 
PHARMACY = C 
LOCAL FREE DISPENSER = D 
FRIENDS/PEERS = E 
BOYFRIEND/GIRLFRIEND = F 
OTHER (SPECIFY) = X 
DON’T KNOW = Y 
REFUSED = Z 
 
209 
  
  
  
If you wanted to, could you yourself 
get a condom?  
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
YES, DK, REFUSED 
→211   
210 Why is it not easy for you to get a 
condom? 
 
SELECT ALL THAT APPLY. 
TOO FAR = A 
COSTS TOO MUCH = B 
DO NOT WANT OTHERS TO KNOW = C 
OTHER (SPECIFY) = X 
DON’T KNOW = Y 
REFUSED = Z 
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MODULE 3: SEXUAL BEHAVIOR 
Interviewer says: “The next questions ask about sexual behavior. There is no right or wrong answer. Your responses will not 
be linked to you in any way or shared with anyone, including your parents. You can choose not to answer any of the 
questions.” 
DO NOT READ: PLEASE LOOK OUT FOR SIGNS OF DISTRESS IN CHILD WHEN ASKING THE FOLLOWING SEXUAL BEHAVIOR 
QUESTIONS.  IF THE CHILD SEEMS DISTRESSED, ASK CHILD IF HE/SHE WANTS TO STOP THE INTERVIEW. 301 
  
  
  
Do you know what sex is? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF AGE <13 & 
RESPONSE = NO, DK, 
REFUSED→ 501 
302 
  
  
  
Have you ever had vaginal, anal or 
oral sex?  
 
 
Vaginal sex is when a penis enters a 
vagina.  Anal sex is when a penis 
enters an anus.  Oral sex is when a 
person puts his/her mouth on the 
penis or vagina of another person. 
SELECT ALL THAT APPLY.  
NEVER HAD SEX = A 
VAGINAL = B 
ANAL = C 
ORAL = D 
DON’T KNOW = Y 
REFUSED = Z  
NEVER, DK, 
REFUSED→ 501 
  
  
303 
  
  
How old were you when you had sex 
for the first time?  
AGE IN YEARS =integer 
DON’T KNOW AGE =-8 
REFUSED =-9 
  
304 
  
  
  
The first time you had sex, was it 
because you wanted to or because 
you were forced? 
WANTED TO =1 
FORCED =2 
DON’T KNOW =-8 
REFUSED =-9 
WANTED, DK, 
REFUSED →306 
305 
  
  
  
The first time you had sex, were you 
physically forced or were you 
pressured into having sex through 
harassment, threats or tricks? 
  
PHYSICALLY FORCED =1 
PRESSURED =2 
DON’T KNOW =-8 
REFUSED =-9 
ALL →307  
306 
  
  
  
  
  
  
  
  
  
What was the main reason that you 
had sex for the first time? 
  
IT JUST HAPPENED =1 
MY FRIENDS PRESSURED ME TO HAVE SEX 
=2 
TO SHOW MY LOVE / TO FEEL LOVED =3 
I WANTED TO HAVE SEX =4 
MY BOYFRIEND / GIRLFRIEND WANTED TO 
HAVE SEX =5  
FOR MONEY / GIFTS =6 
I WANTED TO HAVE A BABY =7 
OTHER (SPECIFY) =96 
DON’T KNOW =-8 
REFUSED =-9 
 
  
307 
  
  
How old was the person you first had 
sex with? Please give your best 
guess. 
  
AGE IN YEARS =integer 
DON’T KNOW AGE =-8 
REFUSED =-9 
  
  
 
NO QUESTIONS CODING CATEGORIES SKIPS 
211 
   
Have you ever seen a male condom 
demonstration?  
 
By a condom demonstration, I mean 
someone like a nurse, peer educator, 
or another trained adult showed you 
how a male condom is correctly used. 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9  
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308 
  
  
  
  
The first time you had sex, was a 
condom used? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
SKIP IF DON’T KNOW 
WHAT CONDOM IS 
309 
  
In your lifetime, how many different 
people have you had sex with? 
Please give your best guess. 
  
NUMBER OF PARTNERS =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
310 
  
  
  
The last time you had sex was a 
condom used? 
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP IF DON’T KNOW 
WHAT CONDOM IS  
311 How often do you use a condom 
during sex?  
ALWAYS = 1 
SOMETIMES = 2 
NEVER = 3 
DON’T REMEMBER = 4 
DON’T KNOW = -8 
REFUSED = -9  
SKIP IF DON’T KNOW 
WHAT CONDOM IS 
312 
  
  
  
Have you ever had sex with someone 
because he/she provided you with, 
or you expected that he/she would 
provide you with gifts, help you to 
pay for thing or help you in other 
ways such as giving you food or 
paying for school fees? 
  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
  
313 
  
  
  
Have you ever been pregnant?  YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
GIRLS ONLY 
314 
  
  
  
Have you ever talked with a parent 
or guardian about sexual 
intercourse?     
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
 
MODULE 4: SOCIAL NORMS, INTENTION TO ABSTAIN, SELF-EFFICACY AND ASSERTIVENESS 
Interviewer says: “Now I would like to ask you some questions about social norms.” 
401 
 
  
  
  
Do you feel pressured by your 
boyfriend/girlfriend to have sex?  
YES = 1 
NO = 2 
DON’T HAVE BOYFRIEND/GIRLFRIEND=3 
DON’T KNOW = -8 
REFUSED = -9  
SKIP IF 301=NO, DK, 
REFUSED 
402 
  
  
  
Do you feel pressured by your 
friends to have sex?  
  
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP IF 301=NO, DK, 
REFUSED 
403 
 
If you did not want to have sex with 
someone, could you tell them that 
you do not want to have sex with 
them?  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
SKIP IF 301=NO, DK, 
REFUSED 
 
NO QUESTIONS CODING CATEGORIES SKIPS 
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NO QUESTIONS CODING CATEGORIES SKIPS 
MODULE 5: HIV RISK PERCEPTIONS 
 501 
  
  
  
How likely do you think it is for you 
to get HIV? 
  
VERY LIKELY =1 
SOMEWHAT LIKELY=2 
NOT LIKELY =3 
I ALREADY HAVE HIV =4 
DON’T KNOW =-8 
REFUSED =-9 
IF NOT LIKELY, I HAVE 
HIV, DK, 
REFUSED→503 
SKIP IF 201 
=NO, DK, REFUSED   
502 
  
  
  
What is the main reason you think 
you are likely to get HIV? 
  
  
I HAVE HAD SEX WITHOUT A CONDOM =1 
I HAVE OR HAD MANY BOY/GIRLFRIENDS =2 
I HAVE HAD BLOOD TRANSFUSIONS =3 
MY MOTHER/FATHER/CLOSE RELATIVE HAS 
HIV =4 
I DON’T TRUST MY BOY/GIRLFRIEND =5 
I AM SICK =6 
MY BOY/GIRLFRIEND IS SICK OR HAS DIED 
=7 
I DESERVE IT / I AM A BAD PERSON =8 
OTHER (SPECIFY) =96 
DON’T KNOW =-8 
REFUSED =-9 
SKIP IF 201 
=NO, DK, REFUSED 
 
ALL → NEXT MODULE  
  
503 What is the main reason you think 
you are not likely to get HIV? 
 
I AM ABSTINANT =1 
I WILL WAIT UNTIL MARRIAGE TO HAVE 
SEX=2 
I ALWAYS USE CONDOMS=3 
I TRUST MY PARTNER=4 
I HAVE ONLY ONE PARTNER=5 
I GO TO CHURCH =6 
I AM A GOOD PERSON =7 
OTHER (SPECIFY) = 96 
DON’T KNOW = -8 
REFUSED = -9 
 
SKIP IF 201 
= NO, DK, REFUSED  
 
MODULE 6: HIV KNOWLEDGE 
Interviewer says: “Now I would like to ask you some questions about what you know.” about some 
things related to health.” 
SKIP TO NEXT 
MODULE IF 201 = NO, 
DK, REF 
601 
  
  
  
Can a person reduce their chance of 
getting HIV by not having sex?    
   
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9  
 
602 
  
  
  
Can a person reduce their chance of 
getting HIV by using condoms when 
having sex? 
 
  
  
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9  
  
  
603 
  
 
Can a healthy-looking person have 
HIV or AIDS? 
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
 
604 
 
Can a mother with HIV or AIDS pass 
HIV to her unborn baby? 
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
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NO QUESTIONS CODING CATEGORIES SKIPS 
605 
 
Are there medicines that people with 
HIV or AIDS can take to help them 
live longer? 
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
606 
 
Can male circumcision help prevent 
HIV infection? 
Circumcision is the removal of the 
foreskin from a penis. 
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
607 
 
Can ARVs make people with HIV less 
likely to spread the virus? 
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
608 
 
Can ARVs can rid HIV from an HIV-
positive person’s body?  
 
YES = 1 
NO = 2 
DON’T KNOW = 3 
REFUSED = -9 
 
 
MODULE 7: HIV TESTING 
Interviewer says: “I would now like to ask you some questions about HIV testing.” 
  
  
SKIP TO NEXT 
MODULE IF 201 = NO, 
DK, REF 
701 
  
  
  
To what extent do you agree with 
the following statement:  Everyone 
should get tested for HIV? 
 
Do you strongly agree, agree, 
disagree, or strongly disagree?  
  
  
STRONGLY AGREE = 1 
AGREE = 2 
DISAGREE = 3 
STRONGLY DISAGREE = 4 
DON’T KNOW = -8 
REFUSED = -9  
  
  
  
  
702 
  
  
  
To what extent do you agree with 
the following statement:  Only 
persons who think they might have 
HIV should get an HIV test. 
 
Do you strongly agree, agree, 
disagree, or strongly disagree?  
STRONGLY AGREE = 1 
AGREE = 2 
DISAGREE = 3 
STRONGLY DISAGREE = 4 
DON’T KNOW = -8 
REFUSED = -9  
  
703 Have you ever been tested for HIV? YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
IF NO, DK, REFUSED 
→901 
 
704 
  
  
  
Did you receive the results of any of 
your HIV tests? 
  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
IF NO, DK, REFUSED 
→901  
705 
  
  
  
What was the result of that HIV test? HIV POSITIVE = 1 
HIV NEGATIVE = 2 
UNKNOWN/DON’T KNOW = 3 
REFUSED = -9  
IF HIV 
NEGATIVE, 
UNKNOWN, REFUSED 
→901 
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NO QUESTIONS CODING CATEGORIES SKIPS 
706 
  
  
  
Are you currently on treatment for 
HIV? 
 
By on treatment, we mean are you 
taking any drugs to prevent or treat 
any opportunistic infections or ARVs. 
  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
  
 
MODULE 8: HIV STIGMA 
Interviewer says: “Now I would like to ask you some more questions about HIV.” SKIP TO NEXT 
MODULE IF 201=NO, 
DK, REFUSED 
801 
  
  
  
Would you be willing to share food 
with someone who has HIV? 
  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
  
802 
  
  
  
Would you be friends with someone 
who has HIV? 
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
 
803 
  
  
Would you be comfortable to have a 
teacher who has HIV?  
  
  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
  
  
  
 
MODULE 9: ALCOHOL AND DRUGS 
Interviewer says: “I would like to ask you some questions about alcohol and drugs or substances that you may have taken 
that were not given to you by doctor. Your answers will not be told to anyone, even your parents. You can choose not to 
answer any of these questions.” 
901 
  
  
  
Have you ever had alcohol, for 
example beer?  
 
DO NOT READ: SHOW CHILD 
GRAPHIC IF HE OR SHE IS UNSURE  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF NO, DK, REFUSED 
→903 
SHOW GRAPHIC OF 
COMMON ALCOHOLIC 
BEVERAGES 
902 
  
  
During the past 1 month, on how 
many days did you have at least one 
drink containing alcohol? 
  
NUMBER OF DAYS =integer 
DON’T KNOW =-8 
REFUSED =-9 
 
903 Have you ever tried drugs such as 
DAGA, COCAINE or others? 
 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
IF NO, DK, REFUSED 
→801 
ADAPT QUESTION TO 
LOCAL CONTEXT 
904 
  
  
  
  
  
  
  
What drugs have you ever tried? 
DO NOT READ: DO NOT READ 
RESPONSES. 
PROBE FOR MULTIPLE RESPONSES. 
RECORD ALL MENTIONED 
DAGA= A 
COCAINE = B 
OTHER = X 
SPECIFY: __________________ 
DON’T KNOW = Y   
REFUSED = Z 
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NO QUESTIONS CODING CATEGORIES SKIPS 
MODULE 10: PARENTAL SUPPORT 
 1001 
  
  
  
Do your parents/guardians 
understand your problems and 
worries?   
  
  
  
ALWAYS = 1 
MOST OF THE TIME = 2 
SOMETIMES = 3 
RARELY = 4 
NEVER = 5 
DON’T KNOW = -8  
REFUSED = -9  
  
  
  
  
1002 
  
  
  
  
  
  
Do your parents/guardians really 
know what you were doing with your 
free time when you were not at 
school or work? 
  
ALWAYS =1 
MOST OF THE TIME =2 
SOMETIMES =3 
RARELY =4 
NEVER =5 
DON’T KNOW =-8 
REFUSED =-9 
  
  
 
MODULE 11: VIOLENCE 
Interviewer says: “Now I would like to ask you questions about some other important aspects of a person’s life.  I know that 
some of these questions are very personal.  However, your answers are important for helping to understand the condition of 
children in Lesotho. Let me assure you that your answers are completely confidential and will not be told to anyone. You can 
choose not to answer any of these questions.” 
1101 
  
  
  
Has anyone ever done any of these 
things to you: 
-       Punched, kicked, whipped, or 
beat you with an object such as a 
stick 
-       Choked smothered, tried to 
drown you, or burned you 
intentionally 
 -      Used or threatened you with a 
knife, gun or other weapon? 
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
  
1102 
  
  
  
Has anyone ever touched your 
[penis or buttock, vagina, buttock, or 
breast] when you did not want them 
to?  This could be pinching, 
grabbing, or touching you on or 
around your [penis or buttock, 
vagina, buttock, or breast].  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
 
1103 
  
  
  
Has anyone ever touched you in a 
sexual way without your permission, 
but did not try and force you to have 
sex? 
Touching in a sexual way without 
permission includes fondling, 
pinching, grabbing, or touching you 
on or around your sexual body parts.  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
IF NO, DK, REFUSED 
→1105 
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NO QUESTIONS CODING CATEGORIES SKIPS 
1104 
  
  
  
  
  
  
  
  
  
  
  
  
The first time this happened, what 
was your relationship to the person 
who did this? If it was more than 
one person, what was your 
relationship with the person you 
knew the best? 
  
BOYFRIEND / GIRLFRIEND / SPOUSE=1 
RELATIVE / FAMILY MEMBER=2 
CLASSMATE / SCHOOLMATE=3 
TEACHER=4 
POLICE / SECURITY / OFFICER / MILITARY=5 
EMPLOYER=6 
NEIGHBOR=7 
COMMUNITY RELIGIOUS LEADER=8 
FRIEND=9 
STRANGER=10 
OTHER (SPECIFY) =96 
DON’T KNOW =-8 
REFUSED =-9 
 
  
1105  
  
  
Has anyone ever tried to make you 
have sex against your will but did 
not succeed?  
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
1106  
  
  
Has anyone ever pressured you to 
have sex, through harassment, 
threats or tricks and did succeed? 
YES =1 
NO =2 
DON’T KNOW=-8 
REFUSED =-9 
  
1107 Has anyone ever physically forced 
you to have sex and did succeed? 
YES = 1 
NO = 2 
DON’T KNOW = -8 
REFUSED = -9 
 
1108 
  
  
  
  
  
  
  
  
  
  
  
  
The first time you were pressured or 
forced to have sex, what was your 
relationship to the person who did 
this? 
  
  
BOYFRIEND / GIRLFRIEND / SPOUSE =1 
RELATIVE / FAMILY MEMBER =2 
CLASSMATE / SCHOOLMATE =3 
TEACHER =4 
POLICE / SECURITY OFFICER / MILITARY =5 
EMPLOYER =6 
NEIGHBOR =7 
COMMUNITY RELIGIOUS LEADER =8 
FRIEND =9 
STRANGER =10 
OTHER (SPECIFY) =96 
DON’T KNOW =-8 
REFUSED =-9 
SKIP IF 1106= NO, DK, 
REFUSED AND 1107 = 
NO, DK, REFUSED 
  
1109 
  
  
  
  
  
  
  
  
After any of these unwanted sexual 
experiences, did you try to seek 
professional help or services from 
any of the following? 
 
SELECT ALL THAT APPLY.  
I DID NOT TRY TO SEEK HELP = A 
HEALTHCARE PROFESSIONAL = B  
POLICE OR OTHER SECURITY PERSONNEL = 
C 
SOCIAL WORKER, COUNSELOR OR NGO = D 
RELIGIOUS LEADER = E  
OTHER (SPECIFY) = X 
DON’T KNOW = Y 
REFUSED = Z 
ALL BUT I DID NOT 
TRY TO SEEK HELP→ 
1111 
 
SKIP IF 1103 = NO,  
DK, REFUSED & 1105 
= NO, DK, REFUSED & 
1106 = NO, DK, 
REFUSED, & 1107 = 
NO, DK, REFUSED  
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NO QUESTIONS CODING CATEGORIES SKIPS 
1110 
  
  
  
  
  
  
  
  
  
What was the main reason that you 
did not try to seek professional help 
or services? 
  
DID NOT KNOW SERVICES WERE AVAILABLE 
=1 
SERVICES NOT AVAILABLE =2 
AFRAID OF GETTING IN TROUBLE =3 
ASHAMED FOR SELF/FAMILY =4 
COULD NOT AFFORD SERVICES =5 
DID NOT THINK IT WAS A PROBLEM =6 
FELT IT WAS MY FAULT =7 
AFRAID OF BEING ABANDONED =8 
DID NOT NEED/WANT SERVICES =9 
OTHER (SPECIFY) =96 
DON’T KNOW =-8 
REFUSED =-9 
 
  
1111 
  
  
  
After any of these unwanted sexual 
experiences, did you tell anyone 
about it?  
  
YES =1 
NO =2 
DON’T KNOW =-8 
REFUSED =-9 
NO, DK, 
REFUSED→END  
1112 
  
  
  
  
  
  
  
  
Which of the following describes 
who you told about any of these 
unwanted sexual experiences? 
 
READ RESPONSES ALOUD. 
 
SELECT ALL THAT APPLY 
PARENT/GUARDIAN = A 
SIBLING = B  
TEACHER = C 
FRIEND/CLASSMATE = D 
POLICE OR OTHER SECURITY PERSONNEL = 
E 
SOCIAL WORKER, COUNSELOR OR NGO = F 
OTHER FAMILY MEMBER = G 
RELIGIOUS LEADER = H 
OTHER (SPECIFY) = X 
DON’T KNOW = Y 
REFUSED = Z  
 
SKIP IF NEVER 
EXPERIENCED SEXUAL 
OR PHYSICAL 
VIOLENCE 
COMMENT DO NOT READ: COMMENTS FROM INTERVIEWER 
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Appendix H    Consent Forms  
Consent for Household Interview 
 
Interviewer reads: 
 
Hello. My name is___________. I would like to invite you to take part in this research study about HIV in 
Lesotho. The Ministry of Health is leading this survey and is conducting it with the United States Centers 
for Disease Control and Prevention and ICAP at Columbia University and the ICAP in Lesotho.  
  
What language do you prefer for our discussion today? 
 
___English 
 
___Sesotho 
 
Title of Survey: This survey is called the Lesotho Population-Based HIV Impact Assessment (LePHIA, 2016-
2017) 
 
Purpose of survey 
This survey will help us know how many people in Lesotho have HIV and need health services. It will also 
tell us about people’s risk for getting HIV. We plan to ask about 12,698 people, ages 15-59 years and 
4,222 children, ages 0-14 years from 10,450 households to join this survey. If you join, your taking part 
will help Lesotho Ministry of Health make health services better in the country. 
 
This form might have some words in it that are not familiar to you. Please ask us to explain anything that 
you do not understand.  
 
Survey Procedures 
There are two parts to this survey– a household interview and individual interviews.  In the household 
interview, we would like to ask you some questions about the people who live here and some of the things 
you have or own.  The interview will take up to 30 minutes.   
 
After the household interview, we will invite you and others living in your household to take part in 
individual interviews. The interview will take about 40 minutes. We will also offer an HIV test after the 
interview. We will ask each person to give permission to take part before joining the survey.  
 
Right to refuse or withdraw 
You do not have to take part in the survey.  If you choose to join the survey, you may change your mind 
at any time and stop taking part.  If you decide not to take part, or if you decide to stop, it will not affect 
your health care in any way.   
 
APPENDIX H CONSENT FORMS  
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Risks and Benefits 
The risks of taking part in the household interview are small. You may feel uncomfortable about some of 
the questions we will ask.  You can refuse to answer any question. We will do everything we can to keep 
your information private.  We cannot guarantee total confidentiality. If you take part, you and your 
household members will get free testing for HIV in your own home.  The information you provide will also 
be used to improve the health of Lesotho. Your responses will help us develop more effective programs 
to fight HIV and other diseases in Lesotho. 
 
1. There is no cost to you for being part of the survey except for your time.  You will not be paid. 
 
Confidentiality and Access to Your Health Information 
What we talk about will be kept private, even from your family, and will not be shown to anyone outside 
of the survey team.  Your answers to the questions will be identified only by a number and not your 
name Your name or any other identifying information will not appear on any survey results that we 
share with Ministry of Health, the public, or publish or present at scientific meetings.  The information 
we collect during the survey will not be released outside of the survey groups listed unless there is an 
issue of safety.  
 
The following individuals and/or agencies will be able to look at your interview records to help oversee 
the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your rights as a person in a research study. These 
include The Ministry of Health Research and Ethics Committee and the Institutional Review Boards 
at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia University Medical 
Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a person taking part in this 
survey 
▪ Study staff and study monitors 
 
Your permission to allow us to use and share your information with the groups above will expire 
immediately after the end of the study. If you want to leave the study, have any questions about the 
survey, feel that you have been harmed by taking part , you should contact the Principal Investigator: 
Dr. Mosilinyane Letsie 
Address: Ministry of Health 
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
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Phone:+266 63066403 
  
Do you want to ask me anything about the survey? 
 
Consent Statement 
Any questions that I had have been answered satisfactorily. I have been offered a copy of this consent 
form. 
 
Do you agree to do the household interview? ‘YES’ means that you agree to do the interview. ‘NO’ 
means that you will NOT do the interview. 
______Yes              ______No 
 
Head of household signature or mark________________________________ Date: ___/___/___            
Printed name of head of household_________________________________ 
Household ID number ____________________________    
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________   
Survey staff ID number _________________________________  
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Consent for Interview: Adults aged 18-59 years and Emancipated Minors aged 15-17 
years 
 
Interviewer reads: 
 
[IF PARTICIPANT HAS BEEN THROUGH HOUSEHOLD CONSENT] 
 
Hello. My name is_________________. 
 
Survey Procedures 
We plan to ask about 12,698 people, ages 15-59 years and 4,222 children, ages 0-14 years from 10,450 
households to join this survey. If you join us for this portion of the survey, we will ask you questions about 
your health, whether you have had any experience with HIV services, and your behavior. The interview 
will take about 40 minutes. 
 
After the interview, we will offer you an HIV test.  We will ask you for consent for the blood draw and HIV 
test after the interview. The testing and counseling session will also take about 40 minutes. You may agree 
to the interview without agreeing to give your blood. 
 
Right to refuse or withdraw 
You do not have to take part in this interview, you may change your mind at any time and stop taking 
part. If you decide not to take part, or if you decide to stop,  it will not affect your health care in any 
way.  
 
2. Confidentiality and access to your health information 
3. We will do everything we can to keep your taking part in the survey private. However, we 
cannot promise complete confidentiality.  
4.  
5. You can contact Dr. Mosilinyane Letsie should you have any questions or concerns. 
 
→ GO TO CONSENT STATEMENT 
 
[IF PARTICIPANT HAS NOT BEEN THROUGH HOUSEHOLD CONSENT] 
 
What language do you prefer for our discussion today? 
 
___English 
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___Sesotho 
 
___Other Language: Specify ___________________________  
  
Hello. My name is_________________. We are doing a research study throughout Lesotho to learn more 
about HIV in the country. The Ministry of Health is leading this survey and is conducting it with the United 
States Centers for Disease Control and Prevention and ICAP at Columbia University and the ICAP in 
Lesotho.  
 
 
Consent for Individual Interview 18-59 and Emancipated Minors 15-17 
 
Title of Survey: This survey is called the Lesotho Population-Based HIV Impact Assessment (LePHIA, 
2016-2017) 
 
Purpose of the survey 
This survey will help us know how many people in Lesotho have HIV and need health services. It will also 
tell us about  people’s risk for getting HIV. We plan to ask about 12,698 men, women, and children from 
10,450 households throughout Lesotho to take part in this survey. If you join, your taking part will help 
the Ministry of Health make health services better in the country.  
 
This form might have some words in it that are not familiar to you.  Please ask us to explain anything that 
you do not understand. 
 
Survey Procedures 
If you join this survey, we will ask you questions about your age, whether you have had any experience 
with HIV services, and your behavior. The interview will take about 40 minutes. 
 
After the interview, we will offer you an HIV test.  We will ask you for consent for the blood draw and 
blood draw and talk to you about your results. The testing and counseling session will take about 40 
minutes. You may agree to the interview without agreeing to give your blood. 
 
Right to refuse or withdraw 
You do not have to take part in the survey. If you choose to join the survey, you may change your mind 
at any time and stop taking part. If you decide not to take part, or if you decide to stop,  it will not affect 
your healthcare in any way.  If you do not wish to participate in the study you may still request HIV 
testing and counselling, pending the availability of supplies. 
 
Risks and benefits 
The risks in being in the survey are small. We will do everything we can to keep your information private. 
However, we cannot promise complete confidentiality.  You may feel uncomfortable about some of the 
questions we will ask. You can refuse to answer any question. If you take part, you will get free testing for 
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HIV in your own home.  The information you provide will also be used to improve the health of Lesotho. 
Your responses will help us develop more effective programs to fight HIV and other diseases in Lesotho. 
 
6. There is no cost to you for being part of the survey except for your time.  You should also know 
that you will not be paid. 
 
Confidentiality, Privacy and Access to Your Health Information  
What we talk about will be kept private, even from your family, and will not be shown to anyone outside 
of the survey team.  Your answers to the questions will be identified only by a number and not your 
name.  Your name or any other identifying information will not appear on any survey results that we 
share with Ministry of Health, the public, or publish or present at scientific meetings. The information 
we collect during the survey will not be released outside of the survey groups listed unless there is an 
issue of safety.  
 
 
The following individuals and/or agencies will be able to look at your research records to help oversee 
the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the 
conduct of this survey to ensure that we are protecting your rights as a person in a research 
study. The Research and Ethics Committee and the Institutional Review Boards at the Centers 
for Disease Control and Prevention (CDC; Atlanta, USA), Columbia University Medical Center and 
Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a person taking part in this 
survey 
▪ Study staff and study monitors 
 
Your permission to allow us to use and share your information with the groups above will expire 
immediately after the end of the study. If you want to leave the study, have any questions about the 
survey, or feel that you have been harmed by taking part, you should contact the Principal Investigator: 
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health 
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Masebeo Koto 
Address: Department of Planning and Statistics 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
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Do you want to ask me anything about the survey? 
 
Consent Statement 
 
Any questions that I had were answered satisfactorily.  I have been offered a copy of this consent form. 
 
7. Do you agree to do the interview?  ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No    
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
 
Printed name of participant________________________________________    
 
Participant ID number ____________________________________________ 
 
 
[For illiterate participants] 
 
Signature of witness______________________________________________ Date: ___/___/___          
 
Printed name of witness___________________________________________   
 
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
 
Printed name of person obtaining consent_____________________________    
 
Survey staff ID number _________________________________   
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Consent for Blood Draw: Adults, ages 18-59 years and Emancipated Minors, ages 
15-17 years 
 
Interviewer Reads: 
 
My colleague is _____________________________, who is a nurse trained in drawing blood. He/she will also 
be providing you with information about testing options in this survey. 
 
We plan to ask about 12,698 people, ages 15-59 years and 4,222 children, ages 0-14 years from 10,450 
households to join this survey. As a part of this survey, we are giving those taking part an opportunity to 
learn about their HIV status. We are also asking people if we can use their blood later in the laboratory 
for future testing. 
 
Blood draw and HIV testing procedures 
If you agree to the HIV testing and blood draw, we will take a small amount of blood from your arm, 14 
mL (about a tablespoonful).  If it is not possible to take blood from your arm, then we will try to take a 
few drops of blood from your finger.  We will give you the results and provide counseling today. The 
testing and counseling session will take about 40 minutes. 
 
If you test positive for HIV, we will measure the amount of CD4 cells in your blood which measures how 
well your body can fight HIV infections and other diseases. We will also test the CD4 of some people 
without HIV.  You will get your CD4 result today. We will also send your blood to a laboratory to measure 
your viral load which measures the amount of HIV in your blood. We will send your viral load result to a 
health facility in about six to twelve weeks from now.  We will give you a referral form and information so 
that you can consult a nurse or doctor to learn more about your HIV, CD4, and viral load test results and 
your health. 
 
We will also do other additional tests related to HIV. If we have test results that might help guide your 
care or treatment, we will contact you to tell you how you and your doctor or nurse may get these 
results. 
 
Storage of specimens 
We would also like your permission to store your leftover blood for future research tests.  These tests 
may be about health issues important in Lesotho, such as nutrition or immunization. This will help 
improve the health of the people of Lesotho. This sample will be stored using a unique ID number for up 
to five (5) years  after study completion but your name will be removed from the sample immediately.   
Only survey staff will be able to link your sample to your contact information. We will attempt to tell you 
about any test results during the five (5) year period that are important for your  health.  Your leftover 
blood will not be sold or used for commercial reasons. If you do not agree to long-term storage of your 
blood samples, we will destroy your blood samples after survey-related testing has been completed. 
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Right to refuse or to withdraw 
You do not have to give blood and you are free to change your mind even after you have started the 
blood draw.  If you decide not to take part, or if you decide to stop,  it will not affect your healthcare in 
any way. If you do not  wish to participate in the study you  may still request HIV testing and counselling, 
pending the availability of supplies. 
 
Risks 
The risks in drawing blood are very small. They include brief pain from the needle stick, bruising, 
lightheadedness, bleeding, and rarely, infection where the needle enters the skin.  If you have any 
discomfort, bleeding or swelling at the site, please contact the study staff.  You may learn that you are 
infected with HIV. Learning that you have HIV can cause some emotional discomfort. You will receive 
counselling on how to cope with learning that you are HIV positive. We will also tell you where you can 
go for care and treatment, which is provided by the Ministry of Health for free. We will do everything we 
can to keep your test results private, but we cannot guarantee total confidentiality.  
 
Benefits  
The main benefit for you to be in the survey is the chance to learn more about your health today.  If you 
test HIV-negative, you will learn about what you can do to stay HIV-negative.  If you test HIV-positive, you 
will learn your HIV status and where to go for treatment. If you already know that you are HIV-positive 
and you are on HIV treatment, the CD4 and viral load tests can help your nurse or doctor judge how well 
your treatment is working. Your taking part in this research could help us learn more about HIV in Lesotho 
and how HIV prevention and treatment programs are working.  
 
 
Confidentiality, Privacy and Access to Your Health Information 
The blood we collect from you will be identified by a number and not by your name. This means that 
besides you, no one else will be able to know your test results except the people working on the survey. 
Your name or any other identifying information will not appear on any survey results that we share with 
Ministry of Health, the public, or publish or present at scientific meetings. The information we collect 
during the survey will not be released outside of the survey groups listed unless there is an issue of 
safety.  
 
[INTERVIEWER: PROVIDE THE FOLLOWING INFORMATION SHEET TO THE PARTICIPANT- DO NOT READ 
ALOUD] 
    
The following individuals and/or agencies will be able to look at your research records to help oversee the 
conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your rights as a person taking part in a research study. 
These include the Research and Ethics Committee and the Institutional Review Boards at the 
Centers for Disease Control and Prevention (CDC; Atlanta, USA), Columbia University Medical Center 
and Westat (a statistical survey research organization) 
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▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a person taking part in this 
survey 
▪ Study staff and study monitors  
 
Your permission to allow us to use and share your information with the groups above will expire 
immediately after the end of the study.  If you want to leave the study, have any questions about the 
survey, or  feel that you have been harmed by taking part,  you should contact the Principal Investigator:  
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
 
Do you want to ask me anything about: 
▪ Taking your blood for HIV testing? 
▪ Testing in the laboratory? 
▪ Storage of blood for future research testing? 
 
 
Consent Statement 
Any questions that I had were answered satisfactorily. I have been offered a copy of this consent form. 
1. Do you agree to give blood for HIV testing and related testing? ‘YES’ means that you agree to 
give blood for HIV testing and related testing. ‘NO’ means that you will NOT give blood for HIV 
testing and related testing. 
______Yes              ______No   
(If “Yes” proceed to the next question) 
2. Do you agree to have your leftover blood stored for future research? ‘YES’ means that you agree 
to have these blood samples stored for future testing. ‘NO’ means that these blood samples will 
NOT be stored for future research. 
______Yes              ______No 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
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Printed name of participant________________________________________    
Participant ID number ____________________________________________ 
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
Printed name of person obtaining consent_____________________________    
 
Survey staff ID number _________________________________   
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Parental Consent/Permission for Interview and/or Blood Draw for Minors, ages 0-
17 years 
 
Interviewer Reads: 
 
[IF PARENT/GUARDIAN HAS BEEN THROUGH CONSENT PROCESS FOR BLOOD DRAW] 
 
Now I would like to ask you to give us permission for your children to take part in the survey. We will ask 
about 12,698 people, ages 15-59 years and 4,222 children, ages 0-14 years from 10, 450 households to 
join this survey. Your consent is all that is required for your 0-11 year old children to take part in the 
survey.  If your children are between the ages of 12 to 17, we will also ask your son/daughter to agree to 
take part in the survey. Your children’s taking part will help the Lesotho Ministry of Health make health 
services for children and young people better in Lesotho.   
 
Survey Procedures 
Interview Procedures 
We will ask your 10-17 year old child to do an interview with us in private to learn what your child knows 
about HIV and about your child’s behaviors that may put him or her at risk for HIV. Children under 10 
years of age will NOT complete an interview.  
 
If you agree, we will ask questions on questions on HIV and your children’s behaviors (about 40 minutes) 
in private.  Your children’s answers will not be shared with you. 
Blood Procedures 
If you and/or your children agree, the following will happen, as described in your own consent: 
▪ [<2 YEARS OLD] To do the HIV test in your home, a trained nurse will take a few drops (about 1 mL) 
from your child’s finger or heel for the HIV test   
▪  [>2 YEARS OLD]A trained nurse will take about [6 mL for 0-14 (about one teaspoonful), 14mL for 15-
17(about one tablespoonful)] of blood from your child’s arm or a few drops of blood from your 
child’s finger. 
▪ [0-11] We will discuss the results with you, and your child if you decide to discuss the results with 
him/her.   
▪ [0-11] We will give you a referral form so you and your child can consult with a doctor or nurse 
regarding his/her HIV test, CD4 count and viral load results 
▪ [12-17] We will return the results of the HIV test to your child. We will not tell you their results but 
will encourage them to tell you. 
▪ [12-17] We will give your child a referral form so your child can consult with a doctor or nurse 
regarding his/her HIV test, CD4 count, and viral load results 
▪ If your child has HIV, he/she will get a CD4 test and you or he/she  will receive the results today 
▪ His/her blood will be sent to a laboratory to measure his/her viral load and the results will be 
returned to the preferred health facility in 6-12 weeks 
  
 
236 
▪ We will also do other additional tests related to HIV. If we have test results that might guide your 
child’s care or treatment, we will contact you or your child to inform you of the results or how you 
and your child’s doctor or nurse may get these results. 
▪ We will ask for your permission to store your and/or your child’s leftover blood for future research 
tests 
▪ [≤ 18 months ONLY] 
▪ The body makes antibodies to fight HIV.  Antibodies from a mother with HIV can enter the baby’s 
blood during pregnancy.  The test we perform on your child today will let us know if your child is 
exposed to HIV. If it is positive, it does not mean your child has the virus in his/her blood, it just 
confirms that he/she has been exposed to HIV. We would then send your child’s blood to a lab for a 
special test to confirm if he/she is infected with HIV.  If you provide us with the name of a health 
facility, we can send the result there in about six weeks from now. We will also contact you to 
inform you that the results have been sent to the facility, if you provide us with your contact 
information. It is very important that you go to the facility for your child’s results, as there is free 
treatment available. 
 
Right to refuse and to withdraw 
It is your decision about whether you will allow all your eligible children to join the survey. Your child 
may stop taking part at any time. Your child can refuse to answer any question.   If your child does not 
want to take part, or if he/she decides to stop, it will not affect your child’s healthcare in any way.  If you 
refuse to have your child tested today, HIV testing and counselling services can be sought at a local 
facility. 
 
Risks  
The risks to your child of taking part in the survey are small.  For the blood draw, the risks include brief 
pain from the needle stick, bruising, lightheadedness, bleeding, and rarely, infection where the needle 
enters the skin. You and/or your child might learn that he/she has HIV. Learning that he/she has HIV 
may cause them to feel worried. We will talk to you/them and help you with this. We will do everything 
we can to keep your child’s information private.  However, we can’t promise complete confidentiality. 
Benefits 
The main benefit for your children to be in the survey is the chance to learn more about his/her health 
today, including if they have HIV. Your child’s taking part in this research could also help us learn more 
about how to improve the health of children in Lesotho.  
 
Confidentiality and Access to Your Child’s Health Information 
The information we collect from your child will not be released outside of the study partners we have 
mentioned unless there is an issue of safety.  
You can contact Dr. Mosilinyane Letsie and  should you have any questions or concerns.  
 
→ GO TO PERMISSION STATEMENT 
 
 [IF PARENT/GUARDIAN HAS NOT BEEN THROUGH CONSENT PROCESS FOR INTERVIEW/BLOOD DRAW] 
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Parental Consent/Permission for Interview and/or Blood Draw for Minors, ages 0-17 years 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Sesotho 
 
__Other:  Specify ____________________________ 
 
Title of Survey: This survey is called the Lesotho Population-Based HIV Impact Assessment (LePHIA, 
2016-2017) 
 
Survey Procedures 
I would like you to allow us to invite your eligible children to take part in the survey.  Your consent is all 
that is required for your 0-11 year olds to take part in the survey. If your child is between the ages of 12 
to 17 and agrees, we will also ask him/her to agree to take part in the survey.We will ask your 10-17 year 
old child to do an interview with us in private to learn what your child knows about HIV and about your 
child’s behaviors that may put him or her at risk for HIV. The interview will take about 40 minutes. We will 
not share your child’s answers to the interview questions with you. The interview will take place in private 
here in your house or an area around your house.   Children under 10 years of age will NOT complete an 
interview.  
 
If you and/or your children agree, a trained nurse will take a small amount or about [1 mL for <18 
months, 6 mL for 0-14 (about one teaspoonful), 14mL for 15-17(about one tablespoonful)] of blood from 
your child’s arm to perform an HIV test here in your home.  If it is not possible to take blood from your 
child’s arm, then we will try to take a few drops of blood from your child’s finger.  
 
[0-11] We will give you the results today and provide counseling about the results and discuss with you 
how to share the results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child.   
[12-17] We will return the results of the HIV test to your child. We will not tell you their results but will 
encourage them to tell you. 
[ALL] The entire testing and counseling session will take about 40 minutes. 
 
[10-11] 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today.  CD4 cells are the part of your immune system that fight infections and other diseases. 
We will also test the CD4 level of some children without HIV.  
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We will also send his/her blood to a laboratory to measure his/her viral load which is the amount of HIV 
in the blood. If you provide us with the name of a health facility, we can send your child’s viral load 
results there about six to twelve weeks from now.   
 
We will give you a referral form and information so that you and your child can consult with a doctor or 
nurse to learn more about his/her HIV test, CD4 count, viral load and health. 
 
[12-17]  
 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give them 
the result today.  CD4 cells are the part of your immune system that fight infections and other diseases. 
We will also test the CD4 level of some children without HIV.  
 
We will also send his/her blood to a laboratory to measure his/her viral load which is the amount of HIV 
in the blood. If  your child provided us with the name of a health facility, we can send your child’s viral 
load results there about six to twelve weeks from now.   
 
We will give your child a referral form and information so that you and your child can consult with a 
doctor or nurse to learn more about his/her HIV test, CD4 count, viral load and health. 
 
We will also do other additional tests related to HIV. If we have test results that might guide your 
children’s care or treatment, we will contact you [0-11]/your child [12-17] to inform you of the results or 
how you and your child’s doctor or nurse may get these results. 
 
 
Storage of specimens 
We would like to ask your permission to store your childrens’ leftover blood for future research tests.  
These tests may be about HIV or other health issues important for the health of Lesotho, such as 
nutrition or immunization. This sample will be stored using a unique ID number for five up to (5) years  
after study completion but your child’s name will be removed from the sample immediately.   Only 
survey staff will be able to link your  child’s sample to his/her contact information. We will attempt to 
tell you about any test results during the five (5) year period that are important for your child’s health.  
We will attempt to tell you about any test results during the five (5) year period that are important for 
your children’s health. Your children’s’ leftover blood will not be sold or used for commercial reasons. If 
you do not agree to long-term storage of your children’s blood samples, we will destroy your children’s 
blood samples after survey-related testing has been completed. 
 
Right to refuse or withdraw 
It is your decision about whether you will allow us to invite all your eligible children to join the survey. 
Your child may stop taking part at any time. If your child does not want to answer some of the questions 
she/he may skip them and move to the next question. If your child does not take part, or if they decide 
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to stop, it will not affect your child’s healthcare in any way.  If your child does not  wish to participate in 
the study he/she may still request HIV testing and counselling, pending the availability of supplies. 
 
Risks  
The risks to your children of taking part in the survey are small.  For the blood draw, the risks include 
brief pain from the needle stick, bruising, lightheadedness, bleeding, and rarely, infection where the 
needle enters the skin. You and/or your child may learn that they have HIV.  Learning that they have HIV 
may cause some emotional discomfort. We will provide counseling to you/them on how to cope with 
learning that they have HIV. We will do everything we can to keep your child’s information private.  We 
cannot guarantee complete confidentiality. 
Benefits 
The main benefit for your children to be in the survey is the chance to learn more about their health 
today. If your child tests HIV-positive you and/or your child will learn where to take your child for life-
saving treatment, which is provided by the Ministry of Health for free.  If you already know that your 
child is HIV-positive and he/she is on treatment, the CD4 and viral load tests can help your child’s doctor 
or nurse judge how well the treatment is working.  Your child’s taking part in this research could help us 
learn more about children’s health in Lesotho.  
 
There is no cost to you for your child being in the survey.  You and your child will not be paid to be in the 
survey. 
 
Confidentiality and Access to Your Health Information 
We will do everything we can to keep your children’s taking part in the survey private. The information 
we collect from your children will be identified by a number and not by your name or your child’s name.  
Your name, your child’s name,  or any other identifying information will not appear on any survey results 
that we share with Ministry of Health, the public, or publish or present at scientific meetings. The 
information we collect from your children will not be released outside of the study partners listed unless 
there is an issue of safety.  
 
The following individuals and/or agencies will be able to look at your children’s research records to help 
oversee the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your children’s rights as a person taking part in a 
research study. These include the Lesotho Ministry of Health Research and Ethics Committee and 
the Institutional Review Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, 
USA), Columbia University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your children’s rights as a person taking part 
in this survey 
▪ Study staff and study monitors  
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Your permission to allow us to use and share your children’s name and contact information with the 
groups above will expire immediately after the end of the study.  
 
If you want to leave the study, have any questions about the survey, or feel that you have been harmed 
by taking part, you should contact the Principal Investigator:  
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
Do you want to ask me anything about your children taking part in the survey? 
 
PERMISSION STATEMENT 
 
Any questions I had have been answered satisfactorily. I have been offered a copy of this consent form. 
 
1. Do you agree for your eligible children to be interviewed or for us to ask your children to be 
interviewed? ‘YES’ means that you give your consent/permission to have your children 
interviewed or for the survey staff to ask your children to be interviewed. ‘NO’ means that you 
will NOT give consent/permission for us your children to be interviewed nor ask your children to 
be interviewed. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. Do you agree for your eligible children to give blood or for us to ask your children to give blood 
for HIV testing and related testing? ‘YES’ means that you give your consent/permission to have 
the nurse collect a blood sample or for us to ask your children to collect a sample of his/her 
blood for HIV testing and related testing. ‘NO’ means that we will NOT collect blood nor ask your 
children to give blood for HIV testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
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3. Do you agree to have your eligible children’s leftover blood sample stored or for us to ask your 
children to have his/her leftover blood sample stored for future research? ‘YES’ means that you 
give consent/permission for us to store your children’s leftover blood samples or ask your 
children to store his/her blood samples for future research. ‘NO’ means that your children’s 
blood samples will NOT be stored for future research nor will we ask your children to store 
his/her blood.  
______Yes              ______No 
 
Parent/guardian signature or mark_______________________________________ Date: 
___/___/___            
Printed name of parent/guardian________________________________________    
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __) 
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
 
Signature of person obtaining permission_____________________ __________ Date: 
___/___/___          
Printed name of person obtaining permission____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 
Child’s participant ID number ___________________________________ 
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Consent/Permission from Parent/Guardian for Blood Draw & Interview for Minors, 
ages 10-17 years 
 
[IF PARENT/GUARDIAN HAS BEEN THROUGH CONSENT PROCESS FOR BLOOD DRAW] 
 
Interviewer Reads: 
 
Now I would like to ask you to give us permission for your children to take part in the survey. We will ask 
about 12,698 people, ages 15-59 years and 4,222 children, ages 0-14 years from 10, 450 households to 
join this survey. Your permission is all that is required for your 10-11 year old to take part in the survey. If 
your child is between the age of 12 to17, we will also ask your son/daughter to provide assent to take part 
in the survey. Your child’s taking part will help the Lesotho Ministry of Health make health services for 
children and young people better in Lesotho.   
 
Survey Procedures 
 
If you and/or your child agree, the following will happen, as described in your own consent: 
▪ We will ask questions on HIV and your child’s behaviors (about 40 minutes) in private.  Your child’s 
answers will not be shared with you. 
▪ To do the HIV test in your home, a trained nurse will take about 5/14 mL [AS PER AGE] of blood from 
your child’s arm or a few drops of blood from your child’s finger. 
▪ [10-11] We will discuss the results with you, and your child if you decide to discuss the results with 
him/her  
▪ [12-17] We will return the results of the HIV test to your child. We will not tell you their results but 
will encourage them to tell you. 
▪ If your child has HIV, he/she will get a CD4 test and you or he/she will receive the results today 
▪ His/her blood will be sent to a laboratory to measure his/her viral load and the results will be 
returned to the preferred health facility in 6-12 weeks 
▪ [10-11] We will give you a referral form so you and your child can consult with a doctor or nurse 
regarding his/her HIV test, CD4 count and viral load results 
▪ [12-17] We will give your child a referral form so your child can consult with a doctor or nurse 
regarding his/her HIV test, CD4 count, and viral load results 
▪ We will also do other additional tests related to HIV. If we have test results that might guide your 
child’s care or treatment, we will contact you or your child to inform you of the results or how you 
or your child and your child’s doctor or nurse may get these results. 
▪ We will ask for your permission to store your child’s leftover blood for future research tests 
 
Right to refuse and to withdraw 
It is your decision about whether you will allow your entire child to join the survey. Your child may stop 
taking part at any time. Your child can refuse to answer any question.   If he/she decides not to take 
part, or if he/she decides to stop, it will not affect your child’s healthcare in any way.  If your child does 
not  wish to participate in the study he/she may still request HIV testing and counselling, pending the 
availability of supplies. 
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Risks  
The risks to your child of taking part in the survey are small.  For the blood draw, the risks include brief 
pain from the needle stick, bruising, lightheadedness, bleeding, and rarely, infection where the needle 
enters the skin. You might learn that he/she has HIV. Learning that he/she has HIV may cause them to 
feel worried. We will talk to you/them and help you with this. We will do everything we can to keep 
your child’s information private.  However, we can’t promise complete confidentiality. 
Benefits 
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today, including if they have HIV. Your child’s taking part in this research could also help us learn more 
about how to improve the health of children in Lesotho.  
 
Confidentiality and Access to Your Child’s Health Information 
The information we collect from your child will not be released outside of the study partners we have 
mentioned unless there is an issue of safety.   You can contact Dr. Mosilinyane Letsie and  should you 
have any questions or concerns.  
 
→ GO TO PERMISSION STATEMENT 
 
[IF PARENT/GUARDIAN HAS NOT BEEN THROUGH CONSENT PROCESS FOR INTERVIEW/BLOOD DRAW] 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Sesotho 
 
__Other Language: Specify _____________________________ 
 
Title of Survey: This survey is called the Lesotho Population-Based HIV Impact Assessment (LePHIA, 
2016-2017) 
 
Survey Procedures 
If you agree to allow us to invite your child to take part in the survey, we will ask your child to do an 
interview with us in private to learn what your child knows about HIV and about your child’s behaviors 
that may put him or her at risk for HIV. The interview will take about 40 minutes. We will not share your 
child’s answers to the interview questions with you. The interview will take place in private here in your 
house or an area around your house.   
 
  
 
244 
If you and your child agree, a trained nurse will take a small amount or about [6 mL for 10-14 (about one 
teaspoonful), 14mL for 15-17(about one tablespoonful)] of blood from your child’s arm to perform an 
HIV test here in your home.  If it is not possible to take blood from your child’s arm, then we will try to 
take a few drops of blood from your child’s finger.  
 
[10-11] We will give you the results today and provide counseling about the results and discuss with you 
how to share the results with your child if you decide to share them with him/her. If you would like, we 
can discuss the test results together with your child.   
[12-17] We will return the results of the HIV test to your child. We will not tell you their results but will 
encourage them to tell you. 
[ALL] The entire testing and counseling session will take about 40 minutes. 
 
[10-11] 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give you 
the result today.  CD4 cells are the part of your immune system that fight infections and other diseases. 
We will also test the CD4 level of some children without HIV.  
 
We will also send his/her blood to a laboratory to measure his/her viral load which is the amount of HIV 
in the blood. If you provide us with the name of a health facility, we can send your child’s viral load 
results there about six to twelve weeks from now.   
 
We will give you a referral form and information so that you and your child can consult with a doctor or 
nurse to learn more about his/her HIV test, CD4 count, viral load and health. 
 
[12-17]  
 
If your child tests positive for HIV, we will also test the amount of CD4 cells in his/her blood and give them 
the result today.  CD4 cells are the part of your immune system that fight infections and other diseases. 
We will also test the CD4 level of some children without HIV.  
 
We will also send his/her blood to a laboratory to measure his/her viral load which is the amount of HIV 
in the blood. If your child provide us with the name of a health facility, we can send your child’s viral 
load results there about six to twelve  weeks from now.   
 
We will give your child a referral form and information so that your child can consult with a doctor or 
nurse to learn more about his/her HIV test, CD4 count, viral load and health. 
 
We will also do other additional tests related to HIV. If we have test results that might guide your child’s 
care or treatment, we will contact  [10-11]/your child [12-17] to inform you of the results or how you 
and your child’s doctor or nurse may get these results. 
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Storage of specimens 
We would like to ask your permission to store your child’s leftover blood for future research tests.  
These tests may be about HIV or other health issues important for the health of Lesotho, such as 
nutrition or immunization. This sample will be stored using a unique ID number for up to five (5) years  
after study completion but your child’s name will be removed from the sample immediately.   Only 
survey staff will be able to link your  child’s sample to his/her contact information. We will attempt to 
tell you about any test results during the five (5) year period that are important for your child’s health.  
We will attempt to tell you about any test results during the five (5) year period that are important for 
your child’s health. Your child’s leftover blood will not be sold or used for commercial reasons. If you do 
not agree to long-term storage of your child’s blood samples, we will destroy your child’s blood samples 
after survey-related testing has been completed. 
 
Right to refuse or withdraw 
It is your decision about whether you will allow us to invite your child to join the survey. Your child may 
stop taking part at any time. If your child does not want to answer some of the questions she/he may 
skip them and move to the next question.  If you agree to allow us to invite your child to take part, you 
will have the option for your child to test for HIV and CD4 counts and the option to have his/her blood 
stored for future research.  If your child does not take part, or if he/she decides to stop, it will not affect 
your child’s healthcare in any way.  If your child does not  wish to participate in the study he/she may still 
request HIV testing and counselling, pending the availability of supplies. 
 
Risks  
The risks to your child of taking part in the survey are small.  For the blood draw, the risks include brief 
pain from the needle stick, bruising, lightheadedness, bleeding, and rarely, infection where the needle 
enters the skin. You and/or your child may learn that they have HIV. Learning that they have HIV may 
cause some emotional discomfort. We will provide counseling to you/them on how to cope with 
learning that they have HIV. We will do everything we can to keep your child’s information private.  We 
cannot guarantee complete confidentiality. 
Benefits 
The main benefit for your child to be in the survey is the chance to learn more about his/her health 
today. If your child tests HIV-positive you and/or your child will learn where to take your child for life-
saving treatment, which is provided by the Ministry of Health for free.  If you already know that your 
child is HIV-positive and he/she is on treatment, the CD4 and viral load tests can help your child’s doctor 
or nurse judge how well the treatment is working.  Your child’s taking part in this research could help us 
learn more about children’s health in Lesotho.  
 
There is no cost to you for your child being in the survey.  You and your child will not be paid to be in the 
survey. 
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Confidentiality and Access to Your Health Information 
We will do everything we can to keep your child’s taking part in the survey private. The information we 
collect from your child will be identified by a number and not by your name or your child’s name Your 
name, your child’s name,  or any other identifying information will not appear on any survey results that 
we share with Ministry of Health, the public, or publish or present at scientific meetings. The 
information we collect from your child will not be released outside of the study partners listed unless 
there is an issue of safety.  
 
The following individuals and/or agencies will be able to look at your child’s research records to help 
oversee the conduct of this survey: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your child’s rights as a person taking part in a research 
study. These include the Lesotho Ministry of Health Research and Ethics Committee and the 
Institutional Review Boards at the Centers for Disease Control and Prevention (CDC; Atlanta, USA), 
Columbia University Medical Center and Westat (a statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your child’s rights as a person taking part in 
this survey 
▪ Study staff and study monitors  
 
Your permission to allow us to use and share your child’s name and contact information with the groups 
above will expire immediately after the end of the study. If you want to leave the study, have any 
questions about the survey, or feel that you have been harmed by taking part, you should contact the 
Principal Investigator:  
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
Do you want to ask me anything about your child’s taking part in the survey? 
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PERMISSION STATEMENT 
 
Any questions I had have been answered satisfactorily.  I have been offered a copy of this permission 
form. 
 
1. [IF EARLY ADOLESCENT QUESTIONNAIRE OR 15-17] Do you agree for us to ask your child to do the 
interview? YES’ means that you give your permission to have the survey staff ask your child to do 
the interview. ‘NO’ means that you will NOT give permission for us to ask your child to be 
interviewed. 
______Yes              ______No 
 
2. Do you agree for us to ask your child to give blood for HIV testing and related testing? ‘YES’ 
means that you give your permission for us to ask your child to have the nurse collect a sample 
of your child’s blood for HIV testing and related testing. ‘NO’ means that we will NOT ask your 
child to give blood for HIV testing and related testing. 
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
3. Do you agree for us to ask your child to have your child’s leftover blood stored for future 
research? ‘YES’ means that you give permission for us to ask your child to store your child’s 
blood samples for future research. ‘NO’ means that you do NOT give us permission to ask your 
child to store his/her blood samples for future research. 
______Yes              ______No 
 
 
Parent/guardian signature or mark_______________________________________ Date: 
___/___/___            
Printed name of parent/guardian________________________________________    
Parent/guardian ID number________________________________ (If applicable. If not applicable check 
here __) 
 
[For illiterate participants] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________  
Signature of person obtaining permission_____________________ __________ Date: 
___/___/___          
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Printed name of person obtaining permission____________________________    
 
Survey staff ID number _________________________________   
 
Child’s name (print) ___________________________________ 
 
Child’s participant ID number ___________________________________ 
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Assent for Interview from Minors, ages 12-14 
 
Interviewer reads: 
 
What language do you prefer to use for this discussion? 
 
___English 
 
___ Sesotho  
 
___Other Language: Specify______________________________  
 
 
Hello. My name is___________. We have talked to your parents/guardian and they said it was okay to 
invite you to take part in a survey. Surveys help us learn new things.   
This form talks about our survey and the choice that you have to take part in it. We want you to ask us 
any questions that you have.  You can ask questions any time.  
 
 
Why are we doing this survey?  
We are doing this survey to help us learn more about the health of adolescents in Lesotho. We plan to 
ask about 4,000 children, ages 0-14 years to join this survey.  A survey is a way to learn about something 
by interviewing and testing many people. We would like to invite you to join this survey.  
 
This form might have some words that you may not have heard before. Please ask us to explain anything 
that you do not understand. 
  
What would happen if I join this survey? 
If you decide to join the survey, here is what would happen: 
▪ We will ask you questions about your age, what you know about HIV, and some of your behaviors.  
▪ The interview will take place in private here in your house or an area around your house.  We will 
not tell your parents about any of your answers. 
▪ The interview will take about 30 minutes. 
▪ After we ask you the questions, we will also ask you if it is okay to take some of your blood to test 
for HIV and to store it for future studies. 
 
Could bad things happen if I join this survey?  
 You may feel uncomfortable answering some of the questions we will ask. You can refuse to answer any 
question or stop the interview at any time.  If you do not take part, or if you decide to stop, it will not 
affect your health care in any way.   If you child do not want to participate in the study you may still 
request HIV testing and counselling, pending the availability of supplies.  
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Could the survey help me? 
You will help figure out ways to help children and learn more about health in Lesotho. Your taking part is 
important. 
 
What else should I know about this survey? 
If you don’t want to be in the survey, you don’t have to be. Nobody will get upset with you if you do not 
want to join the survey. 
It is also OK to say ‘yes’ and change your mind later.  If you want to stop, please tell us.  
We will not tell other people that you are in this survey and will not share information about you to 
anyone who does not work in the survey. Any information about you will have a number on it instead of 
your name. Your name or any other identifying information will not appear on any survey results that 
we share with Ministry of Health, the public, or publish or present at scientific meetings. 
  The following individuals and/or agencies will be able to look at your research records: 
▪ Study staff and study monitors 
▪ Staff members from groups that protect your rights to ensure that we are protecting your rights  
 
The information we collect during the survey will not be released outside of the survey groups listed 
unless there is an issue of safety.  If you want to leave the study, have any questions about the survey, 
or feel that you have been harmed by taking part, you should contact the Principal Investigator:  
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
You should also know that you will not be paid to be in the study. You can ask questions any time.  Ask 
us any questions you have.  Take the time you need to make your choice.   
 
 
  
 
251 
Do you want to ask me anything? 
 
If you want to be asked questions after we talk, please write your name below.  We will write our name 
too.  This shows we talked about the survey and that you want to take part. 
 
1. Do you agree to do the interview? ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No 
 
 
Child signature or mark_______________________________ Date: ___/___/___            
Printed name of child ________________________________________    
Child’s participant ID number ____________________________________________ 
 
Printed name of parent/guardian_____________________________    
 
[For illiterate parent/guardian/participant] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining consent/assent_____________________ __________ Date: 
___/___/___          
Printed name of person obtaining consent/assent____________________________    
 
Survey staff ID number _________________________________   
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Assent for Interview from Minors, ages 15-17 
 
Interviewer reads: 
 
What language do you prefer for our discussion today? 
 
___English 
 
___Sesotho 
 
___Other Language: Specify ___________________________  
  
 
Hello. My name is_________________. We are doing a research study throughout Lesotho to learn more 
about HIV in the country.  
 
Title of Survey: This survey is called the Lesotho Population-Based HIV Impact Assessment (LePHIA, 
2016-2017) 
 
Purpose of the survey 
This survey will help us learn more about the health of young people in Lesotho. It will also tell us about  
young people’s risk for getting HIV. We plan to ask about 12,698 people, ages 15-59 to join this survey. A 
survey is a way to learn new information about something by interviewing and testing many people. If 
you join, your taking part will help the Ministry of Health make health services better in the country.  
 
This form might have some words in it that are not familiar to you.  Please ask us to explain anything that 
you do not understand. 
 
Survey Procedures 
If you agree to join, we will ask you questions about your age, your knowledge about HIV, and your 
behavior. We will ask you to answer these questions without having others present. The interview will 
take about 40 minutes. 
 
After the interview, we will offer you an HIV test.  We will ask you for consent for the HIV test and blood 
draw and talk to you about your results. The testing and counseling session will take about 40 minutes.  
 
Right to refuse or withdraw 
You do not have to take part in the survey. If you choose to join the survey, you may change your mind 
at any time and stop taking part. If you decide not to take part, or if you decide to stop it will not affect 
your healthcare in any way and nobody will get upset with you.  If you do not  want  to participate in the 
study you may still request HIV testing and counselling, pending the availability of supplies. 
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Risks and benefits 
The risks in being in the survey are small. We will do everything we can to keep your information private. 
However, we cannot promise complete confidentiality.  You may feel uncomfortable about some of the 
questions we will ask. You can refuse to answer any question. If you take part, you will get free testing for 
HIV in your own home. Taking part in this research will help us learn more about HIV in Lesotho. Your 
taking part is important. 
 
8. There is no cost to you for being part of the survey.  You should also know that you would not 
be paid. 
 
Confidentiality, Privacy and Access to Your Health Information  
We will do everything we can to keep your taking part in the survey and your answers private. We will not 
tell your family about any of your responses. Your name and signed consent form will be kept separate 
from your answers to the questions, which will only be identified by a number. Your name or any other 
identifying information will not appear on any survey results that we share with Ministry of Health, the 
public, or publish or present at scientific meetings.  The information we collect during the survey will not 
be shared outside of the survey groups listed unless there is an issue of safety. 
 
The following individuals and/or agencies will be able to look at your research records: 
 
▪ Staff members from the Institutional Review Boards or Ethics Committees overseeing the conduct of 
this survey to ensure that we are protecting your rights as a person taking part in a research study. 
The Research and Ethics Committee and the Institutional Review Boards at the Centers for Disease 
Control and Prevention (CDC; Atlanta, USA), Columbia University Medical Center and Westat (a 
statistical survey research organization) 
▪ The U.S. Office of Human Research Protections and other government agencies that oversee the 
safety of human subjects to ensure we are protecting your rights as a person taking part in this 
survey 
▪ Study staff and study monitors 
 
If you want to leave the study, have any questions about the survey, or feel that you have been harmed 
by taking part,  you should contact the Principal Investigator:  
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
 
If you have any questions about your rights as a participant in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
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 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
  
Do you want to ask me anything about the survey? 
 
Consent Statement 
 
Any questions that I had were answered satisfactorily. I have been offered a copy of this consent form. 
 
1. Do you agree to do the interview?  ‘YES’ means that you agree to do the interview. ‘NO’ means 
that you will NOT do the interview. 
______Yes              ______No    
 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
 
Printed name of participant________________________________________    
 
Participant ID number ____________________________________________ 
 
[For illiterate participants] 
 
Signature of witness______________________________________________ Date: ___/___/___          
 
Printed name of witness___________________________________________   
 
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
 
Printed name of person obtaining consent_____________________________    
 
Survey staff ID number _________________________________   
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Assent for Blood Draw from Minors, ages 12-17 
 
Interviewer reads: 
 
Hello. My name is___________. I will give you information about blood testing in this survey.  
 
As a part of this survey, we are giving people a chance to learn if they have HIV.   We will ask about 
12,698 people, ages 15-59 years and 4,222 children, ages 0-14 years from 10, 450 households to join this 
survey. We are also asking people if we can keep some of their blood for future testing.  
 
This form might have some words in it that may be new to you. Please ask me to explain anything that 
you do not understand. 
  
What would happen if I agree to get blood testing? 
 
If you agree to testing, here is what would happen: 
▪ We will use a needle to take about a teaspoon of your blood from your arm. If it’s not possible to 
take blood from your arm, then we will try to take a few drops of blood from your finger.  Then we 
will test your blood for HIV here in your home. 
▪ It will take about 40 minutes to do the test and to talk to you about the results. 
▪ If you have HIV, we will do another test here at home on the blood we have already collected to 
measure some cells in your blood that fight HIV and other infections. We will also measure these 
cells from some children without HIV.  
▪ If you test positive for HIV, we will send your blood to a laboratory to measure the amount of HIV in 
your blood. We will ask you if we can use some of your blood for future testing. These tests may be 
about HIV or other health issues important for in Lesotho. This sample will be stored using a unique 
ID number for up to five (5) years  after study completion but your name will be removed from the 
sample immediately.   Only survey staff will be able to link your  sample to your  contact 
information. We will attempt to tell you about any test results during the five (5) year period that 
are important for your health.  We will try to tell you about any test results during this period that 
are important to your health. Your leftover blood will not be sold. If you do not agree to future 
storage and testing of your blood, we will destroy your blood after survey-related testing has 
finished. 
 
Could bad things happen if I agree to blood testing?  
The needle may hurt when it is put into and taken out of your arm. This will go away quickly.  Sometimes 
the needle can leave a bruise on the skin.  You might bleed a little or feel a little dizzy afterwards.  
Rarely, an infection might occur where the needle enters the skin.  And sometimes we may have to stick 
you with the needle more than one time in order to get the right amount of blood.  We will do our best 
to make it hurt as little as possible.  You may learn that you have HIV. Learning that you have HIV may 
cause you to feel worried or upset. We can assist you with talking to your parents/guardian and help you 
with this.  You do not have to give blood and you are free to change your mind even after you have 
started the blood draw.   
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If you decide not to take part, or if you decide to stop, it will not affect your healthcare in any way. If you 
do not want to participate in the study you may still request HIV testing and counselling, pending the 
availability of supplies. We will do everything we can to keep your information private. However, we 
cannot promise complete confidentiality. 
 
Could getting tested for HIV help me? 
If you do not have HIV, you can learn about what you can do to stay that way. If you have HIV, we will 
tell you where to get help or treatment.  The treatment for HIV is free.  If you already know you have 
HIV and are on HIV treatment, the tests may help your doctor/nurse judge how well your treatment is 
working.  We also hope to learn something from this survey to help other children in Lesotho.  
  
There is no cost to you or your parent/guardian for you being in the survey. You and your 
parent/guardian will not be paid for you to be in the survey. 
  
What else should I know about this survey? 
If you do not want to get a blood test, you do not have to. Nobody will get upset. You can say ‘yes’ and 
change your mind later.  If you want to stop, please tell us.   
We will not tell other people that you are in this survey and will not share information about you to 
anyone who does not work on the survey. Any information about you will have a number on it instead 
of your name. Your name or any other identifying information will not appear on any survey results that 
we share with Ministry of Health, the public, or publish or present at scientific meetings. No one else will 
be able to know your test results except the people working on the survey. 
 The following individuals and/or agencies will be able to look at your survey records: 
▪ Survey staff and survey monitors 
▪ Staff members from groups that protect your rights to ensure that we are protecting your rights  
 
Do you want to ask me anything? 
 
If you want to get an HIV test and give your blood for the survey after we talk, please write your name 
below.  We will write our name too.  This shows we talked about the survey and what you decide about 
taking part. 
  
1. Do you agree to give blood for testing? ‘YES’ means that you agree to give blood for HIV testing 
and related testing. ‘NO’ means that you will NOT give blood for HIV testing and related testing.  
______Yes              ______No 
(If “Yes” proceed to the next question) 
 
2. Do you agree to give your blood to be stored for future research?  ‘YES’ means that you agree to 
have your blood stored for future research. ‘NO’ means that your blood will NOT be stored for 
future research. 
  
 
257 
______Yes              ______No 
 
 
 
Minor’s signature or mark_______________________________ Date: ___/___/___            
Printed name of minor  ________________________________________    
Minor’s participant ID number ____________________________________________ 
 
Printed name of parent/guardian_____________________________ 
 
[For illiterate participant] 
Signature of witness______________________________________________ Date: ___/___/___          
Printed name of witness___________________________________________   
 
Signature of person obtaining consent/assent_____________________ __________ Date: 
___/___/___          
Printed name of person obtaining consent/assent____________________________    
 
Survey staff ID number _________________________________   
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Consent to Share Contact Information of LePHIA Participants with  
Ministry of Health or Their Partners 
 
Interviewer reads: 
 
Purpose of consent 
You had a positive HIV test today. We have provided you with a referral form to bring to a health clinic 
and seek HIV treatment and care.  We would like to help you in accessing the health care that you need. 
If you agree, we may be able to provide your contact information and HIV test results to the village 
health workers (VHW) or nurses from the Ministry of Health (MOH) or to a partner that the MOH work 
with.  This VHW, nurse, or partner will contact you to talk to you about HIV and help you go for HIV care.  
Anyone who is provided with your details will be experienced in providing support to people living with 
HIV and will be trained in maintaining confidentiality. 
What do you have to do if you agree to take part? 
If you agree for your information to be shared and to be contacted, we will provide your name, phone 
number (if you provided it to us) and your address to those individuals to provide you with support. The 
VHW/nurse/partner can contact you by SMS, phone or in person.   
What about confidentiality? 
Your HIV test results and your contact information will not be shared with any other parties aside from 
what was specified in the other consent forms, and with this support organization.  They will also do 
their utmost to maintain your confidentiality. However, we cannot guarantee complete confidentiality. 
What are the potential risks? 
As with all surveys, there is a chance that confidentiality could be compromised.  We are doing everything 
we can to minimize this risk. 
 
What are the potential benefits? 
A trained village health worker or nurse will assist you in accessing the health care that you need. 
Who should you contact if you have questions? 
If you change your mind or have any questions or feel that you have been harmed by taking part, you 
should contact the Principal Investigator listed below: 
 
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
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If you have any questions about your rights as a person in this survey, you can contact:  
Me’ Masebeo Koto 
Address:  Ministry of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
Do you want to ask me anything about the survey? 
 
Consent Statement   
Any questions that I had were answered satisfactorily. I have been offered a copy of this consent form. 
1. Do you agree to allow us to share your contact information with the Ministry of Health or a partner 
that Ministry of Health works with, who may contact you to assist and support you in seeking HIV 
care? ‘YES’ means that you agree for your information to be shared. ‘NO’ means that you do not 
agree for your information to be shared. 
______Yes              ______No 
  
2. If yes, do you agree to be contacted by? 
[MUST SELECT AT LEAST ONE] 
 
SMS           ______Yes              ______No 
Phone call ______Yes              ______No 
In person   ______Yes              ______No 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
Printed name of participant________________________________________    
 
Participant ID number ____________________________________________ 
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
 
Printed name of person obtaining consent_____________________________    
 
Survey staff ID number _________________________________  
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Consent to Share Contact Information of LePHIA Participants with  
Ministry of Health or Their Partners 
 
Interviewer reads: 
 
Purpose of consent 
Your child had a positive HIV test today. We have provided you with a referral form so that you and your 
child can take to a health clinic and seek HIV treatment and care. We would like to help you and your 
child in accessing the health care that your child needs. If you agree, we might be able to provide your 
contact information and your child’s HIV results to health workers or counselors from the Ministry of 
Health  & Public Hygiene (MOHPH) or a partner that the MOHPH works with.  This counselor will contact 
you to talk to you and your child about HIV and help you and your child go for HIV care.  Anyone who is 
provided with you and your child’s details will be experienced in providing support to people living with 
HIV and will be trained in maintaining confidentiality. 
What do you have to do if you agree to take part? 
If you agree for your child’s information to be shared, and to be contacted, we will provide your name, 
phone number (if you provided it to us) and your address to those counselors to provide you with 
support. The counselor can contact you by SMS, phone or in person.   
What about confidentiality? 
Your HIV test results and your contact information will not be shared with any other parties aside from 
what was specified in the other consent forms, and with this support organization.  They will also do 
their utmost to maintain your confidentiality. However, we cannot guarantee complete confidentiality. 
What are the potential risks? 
As with all surveys, there is a chance that confidentiality could be compromised.  We are doing everything 
we can to minimize this risk. 
 
What are the potential benefits? 
A trained health worker or counselor will assist you in accessing the health care needed by your child. 
Who should you contact if you have questions? 
If you change your mind or have any questions or feel that you have been harmed by taking part, you 
should contact the Principal Investigator listed below: 
 
[DO NOT READ BELOW] 
Principal Investigator:   
Dr. Mosilinyane Letsie 
Address: Ministry of Health    
P.O. Box 514, Maseru 100, Lesotho 
Phone: +266 58870982  
Email: lmosilinyane@yahoo.com 
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Consent to Share Contact Information of LePHIA Participants with Ministry of Health or Their Partners  
 
If you have any questions about your rights as a person in this survey, you can contact: 
Me’ Masebeo Koto 
Address:  Ministriy of Development Planning 
 Department of Planning and Statistics 
 P.O. Box 630, Maseru 100, Lesotho 
Email: kotomasebeo@gmail.com 
Phone:+266 63066403 
 
Do you want to ask me anything about the survey? 
 
Consent Statement   
Any questions that I had were answered satisfactorily. I have been offered a copy of this consent form. 
1. Do you agree to allow us to share your contact information with the Ministry of Health or a 
partner that Ministry of Health works with, who may contact you to assist and support you in 
seeking HIV care? ‘YES’ means that you agree for your information to be shared. ‘NO’ means 
that you do not agree for your information to be shared. 
______Yes              ______No 
  
2. If yes, do you agree to be contacted by? 
[MUST SELECT AT LEAST ONE] 
SMS           ______Yes              ______No 
Phone call ______Yes              ______No 
In person   ______Yes              ______No 
 
Participant signature or mark_______________________________________ Date: ___/___/___            
 
Printed name of participant________________________________________    
 
Participant ID number ____________________________________________ 
 
Signature of person obtaining consent_____________________ ___________ Date: ___/___/___          
 
Printed name of person obtaining consent_____________________________    
 
Survey staff ID number _____________________ 
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